	sample_name	run_prefix	experimental_strategy	cgc_base_name	filename	analyte_amount	analyte_A260A280Ratio	aliquot_concentration	cgc_id	cgc_filename	vital_status	gender	race	ethnicity	disease_type	data_subtype	tcga_sample_id	cgc_case_uuid	sample_type	cgc_platform	gdc_file_uuid	primary_site	age_at_diagnosis	cgc_sample_uuid	cgc_aliquot_uuid	tcga_aliquot_id	reference_genome	tcga_case_id	investigation	days_to_death	knightlabID	data_submitting_center_label	tissue_source_site_label	country_of_sample_procurement	portion_is_ffpe	pathologic_t_label	pathologic_n_label	histological_diagnosis_label	pathologic_stage_label	PlateCenter	PlateCenterFlag	TCGAStudy	ImmuneSubtype	TCGASubtype	LeukocyteFraction	StromalFraction	IntratumorHeterogeneity	TILRegionalFraction	Proliferation	WoundHealing	MacrophageRegulation	LymphocyteInfiltrationSignatureScore	IFNgammaResponse	TGFbetaResponse	SNVNeoantigens	IndelNeoantigens	SilentMutationRate	NonsilentMutationRate	NumberofSegments	FractionAltered	AneuploidyScore	HomologousRecombinationDefects	BCREvenness	BCRShannon	BCRRichness	TCRShannon	TCRRichness	TCREvenness	CTAScore	Th1Cells	Th2Cells	Th17Cells	OS	OSTime	PFI	PFITime	flr_F1_F2	blr_F1_F2	ilr_F1_F2	flr_F1_F3	blr_F1_F3	ilr_F1_F3	flr_F2_F3	blr_F2_F3	ilr_F2_F3	log_ratio_class	log_ratio_used
13722.58cfa82ee4b0c9d6adf6ae48	58cfa82ee4b0c9d6adf6ae48	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted.bam	486.4	1.9	0.15	58cfa82ee4b0c9d6adf6ae48	TCGA-05-4384-01A-01D-1751_120228_SN1120_0117_BC0DKWACXX_s_4_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4384-01A	9A50E7E4-831D-489F-87D2-979E987561CC	Primary Tumor	Illumina HiSeq	985192a3-1403-4393-895a-ca9a4d12268f	Lung	66.0	E4416303-50B0-4316-BFEE-030C7B29FAC6	5253B1A2-8C57-414A-8E19-6E8390A6C18D	TCGA-05-4384-01A-01D-1751-02	HG19_Broad_variant	TCGA-05-4384	TCGA-LUAD		s10982	Harvard Medical School	Indivumed	Germany	NO	T2	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	True	LUAD	C3	LUAD.1	0.199447265	0.51	0.02	0.0	-1.2215	-0.2755	0.6438	0.1829	-0.3167	0.0162	51.0	4.0	1.165266489	3.256770445	59.0	0.066063506	1.0	8.0	0.696424099	0.7651000729999999	3.0	2.197224577	9.0	1.0	2.706536803	-555.4953232999999	-1303.858707	3929.1928700000003	0.0	426.0	1.0	183.0	3.243429054922978	7.301175920620503	-0.659144054480926	2.2095669500030297	5.36423444154795	4.392389421709429	-1.0338621049199483	-1.9369414790725528	5.051533476190355	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6ae50	58cfa82ee4b0c9d6adf6ae50	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted.bam	445.53	1.9	0.14	58cfa82ee4b0c9d6adf6ae50	TCGA-05-4382-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_3_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4382-01A	3434B91A-C05F-460F-A078-7B1BB6E7085D	Primary Tumor	Illumina HiSeq	42d76c95-55a7-4160-b22f-4338315e6146	Lung	68.0	CCE6D71F-369E-467F-BD7E-03D20E97B7F3	EE1D241A-B371-433A-9AF7-F1C9074C155F	TCGA-05-4382-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4382	TCGA-LUAD		s11435	Harvard Medical School	Indivumed	None	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C6	LUAD.6	0.460245264	0.79	0.5	5.399125961	-0.1487	-0.0135	1.2892	1.3548	0.2834	0.6156	955.0	291.0	11.61873302	43.39182847	194.0	0.495305039	18.0	33.0	0.804021992	4.5587089569999995	290.0	4.046385053	61.0	0.984312627	5.599278237	-387.7732495	-175.4016867	3395.632436	0.0	607.0	1.0	334.0	7.477534507920421	6.864044500555991	0.30777342299465227	6.230659682050275	7.011097918512488	3.6820379222972197	-1.2468748258701456	0.14705341795649662	3.3742644993025674	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6ae52	58cfa82ee4b0c9d6adf6ae52	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted.bam	372.53	1.9	0.14	58cfa82ee4b0c9d6adf6ae52	TCGA-05-4389-01A-01D-1203_120318_SN1120_0124_AC0HNPACXX_s_5_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4389-01A	A3DE401D-91FE-49A2-BB07-81C1A06506E6	Primary Tumor	Illumina HiSeq	63a06f9b-e1c2-495a-8f7e-88e19c550049	Lung	70.0	ED61AC6A-F21F-4B88-928A-029340D4AEBD	575D4BEF-5610-41F4-B219-C9BBBA72F047	TCGA-05-4389-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4389	TCGA-LUAD		s10769	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Lung Adenocarcinoma Mixed Subtype	Stage IA	1203-02	True	LUAD	C2	LUAD.2	0.33617597299999996	0.52	0.5		0.2406	0.1405	0.9496	1.6249	0.6881	-0.1812	116.0	112.0	2.041442974	5.794095499	251.0	0.8140696340000001	18.0	45.0	0.8309696740000001	2.8535392280000003	31.0	4.36921797	95.0	0.959450173	4.2789271730000005	-664.3550031000001	181.31803689999998	3382.8557990000004	0.0	1369.0	0.0	1369.0	7.242905887921124	7.032330013563767	0.3687810252723691	6.042713806435095	6.677508638274357	1.998232947976538	-1.2001920814860294	-0.3548213752894096	1.6294519227041686	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6ae5a	58cfa82ee4b0c9d6adf6ae5a	TCGA-04-1514-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-04-1514-01A-01D-A324-10_wgs_Illumina	TCGA-04-1514-01A-01D-A324-10_wgs_Illumina.bam	279.67	1.9	0.07	58cfa82ee4b0c9d6adf6ae5a	TCGA-04-1514-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-04-1514-01A	E9483296-CB91-497A-B955-39A3C3289DAC	Primary Tumor	Illumina HiSeq	07a37a5e-5fa5-415b-9814-363bf0a7bc48	Ovary	45.0	18E0F4ED-43E2-451F-82BD-102260A30AAA	C691D6B3-8E70-4951-8551-2EE4E4D0D10B	TCGA-04-1514-01A-01D-A324-10	GRCh37-lite	TCGA-04-1514	TCGA-OV	1720.0	s17412	Baylor College of Medicine	Gynecologic Oncology Group	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Proliferative	0.03777766				0.6666	0.225	-1.5608	-2.1464	0.0832	-0.0666					285.0	0.862190272	9.0	42.0				1.732867951	6.0	0.9671320179999999	5.646226018999999	-1576.159539	486.3232356000001	-1796.02898	1.0	1720.0	1.0	1221.0	6.849066282633458	3.7233006389913896	-0.9694005571881036	4.49769102546998	2.6540869745282993	0.7014459833746403	-2.3513752571634776	-1.0692136644630903	1.670846540562744	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6ae60	58cfa82ee4b0c9d6adf6ae60	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted.bam	827.4	1.9	0.14	58cfa82ee4b0c9d6adf6ae60	TCGA-05-4390-01A-02D-1751_120305_SN1120_0118_AD0L4HACXX_s_1_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4390-01A	B8475929-2D9D-4909-BD62-59684A140BD7	Primary Tumor	Illumina HiSeq	625e3715-ed9e-4946-8c92-f5a93e92e6d4	Lung	58.0	C7F76210-D0F2-4FB8-80F1-35098DBE03DE	4BC393B5-F924-4D66-BC93-58A3CB2EBBC5	TCGA-05-4390-01A-02D-1751-02	HG19_Broad_variant	TCGA-05-4390	TCGA-LUAD		s11328	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1751-02	True	LUAD	C1	LUAD.2	0.189849228	0.43	0.36	0.0	0.5341	0.1485	0.2115	0.4356	-1.1596	0.1018	265.0	290.0	4.358562789	14.63875916	163.0	0.6931165840000001	16.0	27.0	0.921415619	3.874269453	67.0	2.197224577	9.0	1.0	2.278939296	-839.663958	159.24507830000002	1448.640421	0.0	1126.0	1.0	395.0	3.6025671334268043	3.6862094935809555	-0.9171146710990754	2.7787897073035523	3.8007899644504644	1.4078820201280933	-0.823777426123252	0.11458047086950884	2.3249966912271685	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6ae62	58cfa82ee4b0c9d6adf6ae62	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted.filtered.	WGS	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted.bam	385.2	1.9	0.14	58cfa82ee4b0c9d6adf6ae62	TCGA-05-4395-01A-01D-1203_110913_SN208_0238_BC008YACXX_s_8_rg.sorted.bam	Dead	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4395-01A	762DEA8A-5B41-4058-979A-B7876ED13D7E	Primary Tumor	Illumina HiSeq	dcb07672-8bde-427e-9d94-ac644e457e91	Lung	76.0	9DED6605-39A3-4C0F-AD2E-7F6863960DBE	5E9E0A0C-75C0-48AA-BD85-A2E102787EF9	TCGA-05-4395-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4395	TCGA-LUAD	0.0	s11115	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1203-02	True	LUAD	C2	LUAD.3	0.202136549	0.39	0.15	0.090033936	0.2672	0.2735	0.3337	0.3167	0.4369	0.1311	123.0	1.0	2.3827142830000003	6.725889684	197.0	0.633570216	22.0	36.0	0.958556217	2.5958183569999997	15.0	2.6941537039999996	17.0	0.950918048		-789.5480405000001	-367.3401437	3205.151901	1.0	0.0	0.0	0.0	5.934516195237086	6.549114117589863	1.0906141279412762	4.513130514305926	5.632823385715708	1.4338571258055808	-1.421385680931161	-0.9162907318741551	0.34324299786430457	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6ae64	58cfa82ee4b0c9d6adf6ae64	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted.bam	301.7	1.9	0.16	58cfa82ee4b0c9d6adf6ae64	TCGA-05-4396-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_1_rg.sorted.bam	Dead	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4396-01A	9F81C602-8AFA-4588-B0B6-6E5A1A128D5A	Primary Tumor	Illumina HiSeq	61bb72a1-5c87-411d-af04-3e058c2beab2	Lung	76.0	4D85772B-287E-4790-B1E8-CD1C0E88AD48	1F0C98A3-3EED-45E0-BF81-78632C02D375	TCGA-05-4396-01A-21D-1853-02	HG19_Broad_variant	TCGA-05-4396	TCGA-LUAD	303.0	s10640	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1853-02	True	LUAD	C3	LUAD.4	0.118303025	0.18	0.16	0.009099733	-0.4474	-0.2715	-0.2088	-0.1143	-0.3666	-0.0432	137.0	63.0	1.7959414219999998	7.062006948	200.0	0.699200259	8.0	13.0	0.798553965	2.214061718	16.0	1.9459101490000001	7.0	1.0	4.440018171	-1431.270232	-225.02198030000002	3090.921889	1.0	303.0	0.0	303.0	8.270269111436624	7.046607716974455	-0.24070186352758838	7.038125430143992	7.835065077338726	3.556959665383755	-1.2321436812926325	0.7884573603642702	3.7976615289113433	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6ae68	58cfa82ee4b0c9d6adf6ae68	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	211.2	1.9	0.15	58cfa82ee4b0c9d6adf6ae68	TCGA-05-4403-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4403-01A	CE15F31F-2BAD-4485-96FA-495BFA262E66	Primary Tumor	Illumina HiSeq	80e2118c-7ebf-42fc-8600-573afcbb3fe6	Lung	76.0	44B1D21C-0794-428C-BA01-82812D74DA2F	48F1FF7F-84F4-4420-96F9-DA1917577B6D	TCGA-05-4403-01A-01D-1203-02	GRCh37	TCGA-05-4403	TCGA-LUAD		s10980	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C6	LUAD.4	0.255515653	0.54	0.01	0.40500614100000004	-0.8043	-0.068	0.9554	1.0769	0.7037	0.2989	39.0	4.0	1.142155416	3.485038321	87.0	0.027215039	0.0	10.0	0.934386829	3.6738460839999996	51.0	3.662040914	41.0	0.9861235620000001	2.280830611	-102.216841	-614.7957152	1552.259906	0.0	578.0	0.0	578.0	7.712108357615428	8.409703426388027	0.04291456665547533	6.153963739568878	7.913266540074137	3.409794855393501	-1.5581446180465497	-0.49643688631389127	3.3668802887380256	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6ae6a	58cfa82ee4b0c9d6adf6ae6a	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted.bam	403.53	1.9	0.15	58cfa82ee4b0c9d6adf6ae6a	TCGA-05-4398-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_1_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4398-01A	31C96E35-5E2F-429C-B12A-7BC5A497A300	Primary Tumor	Illumina HiSeq	af507e03-fa73-4b22-88ae-8d5d9cee85dc	Lung	47.0	DA010683-C537-478F-8F95-E606B05DBC5C	CC8C5E2D-1878-49EC-9D63-D65EB4FE8256	TCGA-05-4398-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4398	TCGA-LUAD		s10981	Harvard Medical School	Indivumed	Germany	NO	T4	N3	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1203-02	True	LUAD	C2	LUAD.3	0.286317881	0.67	0.25	7.390615283	0.3394	0.1785	1.0578	1.311	0.7471	0.3573	319.0	258.0	6.382111753999999	18.73075589	235.0	0.486607549	19.0	47.0	0.86773412	3.89494293	89.0	4.256652064	75.0	0.9859093879999999	4.624980391999999	-60.11473046	-608.7003592	4026.3850799999996	0.0	1431.0	0.0	1431.0	7.490138482557227	7.438465226053503	-0.10776374207754136	6.385986013513501	6.961541153963194	2.001390055975489	-1.1041524690437257	-0.4769240720903092	2.10915379805303	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6ae6c	58cfa82ee4b0c9d6adf6ae6c	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted.filtered.	WGS	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted.bam	175.7	1.9	0.17	58cfa82ee4b0c9d6adf6ae6c	TCGA-05-4405-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_2.rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4405-01A	F587C9AB-2949-4410-80D6-A050865D48AA	Primary Tumor	Illumina HiSeq	47fe3db4-7a54-4703-b3a4-7ad7def2469c	Lung	74.0	9CE83CC4-7B9B-4CE7-98F5-5CE8A8D70902	8A9ADFB9-6266-490D-B1B6-F66F43F3F657	TCGA-05-4405-01A-21D-1853-02	HG19_Broad_variant	TCGA-05-4405	TCGA-LUAD		s10768	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	True	LUAD	C3	LUAD.3	0.304388607	0.62	0.49	0.144851961	-0.6193	-0.175	0.6655	0.8356	0.4333	0.4508	197.0	233.0	3.198758029	9.740362286	143.0	0.506204314	22.0	21.0	0.936154887	4.253227613	94.0	1.7478680969999998	6.0	0.9755037590000001	3.151559027	383.0049971	-374.0148147	1380.78794	0.0	610.0	0.0	610.0	7.061220009314109	7.208857763067003	-0.5264847631804328	6.63377599448717	7.902004943626949		-0.4274440148269396	0.6931471805599454		higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6ae74	58cfa82ee4b0c9d6adf6ae74	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	176.2	1.9	0.14	58cfa82ee4b0c9d6adf6ae74	TCGA-05-4402-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4402-01A	722D6818-F1CB-49F4-B68A-FD0A31304681	Primary Tumor	Illumina HiSeq	603e16bf-9b05-49c9-a925-f409626c969a	Lung	57.0	07C1FCE4-EC48-47A4-8391-E553936B67F2	5E791B10-E5FD-412D-9F42-72CAC197F253	TCGA-05-4402-01A-01D-1203-02	GRCh37	TCGA-05-4402	TCGA-LUAD	244.0	s10900	Harvard Medical School	Indivumed	Germany	NO	T2	NX	Lung Adenocarcinoma Mixed Subtype	Stage IV	1203-02	True	LUAD	C2	LUAD.2	0.28506428899999997	0.56	0.55	0.868542477	-0.0694	0.0185	0.7332	1.0036	1.4453	0.4149	58.0	48.0	1.050809163	3.0648600569999997	99.0	0.714184253	27.0	21.0	0.7761351259999999	3.448097694	85.0	3.1604362010000004	26.0	0.97002534	6.582860002	-83.24075531	-578.1871083	2362.627316	1.0	244.0	0.0	244.0	6.6138722017978075	4.268016494521835	-0.0371609801902707	5.920725021237862	2.9755050957173284	3.9244455254267034	-0.6931471805599454	-1.292511398804507	3.961606505616974	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6aee7	58cfa82ee4b0c9d6adf6aee7	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted.bam	182.7	1.9	0.16	58cfa82ee4b0c9d6adf6aee7	TCGA-05-4410-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_4_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4410-01A	D28E465C-E553-4C53-8BB7-3D8199B9A8A5	Primary Tumor	Illumina HiSeq	bdcc8e9a-8d27-4167-ae6f-3c41b38c6c51	Lung	62.0	F8961F5C-E28B-44A2-8E4E-B5759FE2D849	51E2038A-2D9D-481D-A3B6-D5D5D6B33E4F	TCGA-05-4410-01A-21D-1853-02	HG19_Broad_variant	TCGA-05-4410	TCGA-LUAD		s10773	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	True	LUAD	C3	LUAD.3	0.428618499	0.76	0.39	0.0	-0.2923	-0.166	0.9173	1.8069	0.7625	0.0366	276.0	47.0	8.582490904	28.06152316	95.0	0.45283054899999997	17.0	32.0	0.706298751	3.5101729269999997	144.0	3.332936633	35.0	0.937443135		-49.76588274	-133.2584347	2783.173406	0.0	0.0	0.0	0.0	6.463895782886661	7.520961372721232	-0.18842759852403834	6.325745444405844	7.867237609439066	3.9209716110041604	-0.13815033848081715	0.3462762367178338	4.109399209528199	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6af20	58cfa82ee4b0c9d6adf6af20	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted.bam	143.7	1.9	0.14	58cfa82ee4b0c9d6adf6af20	TCGA-05-4415-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_5_rg.sorted.bam	Dead	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4415-01A	D15B7B29-C5C5-41D8-B83B-7CC12FE92820	Primary Tumor	Illumina HiSeq	ae778c61-5e62-4f34-9b62-f28d9acf21b1	Lung	57.0	57E160F5-45FC-44EF-95C6-54E112E3B7F5	4CD99514-20D0-439F-9B9F-BDDCEE5D950F	TCGA-05-4415-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4415	TCGA-LUAD	91.0	s11220	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIB	1853-02	True	LUAD	C2	LUAD.6	0.176539342	0.33	0.22	0.411905395	0.9129	0.4435	-0.0966	0.1968	0.6154	-0.2839	82.0	40.0	1.623972149	5.161911473	171.0	0.815406165	19.0	24.0	0.859637402	3.253030945	44.0	2.428339239	16.0	0.8758382440000001	4.793929052	-271.8174716	1400.252582	-1836.4401460000001	1.0	91.0	1.0	60.0	6.0246025497785425	8.585551022598093	0.051592722482131426	6.145230537567158	8.884044011154089	1.1220940305628266	0.12062798778861472	0.2984929885559966	1.070501308080695	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6afae	58cfa82ee4b0c9d6adf6afae	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted.bam	357.4	1.9	0.15	58cfa82ee4b0c9d6adf6afae	TCGA-05-4425-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_3_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4425-01A	69B23036-ADD9-42C9-941F-02FB74D9B08C	Primary Tumor	Illumina HiSeq	bf137f71-691f-42f6-a29c-e37a457bad18	Lung	70.0	98BEE17E-0B07-40D8-A70F-3163DBFD9C79	C0DC5772-8A3E-43BE-9059-FC524A5183C9	TCGA-05-4425-01A-01D-1751-02	HG19_Broad_variant	TCGA-05-4425	TCGA-LUAD		s10775	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IV	1751-02	True	LUAD	C6	LUAD.4	0.228394485	0.39	0.08	0.0	-0.0918	-0.017	1.1021	0.9734	0.6359	0.2405			0.382436537	1.029636831	83.0	0.23523482	9.0	10.0	0.842612562	2.387301156	17.0	3.127386308	27.0	0.948889898	2.022140034	-89.59658552	-457.0587766	1403.118289	0.0	669.0	0.0	669.0	4.8388157744021205	3.8854713185012137	-0.2596783881122793	4.017917192904901	4.077380676450322	1.9559580218515942	-0.8208985814972198	0.19190935794910846	2.2156364099638735	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6afc4	58cfa82ee4b0c9d6adf6afc4	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	313.3	1.9	0.15	58cfa82ee4b0c9d6adf6afc4	TCGA-05-4418-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4418-01A	D2C1E896-6886-4122-BB48-5FBCD3F641F4	Primary Tumor	Illumina HiSeq	961e7ff2-7efc-46b6-9fe6-3f19366eeab8	Lung	69.0	C9E092B2-D6C3-4161-BD9E-0FA4015BEBBB	AA7559AC-F8C0-40E5-A313-3914A6E4559A	TCGA-05-4418-01A-01D-1203-02	GRCh37	TCGA-05-4418	TCGA-LUAD	274.0	s11440	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1203-02	True	LUAD	C2	LUAD.6	0.43781692899999997	0.45	0.59	22.47367449	0.1704	0.273	0.7954	1.8467	1.4031	0.1044	70.0	13.0	2.086539836	6.91538917	65.0	0.22372985199999998	5.0	5.0	0.8223541670000001	3.850370126	108.0	4.260094393999999	77.0	0.980728642	6.027494862999999	-233.03516859999996	-541.3422128999999	2657.651757	1.0	274.0	0.0	274.0	7.705994189080156	7.783247164216271	0.13577745957063903	6.789703457206002	6.648267231377286	3.967457712316246	-0.9162907318741551	-1.1349799328389851	3.831680252745607	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6b001	58cfa82ee4b0c9d6adf6b001	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted.bam	342.2	1.9	0.15	58cfa82ee4b0c9d6adf6b001	TCGA-05-4430-01A-02D-1203_111013_SN208_0253_B00PJACXX_s_6_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4430-01A	3A23CDB5-2327-45AC-B0B5-D4AFE038C757	Primary Tumor	Illumina HiSeq	e4ae6498-889f-4900-a73c-2e61a6e154d1	Lung	59.0	122AAA4F-8FD5-4C41-BFF8-8A45BDFB3F81	C14A77D1-DB59-434E-BD3C-DBBE647D790C	TCGA-05-4430-01A-02D-1203-02	HG19_Broad_variant	TCGA-05-4430	TCGA-LUAD		s10646	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C2	LUAD.5	0.295727418	0.8	0.32	1.700862485	-0.2684	0.1235	0.9349	1.2705	0.9454	0.6665	120.0	51.0	2.116684341	7.05561447	133.0	0.299412544	17.0	20.0	0.92181649	3.194772506	32.0	3.271689322	27.0	0.99267332	4.732450341	-297.724818	-771.266982	1792.795915	0.0	761.0	0.0	761.0	7.0695096305503995	5.270573400011973	-0.027075445265711928	5.924377326247397	6.255072381912661	3.3268536021619415	-1.1451323043030028	0.9844989819006882	3.3539290474276537	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6b00e	58cfa82ee4b0c9d6adf6b00e	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted.bam	631.63	1.9	0.15	58cfa82ee4b0c9d6adf6b00e	TCGA-05-4422-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_5_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4422-01A	44DEC838-B653-42A7-A58B-A1FD232CD68C	Primary Tumor	Illumina HiSeq	9fcb53c6-7d0c-4468-8a77-40e6ea3d43d8	Lung	68.0	DACBC55D-25C6-4E86-BD1B-38345B4DF7A7	09DD9098-5702-44A6-B9EA-F148ECE1E264	TCGA-05-4422-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4422	TCGA-LUAD		s11223	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C2	LUAD.1	0.321979601	0.38	0.01	26.50796492	-0.1697	-0.0085	0.9237	1.9779	-0.3273	-0.4185	13.0	26.0	0.44391327399999997	1.03579764	281.0	0.23091268899999998	6.0	20.0	0.909719886	4.284353277	111.0	3.859738826	86.0	0.866510528	1.922788947	151.1896341	-595.6018196	3493.228004	0.0	365.0	0.0	365.0	7.150536834989471	6.758911480372383	0.20157078553192043	5.896011751500704	6.264892974922774	3.7721170526839916	-1.2545250834887671	-0.4940185054496089	3.5705462671520714	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6b014	58cfa82ee4b0c9d6adf6b014	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted.bam	199.7	1.9	0.16	58cfa82ee4b0c9d6adf6b014	TCGA-05-4433-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_3_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4433-01A	AEA68827-DC0F-484D-A00D-06DEEAA4B3CE	Primary Tumor	Illumina HiSeq	d1b6064d-6736-4aad-8ad3-70ab64c92e3d	Lung	82.0	1E9DAC94-1A10-47D0-AE92-81D38A264376	61B1812A-9455-437F-ACF7-D1AC3FA9F215	TCGA-05-4433-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4433	TCGA-LUAD		s10986	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	True	LUAD	C3	LUAD.6	0.280132698	0.38	0.09	2.7180032030000003	-0.1754	-0.195	1.0706	1.0588	0.7906	-0.0091	18.0	0.0	0.29175708300000003	0.87527125	127.0	0.18890197600000003	6.0	17.0				3.2331834839999996	26.0	0.9923534940000001	1.801427889	-68.4494889	-76.77195903	3536.57571	0.0	730.0	0.0	730.0	5.916767940204352	6.72265714378679	-0.44828945388290975	5.033000400035757	6.635645766797161	1.8420213040089433	-0.8837675401685949	-0.08701137698963013	2.290310757891853	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6b020	58cfa82ee4b0c9d6adf6b020	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted.bam	306.53	1.9	0.14	58cfa82ee4b0c9d6adf6b020	TCGA-05-4432-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_4_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4432-01A	E737F650-B72D-44E7-B750-558A56716803	Primary Tumor	Illumina HiSeq	6110bc85-6f14-48d5-b166-2b3f42776573	Lung	66.0	2A675528-1ABC-4220-A61A-25109850CE0D	A4E437A5-1603-4AE4-89C2-CD741FDE5015	TCGA-05-4432-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4432	TCGA-LUAD		s11334	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1203-02	True	LUAD	C2	LUAD.2	0.34603879	0.64	0.49	11.57628634	0.2749	0.11	0.6707	1.5551	-0.1633	0.2037	275.0	338.0	5.038556516	14.49325963	267.0	0.642010219	18.0	29.0	0.794396922	4.031702459	160.0	3.726795348	43.0	0.9908527159999999	5.670477559	-551.6964212	-71.35945646	3693.555629	0.0	761.0	0.0	761.0	6.959279796635528	6.576469569048223	-0.141119715835619	5.860667507967419	6.650577541201946	2.521274293958875	-1.09861228866811	0.07410797215372167	2.662394009794494	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6b02c	58cfa82ee4b0c9d6adf6b02c	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted.bam	651.3	1.9	0.16	58cfa82ee4b0c9d6adf6b02c	TCGA-05-4420-01A-01D-1203_120316_SN208_0275_BD0PL2ACXX_s_3_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4420-01A	3D2AA654-1B5F-4EB4-A1C2-AF31F5760069	Primary Tumor	Illumina HiSeq	067a9600-61b8-4de1-ac32-914605c3033e	Lung	41.0	4B202550-9744-4C6C-AD17-97F764EA3F18	A50583F2-BB90-4848-9A5F-EAF4656A1866	TCGA-05-4420-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4420	TCGA-LUAD		s11332	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C1	LUAD.2	0.204150962	0.41	0.28	2.0026058	0.6729999999999999	0.33299999999999996	-0.0875	0.1669	-0.8136	0.1043	118.0	16.0	2.335529155	7.243096745	243.0	0.809257599	21.0	46.0	0.875894699	3.988716627	95.0	2.163955657	9.0	0.984858662	4.242182912	-1758.011664	272.1653441	-361.7889162	0.0	912.0	0.0	912.0	7.597732884780803	7.564456293769949	-0.00833886771984682	6.564503355375545	7.010571180543511	1.633524714734706	-1.0332295294052578	-0.5538851132264377	1.6418635824545529	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6b034	58cfa82ee4b0c9d6adf6b034	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted.bam	666.2	1.9	0.14	58cfa82ee4b0c9d6adf6b034	TCGA-05-4426-01A-01D-1203_111013_SN208_0253_B00PJACXX_s_8_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4426-01A	36BF02F8-C1C8-49F9-A417-ADF88A205C70	Primary Tumor	Illumina HiSeq	63037227-adb0-4505-bd71-2527743ec736	Lung	71.0	0C06CF85-61EB-4E6D-AE54-B8F5CBAB9B63	EA6C652F-4896-4D57-978D-7528578BB153	TCGA-05-4426-01A-01D-1203-02	HG19_Broad_variant	TCGA-05-4426	TCGA-LUAD		s10645	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1203-02	True	LUAD	C6	LUAD.5	0.226345684	0.3	0.08	2.094842609	-0.2883	-0.055	0.5145	0.2404	0.4557	0.2166	24.0	80.0	0.177638462	1.3026820540000001	133.0	0.148541168	4.0	14.0	0.8426645290000001	0.584090542	2.0	3.1265850239999997	27.0	0.948646778	2.044923911	-407.97463039999997	-763.9785381	2513.969668	0.0	791.0	1.0	457.0	7.076442644500288	6.247990596493937	-0.16996755012469267	5.371694552261863	6.968536751241996	4.898936652095539	-1.7047480922384255	0.7205461547480598	5.0689042022202315	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6b038	58cfa82ee4b0c9d6adf6b038	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted.bam	16.7	1.9	0.14	58cfa82ee4b0c9d6adf6b038	TCGA-05-4424-01A-22D-1853_120312_SN1120_0120_AD0PYGACXX_s_1_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4424-01A	66763A0C-6CDA-4832-A0CC-E7B496D78EAA	Primary Tumor	Illumina HiSeq	1e635509-6178-417e-9452-bc77482ee8ed	Lung	70.0	A4D06D63-8DA9-4C3C-A75D-4079C2238AA8	D1052F23-44EC-4C05-A164-6FBD72DFC9E2	TCGA-05-4424-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4424	TCGA-LUAD		s11438	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1853-02	True	LUAD	C2	LUAD.5	0.326199535	0.76	0.45	4.438671787	0.3447	0.02	0.9873	0.9145	0.6653	0.3044	395.0	421.0	5.336188214	18.32482216	111.0	0.621672541	15.0	29.0	0.886579711	3.394395783	46.0	3.0981394960000004	23.0	0.9880864970000001	6.213827577000001	-503.66576619999995	203.2766107	1689.0684820000001	0.0	913.0	1.0	153.0	6.269930171134712	8.218560714871375	-0.8005915729812593	5.241161455833867	7.448452493175301	3.4438136838165745	-1.0287687153008456	-0.770108221696074	4.244405256797833	lower	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6b092	58cfa82ee4b0c9d6adf6b092	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted.bam	184.7	1.9	0.16	58cfa82ee4b0c9d6adf6b092	TCGA-05-4417-01A-22D-1853_111204_SN208_0256_C0562ACXX_s_6_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4417-01A	A244A99A-D7CC-4FB1-BC76-B66886481621	Primary Tumor	Illumina HiSeq	f4f3791e-3b72-4f33-986c-dca1cf3ada94	Lung	51.0	9AB40E48-6979-43CB-9ACF-1D4F474CAD4D	B7C6B0BD-AB9E-4211-8B3A-786B45C43F3D	TCGA-05-4417-01A-22D-1853-02	HG19_Broad_variant	TCGA-05-4417	TCGA-LUAD		s11437	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1853-02	True	LUAD	C3	LUAD.6	0.35519708	0.6	0.36	8.617588161	-0.2947	-0.133	0.9571	1.8551	0.2404	0.5142	136.0	33.0	2.09507924	7.406547736	85.0	0.5519829070000001	15.0	22.0	0.883451916	4.371991409	141.0	3.738230895	43.0	0.993893114	2.149556115	643.8292002999999	-305.52112	2236.117859	0.0	455.0	0.0	455.0	7.29535809834138	6.6735159134128725	-0.3119905129283226	6.273706850809399	6.949769290041031	2.3566796549705336	-1.021651247531981	0.2762533766281581	2.6686701678988562	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6b0a5	58cfa82ee4b0c9d6adf6b0a5	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted.filtered.	WGS	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted.bam	64.93	1.9	0.15	58cfa82ee4b0c9d6adf6b0a5	TCGA-05-4249-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_1_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-05-4249-01A	4ADDF05F-3668-4B3F-A17F-C0227329CA52	Primary Tumor	Illumina HiSeq	94e6a5cd-7ba5-4f3e-bf83-7d07522963b4	Lung	67.0	80F196FE-1EAF-40CB-AB58-C84795ACC5C7	E3F50937-D6CF-423B-9DD3-31D715892FC7	TCGA-05-4249-01A-01D-1103-02	HG19_Broad_variant	TCGA-05-4249	TCGA-LUAD		s10642	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1103-02	True	LUAD	C3	LUAD.5	0.251680895	0.51	0.26	2.15188989	-0.8788	-0.1325	0.7904	0.9536	0.4666	0.2006	172.0	153.0	1.949942901	8.172554806	97.0	0.6430591489999999	22.0	10.0	0.6824665209999999	2.48253077	38.0	3.476845417	35.0	0.977919843	2.078720038	-420.27373279999995	-1082.674145	3999.4556759999996	0.0	1523.0	0.0	1523.0	7.381046766524051	7.255624120909058	0.03287884755708825	6.650159257981258	7.0465323230504975	0.0	-0.7308875085427924	-0.20909179785855958	-0.03287884755708825	higher	flr_F1_F2
13722.58cfa82ee4b0c9d6adf6b197	58cfa82ee4b0c9d6adf6b197	TCGA-09-1666-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-09-1666-01A-01D-A324-10_wgs_Illumina	TCGA-09-1666-01A-01D-A324-10_wgs_Illumina.bam	788.97	1.9	0.08	58cfa82ee4b0c9d6adf6b197	TCGA-09-1666-01A-01D-A324-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-09-1666-01A	4EAC2C98-86D2-4EE6-A1D3-157D013C78DC	Primary Tumor	Illumina HiSeq	6d2f46e9-b19b-431a-aa4e-c409eb1787dc	Ovary	57.0	77AB9685-021C-4D99-8980-79BEC534828E	127B0F7D-D24E-48B7-AC25-D3F14A43952D	TCGA-09-1666-01A-01D-A324-10	GRCh37-lite	TCGA-09-1666	TCGA-OV		s17490	Baylor College of Medicine	UCSF	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Differentiated	0.084944091				0.4661	0.2685	0.2283	-0.3554	1.8776	-0.4095					335.0	0.98051996	3.0	64.0				3.8365870639999997	53.0	0.966323673	3.018458545	-1123.240243	-483.5727005	695.7985731000001	0.0	1752.0	1.0	480.0	6.5297107664499645	1.3606214214794914	0.30131278634765135	5.431098477781855	2.9298309873775263	2.4139398770131413	-1.0986122886681096	1.569209565898035	2.11262709066549	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b290	58cfa82fe4b0c9d6adf6b290	TCGA-09-2045-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-09-2045-01A-01D-A324-10_wgs_Illumina	TCGA-09-2045-01A-01D-A324-10_wgs_Illumina.bam	598.97	1.9	0.08	58cfa82fe4b0c9d6adf6b290	TCGA-09-2045-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-09-2045-01A	3768D34F-1527-40DB-B116-CD80CEE5EC3A	Primary Tumor	Illumina HiSeq	51ef343e-2d9c-48c4-9a6f-6c4f0dcac50d	Ovary	50.0	4D5AAF12-A500-4709-9C99-5B9FEF2C79B1	6797443C-EB4A-4654-B957-C0056E5A4206	TCGA-09-2045-01A-01D-A324-10	GRCh37-lite	TCGA-09-2045	TCGA-OV	1069.0	s17170	Baylor College of Medicine	UCSF	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C4	OVCA.Differentiated	0.078582979				-0.6678	-0.1495	-0.2707	-1.1106	1.7729	-0.2658	13.0		0.318889886	1.211781565				49.0		0.0	1.0	2.599301927	14.0	0.9849357559999999	3.360733968	-1437.269566	-1753.445554	1706.7154460000002	1.0	1069.0	1.0	631.0	6.911747300251674	2.2959764777736886	1.0811945126406952	4.386018655943419	1.3808840683916426	3.3923145080845782	-2.525728644308255	-0.9150924093820461	2.311119995443883	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b384	58cfa82fe4b0c9d6adf6b384	TCGA-24-2024-01A-02D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-24-2024-01A-02D-A324-10_wgs_Illumina	TCGA-24-2024-01A-02D-A324-10_wgs_Illumina.bam	798.27	1.8	0.07	58cfa82fe4b0c9d6adf6b384	TCGA-24-2024-01A-02D-A324-10_wgs_Illumina.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-24-2024-01A	0A48873A-092A-4B25-822B-B0B3C18C08A8	Primary Tumor	Illumina HiSeq	03e36495-9e80-442c-bc07-456ee80a47ca	Ovary	72.0	A3F8DCAD-C42A-4070-80C4-782627BBACA2	46F19B5C-3EBA-4B23-A1AB-9748090CA4E5	TCGA-24-2024-01A-02D-A324-10	GRCh37-lite	TCGA-24-2024	TCGA-OV	1769.0	s17944	Baylor College of Medicine	Washington University	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C1	OVCA.Differentiated	0.041457257000000004	0.09	0.0		0.0805	0.142	-0.2128	-0.8171	-0.2406	0.1921			0.9251359440000001	2.946729302	313.0	0.947136929	4.0	59.0	0.8433957940000001	3.5587150519999997	68.0	1.790171779	23.0	0.570937675	3.961961718	-1137.19001	-937.3506612	-107.99515009999999	1.0	1769.0	1.0	421.0	7.996317231796745	2.323244006913118	-0.013492925737445982	5.598421958998374	2.102044090807479	0.9958767596028953	-2.3978952727983707	-0.22119991610563883	1.0093696853403413	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b3a2	58cfa82fe4b0c9d6adf6b3a2	TCGA-24-1419-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-24-1419-01A-01D-A324-10_wgs_Illumina	TCGA-24-1419-01A-01D-A324-10_wgs_Illumina.bam	589.97	1.9	0.09	58cfa82fe4b0c9d6adf6b3a2	TCGA-24-1419-01A-01D-A324-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-24-1419-01A	5E18B17D-4626-4B6D-8AC6-E560CEE0376C	Primary Tumor	Illumina HiSeq	915b863a-f427-4e28-8809-4e9f244f9f4d	Ovary	62.0	92D562DF-4A58-43DA-8811-843D3D3C9438	2F2EAECC-6509-423F-B63A-8C3BEA1BA4A4	TCGA-24-1419-01A-01D-A324-10	GRCh37-lite	TCGA-24-1419	TCGA-OV		s17620	Baylor College of Medicine	Washington University	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Proliferative	0.057877017	0.02	0.11		0.5539999999999999	0.2265	-1.2627	-2.7824	1.2183	-0.4038	20.0		0.23807232399999997	1.190361618	139.0	0.957207675	6.0	28.0					0.0		3.065815389	-1219.2846	286.74399589999996	-1587.257517	0.0	239.0	0.0	239.0	6.049733455231958	2.4220525329993743	-0.24323290668661657	3.6073864198627534	1.5266684859445325	4.599700710183556	-2.4423470353692043	-0.8953840470548418	4.842933616870172	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b3fa	58cfa82fe4b0c9d6adf6b3fa	TCGA-24-1552-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-24-1552-01A-01D-A324-10_wgs_Illumina	TCGA-24-1552-01A-01D-A324-10_wgs_Illumina.bam	719.67	1.9	0.08	58cfa82fe4b0c9d6adf6b3fa	TCGA-24-1552-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-24-1552-01A	62379BE5-13F0-474B-94D3-6F944EC4EE96	Primary Tumor	Illumina HiSeq	5549fe8c-2ced-4cb8-826b-b212f6ba24d5	Ovary	77.0	411B4C26-FCC4-438A-8731-D0CF5DD6C74F	14ED7388-41ED-43D4-AFB2-04CD6410D5D2	TCGA-24-1552-01A-01D-A324-10	GRCh37-lite	TCGA-24-1552	TCGA-OV	1259.0	s17300	Baylor College of Medicine	Washington University	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C4	OVCA.Differentiated	0.029075361	0.09	0.04		1.0479	0.18100000000000002	-0.6196	-1.7569	0.6691	-0.2425	25.0		0.263025067	1.432025365	359.0	0.9457341090000001	14.0	27.0	0.990122631	0.68630071	2.0	2.2718685130000003	10.0	0.986659959	3.396691368	-1232.8673099999999	459.0098343	-2511.076994	1.0	1259.0	1.0	403.0	6.318476592478245	1.317106005319932	-2.4227957351833727	5.420534999272286	2.3451629221831993	0.29640052349166224	-0.8979415932059585	1.0280569168632674	2.719196258675035	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b408	58cfa82fe4b0c9d6adf6b408	TCGA-24-1558-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-24-1558-01A-01D-A324-10_wgs_Illumina	TCGA-24-1558-01A-01D-A324-10_wgs_Illumina.bam	326.97	1.9	0.08	58cfa82fe4b0c9d6adf6b408	TCGA-24-1558-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-24-1558-01A	BA68F2CF-9271-41FD-9655-1FAC7681F588	Primary Tumor	Illumina HiSeq	ff5c5c7d-21a4-4a46-b611-efb7750a4316	Ovary	73.0	3E8BD387-4FDA-4623-924E-314267C55EEA	9020B6A5-8325-4B0D-84D9-04371C857910	TCGA-24-1558-01A-01D-A324-10	GRCh37-lite	TCGA-24-1558	TCGA-OV	594.0	s18117	Baylor College of Medicine	Washington University	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C4	OVCA.Proliferative	0.041680866000000004				0.6653	0.187	-0.62	-1.3858	0.2688	-0.1707					393.0	0.646788212	17.0	39.0				1.7478680969999998	6.0	0.9755037590000001	3.614860306	-1570.569172	-417.4057475	-573.3029836000001	1.0	594.0	1.0	273.0	6.640311468771347	1.7300377545972472	-0.6240695489441077	4.520047932571256	1.3051545606319808	2.299918819751042	-2.120263536200091	-0.4248831939652664	2.9239883686951496	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b440	58cfa82fe4b0c9d6adf6b440	TCGA-24-2290-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-24-2290-01A-01D-A324-10_wgs_Illumina	TCGA-24-2290-01A-01D-A324-10_wgs_Illumina.bam	683.97	1.9	0.08	58cfa82fe4b0c9d6adf6b440	TCGA-24-2290-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-24-2290-01A	2B14123B-8FCD-402C-9399-4E7C47F20252	Primary Tumor	Illumina HiSeq	f1ffb755-85ec-4449-b604-8e9cd194d527	Ovary	56.0	BBFED693-79E1-4DC7-896E-15B98FC7DBAC	FEA5827B-251D-474B-8713-FC76DB995FE7	TCGA-24-2290-01A-01D-A324-10	GRCh37-lite	TCGA-24-2290	TCGA-OV	1102.0	s17878	Baylor College of Medicine	Washington University	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C4	OVCA.Immunoreactive	0.128241729	0.19	0.17		0.8346	0.205	0.3945	-0.778	1.0362	-0.0725			0.670887636	1.661245575	362.0	0.960283343	7.0	72.0	0.834127587	1.832765634	9.0	2.924009467	26.0	0.897459432	2.182674706	-830.1681014999999	443.7782063	1466.949819	1.0	1102.0	1.0	324.0	7.12259780525696	2.643791361129935	0.3011505004310816	5.130167640566754	1.962957440803346	2.062597089731448	-1.9924301646902063	-0.680833920326589	1.7614465893003661	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b524	58cfa82fe4b0c9d6adf6b524	TCGA-29-1705-01A-01D-0926-12_Illumina.filtered.	WGS	TCGA-29-1705-01A-01D-0926-12_Illumina	TCGA-29-1705-01A-01D-0926-12_Illumina.bam	135.7	1.9	0.15	58cfa82fe4b0c9d6adf6b524	TCGA-29-1705-01A-01D-0926-12_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-29-1705-01A	F9C835DB-2AB6-4BF5-826F-48723493C0EC	Primary Tumor	Illumina HiSeq	862f409b-92fe-4bea-95cc-97f8beae4add	Ovary	47.0	FD3E7BA8-21A5-438B-82EE-482ED6905310	6730E18B-CC34-493E-AAE2-54E51D5D9CFF	TCGA-29-1705-01A-01D-0926-12	NCBI36_BCM_variant	TCGA-29-1705	TCGA-OV	555.0	s17530	Baylor College of Medicine	Duke	None	NO			Serous Cystadenocarcinoma		0926-12	True	OV	C4	OVCA.Mesenchymal	0.250474556	0.21	0.2		0.7368	0.2885	0.1289	-0.8574	-0.5206	0.4307	14.0		0.683732277	1.106995115	325.0	0.7941646290000001	6.0	57.0	0.9925403540000001	0.687976548	2.0	3.245427493	28.0	0.973958076	2.65702882	-1441.460592	-162.60049080000002	238.21805330000004	1.0	555.0	1.0	283.0	2.332998800895745	2.1610053021500075	-0.7109805079370775	4.1199296755176045	4.939810489732568	4.288631287074328	1.7869308746218593	2.7788051875825603	4.999611795011406	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b541	58cfa82fe4b0c9d6adf6b541	TCGA-25-2391-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-25-2391-01A-01D-A324-10_wgs_Illumina	TCGA-25-2391-01A-01D-A324-10_wgs_Illumina.bam	896.97	1.9	0.07	58cfa82fe4b0c9d6adf6b541	TCGA-25-2391-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-25-2391-01A	F5033D52-EC36-4E67-88D8-B6D898B81B2F	Primary Tumor	Illumina HiSeq	4c0ed657-169e-4ee1-b8b9-4544a43ed2ee	Ovary	57.0	2179798C-4FD4-4434-B1D5-1453F6054FA2	58FAF969-BF37-4180-8807-2F44F2CC8EDA	TCGA-25-2391-01A-01D-A324-10	GRCh37-lite	TCGA-25-2391	TCGA-OV	1492.0	s17137	Baylor College of Medicine	Mayo Clinic - Rochester	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Differentiated	0.122861755	0.12	0.1		0.6128	0.299	0.0102	-0.7492	1.2599	-0.2958	40.0		0.47890195799999996	2.171022211	280.0	0.9164875229999999	3.0	49.0				3.565537524	40.0	0.966563849	3.504118327	-515.5895779	262.448236	1519.820267	1.0	1492.0	0.0	1492.0	6.78260425716679	1.3889930243674193	1.888397188145528	5.922402991943679	2.755330107058003	2.3000850916919613	-0.8602012652231115	1.3663370826905838	0.41168790354643336	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b5cc	58cfa82fe4b0c9d6adf6b5cc	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted.filtered.	WGS	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted.bam	32.52	1.9	0.13	58cfa82fe4b0c9d6adf6b5cc	TCGA-38-4628-01A-01D-1203_110804_SN208_0217_BC03EKABXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4628-01A	CC4BD56A-25C5-4C48-B583-AC3AEB778CA6	Primary Tumor	Illumina HiSeq	f215f323-8551-4bdc-bce7-17bc9bd45bf4	Lung	65.0	A74F6423-B5D3-4AE2-B61F-3EE04B1073BF	606E6830-C9FB-4107-8BD4-253C193D56B6	TCGA-38-4628-01A-01D-1203-02	HG19_Broad_variant	TCGA-38-4628	TCGA-LUAD	1492.0	s10652	Harvard Medical School	UNC	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	True	LUAD	C4	LUAD.3	0.152455206	0.5	0.32	0.49200492	-0.0921	0.209	0.5049	-0.1006	-0.2032	0.0916	62.0	12.0	0.9191171290000001	3.0538407839999997	329.0	0.757525928	20.0	46.0	0.973139192	1.743631362	6.0	2.138397246	9.0	0.973226528	2.804093675	253.9096423	-919.9677129	2630.39041	1.0	1492.0	1.0	1083.0	4.610898429083178	6.287263587661711	0.4183751763900734	3.8263170425636	5.768469794246544	2.953372211568259	-0.7845813865195774	-0.5187937934151678	2.5349970351781854	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b5dc	58cfa82fe4b0c9d6adf6b5dc	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted.bam	111.7	1.9	0.15	58cfa82fe4b0c9d6adf6b5dc	TCGA-50-5939-01A-11D-1623_120302_SN208_0271_BC0D91ACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5939-01A	12B79B4F-C28C-418E-A1E7-E622F33FDCC2	Primary Tumor	Illumina HiSeq	7a3d6187-a909-4946-83bf-0d6fc6a753ee	Lung	85.0	6A27F5F8-F4EE-45C7-B953-DDD7D0291DBB	08D803D0-A294-4F70-9560-563357172BBB	TCGA-50-5939-01A-11D-1623-02	HG19_Broad_variant	TCGA-50-5939	TCGA-LUAD	460.0	s11007	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1623-02	True	LUAD	C1	LUAD.6	0.45048425700000005	0.62	0.17	13.626411	0.1158	0.0295	0.8781	1.237	0.0707	0.6289	35.0	4.0	0.550471526	2.048977348	119.0	0.238353433	7.0	35.0	0.8873604759999999	4.70151742	200.0	2.6156305769999997	14.0	0.99112306	3.1062414830000002	238.8044249	175.1137158	2558.210697	1.0	460.0	0.0	460.0	7.6335676411665965	9.044176799779976	-0.6898304279339513	7.113692181880689	8.112618595775032	1.1460788259070334	-0.5198754592859083	-0.9315582040049435	1.8359092538409847	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b5f0	58cfa82fe4b0c9d6adf6b5f0	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted.filtered.	WGS	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted.bam	168.4	2.0	0.15	58cfa82fe4b0c9d6adf6b5f0	TCGA-50-5933-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5933-01A	7A0EA814-F0DE-4BC4-A81A-DAA000559369	Primary Tumor	Illumina HiSeq	ca97b42b-d723-4c0a-8f71-819eca1bb805	Lung	72.0	D2355F3A-E2CE-4791-B1FB-B570850681DF	1D83B47D-66A8-4AE9-81BB-BDC03FA64AC6	TCGA-50-5933-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5933	TCGA-LUAD	2393.0	s11009	Harvard Medical School	University of Pittsburgh	United States	NO	T4	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIB	1751-02	True	LUAD	C6	LUAD.3	0.365416423	0.7	0.33		0.302	0.026000000000000002	1.0483	0.3428	0.149	0.6071	221.0	136.0	4.011924665	13.47516681	146.0	0.49247298100000003	19.0	25.0	0.926706756	2.678527035	18.0	2.890371758	18.0	1.0	2.7691128139999996	121.98713980000001	50.88663197	1901.2922760000001	1.0	2393.0	0.0	2393.0	7.031652915638374	7.488954638584733	-0.6149507347316775	6.002033498457216	8.228621834779572	1.916383350956853	-1.029619417181158	0.739667196194838	2.5313340856885307	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b5fe	58cfa82fe4b0c9d6adf6b5fe	TCGA-36-1574-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-36-1574-01A-01D-A324-10_wgs_Illumina	TCGA-36-1574-01A-01D-A324-10_wgs_Illumina.bam	475.97	1.9	0.08	58cfa82fe4b0c9d6adf6b5fe	TCGA-36-1574-01A-01D-A324-10_wgs_Illumina.bam	Alive	FEMALE	ASIAN		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-36-1574-01A	EEB9D147-608D-4692-8ADF-2F601D23A8FF	Primary Tumor	Illumina HiSeq	e3ba53fc-a70c-4bd4-8dc4-60969af737fa	Ovary	48.0	353B6C00-EBFE-4650-8379-F46C8FE3E9CF	80F02AEC-C07A-4BCB-B547-E60F8C33A7B1	TCGA-36-1574-01A-01D-A324-10	GRCh37-lite	TCGA-36-1574	TCGA-OV		s17538	Baylor College of Medicine	BC Cancer Agency	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Immunoreactive	0.067604575				0.9089	0.3955	0.0811	-0.5961	1.4219	0.273					330.0	0.938823834	6.0	63.0	0.8141861090000001	1.9523330230000002	11.0	3.652629783	40.0	0.990173257	2.481495703	-827.7932281000001	755.1770176	-1844.181996	0.0	686.0	1.0	648.0	6.002033498457216	3.1209596322729896	-1.3461042848642495	3.832979798087693	2.2538958411639856	1.360619656096607	-2.169053700369523	-0.867063791109004	2.7067239409608566	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b60d	58cfa82fe4b0c9d6adf6b60d	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted.bam	387.4	1.9	0.15	58cfa82fe4b0c9d6adf6b60d	TCGA-38-4631-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4631-01A	2483621A-4DB3-41AB-AA33-B9427EA8A0AF	Primary Tumor	Illumina HiSeq	b1dd06d4-cd7d-4e62-8deb-12fed31731b5	Lung	72.0	13B0D336-205A-42AC-8A50-DB0EB065013D	B1FA802A-C88E-4B8D-88FF-4545DCF326DE	TCGA-38-4631-01A-01D-1751-02	HG19_Broad_variant	TCGA-38-4631	TCGA-LUAD	354.0	s11229	Harvard Medical School	UNC	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C2	LUAD.6	0.31096098899999997	0.51	0.65	4.265981368	0.8282	0.564	0.0869	0.5354	0.8751	-0.1696	314.0	229.0	5.860813514	19.61702347	316.0	0.6140737620000001	16.0	42.0	0.882721816	4.0198064769999995	95.0	1.791759469	6.0	1.0	6.82378843	-995.5703424000001	-278.5579141	-3579.417429	1.0	354.0	1.0	354.0	6.0369158100119	6.733452910944025	-0.16422740432052296	5.033776315995209	4.915840062889637	1.1464169176683572	-1.0031394940166907	-1.817612848054388	1.3106443219888804	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b624	58cfa82fe4b0c9d6adf6b624	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted.filtered.	WGS	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted.bam	692.7	1.9	0.15	58cfa82fe4b0c9d6adf6b624	TCGA-75-5146-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_5_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-5146-01A	1D276B62-5E64-48FB-B2CE-5192B511FE37	Primary Tumor	Illumina HiSeq	926ac8ca-ff8f-4822-bf62-819bf5525a5d	Lung		373C5231-B6AE-49DB-AC0D-D674A0C9C100	2578C781-0BDF-4CA2-A8FA-8B624489818B	TCGA-75-5146-01A-01D-1623-02	HG19_Broad_variant	TCGA-75-5146	TCGA-LUAD		s10668	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	True	LUAD	C2	LUAD.5	0.270856033	0.42	0.18	9.721115538	-0.7824	0.045	0.6121	1.7552	-0.0776	-0.4172	82.0	124.0	1.5851050359999999	5.090625789	191.0	0.793192646	8.0	18.0	0.954134413	2.0964475819999997	9.0	3.2331834839999996	26.0	0.9923534940000001	2.128916498	341.0651328	-733.6537860000001	1949.4133550000001	0.0	2368.0	1.0	1773.0	7.553361514773082	6.701345926659093	-0.12960725416838825	6.454749226104973	6.456223468626108	3.2854471621551937	-1.0986122886681098	-0.24512245803298516	3.415054416323582	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b62c	58cfa82fe4b0c9d6adf6b62c	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.bam	237.4	1.9	0.16	58cfa82fe4b0c9d6adf6b62c	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-50-5941-01A	F3F024C2-52F1-400E-946C-398F5B72E6DC	Primary Tumor	Illumina HiSeq	f7c353bf-7be8-42d0-88d0-e89032718c2f	Lung	55.0	91719392-76CE-479F-BA05-E43BF0201CC4	666720AF-64D9-4A63-BE57-2B8E49E79413	TCGA-50-5941-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5941	TCGA-LUAD		s11128	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	True	LUAD	C2	LUAD.5	0.44653042200000004	0.73	0.64		0.1331	0.039	1.298	2.1424	1.3185	0.3276	195.0	123.0	2.7801187080000003	9.894831099	164.0	0.5345951729999999	27.0	29.0	0.8838353390000001	3.804084833	74.0	4.0601572180000005	64.0	0.9762614470000001	1.912808281	88.09969435	-287.8586325	1567.101182	0.0	1474.0	0.0	1474.0	6.950814768442584	6.62398860825421	0.37841857554753655	6.257667587882638	6.911670680705991	2.2935175582024523	-0.6931471805599454	0.28768207245178123	1.9150989826549156	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b62e	58cfa82fe4b0c9d6adf6b62e	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted.bam	304.4	1.9	0.16	58cfa82fe4b0c9d6adf6b62e	TCGA-75-6206-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_5_rg.sorted.bam	Alive	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-6206-01A	C4C1469D-752F-42B6-8686-714AD4A8AC97	Primary Tumor	Illumina HiSeq	2b0c2142-3073-4443-9998-a7e909add85d	Lung		4AFC6152-819B-4E55-817D-DF8A42EB0D36	B6836DCC-F7D7-45BF-AE7C-DE6F2140779E	TCGA-75-6206-01A-11D-1751-02	HG19_Broad_variant	TCGA-75-6206	TCGA-LUAD		s11131	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C3		0.122679154			1.09921242	-1.7797	-0.354	0.5161	-0.0099	0.0121	0.0636	53.0	1.0	0.5528639439999999	2.426458422	111.0	0.420275799	14.0	14.0	0.705637638	1.26433292	6.0	2.397895273	11.0	1.0	1.119200277	583.2810253	-1225.075131	4640.64801	0.0	2590.0	0.0	2590.0	7.161658944884925	7.171560812015237	-0.5933040553697557	6.804984000946192	7.473229126441757	1.9898798935679163	-0.35667494393873245	0.30166831442652065	2.583183948937672	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b648	58cfa82fe4b0c9d6adf6b648	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.bam	237.4	1.9	0.13	58cfa82fe4b0c9d6adf6b648	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-86-6562-01A	DCD066BA-5894-453E-B1DA-82092858C3DB	Primary Tumor	Illumina HiSeq	71d960e2-40e8-4084-bcc1-5ebbefc183af	Lung	52.0	DE4BB1D0-8BD9-4614-85CA-C39D8C636BCC	3AB9FD95-4329-4DD3-823D-F2E050CBA3C1	TCGA-86-6562-01A-11D-1751-02	HG19_Broad_variant	TCGA-86-6562	TCGA-LUAD		s11014	Harvard Medical School	Asterand	Russia	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	True	LUAD	C6	LUAD.3	0.19516963699999998	0.54	0.25	0.22734489100000002	-0.0838	-0.106	0.5357	0.4384	0.3181	0.5408	21.0		0.390818107	1.202517253	111.0	0.51425325	13.0	16.0	0.9626383409999999	2.115132621	9.0	2.540036304	13.0	0.990287117	2.1593990780000003	37.12008777	-112.39669209999998	2700.887691	1.0	376.0	1.0	274.0	6.728943345721927	8.693790060073326	-0.16322925689835976	5.784116306582837	7.084352147639226	2.5417599125426262	-0.9448270391390894	-1.6094379124341	2.704989169440986	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b64a	58cfa82fe4b0c9d6adf6b64a	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.filtered.	WGS	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.bam	337.2	1.9	0.15	58cfa82fe4b0c9d6adf6b64a	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4662-01A	294FF941-AEA1-4588-9A0E-E9F5393E2BB6	Primary Tumor	Illumina HiSeq	bb68d6e1-efca-4ccb-bbd6-45c4da207bb7	Lung	65.0	C7D727B6-47C6-4339-B9DD-5BAF41527BD4	DCC0A32E-EF17-4AA8-8321-A03137A61D72	TCGA-73-4662-01A-01D-1203-02	HG19_Broad_variant	TCGA-73-4662	TCGA-LUAD		s10663	Harvard Medical School	Roswell Park	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	True	LUAD	C3	LUAD.3	0.30101377100000004	0.52	0.26	5.680388579	-0.5629	-0.099	0.8098	1.6729	0.0622	0.0869	90.0	64.0	1.5342558259999999	5.745938486	190.0	0.675318042	10.0	36.0	0.87782023	4.141993766000001	112.0	4.55456403	99.0	0.9911741540000001	1.923729808	368.1024585	-645.5503152000001	3487.3238229999997	0.0	2515.0	1.0	21.0	8.054734361787952	7.156065198242745	-0.5530898054998569	6.668440000668062	6.617068697510058	1.9433198468442758	-1.3862943611198904	-0.5389965007326873	2.496409652344133	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b64b	58cfa82fe4b0c9d6adf6b64b	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted.bam	392.4	1.9	0.15	58cfa82fe4b0c9d6adf6b64b	TCGA-75-5126-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_5_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-5126-01A	93766482-2F20-4C8F-BBD8-BDD203C37D5A	Primary Tumor	Illumina HiSeq	8c670948-9cf1-4db3-82d5-39ed824c61ff	Lung		39509EA1-E728-4350-B444-798C72ADE33A	7BCB1D5A-871F-472E-A964-9B68259D9716	TCGA-75-5126-01A-01D-1751-02	HG19_Broad_variant	TCGA-75-5126	TCGA-LUAD		s11251	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T3	N2	Lung Papillary Adenocarcinoma	Stage IIIA	1751-02	True	LUAD	C4	LUAD.6	0.473820003	0.76	0.51	2.179409697	0.3646	0.1585	1.5019999999999998	1.0558	0.8612	0.3769	338.0	409.0	5.1435470180000005	16.09627655	94.0	0.201161587	7.0	17.0	0.846239739	0.586568689	2.0	2.83094043	18.0	0.979438172		531.6884364	-142.76156799999998	548.6406836	0.0		0.0		10.213093702837881	9.08452823798524	0.376051222901871	8.609555512530967	8.790767119457076	1.8562611382715017	-1.603538190306912	-0.2937611185281632	1.4802099153696306	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b657	58cfa82fe4b0c9d6adf6b657	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.bam	702.7	1.9	0.15	58cfa82fe4b0c9d6adf6b657	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5778-01A	8FDBD88F-19AE-4AB8-BCD7-6BFA1BBDE742	Primary Tumor	Illumina HiSeq	bd5570f2-ed45-408a-a615-0a6808c31d84	Lung	60.0	92514FD2-A178-42E8-8929-0910558E7F87	BC8FFDB4-AB99-44B7-95B0-7BC2F8110B76	TCGA-64-5778-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5778	TCGA-LUAD		s10796	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Bronchioloalveolar Carcinoma Nonmucinous	Stage IB	1623-02	True	LUAD	C2	LUAD.5	0.316319533	0.41	0.15	9.708212037000001	0.0513	0.2185	0.9693	2.4054	1.4993	-0.2758	184.0	193.0	3.4024458760000003	12.80556902	116.0	0.8392103959999999	9.0	27.0	0.931258989	3.872997256	64.0	4.415035405	91.0	0.978757019	2.279322074	471.97672769999997	-737.069254	2159.740089	0.0	1305.0	1.0	962.0	6.091498401260084	7.031339636202606	0.5628667389918318	4.912843404918438	6.826545223556593	2.35345798378796	-1.178654996341646	-0.2047944126460135	1.7905912447961283	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b668	58cfa82fe4b0c9d6adf6b668	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.filtered.	WGS	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.bam	245.7	1.9	0.14	58cfa82fe4b0c9d6adf6b668	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-6642-01A	474B86D9-D897-467D-85D4-51DFA26EA107	Primary Tumor	Illumina HiSeq	9b12800d-6911-4d3f-a25e-4d1b686b63aa	Lung	63.0	08D8F333-08F9-4268-99B7-61F7B057F542	93AF51CC-26FF-4904-84BC-2DFFB317D86A	TCGA-55-6642-01A-11D-1853-02	HG19_Broad_variant	TCGA-55-6642	TCGA-LUAD		s11552	Harvard Medical School	International Genomics Consortium	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True	LUAD	C3	LUAD.2	0.369819356	0.63	0.39	9.642930222999999	-0.1457	-0.0875	0.6363	1.5944	-0.0118	0.6706	45.0	141.0	1.063123112	3.248431731	98.0	0.39832252700000004	12.0	34.0	0.873926368	5.702395469	682.0	3.244461365	29.0	0.963521332	2.66409517	-64.11983347	399.4169027	1109.602027	0.0	2449.0	0.0	2449.0	6.446116566068028	8.847924490550023	-0.7297047762937428	6.105189979097435	7.1431763983115975	0.7515579427163597	-0.3409265869705931	-1.7047480922384257	1.4812627190101024	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b66c	58cfa82fe4b0c9d6adf6b66c	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.bam	242.4	1.9	0.14	58cfa82fe4b0c9d6adf6b66c	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-50-5946-01A	C95957A7-1A1A-4C8D-BB61-7C99B500F224	Primary Tumor	Illumina HiSeq	b7f024ff-9569-4d31-b652-ffc2ceaa2789	Lung	62.0	AD9A794F-52DD-4572-BF29-CD3D11BA6C24	F9F38A15-2964-4AE0-90AA-E5F3F7461AB3	TCGA-50-5946-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5946	TCGA-LUAD		s10790	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma Mixed Subtype	Stage IA	1751-02	True	LUAD	C2		0.068325795	0.25	0.48	18.16596489	0.9896	0.1055	-0.3455	-0.034	0.5532	-0.0503	190.0		2.7818640439999998	8.437301936	138.0	0.891684493	17.0	32.0	0.909725695	2.812000743	22.0	2.043191871	8.0	0.982567593	5.733293502	-235.8700952	483.04330880000003	1608.485871	0.0	1617.0	1.0	221.0	5.43580399508606	7.41683392312199	0.3158979448064577	5.723486067537841	8.022969726692306	3.863357833446865	0.2876820724517808	0.6061358035703157	3.5474598886404074	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b674	58cfa82fe4b0c9d6adf6b674	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.bam	406.7	1.9	0.14	58cfa82fe4b0c9d6adf6b674	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-71-6725-01A	4B7CD595-E7F9-45A8-B736-A8C7C42D9539	Primary Tumor	Illumina HiSeq	9c1abbc4-5f6b-486c-a6a3-17a01c8783cb	Lung	48.0	83973755-FA6A-460A-A042-385B34698C39	1AD7566E-B9DD-43A3-94DC-96F525007EAA	TCGA-71-6725-01A-11D-1853-02	HG19_Broad_variant	TCGA-71-6725	TCGA-LUAD		s11554	Harvard Medical School	ILSbio	Vietnam	NO	T2	N0	Lung Papillary Adenocarcinoma	Stage IB	1853-02	True	LUAD	C4	LUAD.3	0.24839929300000002	0.37	0.2	0.633252635	-0.5183	-0.114	-0.1407	-1.3718	0.1979	-0.2364	27.0	1.0	0.47144907399999997	1.2964849520000001	210.0	0.929285035	19.0	42.0					0.0		1.892587585	-354.3393788	-721.759596	193.0592178	0.0	256.0	1.0	164.0	2.245821620476102	5.439708415989987	0.16303341700941587	1.1579726451099805	3.5520076530205973	1.982542799190373	-1.0878489753661214	-1.8877007629693892	1.8195093821809571	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b676	58cfa82fe4b0c9d6adf6b676	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	375.23	1.9	0.16	58cfa82fe4b0c9d6adf6b676	TCGA-73-4666-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4666-01A	4C31127E-D095-4978-9DAC-35153C27F6ED	Primary Tumor	Illumina HiSeq	7af89597-2a6c-4030-acf6-4bd33963a3f3	Lung	52.0	5BAE2E45-6DBC-458C-A66F-702EB1AF7357	AC0D75F8-B4C5-40A8-9044-0B74722424D8	TCGA-73-4666-01A-01D-1203-02	GRCh37	TCGA-73-4666	TCGA-LUAD		s11461	Harvard Medical School	Roswell Park	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1203-02	True	LUAD	C2		0.334216293	0.55	0.28	5.457914017	0.9568	0.24	1.0713	1.1073	0.3996	-0.0069	169.0	123.0	3.05983989	9.44179166	104.0	0.638753848	20.0	17.0	0.91638359	3.0202508210000003	27.0	3.27304198	67.0	0.778425982	1.6077988669999999	-44.99235381	596.1566664	2470.544598	0.0	800.0	0.0	800.0	8.285064953974995	7.660768623867699	0.5164833474858495	7.0645628476978475	6.639117376335717	1.7931709020664626	-1.2205021062771468	-1.0216512475319814	1.2766875545806131	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b678	58cfa82fe4b0c9d6adf6b678	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	343.9	1.9	0.16	58cfa82fe4b0c9d6adf6b678	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4670-01A	1B354837-4925-4480-AC32-6B44D0957314	Primary Tumor	Illumina HiSeq	8e4449ab-641c-44ea-af17-a681182f7299	Lung	69.0	646402AF-BA5F-438C-AE63-213EBD58B16D	D2FFA731-14A2-4A83-964E-C9969080263C	TCGA-73-4670-01A-01D-1203-02	GRCh37	TCGA-73-4670	TCGA-LUAD		s11356	Harvard Medical School	Roswell Park	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1203-02	True	LUAD	C1		0.181372195	0.38	0.26	6.593572332999999	0.6394	0.315	0.0377	0.0601	-0.3871	0.447	184.0	179.0	2.4586418119999998	8.851110524	272.0	0.7045332879999999	24.0	27.0	0.859831143	3.6153256610000004	67.0	2.3419942519999997	11.0	0.9766874640000001	4.3319466680000005	-1118.734862	-395.3038414	2915.962761	0.0	131.0	0.0	131.0	7.599267790865621	7.873869654407329	0.20814458790443469	6.696400079323608	6.208861890818419	2.127305136406095	-0.9028677115420143	-1.6650077635889111	1.9191605485016603	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b67d	58cfa82fe4b0c9d6adf6b67d	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	142.53	1.9	0.14	58cfa82fe4b0c9d6adf6b67d	TCGA-49-4486-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4486-01A	61C655EC-52B5-453F-A6CC-B2ABA445B027	Primary Tumor	Illumina HiSeq	cb4d8cf1-9903-481c-8ba1-df0586b69916	Lung	72.0	5AE9B10F-347C-48C3-90CD-9290055CFE4B	EC0EE49C-D1D4-490D-BA82-CFAE6D451B8D	TCGA-49-4486-01A-01D-1203-02	GRCh37	TCGA-49-4486	TCGA-LUAD	2318.0	s10907	Harvard Medical School	Johns Hopkins	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	True	LUAD	C3	LUAD.1	0.091577638	0.27	0.1	0.644325322	-1.1296	0.0315	-0.6073	0.1189	-0.8323	-0.9281	74.0	35.0	1.575225004	3.6259896310000004	208.0	0.14684154800000002	1.0	9.0	0.956955345	1.989932697	8.0	2.5649493569999997	13.0	1.0	1.351237891	43.81513815	-1235.571391	3268.440929	1.0	2318.0	1.0	2045.0	9.9057765973396	6.897026286841984	0.27174473315292724	8.142188005078241	7.635983003433223	2.0560912699918568	-1.7635885922613586	0.7389567165912392	1.7843465368389295	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b680	58cfa82fe4b0c9d6adf6b680	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted.filtered.	WGS	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted.bam	195.4	1.9	0.14	58cfa82fe4b0c9d6adf6b680	TCGA-49-4488-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4488-01A	D721BFE0-90E3-415E-B9F3-1A270EFA5FBB	Primary Tumor	Illumina HiSeq	26421230-2518-42aa-85ee-f9c83d47a6ba	Lung	74.0	1AEA8530-43FD-47EA-A2F1-377267DC9D33	DA0D3199-053B-4789-A217-CA2BFB83D57E	TCGA-49-4488-01A-01D-1751-02	HG19_Broad_variant	TCGA-49-4488	TCGA-LUAD	869.0	s11236	Harvard Medical School	Johns Hopkins	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True	LUAD	C2	LUAD.3	0.23271017300000002	0.55	0.51		0.037000000000000005	0.073	0.4484	1.2728	0.2446	-0.0332	134.0	91.0	2.305942989	7.919093684	311.0	0.778496744	22.0	59.0	0.9166366159999999	2.7459978919999997	20.0	2.813355405	17.0	0.9929910190000001	2.5365069940000002	779.3671347999999	-891.9394091	2191.501933	1.0	869.0	1.0	634.0	8.00252686826431	7.251001753576499	-0.03358062005428508	7.012128164236433	6.7053073041596845	1.354488364423974	-0.9903987040278763	-0.5456944494168141	1.3880689844782592	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b687	58cfa82fe4b0c9d6adf6b687	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.bam	164.4	1.9	0.16	58cfa82fe4b0c9d6adf6b687	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6148-01A	8994C8C4-9EA0-46CB-B4A5-0055D7DA5BFA	Primary Tumor	Illumina HiSeq	e3f95d46-09ce-43a0-a2c7-581cb9fe8da9	Lung	60.0	C0FE5FFE-C0A3-4E62-AA55-2BC18788E505	F8A1C395-E730-48F9-BF82-E8931E4AF154	TCGA-44-6148-01A-11D-1751-02	HG19_Broad_variant	TCGA-44-6148	TCGA-LUAD		s10995	Harvard Medical School	Christiana Healthcare	United States	NO	T1b	N0	Lung Mucinous Adenocarcinoma	Stage IA	1751-02	True	LUAD	C3		0.177418319			14.65739562	-1.8732	-0.3625	0.6746	1.125	-0.2376	0.1702	2.0		0.061515039	0.12303007699999999	67.0	0.027558316	2.0	0.0	0.931206842	3.387345119	38.0	2.2718685130000003	10.0	0.986659959	2.9091360739999996	-29.48103552	-1189.900777	1324.908509	0.0	704.0	0.0	704.0	7.056276698836059	8.337605038325426	0.18263072359190347	6.392982481425795	8.373972682496301	2.313463211141229	-0.6632942174102641	0.03636764417087468	2.130832487549325	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b691	58cfa82fe4b0c9d6adf6b691	TCGA-36-1570-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-36-1570-01A-01D-A324-10_wgs_Illumina	TCGA-36-1570-01A-01D-A324-10_wgs_Illumina.bam	286.97	1.9	0.09	58cfa82fe4b0c9d6adf6b691	TCGA-36-1570-01A-01D-A324-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-36-1570-01A	0F530B3E-5B6D-4892-9EBD-9138D76FDCA7	Primary Tumor	Illumina HiSeq	7bd2e9c4-4e02-4a02-83d2-c1da3a047b3a	Ovary	49.0	22B7E0E2-334C-419C-A243-358BA22E479A	A2F38E9E-48B2-4463-B2E3-61CC8475257F	TCGA-36-1570-01A-01D-A324-10	GRCh37-lite	TCGA-36-1570	TCGA-OV		s18070	Baylor College of Medicine	BC Cancer Agency	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C4	OVCA.Differentiated	0.047691625999999994				0.7354	0.309	-0.3618	-1.5718	1.7838	-0.4803					392.0	0.495224712	5.0	59.0				2.7502140010000002	18.0	0.9515087440000001	3.801737661	-1687.7720379999998	-382.621334	170.9739279	0.0	655.0	1.0	375.0	7.215975002651466	2.737288883829737	0.5229740585223221	4.773627967282262	2.136160601990044	3.4573243358954415	-2.4423470353692043	-0.601128281839693	2.9343502773731194	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b6aa	58cfa82fe4b0c9d6adf6b6aa	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.bam	62.7	1.9	0.17	58cfa82fe4b0c9d6adf6b6aa	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6774-01A	33C71EAD-4C2A-476D-85EF-885DBBFC2CBD	Primary Tumor	Illumina HiSeq	5ff8e7e5-3b91-49af-b384-9d870bd9e425	Lung	56.0	79CF84B5-84FF-42E5-B438-697B35D272FC	6B977266-994D-4440-BC09-59FD8737F2D0	TCGA-44-6774-01A-21D-1853-02	HG19_Broad_variant	TCGA-44-6774	TCGA-LUAD		s10996	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True	LUAD	C1	LUAD.2	0.375200885	0.55	0.49	2.674586506	-0.2189	-0.111	0.7288	0.7294	0.3016	0.9725	81.0	7.0	2.19017705	7.319802247	136.0	0.32798056800000003	4.0	14.0	0.565158653	2.294794502	58.0	3.040727294	22.0	0.983722269	1.579929616	349.9317339	192.6167943	-564.3049782	0.0	658.0	0.0	658.0	6.463133455672779	7.043790478907883	-0.7770919200015685	5.952307831906788	6.7986680208748975	2.7677445338552533	-0.5108256237659905	-0.24512245803298516	3.544836453856822	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b6b7	58cfa82fe4b0c9d6adf6b6b7	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.bam	555.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6b7	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5781-01A	41C4C704-825E-49F5-9D54-DBD7D30725E0	Primary Tumor	Illumina HiSeq	901f4776-2659-4626-abec-5a9323e6f75e	Lung	55.0	B32F509D-91E5-4601-B8B3-4B0A5212C22B	69DEF564-A4D8-4820-9ED6-F17AF2CAB0A7	TCGA-64-5781-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5781	TCGA-LUAD		s11352	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1623-02	True	LUAD	C1	LUAD.6	0.41173546899999997	0.62	0.34	28.48555229	0.1315	0.2315	0.3987	1.9334	0.3786	0.3925	385.0	406.0	9.386768661	30.41313046	37.0	0.37091669	9.0	15.0	0.7700695009999999	2.6925538319999998	33.0	3.042475876	23.0	0.970333755	2.660290329	11.24031264	-434.58440010000004	318.33122389999994	0.0	1559.0	1.0	96.0	5.8986980045138555	5.129379531068412	0.21461051627626093	5.339082216578433	5.508869152773316	0.9404204398619908	-0.5596157879354227	0.37948962170490397	0.7258099235857298	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b6be	58cfa82fe4b0c9d6adf6b6be	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.filtered.	WGS	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.bam	127.4	1.9	0.15	58cfa82fe4b0c9d6adf6b6be	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-6543-01A	E68219B0-A9C2-49DF-8F0D-DB5EA97FD2DC	Primary Tumor	Illumina HiSeq	0715b83e-fcd8-41e9-88ac-cfeb5fabd3de	Lung	60.0	8D9491E7-9B14-4988-8FA7-E6AF041120BD	1D88DA12-E71A-4F44-8D71-DA8957BDFCD4	TCGA-55-6543-01A-11D-1751-02	HG19_Broad_variant	TCGA-55-6543	TCGA-LUAD		s10791	Harvard Medical School	International Genomics Consortium	United States	NO	T1b	N0	Lung Bronchioloalveolar Carcinoma Mucinous	Stage IA	1751-02	True	LUAD	C3	LUAD.5	0.18790563899999999	0.35	0.0	2.199477767	-1.1502	-0.153	0.8145	0.2996	0.1477	0.3165	13.0	38.0	0.12050144	0.632632561	70.0	0.356415372	9.0	4.0	0.908136924	2.572945651	17.0	2.3025850930000002	10.0	1.0	1.326564768	-768.0306126	-1067.60691	796.7847415	0.0	435.0	0.0	435.0	6.720642261452053	7.246368080102462	0.016317619105948866	6.027495080892107	7.112836687477939	2.7342036220098667	-0.6931471805599454	-0.13353139262452274	2.717886002903918	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b6d2	58cfa82fe4b0c9d6adf6b6d2	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.bam	472.3	1.9	0.15	58cfa82fe4b0c9d6adf6b6d2	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3396-01A	3BD6BADB-27FF-4D8D-B206-4D28DC264862	Primary Tumor	Illumina HiSeq	bf55243b-c7c6-46fc-9d54-e1916b0d7ea2	Lung	74.0	B560DF97-986B-4A88-A0F1-C38A30080EDB	ECCC6A5C-BB25-4591-996A-EE2A7507F771	TCGA-44-3396-01A-01D-1203-02	HG19_Broad_variant	TCGA-44-3396	TCGA-LUAD		s10653	Harvard Medical School	Christiana Healthcare	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True	LUAD	C2	LUAD.6	0.5650211589999999	0.76	0.16	6.3803451739999995	0.214	0.1555	1.227	1.7723	0.33799999999999997	0.6029	80.0	16.0	1.5610944830000002	4.967118809	111.0	0.160760972	6.0	10.0	0.8715762690000001	4.859864915	264.0	4.476237911	96.0	0.980695978	4.521725677	-110.0823496	-295.4203149	-75.55791497	0.0	1130.0	0.0	1130.0	5.280483223050919	6.111610380555704	-0.40247881567575505	5.186454273402643	6.079861682241123	1.5347685829423436	-0.09402894964827624	-0.03174869831458027	1.9372473986180987	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b6d8	58cfa82fe4b0c9d6adf6b6d8	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.filtered.	WGS	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.bam	168.4	1.9	0.14	58cfa82fe4b0c9d6adf6b6d8	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5942-01A	75DD635E-8E0C-4C0B-B21C-20F77770218D	Primary Tumor	Illumina HiSeq	915fe8ed-278a-43fb-90cd-986d5c65e9ad	Lung	67.0	AED669E8-23B6-4786-9398-6BB048815DFA	8DC8F884-F58B-4EFA-AE96-C87AB7F6D991	TCGA-50-5942-01A-21D-1751-02	HG19_Broad_variant	TCGA-50-5942	TCGA-LUAD		s10794	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True	LUAD	C3	LUAD.4	0.14045702300000001	0.31	0.0	3.6842860219999998	-1.5752	-0.361	0.3612	1.04	0.0151	0.187	31.0	14.0	0.394405725	1.607961802	65.0	0.048331199000000005	2.0	4.0	0.869858875	3.811744758	80.0	3.17805383	24.0	1.0	2.044227592	-402.8065735	-933.2839436	4007.5601049999996	0.0	1847.0	1.0	1378.0	7.393746494390925	6.914044981079661	-0.5282154702561763	6.700599313830979	7.473660769015083	2.925914886423242	-0.6931471805599454	0.5596157879354227	3.4541303566794186	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b6dc	58cfa82fe4b0c9d6adf6b6dc	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted.filtered.	WGS	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted.bam	190.4	1.9	0.15	58cfa82fe4b0c9d6adf6b6dc	TCGA-50-5935-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5935-01A	100430C8-1446-45C8-AF36-B6DBB3DDD0C1	Primary Tumor	Illumina HiSeq	f4ad5c7d-a36e-4d9a-9c36-444e4b443953	Lung	86.0	98687ADB-F8E9-4E6E-BC1B-396A3DDFAC96	6F0D56B0-E246-4566-AFFB-B8DD5E88B5BA	TCGA-50-5935-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5935	TCGA-LUAD	653.0	s10908	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True	LUAD	C3	LUAD.4	0.19445574699999998	0.61	0.22		-0.9375	-0.1845	0.5870000000000001	1.038	0.3166	0.0999	41.0	5.0	0.573643941	2.536110056	140.0	0.50264096	16.0	13.0	0.8031197240000001	2.05996142	13.0	3.528141868	35.0	0.992347812	2.91191553	-4.088510884	-915.9038224	1981.353559	1.0	653.0	0.0	653.0	7.004579463617677	6.162542576118839	-0.17823916107039894	6.055498908920531	7.12139292241179	3.6160421301616696	-0.9490805546971459	0.9588503462929507	3.7942812912320685	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b6f8	58cfa82fe4b0c9d6adf6b6f8	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted.bam	245.4	1.8	0.13	58cfa82fe4b0c9d6adf6b6f8	TCGA-50-6593-01A-11D-1751_120105_SN1120_0107_AC054PACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6593-01A	E10568FE-0436-43F2-9F0F-48F9903868C4	Primary Tumor	Illumina HiSeq	f552d49e-eaf1-4d8f-bd11-0f2017c95ba3	Lung	49.0	3B2ED302-D8F1-4078-95F0-3B5C5B322DEB	BC00F0B2-D91E-444A-91A4-08AC5F09CA1F	TCGA-50-6593-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-6593	TCGA-LUAD	336.0	s11456	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	True	LUAD	C1	LUAD.3	0.288503946	0.69	0.26	2.8339611710000003	0.1201	0.07400000000000001	0.8365	0.5155	-0.1463	0.64	136.0	111.0	2.555572055	8.366456133	126.0	0.795681692	25.0	28.0	0.910786386	2.525236063	16.0	2.197224577	9.0	1.0	2.174245542	224.36018430000004	-461.779823	1810.910032	1.0	336.0	1.0	266.0	5.851282516508119	6.15180141012938	-0.8672165672883273	5.604422438576593	7.068092142003534	0.7830231883294905	-0.24686007793152598	0.9162907318741547	1.6502397556178177	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b6fc	58cfa82fe4b0c9d6adf6b6fc	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.bam	218.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6fc	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-6712-01A	F17D3463-AF6C-42C2-A8E9-FAE45F69286F	Primary Tumor	Illumina HiSeq	fb1682cf-0fca-4bf1-963d-67a3a177fe98	Lung	71.0	EA75499C-7BF0-47BE-9B09-3C12AAA22F12	61ADB041-60CE-4263-BEB3-33A4DBBA217B	TCGA-55-6712-01A-11D-1853-02	HG19_Broad_variant	TCGA-55-6712	TCGA-LUAD		s11345	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1853-02	True	LUAD	C3	LUAD.3	0.473691774	0.71	0.39	0.007646429000000001	0.0936	-0.061	1.0001	1.9617	0.4376	0.4685	56.0	16.0	1.60931879	3.33784638	137.0	0.440322279	18.0	27.0	0.952495807	2.986545094	23.0	3.6600032089999996	42.0	0.979220633	2.512057696	166.0181301	232.89654240000002	214.950132	1.0	171.0	1.0	171.0	2.8616404998556844	6.91901309981785	-0.16351269096640741	1.6197406436176873	4.952900243445018	3.447780526617482	-1.241899856237997	-1.9661128563728325	3.6112932175838894	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b700	58cfa82fe4b0c9d6adf6b700	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted.bam	360.7	1.9	0.14	58cfa82fe4b0c9d6adf6b700	TCGA-64-5775-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5775-01A	C8544FB3-B26E-4672-BB81-A271DB724B04	Primary Tumor	Illumina HiSeq	af9f3482-e78b-4fe4-ac01-64f69b84d78d	Lung	71.0	5449BCED-1356-4DE5-9352-349725656C5C	11AEF70D-D22B-4936-BD8C-863BDBD4940E	TCGA-64-5775-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5775	TCGA-LUAD	62.0	s10664	Harvard Medical School	Fox Chase	United States	NO	T4	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1623-02	True	LUAD	C4	LUAD.3	0.145016315	0.29	0.18	1.5853868690000001	0.5981	0.2215	0.1987	-0.7823	0.5844	0.3988	208.0	332.0	3.9107461789999998	12.77920996	158.0	0.525224163	12.0	16.0	0.846973755	1.517573246	6.0	1.5607104090000001	5.0	0.9697239	4.988163372	173.5022564	939.6675263000001	-2820.967332	1.0	62.0	1.0	62.0	6.405558981914201	5.446595457240471	0.40786524641105726	5.679621978531265	7.413296375964857	3.0520852101051226	-0.7259370033829362	1.9667009187243867	2.6442199636940655	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b701	58cfa82fe4b0c9d6adf6b701	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.filtered.	WGS	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.bam	237.3	1.9	0.16	58cfa82fe4b0c9d6adf6b701	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6775-01A	3C4FF061-D214-4D1C-8D2E-3034F207C252	Primary Tumor	Illumina HiSeq	c17b3c9b-e41f-48e2-9cde-facc8537afbc	Lung	72.0	7C606F64-69A1-465C-9F4E-2EB1EBEDA5D7	8B286297-0077-44ED-9093-6F13E2CA4EBA	TCGA-44-6775-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6775	TCGA-LUAD		s11454	Harvard Medical School	Christiana Healthcare	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True	LUAD	C6	LUAD.5	0.465366124	0.73	0.46	9.580592908	0.1737	-0.005	1.1413	0.9586	0.7698	0.7537	31.0	11.0	0.5188742679999999	1.5566228030000002	94.0	0.616364508	24.0	27.0	0.9493378790000001	4.5449472580000005	120.0	3.535983082	35.0	0.994553282	2.438527763	128.2293964	256.6605864	862.5071525000001	0.0	705.0	1.0	684.0	7.528797608007126	7.84285991423191	-0.25617286641471937	6.77111190630961	7.627748534614965	2.273084428597348	-0.7576857016975165	-0.2151113796169457	2.5292572950120675	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b704	58cfa82fe4b0c9d6adf6b704	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	665.52	1.9	0.15	58cfa82fe4b0c9d6adf6b704	TCGA-73-4659-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4659-01A	CD0DC947-B708-464E-BEB7-954C9D4583E7	Primary Tumor	Illumina HiSeq	37276b21-3a00-4b58-b1df-cc2199584cb0	Lung	66.0	C35A5ED1-1821-4077-BA1E-B972DFA3233B	277D2F7F-1A7F-4D39-BD15-0334CC02840E	TCGA-73-4659-01A-01D-1203-02	GRCh37	TCGA-73-4659	TCGA-LUAD	711.0	s11246	Harvard Medical School	Roswell Park	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True	LUAD	C4	LUAD.2	0.24955424699999998	0.67	0.22	0.97933513	0.2275	0.1125	0.7764	0.2562	-0.5435	0.316	58.0	11.0	1.698423056	5.2740505419999995	132.0	0.338892363	19.0	16.0	0.897662995	4.029282769	89.0	2.163955657	9.0	0.984858662	1.722223017	-722.3360203999999	94.45023998	2796.060269	1.0	711.0	1.0	35.0	8.57385703853378	8.570373703886961	0.34915799548943327	7.219311375728469	7.928519817714568	2.8921338728895636	-1.3545456628053105	-0.6418538861723944	2.5429758774001305	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b70a	58cfa82fe4b0c9d6adf6b70a	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.filtered.	WGS	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.bam	355.4	1.9	0.14	58cfa82fe4b0c9d6adf6b70a	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6216-01A	CCECCE70-DD54-4C5B-BF9F-CA87D290CB00	Primary Tumor	Illumina HiSeq	ae4aaef1-8b47-476b-933a-ff69761aa0a9	Lung	57.0	4EAA4B4A-E9DB-4E65-97D6-7FA1A205DA95	1003F495-01FE-47ED-A717-B8769F0FA3A3	TCGA-67-6216-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6216	TCGA-LUAD		s11242	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T1a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True	LUAD	C3	LUAD.4	0.331484918	0.44	0.15	7.385021927	-0.5075	-0.0845	0.8636	1.4422	0.39399999999999996	0.1659	22.0	30.0	0.183621473	0.918107363	110.0	0.148905806	2.0	6.0	0.9506348240000001	3.059975454	25.0	2.833213344	17.0	1.0	1.853635731	440.6437244	-827.532046	2471.750881	0.0	141.0	0.0	141.0	6.490033546204934	5.188227266972831	0.08430195098371829	5.843406381279882	5.8151250619915755	1.1768748445586852	-0.6466271649250523	0.6268977950187447	1.092572893574967	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b720	58cfa82fe4b0c9d6adf6b720	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.bam	282.4	1.9	0.13	58cfa82fe4b0c9d6adf6b720	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6217-01A	108A71CF-B9DB-47CD-AA74-C03EC989B41B	Primary Tumor	Illumina HiSeq	cb2962fe-7f6e-4a68-871a-11d696bb5279	Lung	73.0	BC0FE45C-3249-46D7-8991-C6888F0B9579	565E717D-310B-4FB1-B79A-5F40FF12BBB8	TCGA-67-6217-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6217	TCGA-LUAD		s11244	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	True	LUAD	C3	LUAD.5	0.348091875	0.75	0.32	18.40532159	-1.3492	-0.23	0.7276	1.6018	0.1587	-0.023	85.0	32.0	1.394699505	5.063365595	234.0	0.609049304	19.0	35.0	0.729339698	2.9227071760000003	55.0	3.6121358939999997	38.0	0.9930035290000001	2.82422526	659.7825311	-1272.441123	2770.2742670000002	0.0	422.0	1.0	296.0	5.89645083498068	6.76126407918901	-0.344915423531826	5.53051656562915	6.068116898629064	1.846683515158753	-0.3659342693515293	-0.6931471805599454	2.191598938690579	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b726	58cfa82fe4b0c9d6adf6b726	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted.filtered.	WGS	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted.bam	817.7	1.9	0.15	58cfa82fe4b0c9d6adf6b726	TCGA-75-5147-01A-01D-1623_110913_SN208_0238_BC008YACXX_s_4_rg.sorted.bam	Alive	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-5147-01A	D2824E6D-3784-45C2-9B0F-52B17356B5DA	Primary Tumor	Illumina HiSeq	ca549b28-f771-489d-93fe-90211aa22391	Lung		F9F9C1DD-8462-4560-82B8-AEA4309854C9	1291FD50-F1A9-4A2A-A2FD-2320ED01FB4E	TCGA-75-5147-01A-01D-1623-02	HG19_Broad_variant	TCGA-75-5147	TCGA-LUAD		s11466	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	True	LUAD	C2	LUAD.5	0.306668646	0.6	0.35	4.76968311	0.5836	0.4005	0.8315	1.5269	1.4915	0.0667	12.0	3.0	0.213465391	1.128317065	157.0	0.5327707389999999	12.0	28.0	0.9331607909999999	4.840665041	179.0	3.997243179	56.0	0.993017129	7.4218279129999996	159.4412927	-47.29241937	-1343.586007	0.0	1333.0	0.0	1333.0	7.841885928984622	6.270610288537478	-0.04880012834820946	6.774045298983266	5.739982037475307	3.158780619536371	-1.0678406300013559	-0.5306282510621707	3.2075807478845806	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b72a	58cfa82fe4b0c9d6adf6b72a	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.bam	291.7	1.9	0.14	58cfa82fe4b0c9d6adf6b72a	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-49-6767-01A	6BFFE800-EC2B-4638-9333-97FE85DCD91C	Primary Tumor	Illumina HiSeq	759c1dd3-0f7d-4ba7-8c8e-c276faf0255b	Lung	46.0	708A8742-F6D6-411D-9340-2C6C25885D22	FBCE84D6-2880-45F5-BD6F-B079C33C353E	TCGA-49-6767-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6767	TCGA-LUAD		s11233	Harvard Medical School	Johns Hopkins	United States	NO	T3	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1853-02	True	LUAD	C1	LUAD.3	0.34856916299999996	0.57	0.26	14.64443103	0.6171	0.2375	0.3779	0.6282	0.2599	0.2542	166.0	60.0	4.1612900569999995	11.80022966	172.0	0.581840343	21.0	30.0				2.6795438590000002	17.0	0.945761414	2.304205773	68.31754729	282.2270793	-2484.773402	0.0	677.0	0.0	677.0	6.87982333450776	6.927290490846852	-0.5969147142983608	6.142224391376981	6.552597041405441	2.2095922261448813	-0.737598943130779	-0.3746934494414105	2.806506940443242	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b748	58cfa82fe4b0c9d6adf6b748	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.bam	142.7	1.9	0.15	58cfa82fe4b0c9d6adf6b748	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-44-6776-01A	C2A1DE2E-6451-4C95-8CE6-263F2B7E6EFF	Primary Tumor	Illumina HiSeq	bb5d193c-cc97-466b-9b28-bdbf5cf255e8	Lung	60.0	64FB8EBA-A055-4128-92CA-695A3A6F8EBD	5BC01EC3-A1C2-41BB-A9C5-95946A066FA6	TCGA-44-6776-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6776	TCGA-LUAD		s10660	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	True	LUAD	C3	LUAD.1	0.085246584	0.35	0.0	1.172910191	-1.3988	-0.259	-0.3545	0.1043	-1.2228	-0.2694	110.0	41.0	1.398990687	5.129632517	62.0	0.16653796	4.0	14.0	0.870619113	2.466649689	17.0	1.7478680969999998	6.0	0.9755037590000001	1.173365972	-279.1922951	-873.4740129	3444.2197439999995	0.0	2616.0	0.0	2616.0	7.312710453174531	7.943827049175349	-0.00853065527261776	6.813719287055543	7.2506798686154035	2.017369113037458	-0.49899116611898764	-0.6931471805599454	2.025899768310076	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b756	58cfa82fe4b0c9d6adf6b756	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.filtered.	WGS	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.bam	328.7	1.9	0.14	58cfa82fe4b0c9d6adf6b756	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6835-01A	2F09479F-87FC-4C34-8E2C-333E970A3681	Primary Tumor	Illumina HiSeq	8c5e1a0f-e9a8-4ce4-b066-97b2040c5327	Lung	81.0	EFD3F14F-F785-4AEC-9EFD-6DD8E9C41EBA	A4DC40A6-EE0F-4637-937F-406F5FC8579F	TCGA-91-6835-01A-11D-1853-02	HG19_Broad_variant	TCGA-91-6835	TCGA-LUAD		s10913	Harvard Medical School	ABS - IUPUI	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	True	LUAD	C3	LUAD.5	0.506208099	0.79	0.45		-0.0573	-0.159	1.534	2.3644	0.8918	0.3818	36.0	0.0	0.701133637	2.191042615	63.0	0.423550975	10.0	23.0	0.89661571	1.744733609	7.0	4.720321087	125.0	0.977633465	3.260736693	469.5418047	41.10003208	2743.658696	0.0	79.0	0.0	79.0	7.7795715207544625	7.380769995351535	-0.6547793031369864	7.086424340194517	7.85077362459727	1.5509559638671417	-0.6931471805599454	0.4700036292457357	2.205735267004128	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b760	58cfa82fe4b0c9d6adf6b760	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted.bam	466.4	1.9	0.15	58cfa82fe4b0c9d6adf6b760	TCGA-75-5122-01A-01D-1751_120309_SN208_0273_BC0HEAACXX_s_1_rg.sorted.bam	Dead	MALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-5122-01A	78AE716B-0CA5-4C01-A053-D41288385FCD	Primary Tumor	Illumina HiSeq	611aeb0f-3dbe-41c6-8b8e-b4a7c827ac1d	Lung		DD9C2F71-145A-4F7F-8B64-095B1FC75C3D	4ADD8465-F06A-4752-8B9F-A6F790F727B1	TCGA-75-5122-01A-01D-1751-02	HG19_Broad_variant	TCGA-75-5122	TCGA-LUAD		s11249	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C2	LUAD.6	0.537361008	0.68	0.52	33.25353761	0.2048	0.028999999999999998	2.0633	2.2628	0.858	0.1389	64.0	213.0	1.3248155320000001	3.041053835	115.0	0.23291638399999998	8.0	17.0	0.84968202	2.996285135	34.0	3.614912439	60.0	0.8829038159999999		1101.938811	-394.6534537	346.3104605	1.0		1.0		9.654613002472974	9.208423830701324	0.7857182947671519	8.37573888997392	8.315943747520887	1.8474952863049106	-1.2788741124990537	-0.8924800831804367	1.0617769915377586	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b77c	58cfa82fe4b0c9d6adf6b77c	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.filtered.	WGS	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.bam	466.6	1.9	0.16	58cfa82fe4b0c9d6adf6b77c	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-5645-01A	DDEACCCF-0953-4952-8A4E-C2617F2E7BCC	Primary Tumor	Illumina HiSeq	e1f13e42-abbc-4a28-91d2-65b2a95b0018	Lung	61.0	37A8D3A5-BAA0-427C-AB43-48AE4B93633B	A35054A5-9324-47AD-841E-E2ADCD97126D	TCGA-44-5645-01A-01D-1623-02	HG19_Broad_variant	TCGA-44-5645	TCGA-LUAD		s10993	Harvard Medical School	Christiana Healthcare	United States	NO	T1	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	True	LUAD	C3	LUAD.5	0.357824851	0.46	0.0	8.21370393	-1.065	-0.255	1.0398	1.7929	-0.1896	-0.0088	11.0	0.0	0.260661052	1.013681867	176.0	0.9477171409999999	10.0	10.0	0.9164922670000001	2.649003366	18.0	4.189654742	66.0	1.0	2.301088498	-164.5811392	-1223.373722	1590.2777449999999	0.0	852.0	0.0	852.0	5.104597764801712	5.237505227151279	-0.25886608327480265	4.210779888779616	4.321214495277124	1.4232351492830406	-0.8938178760220965	-0.9162907318741547	1.6821012325578433	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b780	58cfa82fe4b0c9d6adf6b780	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted.bam	1032.7	1.9	0.17	58cfa82fe4b0c9d6adf6b780	TCGA-50-5045-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_1_rg.sorted.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5045-01A	9EE20C0D-A1C3-47F3-ABDA-131B3F190F52	Primary Tumor	Illumina HiSeq	e3bc7a3f-c296-412c-8974-8c21cf01dbfb	Lung	57.0	BDD75BCA-6224-4743-A367-CB1FF01E8121	42839A7D-81DB-428A-AB3B-072ACD26CA91	TCGA-50-5045-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5045	TCGA-LUAD	2174.0	s11004	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	True	LUAD	C2		0.467012991	0.78	0.44	3.675148442	-0.1355	0.251	1.4425	2.5693	0.922	0.5228	195.0	279.0	2.003592966	8.353441444	75.0	0.208533429	3.0	11.0	0.931909896	4.380424167	110.0	4.41954606	88.0	0.987092605	2.379315823	97.19337735	-741.8826917	55.81688557	1.0	2174.0	1.0	1433.0	7.062477224177687	5.243591013369363	0.5680815938227864	6.244166900663736	5.766112676898544	1.2872556099862402	-0.8183103235139515	0.5225216635291816	0.7191740161634537	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b790	58cfa82fe4b0c9d6adf6b790	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.filtered.	WGS	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.bam	72.0	1.9	0.16	58cfa82fe4b0c9d6adf6b790	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6146-01A	0C0B610E-FE4C-406D-A5ED-5CC3B11DABF5	Primary Tumor	Illumina HiSeq	99148000-be38-4da1-aeaa-4b0271725662	Lung	64.0	AD66185F-983D-4416-B705-25D3D4D8B5A5	2D5C6425-E3F4-4389-9DDF-FDE694B4227E	TCGA-44-6146-01A-11D-1751-02	HG19_Broad_variant	TCGA-44-6146	TCGA-LUAD		s11337	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Lung Mucinous Adenocarcinoma	Stage IIB	1751-02	True	LUAD	C3	LUAD.1	0.165765212	0.3	0.0	0.529289518	-1.0419	-0.387	-0.4049	-0.3729	0.3009	0.0007	7.0	2.0	0.319427354	1.016359762	74.0	0.322302393	4.0	11.0	0.962040682	1.548344746	5.0	2.197224577	9.0	1.0	1.356616267	-1148.8301470000001	96.57722816	2608.442684	0.0	728.0	1.0	631.0	7.189658184169879	7.966749912981007	-1.105992395965732	6.4241903420303075	8.315056607249224	0.34826729394118794	-0.7654678421395715	0.3483066942682158	1.45425968990692	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b7b0	58cfa82fe4b0c9d6adf6b7b0	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	245.2	1.9	0.16	58cfa82fe4b0c9d6adf6b7b0	TCGA-49-4494-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4494-01A	C6D78E27-E510-4F57-ABAE-19EFA6105A8D	Primary Tumor	Illumina HiSeq	3cb48d09-95ac-452f-9c92-19d7f966aec0	Lung	77.0	7CA68089-C61F-4D31-8CC8-FB11AE70910A	8DF0AEB4-1455-4760-A230-54FE1551D08C	TCGA-49-4494-01A-01D-1203-02	GRCh37	TCGA-49-4494	TCGA-LUAD	1081.0	s10783	Harvard Medical School	Johns Hopkins	United States	NO	T3	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True	LUAD	C2	LUAD.3	0.304768286	0.54	0.32	9.317909018	0.2416	0.304	0.3948	0.8196	1.1194	0.0655	72.0	5.0	1.449654391	4.67439579	139.0	0.331858502	3.0	15.0	0.932007329	2.837517224	21.0	2.819170195	23.0	0.8991151	2.8484947810000003	-736.099831	-629.7702863	2234.0196309999997	1.0	1081.0	1.0	1081.0	9.402467859759202	7.370860166536716	0.43230208425267425	7.76833733473473	7.865556408372823	1.0081834794651874	-1.6341305250244722	0.4946962418361074	0.575881395212513	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b7b4	58cfa82fe4b0c9d6adf6b7b4	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted.bam	181.4	2.0	0.16	58cfa82fe4b0c9d6adf6b7b4	TCGA-50-5930-01A-11D-1751_111007_SN590_0110_C003AACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5930-01A	368E23F0-E573-4547-BF5A-14080BAF737B	Primary Tumor	Illumina HiSeq	09c8fefe-47f0-44eb-b4f4-160944e2991a	Lung	47.0	3E30DBD1-10BF-4450-8D19-6F44D3284E02	31047F3B-8F9D-47D9-87D3-BB2F8CF7E1EF	TCGA-50-5930-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5930	TCGA-LUAD	282.0	s11347	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N2	Lung Adenocarcinoma Mixed Subtype	Stage IIIA	1751-02	True	LUAD	C3		0.438795901	0.05	0.18		-0.158	-0.0745	0.7107	1.6898	-0.3308	0.5071	259.0	79.0	8.329810076000001	28.68483688	235.0	0.230143367	2.0	24.0	0.88811506	3.8104216419999997	73.0	2.3025850930000002	10.0	1.0	5.1439943239999995	-833.6280845	-592.8086931	2664.996825	1.0	282.0	1.0	177.0	7.616596837780669	7.323778829130106	-0.10777140024213683	6.682287600403836	8.365232703958267	3.1849742731925197	-0.9343092373768331	1.0414538748281612	3.2927456734346565	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b7d4	58cfa82fe4b0c9d6adf6b7d4	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.bam	427.33	1.9	0.15	58cfa82fe4b0c9d6adf6b7d4	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3919-01A	66ED89F6-8BA2-49D0-AF0F-4B6EBF2381BF	Primary Tumor	Illumina HiSeq	14d2cfc2-f4ac-4ab1-93d3-0e178305e26f	Lung	71.0	9DE8D353-3442-41D8-8BFE-A08C4975EACA	9C982400-B6C3-4D00-9981-BA06775FEF4F	TCGA-44-3919-01A-02D-1103-02	HG19_Broad_variant	TCGA-44-3919	TCGA-LUAD		s10994	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	True	LUAD	C2	LUAD.3	0.33970977	0.49	0.25	13.45053148	-0.055999999999999994	0.013000000000000001	1.1213	1.8246	1.2168	0.4013	24.0	33.0	0.334584148	1.031634457	121.0	0.31090371	5.0	16.0	0.773997948	3.129313385	57.0	4.489323947	96.0	0.983562988	2.43602751	-11.43671092	-417.96540739999995	1854.2984350000002	1.0	1026.0	1.0	921.0	5.604207658648486	6.81278504139091	-0.03834730827462374	4.815750298284216	5.909917329848897	2.7704892043574985	-0.7884573603642697	-0.9028677115420143	2.808836512632122	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b7de	58cfa82fe4b0c9d6adf6b7de	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted.bam	345.4	1.9	0.15	58cfa82fe4b0c9d6adf6b7de	TCGA-50-5931-01A-11D-1751_110928_SN590_0108_BB01CWACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5931-01A	12CCD581-A921-41BC-BCEE-4E9BE54532CC	Primary Tumor	Illumina HiSeq	ba1d7028-7d97-4a0b-917e-b861a8656748	Lung	75.0	16A2D381-75A0-423B-AAC2-D5710AFB183B	5EA8E18D-2D34-4C6E-A89D-36DE5E91E80C	TCGA-50-5931-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5931	TCGA-LUAD	434.0	s11458	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C1	LUAD.2	0.083668491	0.14	0.43	1.4559812	0.8005	0.3175	-0.6178	-1.0374	-0.5597	0.4122	113.0	85.0	2.427148893	8.37055195	219.0	0.734883451	9.0	18.0	0.906519527	0.628351454	2.0	0.693147181	2.0	1.0	5.1565317969999995	-558.9678293	1015.30296	-3124.417919	1.0	434.0	1.0	425.0	6.565405805188048	6.2302961594549195	-0.17988404185109574	5.9502201660978145	7.062029503301012	1.6205143560414967	-0.6151856390902335	0.8317333438460923	1.8003983978925924	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b7ee	58cfa82fe4b0c9d6adf6b7ee	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted.bam	62.7	1.9	0.15	58cfa82fe4b0c9d6adf6b7ee	TCGA-91-6829-01A-21D-1853_120305_SN1120_0119_BD0REAACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6829-01A	1427CD18-5AD3-491A-9981-908E31AE49DB	Primary Tumor	Illumina HiSeq	be9bb40c-b149-4b91-b271-b8881bb90d6f	Lung	78.0	9B416640-9AEC-4B0D-AA88-B94287375950	E6E4F55E-8C3A-45E9-8F3B-9FDFE9D2965D	TCGA-91-6829-01A-21D-1853-02	HG19_Broad_variant	TCGA-91-6829	TCGA-LUAD	1258.0	s11361	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N0	Lung Bronchioloalveolar Carcinoma Nonmucinous	Stage IB	1853-02	True	LUAD	C1	LUAD.2	0.22654524	0.51	0.52		0.2526	0.006999999999999999	0.4816	0.2086	0.3683	0.7769	209.0	79.0	4.530250573	16.19199237	179.0	0.63593399	15.0	59.0	0.8635561359999999	2.7444278860000004	24.0	2.079441542	8.0	1.0	5.2757994539999995	30.70129277	1027.155679	-2458.074889	1.0	1258.0	0.0	1258.0	5.190991958790487	8.417397410774242	0.04903534032973056	3.99909173569882	6.977035828384075	4.70815832456606	-1.1919002230916673	-1.4403615823901665	4.65912298423633	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b7f6	58cfa82fe4b0c9d6adf6b7f6	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	153.0	1.9	0.15	58cfa82fe4b0c9d6adf6b7f6	TCGA-73-4677-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4677-01A	03C3409A-9D16-41D0-9E26-F9FC2547A4C8	Primary Tumor	Illumina HiSeq	5dd207d7-c666-46ae-8154-cb0c0cd6467f	Lung	74.0	EF88B85A-61EE-44E1-BB63-1B4CE9154BFB	2E41BAD5-941E-4EE8-A1DC-5BBA14E89141	TCGA-73-4677-01A-01D-1203-02	GRCh37	TCGA-73-4677	TCGA-LUAD	38.0	s10914	Harvard Medical School	Roswell Park	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	True	LUAD	C3		0.17573580600000002	0.53	0.04	17.48283415	-1.2486	-0.207	0.3393	1.0607	-0.802	-0.2105	109.0	106.0	1.710531061	6.2622832079999995	67.0	0.383026084	11.0	9.0	0.8139544790000001	3.3326100939999996	60.0	3.69076133	45.0	0.969553077	1.774423595	-396.2511131	-1093.164894	4121.630802000001	1.0	38.0	1.0	38.0	8.065202353371138	6.943122422819428	0.0006283380665415006	6.966590064703029	7.179511200883658	2.35989131556976	-1.0986122886681096	0.2363887780642302	2.359262977503218	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b7fc	58cfa82fe4b0c9d6adf6b7fc	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.filtered.	WGS	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.bam	240.4	1.9	0.14	58cfa82fe4b0c9d6adf6b7fc	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-6178-01A	EDF80622-AEA2-4B50-BB69-691D6708AA83	Primary Tumor	Illumina HiSeq	f309d501-6d91-40ce-839c-bef9a434bae1	Lung	70.0	81FB5FA9-D901-4FAA-B909-376B8676D2BC	DE9A3263-6ACD-4BBB-9F91-D4E7FCBEFA04	TCGA-38-6178-01A-11D-1751-02	HG19_Broad_variant	TCGA-38-6178	TCGA-LUAD		s11119	Harvard Medical School	UNC	United States	NO	T2b	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	True	LUAD	C2	LUAD.5	0.309406366	0.68	0.48	5.478592658999999	-0.4793	-0.0735	0.2338	0.4771	0.9779	0.5333	32.0	3.0	0.707632322	1.753697494	206.0	0.763148877	18.0	30.0	0.8496711859999999	2.626369707	22.0	2.079441542	8.0	1.0	2.313485629	30.99919751	-628.6276232000001	-235.264132	0.0	448.0	0.0	448.0	5.4359030295006	7.014261292153256	-0.07552272603640808	4.407249329439401	5.553858958879642	4.811350153029985	-1.0286537000611986	-1.460402333273613	4.886872879066393	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b800	58cfa82fe4b0c9d6adf6b800	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted.bam	465.4	1.9	0.15	58cfa82fe4b0c9d6adf6b800	TCGA-38-4632-01A-01D-1751_120305_SN1120_0118_AD0L4HACXX_s_7_rg.sorted.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-4632-01A	875333AB-9048-462D-AAA2-693AD127E3CC	Primary Tumor	Illumina HiSeq	ee38fc59-2812-43a0-b6c0-ab684daab63d	Lung	42.0	D994817A-474E-4F92-8A78-7586CAA85D52	77D4D914-9C77-401B-BD71-9CF71A58DCE7	TCGA-38-4632-01A-01D-1751-02	HG19_Broad_variant	TCGA-38-4632	TCGA-LUAD	1357.0	s11449	Harvard Medical School	UNC	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1751-02	True	LUAD	C2	LUAD.3	0.314434928	0.63	0.55	7.387088165	0.7092	0.425	0.9484	1.2436	0.5239	0.0138	279.0	201.0	3.60897261	13.88999542	229.0	0.644232908	20.0	40.0	0.9259453129999999	1.017254899	3.0	3.2163581339999996	26.0	0.9871893279999999	2.392948102	303.4150981	-28.033561	760.7620294	1.0	1357.0	1.0	680.0	4.01129638928762	6.892569122226481	0.6747032789006868	3.1360876961427007	5.515243431089352	1.0435658080313044	-0.875208693144919	-1.3773256911371297	0.36886252913061757	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b80a	58cfa82fe4b0c9d6adf6b80a	TCGA-36-1571-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-36-1571-01A-01D-A324-10_wgs_Illumina	TCGA-36-1571-01A-01D-A324-10_wgs_Illumina.bam	740.97	1.9	0.07	58cfa82fe4b0c9d6adf6b80a	TCGA-36-1571-01A-01D-A324-10_wgs_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-36-1571-01A	12581634-EEBB-4841-8498-71DC9D78C546	Primary Tumor	Illumina HiSeq	9c491361-7721-46fe-ae77-f268796b5b9a	Ovary	53.0	A1D026C2-4D7A-4454-A8E3-30E5C243ABA0	BA577913-356C-4488-8F9D-C45778E7B9E1	TCGA-36-1571-01A-01D-A324-10	GRCh37-lite	TCGA-36-1571	TCGA-OV	695.0	s17463	Baylor College of Medicine	BC Cancer Agency	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Proliferative	0.034988652				0.8228	0.2615	-0.9471	-2.1126	1.4275	-0.2586					322.0	0.584637404	15.0	25.0				2.5649493569999997	13.0	1.0	4.517199416	-1485.918423	11.02307873	-1443.955041	1.0	695.0	1.0	375.0	6.44022132484945	1.9229320161638013	0.42999081360578906	2.1610331364006843	2.9440883743695805	1.357339527675596	-4.2791881884487655	1.0211563582057792	0.9273487140698069	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b80c	58cfa82fe4b0c9d6adf6b80c	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.bam	452.63	1.9	0.15	58cfa82fe4b0c9d6adf6b80c	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-4112-01A	68B86559-38B2-41F2-B66E-C3C2B628B14D	Primary Tumor	Illumina HiSeq	7c0e7b16-7643-4891-96de-63f2106bfb1a	Lung	60.0	6C206676-E511-4281-91F5-BFE91B3279A4	68185A4B-CC12-494D-99F5-84F5888A24F9	TCGA-44-4112-01A-01D-1103-02	HG19_Broad_variant	TCGA-44-4112	TCGA-LUAD		s10651	Harvard Medical School	Christiana Healthcare	None	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1103-02	True	LUAD	C1	LUAD.3	0.39141854	0.43	0.21	8.916229806	0.081	0.19	0.5206	0.8395	-0.0931	0.423	195.0	298.0	3.7506184160000005	12.00779384	99.0	0.293012063	5.0	20.0	0.8885911129999999	3.2554083210000004	39.0	3.091042453	22.0	1.0	2.970278956	-105.9005324	-65.15646952	985.139718	1.0	808.0	1.0	619.0	6.322069853205901	6.126054701080746	0.41592735389999425	5.299040245703798	5.512244262757322	2.804220892103254	-1.023029607502103	-0.6138104383234246	2.3882935382032597	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b81e	58cfa82fe4b0c9d6adf6b81e	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted.bam	82.92	2.0	0.17	58cfa82fe4b0c9d6adf6b81e	TCGA-A5-A0GE-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GE-01A	A587E62E-430E-4F1B-82B7-6FBE856FDAF1	Primary Tumor	Illumina HiSeq	d3918efd-f063-4ea7-b839-9c0c143fd07c	Uterus	38.0	20C3F64D-ACF6-45B3-9ACE-2F93B3A951C8	3E23FB82-C875-460A-B19D-5EF9DCC58B9A	TCGA-A5-A0GE-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GE	TCGA-UCEC		s4995	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.188361712	0.4	0.01	0.356920615	0.3762	0.237	-0.588	0.3759	-0.826	0.062	10.0		0.20871703100000003	0.8348681240000001	89.0	0.142074192	6.0	0.0							2.180944181	-1629.775838	-193.8883169	-2341.4638379999997	0.0	3205.0	0.0	3205.0	6.181474277044542	3.724656899128801	-0.8226567349566476	6.033838278238477	5.513236715439477	7.330405211844403	-0.1476359988060647	1.7885798163106754	8.153061946801051	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b82d	58cfa82fe4b0c9d6adf6b82d	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted.bam	62.7	1.9	0.15	58cfa82fe4b0c9d6adf6b82d	TCGA-44-6779-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_8_rg.sorted.bam	Dead	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-44-6779-01A	CBBEA9F1-396A-4BF3-B67C-2CAC3394DCEB	Primary Tumor	Illumina HiSeq	ab458a7b-afac-4c72-8db7-45994af6ceb8	Lung	50.0	5E04D394-7A40-4E89-BA20-892774DCB469	DB5F07FE-8DC0-4259-A6B1-E75B6F1188C5	TCGA-44-6779-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6779	TCGA-LUAD	500.0	s11344	Harvard Medical School	Christiana Healthcare	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1853-02	True	LUAD	C6	LUAD.6	0.390883573	0.4	0.37	1.133794615	0.3987	-0.08800000000000001	1.0667	1.2662	0.8311	0.4513	48.0	156.0	0.79330451	2.468058475	154.0	0.6733319879999999	15.0	33.0	0.965534014	2.3152494480000003	11.0	3.5106997210000004	35.0	0.987441921	1.5684602909999998	-649.2524945	451.61798780000004	2663.2510620000003	1.0	500.0	1.0	232.0	6.648761889227338	7.973987845909496	-0.24636565472428051	5.797009678490754	7.091598665711022	3.067820349948245	-0.851752210736584	-0.8823891801984738	3.3141860046725253	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b834	58cfa82fe4b0c9d6adf6b834	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.bam	85.83	2.23	0.16	58cfa82fe4b0c9d6adf6b834	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0RA-01A	AFD710B8-D172-4AC4-9973-E969DB1ED231	Primary Tumor	Illumina HiSeq	d644ff0f-6dc7-4922-a46d-3223823e8118	Uterus	68.0	4ED231EE-0E54-4AC5-8278-1061AD3972A2	01EFCC42-CCFA-4D41-87BE-CA8F1C551823	TCGA-A5-A0RA-01A-21D-A101-02	HG19_Broad_variant	TCGA-A5-A0RA	TCGA-UCEC		s5195	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_LOW	0.268427226	0.45	0.0	3.877849822	0.3344	0.159	-0.5121	0.1294	1.1248	-0.3693	39.0		0.42842585200000005	1.901139717	47.0	0.001793066	0.0	0.0							2.667313627	-1487.516763	-218.69863790000002	-1550.051056	0.0	884.0	0.0	884.0	5.499308258675647	6.752186928067259	-0.07794465323883804	4.512813268128244	5.6300441419889555	1.7679514696497307	-0.9864949905474041	-1.122142786078304	1.8458961228885689	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b842	58cfa82fe4b0c9d6adf6b842	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	260.29	1.9	0.14	58cfa82fe4b0c9d6adf6b842	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2674-01A	57CDAA1C-4E94-4A28-AB3B-300C0457555F	Primary Tumor	Illumina HiSeq	92b3a16b-1a9e-47a3-9146-1a297c51c5a3	Colorectal	71.0	8ACA008C-F55A-420A-82C7-ACD2CCA77D85	9FDFC199-B878-4049-994E-B5CA384678FB	TCGA-A6-2674-01A-02D-1167-02	HG18	TCGA-A6-2674	TCGA-COAD		s13013	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IV	1167-02	True	COAD	C1		0.5082223220000001	0.75	0.25	5.217337993	0.6114	0.228	0.8464	0.9229999999999999	-0.1235	0.5433	62.0		1.007965713	2.423917548	155.0	0.486147528	20.0	19.0							2.229933405	-113.5524416	172.3277077	-2287.723603	0.0	1331.0	1.0	735.0	6.055465814575642	2.84512875422722	-0.7056223335225396	4.551388417799369	1.7471455942366712	-0.537653423303853	-1.5040773967762742	-1.097983159990549	0.16796891021868654	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b84e	58cfa82fe4b0c9d6adf6b84e	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.filtered.	WGS	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.bam	80.74	2.11	0.16	58cfa82fe4b0c9d6adf6b84e	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R8-01A	06D16B6B-9CA6-4CEC-A785-F27AA4323CEC	Primary Tumor	Illumina HiSeq	ed11d53d-5cbb-44e2-b4d2-1603cef4ec13	Uterus	81.0	5B5CC2BA-6A10-4279-A0AA-8DDAE94D56EA	289CE7E4-AF92-4857-9D07-7CF334C40542	TCGA-A5-A0R8-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R8	TCGA-UCEC		s4420	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_LOW	0.29069162	0.55	0.0	15.49728752	0.1164	0.127	0.1119	0.9225	0.3237	-0.0522	15.0		0.546313732	2.070241512	55.0	2.13e-05	0.0	0.0							3.1330027310000004	-1459.41749	-640.1692079	-1113.199096	0.0	596.0	1.0	42.0	6.355890623256082	6.8463633173812735	-0.7209013508610305	5.285449211554668	5.986162052158162	1.156901419443478	-1.0704414117014136	-0.8602012652231115	1.8778027703045084	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b852	58cfa82fe4b0c9d6adf6b852	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.bam	112.95	1.93	0.17	58cfa82fe4b0c9d6adf6b852	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R9-01A	284174FD-1320-4617-9E99-75BD75DF9BF3	Primary Tumor	Illumina HiSeq	4139f46d-ae94-47a2-a3ae-0b96262c6a89	Uterus	51.0	986AC6AC-087F-412B-BB0C-9BE10D104989	6BBEF031-7106-4D36-86A9-F8A2333448BB	TCGA-A5-A0R9-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R9	TCGA-UCEC		s4419	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.07409809099999999	0.18	0.0	1.6979521080000002	-0.1699	0.11800000000000001	-0.2173	0.2125	-0.2456	0.0075	21.0	13.0	0.26450758	1.058030318	47.0	0.046539529	2.0	0.0							2.352061152	-761.9058734	-188.7275438	-2651.136444	0.0	749.0	0.0	749.0	7.4286726663149185	8.042442311787237	-0.21604984328684107	5.973385433708076	5.926186796984684	2.6759983609365756	-1.4552872326068422	-2.1162555148025524	2.892048204223417	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b858	58cfa82fe4b0c9d6adf6b858	TCGA-29-1710-01A-02D-0926-12_Illumina.filtered.	WGS	TCGA-29-1710-01A-02D-0926-12_Illumina	TCGA-29-1710-01A-02D-0926-12_Illumina.bam	265.0	1.9	0.15	58cfa82fe4b0c9d6adf6b858	TCGA-29-1710-01A-02D-0926-12_Illumina.bam	Dead	FEMALE	WHITE		Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-29-1710-01A	4261267C-7042-4C6E-83ED-12FB401003FC	Primary Tumor	Illumina HiSeq	3d865220-b0b8-4ca4-b4a1-56e05dc83e6f	Ovary	54.0	61513DA0-4EB3-4CAE-BFFF-7B05F3362488	6BA4DE87-C332-42B8-AF95-EB14A4C7F229	TCGA-29-1710-01A-02D-0926-12	NCBI36_BCM_variant	TCGA-29-1710	TCGA-OV	951.0	s17882	Baylor College of Medicine	Duke	None	NO			Serous Cystadenocarcinoma		0926-12	True	OV	C2	OVCA.Immunoreactive	0.146755266	0.53	0.22		-0.2323	0.004	0.8975	1.2541	0.9255	0.2604	30.0		0.442837476	1.121854939	176.0	0.482236184	9.0	21.0	0.8166074659999999	5.008578633	461.0	3.8636203080000002	205.0	0.725833753	4.401627059	-207.51186030000002	-668.6932776000001	1608.150509	1.0	951.0	1.0	315.0	5.479017238751678	0.6228356689648074	0.5655436827847147	5.111292458626361	3.5801584944039275	2.60754466309423	-0.3677247801253176	2.95732282543912	2.042000980309515	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b85e	58cfa82fe4b0c9d6adf6b85e	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	38.0	1.9	0.16	58cfa82fe4b0c9d6adf6b85e	TCGA-A6-2680-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2680-01A	FF1407C6-9174-4BAE-A19B-D34CA71B898C	Primary Tumor	Illumina HiSeq	b2bf326b-6022-44c8-87fd-c3777c1ab858	Colorectal	72.0	D664F620-CFEE-4700-B00E-68B65387883C	22A3FC8C-A661-4B3D-A4BA-B35DFDBE24BC	TCGA-A6-2680-01A-01D-1405-02	HG18	TCGA-A6-2680	TCGA-COAD		s13356	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	True	COAD	C1		0.120522879			13.89243895	0.4341	0.203	-0.3673	-0.0889	-0.2521	0.22					92.0	0.510387334	15.0	6.0							1.254761391	-898.1483911	-319.54133260000003	-1017.8321890000001	0.0	1068.0	0.0	1068.0	6.71430536440034	6.672847318859241	-0.8261228632507451	4.88617825100141	6.996634395953138	0.8683827909644142	-1.8281271133989296	0.32378707709389687	1.6945056542151593	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b864	58cfa82fe4b0c9d6adf6b864	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.bam	101.03	2.18	0.17	58cfa82fe4b0c9d6adf6b864	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GU-01A	ADC22472-E31D-419F-AEAE-CB01B9423343	Primary Tumor	Illumina HiSeq	7666f932-cff3-4ea2-8650-8d4bdae72cac	Uterus	58.0	074D4466-E072-42CD-9A6C-A595DC9363E7	BB726D7A-6861-48AA-9BFD-5DF8DAAA1538	TCGA-A5-A0GU-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GU	TCGA-UCEC		s4241	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_LOW	0.12776543099999998	0.23	0.0	2.365703749	-0.0124	0.048	-0.1463	0.0748	0.5667	-0.1303	22.0	67.0	0.34177936200000003	1.435473321	73.0	0.11245947	4.0	2.0							2.530530299	-254.6873884	-137.4246874	-263.71701129999997	0.0	860.0	0.0	860.0	4.433678661005729	6.289174298906609	0.25021218908596343	3.6733921776081555	5.4418764385194045	4.081855550651325	-0.7602864833975733	-0.8472978603872039	3.8316433615653622	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b866	58cfa82fe4b0c9d6adf6b866	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted.filtered.	WGS	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted.bam	618.0	1.9	0.16	58cfa82fe4b0c9d6adf6b866	TCGA-A6-2682-01A-01D-1405_110114_SN177_0133_A809KVABXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2682-01A	77A44132-AF22-4115-9FA2-78F2F74BF687	Primary Tumor	Illumina HiSeq	dd9a1c6d-4344-4fed-a29f-b60afcfaa5eb	Colorectal	70.0	F10F139D-1D7F-4923-8129-F103F5D3163B	F8B17713-D431-4418-A6F7-DC6DE3077212	TCGA-A6-2682-01A-01D-1405-02	HG18_Broad_variant	TCGA-A6-2682	TCGA-COAD	424.0	s13651	Harvard Medical School	Christiana Healthcare	United States	NO	T4b	N1	Colon Adenocarcinoma	Stage IV	1405-02	True	COAD	C1		0.342627178			0.234126241	0.5489	0.3445	-0.0893	-0.1592	-0.8502	0.4234					69.0	0.382922954			0.790677435	2.285351728	18.0	1.609437912	5.0	1.0	1.286925519	-433.7188187	-242.4913358	-2016.2461469999998	1.0	424.0	1.0	381.0	6.367485240371508	4.844446468063787	-3.506506875610233	5.089079841262802	7.272840907588446	-2.81504203849212	-1.2784053991087054	2.4283944395246584	0.6914648371181129	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b868	58cfa82fe4b0c9d6adf6b868	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.bam	88.28	1.87	0.17	58cfa82fe4b0c9d6adf6b868	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R7-01A	02B25675-094D-4098-96DA-51D121380FEC	Primary Tumor	Illumina HiSeq	daa92f08-7339-46a6-8a74-e6756c170ed5	Uterus	55.0	550C6341-260A-4156-B00C-0AE9031D647F	4C9B54D0-A58E-44CF-8937-913A34F0788C	TCGA-A5-A0R7-01A-31D-A101-02	HG19_Broad_variant	TCGA-A5-A0R7	TCGA-UCEC		s4777	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_LOW	0.178070617	0.28	0.43	1.188192443	0.442	0.115	-0.1412	1.1273	0.5392	0.3646	20.0	10.0	0.590061376	1.6092582990000002	107.0	0.53239216	7.0	5.0							2.275530496	-1313.281454	228.9044071	-2752.814725	0.0	535.0	0.0	535.0	7.619417493539796	7.782355583802083	-0.5264902797404621	6.035297389089986	7.22273979586666	2.071298860160053	-1.5841201044498106	-0.5596157879354227	2.5977891399005153	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b86a	58cfa82fe4b0c9d6adf6b86a	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina.bam	38.0	1.9	0.05	58cfa82fe4b0c9d6adf6b86a	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2680-01A	FF1407C6-9174-4BAE-A19B-D34CA71B898C	Primary Tumor	Illumina HiSeq	d43e0ed3-ab1d-486a-bbf5-91dabacf8220	Colorectal	72.0	D664F620-CFEE-4700-B00E-68B65387883C	2CDC4CCE-0877-4EC1-85F5-20C909912E65	TCGA-A6-2680-01A-01D-1554-10	GRCh37-lite	TCGA-A6-2680	TCGA-COAD		s13172	Baylor College of Medicine	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage II	1554-10	False	COAD	C1		0.120522879			13.89243895	0.4341	0.203	-0.3673	-0.0889	-0.2521	0.22					92.0	0.510387334	15.0	6.0							1.254761391	-898.1483911	-319.54133260000003	-1017.8321890000001	0.0	1068.0	0.0	1068.0	6.734353819562741	6.988466980404323	-0.8261228632507451	5.299269294273419	8.078539507524297	0.8683827909644142	-1.4350845252893227	1.0900725271199754	1.6945056542151593	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b86c	58cfa82fe4b0c9d6adf6b86c	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.bam	77.93	2.03	0.16	58cfa82fe4b0c9d6adf6b86c	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0VP-01A	2DB0FB62-64CE-457C-9E22-DD05EF59F684	Primary Tumor	Illumina HiSeq	26cc510d-e8a9-4782-9488-478373dbc1df	Uterus	74.0	F1FBE4AC-F3FD-4609-9A2B-507820ABE77E	E23FE404-0449-453D-971C-6E940B546119	TCGA-A5-A0VP-01A-21D-A101-02	HG19_Broad_variant	TCGA-A5-A0VP	TCGA-UCEC		s4992	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.POLE	0.157312652	0.15	0.04	0.34627037899999996	0.2954	0.114	-0.545	0.2528	-0.059000000000000004	-0.0943	520.0		15.76493612	39.78361597	57.0	0.081252318	2.0	0.0							2.064174894	-663.8111048	-2.605393555	-1424.31621	0.0	1288.0	0.0	1288.0	7.682828008940755	8.242975619917747	0.36530778626110016	5.157099364632499	7.26214636690602	1.8857416275888603	-2.5257286443082556	-0.9808292530117262	1.52043384132776	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b86e	58cfa82fe4b0c9d6adf6b86e	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	243.0	1.9	0.15	58cfa82fe4b0c9d6adf6b86e	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2671-01A	565E2726-4942-4726-89D3-C5E3797F7204	Primary Tumor	Illumina HiSeq	866dc7b9-86cd-4842-ad2f-1d5e7c714ccb	Colorectal	85.0	81505915-6C01-4299-AE89-964DC20D93CB	82E23BAF-DA11-4175-BEE0-81C0C0137D72	TCGA-A6-2671-01A-01D-1405-02	HG18	TCGA-A6-2671	TCGA-COAD		s13649	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Adenocarcinoma	Stage IV	1405-02	True	COAD	C2	GI.CIN	0.090780355	0.27	0.29	0.196756182	0.5382	0.252	-0.2334	-0.6621	0.4517	0.4229	20.0	52.0	0.9301965520000001	1.550327587	182.0	0.860899243	21.0	27.0	0.9589012809999999	3.436240901	36.0				0.851149314	-1067.174364	-723.8012668	-636.3894188999999	1.0	1331.0	1.0	535.0	7.015156567987615	5.897269942001848	-0.7013336242643542	5.042399168896114	6.320497506449852	1.9324070391914638	-1.9727573990915013	0.4232275644480046	2.633740663455818	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b874	58cfa82fe4b0c9d6adf6b874	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted.bam	105.24	2.0	0.15	58cfa82fe4b0c9d6adf6b874	TCGA-A5-A0VQ-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_2_rg.sorted.bam	Alive	FEMALE		HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0VQ-01A	23489245-48D7-4F19-8A42-E23B1181412B	Primary Tumor	Illumina HiSeq	b4dd6449-2e78-432b-86c6-348339f37763	Uterus	62.0	952CB6A5-7527-470A-978E-EDD44E3A368F	97FE43D0-30DF-45A1-83F0-B4ED5EDF76AE	TCGA-A5-A0VQ-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0VQ	TCGA-UCEC		s5381	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.080162556	0.16	0.0	12.52508666	-0.2633	-0.027000000000000003	-0.5309	0.1054	-0.7547	0.1601	173.0	1085.0	3.114912074	10.40263089	47.0	7.099999999999999e-05	0.0	0.0							1.852927351	-946.1753448999999	-757.1435478	255.21428930000002	0.0	485.0	0.0	485.0	7.31183848031586	7.55522494604543	-0.11044311872129209	6.367376871475009	6.862077765485486	1.417685461424079	-0.9444616088408515	-0.693147180559945	1.528128580145371	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b882	58cfa82fe4b0c9d6adf6b882	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	493.29	1.9	0.15	58cfa82fe4b0c9d6adf6b882	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2678-01A	3A785E32-7960-4C72-84C4-FB42C4DD86F1	Primary Tumor	Illumina HiSeq	31675676-aba0-4d34-a2dc-0356129ceaa2	Colorectal	43.0	20ECCD8A-DFAF-40E4-8128-D77AA41680C4	83E77250-E68B-4ECA-9592-4424151E0D79	TCGA-A6-2678-01A-01D-1167-02	HG18	TCGA-A6-2678	TCGA-COAD		s12856	Harvard Medical School	Christiana Healthcare	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1167-02	True	COAD	C1		0.08780803300000001	0.18	0.15	3.850381374	0.8639	0.35	-0.1362	-0.1358	0.0303	-0.0352			0.510069885	4.250582372	175.0	0.889683412	5.0	31.0	0.8953732	3.62003975	57.0				3.2931244410000002	-578.1910761	824.7166388999999	-9.411211377999999	0.0	1286.0	0.0	1286.0	7.133960804332165	5.758978091306946	-0.36491160600461126	5.531211880048862	6.079449986581718	1.4069136483226266	-1.6027489242833037	0.32047189527477205	1.7718252543272377	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b88f	58cfa82fe4b0c9d6adf6b88f	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.bam	216.0	1.9	0.15	58cfa82fe4b0c9d6adf6b88f	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4676-01A	195A5AFB-B79F-44D2-9D12-884487630C2B	Primary Tumor	Illumina HiSeq	a2b68d59-a4d4-4793-9e6c-72ccaf7c242b	Lung	45.0	22434A49-EB8A-43AC-8C08-AE6DCBE6FBB8	A79111BF-CB9D-4790-AE9F-6CB13C9334E2	TCGA-73-4676-01A-01D-1751-02	HG19_Broad_variant	TCGA-73-4676	TCGA-LUAD		s11465	Harvard Medical School	Roswell Park	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	True	LUAD	C4	LUAD.3	0.18810130100000003	0.23	0.51	15.70444452	0.6599	0.2985	0.5375	-0.2732	-0.3892	0.0533	38.0	34.0	0.8429175659999999	2.46631436	166.0	0.91212221	9.0	20.0				1.5607104090000001	5.0	0.9697239	3.969147928	-287.6476414	570.0622929	1275.454745	1.0	281.0	1.0	281.0	8.419638389067373	7.708621555198421	0.21553859712586987	7.780558429777702	7.693583677833881	2.6965022985143143	-0.6390799592896697	-0.015037877364540542	2.4809637013884442	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b892	58cfa82fe4b0c9d6adf6b892	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	308.0	1.9	0.15	58cfa82fe4b0c9d6adf6b892	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2681-01A	7D8EAB0A-E6C8-4449-9EBF-50C41DB94A06	Primary Tumor	Illumina HiSeq	eda754a1-3a13-47a5-8e0e-49ef1384646d	Colorectal	73.0	0537BAD8-0E85-4B05-91B3-FD965E96D0D7	BFF8CDA3-3C4B-416F-AF46-6811B139D670	TCGA-A6-2681-01A-01D-1405-02	HG18	TCGA-A6-2681	TCGA-COAD		s12860	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	True	COAD	C1	GI.CIN	0.158554139	0.28	0.52	6.232465795	0.2784	0.18	-0.0352	0.1826	-0.1314	0.44799999999999995	49.0	13.0			147.0	0.491324508	10.0	21.0							1.190940728	-574.9617732999999	-447.9774324	-353.9483236	0.0	1387.0	1.0	1150.0	6.875920555462118	6.392928372158752	-1.024922050423966	4.540545639645082	7.192182058713246	0.6914333840822104	-2.3353749158170363	0.7992536865544935	1.7163554345061764	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b896	58cfa82fe4b0c9d6adf6b896	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.bam	39.7	2.0	0.13	58cfa82fe4b0c9d6adf6b896	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-6742-01A	21FB46F9-4BBB-441C-AF19-A687E9138344	Primary Tumor	Illumina HiSeq	eeeb9a6f-97a9-4db9-aeb9-c5afaf9d0153	Lung	70.0	F0A4AE58-D5BC-4AB0-B1CF-0D951EA91FC7	04467FAB-BB2F-4F26-AF9E-39C09D920A63	TCGA-49-6742-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6742	TCGA-LUAD		s10655	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N1	Mucinous (Colloid) Carcinoma	Stage IIA	1853-02	True	LUAD	C2	LUAD.1	0.184550443	0.51	0.16	6.488996263	0.5312	0.1055	-0.1611	-0.4244	0.9717	-0.0655	101.0	39.0	2.454418741	6.486678102000001	120.0	0.79654434	18.0	9.0	0.977603771	1.074007516	3.0	1.609437912	5.0	1.0	6.85347966	104.9344666	692.3114479	3032.317442	1.0	488.0	1.0	214.0	7.129831594335924	9.130464317081968	0.4957728756653238	5.20801899685967	9.09272398909912	2.9666024115624876	-1.921812597476253	-0.03774032798284699	2.4708295358971637	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b898	58cfa82fe4b0c9d6adf6b898	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.filtered.	WGS	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.bam	296.29	1.9	0.17	58cfa82fe4b0c9d6adf6b898	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2676-01A	89A6384E-1CEA-440B-9F17-D57CB0805174	Primary Tumor	Illumina HiSeq	c175a01b-eba5-4c4d-b786-fc9f54a2fa60	Colorectal	75.0	CBBD1187-E8F7-4E63-A8E2-3C19863E89F5	D02407DB-AECE-475A-AA3F-00653B1E7BEE	TCGA-A6-2676-01A-01D-1167-02	HG18_Broad_variant	TCGA-A6-2676	TCGA-COAD		s13022	Harvard Medical School	Christiana Healthcare	None	NO	T4	N0	Colon Adenocarcinoma	Stage IIB	1167-02	True	COAD	C2		0.25463716			9.319250578	1.1417	0.39	0.4016	0.0904	0.0309	-0.2207					181.0	0.04364106	1.0	5.0							0.259663365	496.3994431	955.0996397	-1534.821392	1.0	1305.0	0.0	1305.0	6.1132482838736735	6.019011314428208	0.28813498566194307	5.082229286338093	6.265871392359733	1.655708451275971	-1.0310189975355812	0.2468600779315251	1.367573465614028	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b89a	58cfa82fe4b0c9d6adf6b89a	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	467.29	1.9	0.16	58cfa82fe4b0c9d6adf6b89a	TCGA-A6-2683-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2683-01A	FAFD4576-0709-49E1-926F-AD1EE09907EC	Primary Tumor	Illumina HiSeq	06c41745-bee7-471d-9c51-8886c6c8dd9c	Colorectal	57.0	C24759F8-566B-42DA-A26D-BB0BF51EE15F	B22E3766-3FC6-4E77-86D0-0A10A810D313	TCGA-A6-2683-01A-01D-1167-02	HG18	TCGA-A6-2683	TCGA-COAD		s12852	Harvard Medical School	Christiana Healthcare	None	NO	T4	N0	Colon Adenocarcinoma	Stage IV	1167-02	True	COAD	C4		0.012108988999999999	0.15	0.25	5.610129489	-0.3185	-0.239	-1.2731	-1.1308	-2.0227	-0.1281			1.812045573	5.617341276	200.0	0.6207420539999999	16.0	15.0	0.889716753	3.137462036	34.0				0.702937452	-867.4073686	-1378.026545	3408.0083590000004	1.0	504.0	1.0	300.0	6.425821949458725	7.396845083364349	-0.6212050080639286	5.963198427510612	7.6631130613123135	1.9831777482891788	-0.46262352194811296	0.2662679779479644	2.6043827563531075	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b89b	58cfa82fe4b0c9d6adf6b89b	TCGA-A6-A566-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-A6-A566-01A-11D-A28G-10_wgs_Illumina	TCGA-A6-A566-01A-11D-A28G-10_wgs_Illumina.bam	17.81		0.08	58cfa82fe4b0c9d6adf6b89b	TCGA-A6-A566-01A-11D-A28G-10_wgs_Illumina.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-A566-01A	790266BC-C252-43F4-85D1-1B06EE529CF8	Primary Tumor	Illumina HiSeq	dd970455-c925-43f6-b58d-24982c846bdd	Colorectal	55.0	615FDEE9-637E-45C6-8909-36B9201A8EB7	492B4E58-12E2-47B2-BD47-28F8607072FA	TCGA-A6-A566-01A-11D-A28G-10	GRCh37-lite	TCGA-A6-A566	TCGA-COAD	758.0	s13351	Baylor College of Medicine	Christiana Healthcare	United States	NO	T4	N1	Colon Mucinous Adenocarcinoma	Stage IIIB	A28G-10	True	COAD	C1	GI.GS	0.46814417799999997	0.61	0.0	0.09889999	0.4912	0.161	0.8537	0.3945	0.1403	0.8095	87.0	54.0	1.572779259	3.853309185	79.0	0.12085626199999999	4.0	4.0				2.6156305769999997	14.0	0.99112306	1.52474475	-212.9376332	460.1294871	-1704.622527	1.0	758.0	1.0	257.0	7.1383377593933455	3.914540841420486	-1.3696734798838504	5.145907594703139	5.657580765454457	2.797880915141909	-1.9924301646902063	1.7430399240339716	4.16755439502576	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8a5	58cfa82fe4b0c9d6adf6b8a5	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina.bam	467.29	1.9	0.05	58cfa82fe4b0c9d6adf6b8a5	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2683-01A	FAFD4576-0709-49E1-926F-AD1EE09907EC	Primary Tumor	Illumina HiSeq	9e91b702-c4fb-4c6e-9060-987e5ff14421	Colorectal	57.0	C24759F8-566B-42DA-A26D-BB0BF51EE15F	FC453F67-6623-4E8C-B519-0BD79E4D4651	TCGA-A6-2683-01A-01D-1554-10	GRCh37-lite	TCGA-A6-2683	TCGA-COAD		s13015	Baylor College of Medicine	Christiana Healthcare	None	NO	T4	N0	Colon Adenocarcinoma	Stage IV	1554-10	False	COAD	C4		0.012108988999999999	0.15	0.25	5.610129489	-0.3185	-0.239	-1.2731	-1.1308	-2.0227	-0.1281			1.812045573	5.617341276	200.0	0.6207420539999999	16.0	15.0	0.889716753	3.137462036	34.0				0.702937452	-867.4073686	-1378.026545	3408.0083590000004	1.0	504.0	1.0	300.0	4.901204378948056	6.880759306015396	-0.6212050080639286	5.339459309879212	8.496669732955114	1.9831777482891788	0.4382549309311554	1.6159104269397178	2.6043827563531075	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8b3	58cfa82fe4b0c9d6adf6b8b3	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.bam	416.7	1.9	0.15	58cfa82fe4b0c9d6adf6b8b3	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5051-01A	E1C55BAC-BB41-4964-ADD5-ECD6BA04B58D	Primary Tumor	Illumina HiSeq	fd2a1c20-3ed6-4057-8fb5-4027ce0eec74	Lung	42.0	180EB213-0DDC-4F10-AB0E-B3AF92CDE3C3	80170E98-4886-4A34-BC88-F2B2F84743B2	TCGA-50-5051-01A-21D-1853-02	HG19_Broad_variant	TCGA-50-5051	TCGA-LUAD		s10789	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True	LUAD	C1	LUAD.3	0.20476021100000003	0.41	0.26		0.1488	0.049	-0.2444	0.7024	-1.0188	0.0887	43.0	4.0	1.12645884	2.83058888	99.0	0.589783362	18.0	7.0	0.934572491	3.11418667	28.0	2.163955657	9.0	0.984858662	2.551435376	-637.1228579	-50.48416948	1639.712896	1.0	478.0	1.0	184.0	7.168856418627073	7.610264746244045	-0.07602255187577867	6.389766808266403	6.886345907017347	2.697163125908543	-0.7790896103606704	-0.7239188392266991	2.773185677784322	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8b8	58cfa82fe4b0c9d6adf6b8b8	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	482.2	1.9	0.16	58cfa82fe4b0c9d6adf6b8b8	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4675-01A	AE39E358-08D7-4367-AE68-82B469E791E4	Primary Tumor	Illumina HiSeq	14b3ad66-64c9-4b39-a34e-5cb29788735a	Lung	59.0	1F5FA8FD-1DE8-4456-8935-71B5A8B54BD2	356D01E0-DF80-40C6-BA06-8CD4EDFBD1EC	TCGA-73-4675-01A-01D-1203-02	GRCh37	TCGA-73-4675	TCGA-LUAD		s11013	Harvard Medical School	Roswell Park	United States	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True	LUAD	C3	LUAD.4	0.133261342	0.43	0.07	1.252497564	-0.7634	-0.113	0.3031	0.3204	-0.6313	0.28300000000000003	24.0	237.0	0.714646015	1.727061203	123.0	0.774866155	22.0	13.0	0.954739862	1.710664189	6.0	2.2718685130000003	10.0	0.986659959	2.115296481	-911.7271651000001	-1104.928668	4040.9521	1.0	922.0	1.0	361.0	9.584250925749025	7.216893023463208	-0.42553332601058924	7.81658900810003	7.216893023463208	0.8306275390601834	-1.767661917648995	0.0	1.2561608650707727	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8bc	58cfa82fe4b0c9d6adf6b8bc	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	311.9	1.9	0.15	58cfa82fe4b0c9d6adf6b8bc	TCGA-73-4668-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	AMERICAN INDIAN OR ALASKA NATIVE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4668-01A	B2285924-9813-4F46-BB8F-91A0EFD8A9B6	Primary Tumor	Illumina HiSeq	c3c82aae-4b64-4f65-b4ed-048053aef739	Lung	66.0	FDBFDF52-C0CD-4FBB-A910-B747516DFEF4	DC227D17-FED3-489A-B5C6-3D4C910310FF	TCGA-73-4668-01A-01D-1203-02	GRCh37	TCGA-73-4668	TCGA-LUAD		s10795	Harvard Medical School	Roswell Park	United States	NO	T2	N1	Lung Micropapillary Adenocarcinoma	Stage IIB	1203-02	True	LUAD	C1		0.220254454	0.47	0.35	3.804938998	0.0276	0.161	0.0142	0.2742	-1.0243	0.6224	277.0	152.0	3.192446972	13.14707708	226.0	0.637350441	20.0	35.0	0.868664078	4.749907422	237.0	1.7478680969999998	6.0	0.9755037590000001	2.483417596	-244.45323530000002	-219.54078379999999	1963.312032	0.0	467.0	1.0	236.0	8.642784050373342	6.361034440939718	0.0008121827857625608	7.351799869057777	6.866129389996724	3.4918502684477075	-1.2909841813155656	0.5050949490570056	3.491038085661945	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8c4	58cfa82fe4b0c9d6adf6b8c4	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	177.53	1.9	0.14	58cfa82fe4b0c9d6adf6b8c4	TCGA-49-4510-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4510-01A	F77B6930-A1CE-446E-A15D-C018CBBECFEE	Primary Tumor	Illumina HiSeq	abe8920d-80b9-4fc8-a249-5bf0a4a06ac7	Lung	51.0	9A479D32-13A4-46C2-B26D-34CB6051A891	3324FA3E-B195-4974-A15B-0C8D8AC2EFA9	TCGA-49-4510-01A-01D-1203-02	GRCh37	TCGA-49-4510	TCGA-LUAD	896.0	s11338	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	True	LUAD	C3	LUAD.1	0.131528736	0.36	0.48	3.81020079	-1.5092	-0.028999999999999998	0.1	0.7584	-0.7169	0.0766	19.0	2.0	0.36054473600000003	1.2919519720000001	184.0	0.653190021	21.0	21.0	0.843413837	3.424633821	58.0	1.906154747	7.0	0.979569765	2.535424891	-630.0956186000001	-1516.006852	1527.6532650000001	1.0	896.0	1.0	502.0	8.732696199405904	7.752139808830984	0.007790117296414545	7.311310518474743	7.154302808075364	3.0074403255456312	-1.421385680931161	-0.5978370007556202	2.9996502082492165	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8c6	58cfa82fe4b0c9d6adf6b8c6	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.bam	89.76	2.06	0.14	58cfa82fe4b0c9d6adf6b8c6	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GX-01A	553F0CCD-4E6F-4AE2-9B39-97529EB3D826	Primary Tumor	Illumina HiSeq	cae767f1-aaee-4821-aa36-3ceb0b1756e8	Uterus	53.0	983A35A9-C825-4961-86C0-4C6133B5C9C1	FE0654FE-39AA-4993-8F36-768C7D829092	TCGA-A5-A0GX-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GX	TCGA-UCEC		s4989	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_LOW	0.141398764	0.69	0.0	1.072099621	-1.1378	-0.348	-0.2959	0.5406	-0.8162	0.3931	16.0	1.0	0.241602917	0.936211303	61.0	0.029858481	0.0	3.0							2.6930270530000002	-215.3142048	-2173.227207	1384.770059	0.0	2088.0	0.0	2088.0	5.505992498758907	6.871506146307016	0.008457651127819932	4.809837797135007	6.283719481404897	1.491851901702007	-0.6961547016239003	-0.5877866649021191	1.4833942505741873	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8c8	58cfa82fe4b0c9d6adf6b8c8	TCGA-A6-2681-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-A6-2681-01A-01D-1554-10_wgs_Illumina	TCGA-A6-2681-01A-01D-1554-10_wgs_Illumina.bam	308.0	1.9	0.05	58cfa82fe4b0c9d6adf6b8c8	TCGA-A6-2681-01A-01D-1554-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2681-01A	7D8EAB0A-E6C8-4449-9EBF-50C41DB94A06	Primary Tumor	Illumina HiSeq	11d59d80-a10a-4e78-b8a8-64a9569a9e32	Colorectal	73.0	0537BAD8-0E85-4B05-91B3-FD965E96D0D7	D3DAF373-1485-455E-A0A1-8E33D215D623	TCGA-A6-2681-01A-01D-1554-10	GRCh37-lite	TCGA-A6-2681	TCGA-COAD		s13650	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1554-10	False	COAD	C1	GI.CIN	0.158554139	0.28	0.52	6.232465795	0.2784	0.18	-0.0352	0.1826	-0.1314	0.44799999999999995	49.0	13.0			147.0	0.491324508	10.0	21.0							1.190940728	-574.9617732999999	-447.9774324	-353.9483236	0.0	1387.0	1.0	1150.0	6.993703591118502	7.019715943679848	-1.024922050423966	5.288955498880076	7.464401764941294	0.6914333840822104	-1.7047480922384255	0.4446858212614462	1.7163554345061764	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8ca	58cfa82fe4b0c9d6adf6b8ca	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina.bam	55.16		0.09	58cfa82fe4b0c9d6adf6b8ca	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-A4-A4ZT-01A	8B3C068D-5090-4030-8E7E-39DA005DEE79	Primary Tumor	Illumina HiSeq	90b348f5-ec38-4672-a60b-2bf4add19464	Kidney	71.0	460188E7-2A1E-4C3F-9C96-48C59A3FA9A0	483BB781-0179-42E1-BF9C-487B240769B8	TCGA-A4-A4ZT-01A-11D-A26P-10	GRCh37-lite	TCGA-A4-A4ZT	TCGA-KIRP		s11635	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True	KIRP	C3	KIRP.C1	0.15759088599999999	0.18	0.06		-2.4867	-0.2655	0.0052	-0.2944	-0.3365	-0.3358	24.0	2.0	0.29425704199999997	1.177028166	45.0	0.947731338	12.0	0.0				2.094729048	9.0	0.9533522740000001	2.366762694	-1279.4877880000001	-1988.653079	323.98747599999996	0.0	516.0	0.0	516.0	6.961296045910166	2.9464709839296352	-0.2006706954621511	5.203438128357792	2.291482278964734	4.670155036077504	-1.7578579175523739	-0.654988704964901	4.8708257315396555	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8d2	58cfa82fe4b0c9d6adf6b8d2	TCGA-61-2000-01A-01D-A324-10_wgs_Illumina.filtered.	WGS	TCGA-61-2000-01A-01D-A324-10_wgs_Illumina	TCGA-61-2000-01A-01D-A324-10_wgs_Illumina.bam	730.97	1.9	0.08	58cfa82fe4b0c9d6adf6b8d2	TCGA-61-2000-01A-01D-A324-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Ovarian Serous Cystadenocarcinoma	Aligned reads	TCGA-61-2000-01A	29949B65-2913-4C86-BBD7-B85C5DF6F15E	Primary Tumor	Illumina HiSeq	19381aa5-278b-49eb-87b8-c53fac7ee2e4	Ovary	67.0	FDB8966D-55C9-49BE-80DD-369246604AAD	B243ADB4-B3E7-4E0E-BC0D-625AA8DBB1BE	TCGA-61-2000-01A-01D-A324-10	GRCh37-lite	TCGA-61-2000	TCGA-OV		s17798	Baylor College of Medicine	University of Pittsburgh	None	NO			Serous Cystadenocarcinoma		A324-10	True	OV	C2	OVCA.Immunoreactive	0.051726456	0.08	0.09		0.7873	0.3435	-0.0031	-0.5024	0.9411	0.0567			0.666748566	2.000245697	846.0	0.382055729	5.0	43.0		0.0	1.0	3.5317065469999998	37.0	0.978063371	2.800464204	-1826.1052550000002	95.38785886	-2234.181873	0.0	441.0	1.0	339.0	5.969985515430857	3.3112832450145637	0.423027778005469	2.8344912995017078	1.9904940556633397	1.9036963758988266	-3.1354942159291497	-1.320789189351224	1.4806685978933576	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8d4	58cfa82fe4b0c9d6adf6b8d4	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.bam	743.7	1.9	0.16	58cfa82fe4b0c9d6adf6b8d4	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5049-01A	9944F46F-9FA8-4E2C-A806-776BEC7F8803	Primary Tumor	Illumina HiSeq	16ea05eb-f830-4b36-83bb-989c8de99568	Lung	70.0	21B2F32E-CCEA-4B20-86D3-6647E99825CF	26ED24EC-1AD1-492D-B2CB-46314B47919E	TCGA-50-5049-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5049	TCGA-LUAD		s11457	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	True	LUAD	C2	LUAD.6	0.568415873	0.74	0.49		0.017	0.1185	1.7417	2.8005	0.6184	0.3579	465.0	779.0	6.1515208260000005	21.92064782	132.0	0.469644302	14.0	26.0	0.718684765	4.0648751469999995	286.0	4.654619886	112.0	0.986462011	4.7147008360000005	543.5997721	-376.5524606	-463.12968600000005	0.0	3094.0	1.0	1568.0	7.517928376248827	7.993141599974028	-0.256449127375883	6.506327464570346	7.993141599974028	2.821755250734318	-1.0116009116784803	0.0	3.0782043781102013	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8d8	58cfa82fe4b0c9d6adf6b8d8	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina.filtered.	WGS	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina.bam	190.3	1.9	0.05	58cfa82fe4b0c9d6adf6b8d8	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-6781-01A	B54865B6-824E-4163-B759-21A6EACC98CE	Primary Tumor	Illumina HiSeq	bee0f5f3-5654-4349-b3dd-afe0b89cc488	Colorectal	43.0	F1B2CA40-F20A-42DE-ABA2-4F730D7CCC09	2182CE2C-5941-4B65-9419-FC7966D5E6D5	TCGA-A6-6781-01A-22D-1924-10	GRCh37-lite	TCGA-A6-6781	TCGA-COAD		s13354	Baylor College of Medicine	Christiana Healthcare	United States	NO	T4b	N1b	Colon Mucinous Adenocarcinoma	Stage IIIC	1924-10	False	COAD	C1		0.44507442399999997	0.5	0.02		0.33799999999999997	0.1065	0.7452	0.6659999999999999	0.1932	0.884	437.0	1516.0	15.64698589	45.66164436	39.0	0.000147524	0.0	0.0	0.877555715	3.258866392	41.0	3.193148395	25.0	0.992007324	1.690261411	-831.2414569	213.2778568	2422.823532	0.0	598.0	0.0	598.0	6.978912473298465	4.454940594285265	-1.2672296474552571	5.750247056382157	7.27595965667725	2.2381047943245416	-1.2286654169163076	2.8210190623919846	3.5053344417797985	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8d9	58cfa82fe4b0c9d6adf6b8d9	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.bam	853.7	1.9	0.17	58cfa82fe4b0c9d6adf6b8d9	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5055-01A	CC3D9750-7CE0-489F-86D4-8017B7EBED29	Primary Tumor	Illumina HiSeq	97723d64-755b-4f00-b641-95ad083c397e	Lung	79.0	68D19E88-7FBD-48CC-A09F-55C47BFAF6E7	323E338B-1BA7-49E2-811B-C1FEE673A926	TCGA-50-5055-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5055	TCGA-LUAD		s11008	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIA	1623-02	True	LUAD	C2	LUAD.6	0.6179358939999999	0.87	0.18	15.64200601	-0.4041	0.0665	1.4269	3.1334	0.8607	0.441	17.0	5.0	0.030094961	0.57180426	96.0	0.037694366	1.0	2.0	0.967225452	3.4660707239999997	36.0	4.438814863	88.0	0.991396235	3.383425111	129.2780956	-968.7327696000001	45.44032255	1.0	1830.0	1.0	771.0	6.823772803059816	8.072370533206836	-0.16205382522851863	7.20326242476472	8.107461853018107	0.8986228801598237	0.3794896217049035	0.03509131981127034	1.0606767053883424	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8de	58cfa82fe4b0c9d6adf6b8de	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.bam	59.5	2.02	0.17	58cfa82fe4b0c9d6adf6b8de	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A0D9-01A	17BAEF7C-D97D-4B98-AB53-503EF856523D	Primary Tumor	Illumina HiSeq	43dc32db-2202-486d-82f4-388e37224379	Breast	37.0	C144AE50-ED29-4E27-BBEE-FA81E79AC7DB	7CD9AC40-F6B5-4C68-9D9A-D57845B812DB	TCGA-A7-A0D9-01A-31D-A060-02	HG19_Broad_variant	TCGA-A7-A0D9	TCGA-BRCA		s5638	Harvard Medical School	Christiana Healthcare	None	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True	BRCA	C1	BRCA.Normal	0.061319279000000004	0.2	0.01	2.399320084	-0.6477	-0.086	-0.7559	-1.2619	-0.9596	0.3222	9.0		0.23806566399999998	0.565405952	251.0	0.187991722	7.0	16.0				1.609437912	5.0	1.0	1.81523756	-515.8217777	623.8602628	347.3096347	0.0	1139.0	0.0	1139.0	6.542471960506805	6.694011852179842	-0.31949017964800674	4.29118016190031	6.326287072054525		-2.251291798606495	-0.3677247801253176		lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8e1	58cfa82fe4b0c9d6adf6b8e1	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina.bam	38.26		0.08	58cfa82fe4b0c9d6adf6b8e1	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-A56B-01A	74A0264D-1D31-430D-9A88-E7334C8AA96C	Primary Tumor	Illumina HiSeq	319d9aec-3e76-4b48-b4a8-9ffcb0f3acc4	Colorectal	57.0	4425892C-8C35-4F6C-B531-1EC510AD19D2	D3D65DB3-36F9-41C7-8E5E-1683CE94DFCB	TCGA-A6-A56B-01A-31D-A28G-10	GRCh37-lite	TCGA-A6-A56B	TCGA-COAD		s13353	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	A28G-10	True	COAD	C1	GI.CIN	0.091189779	0.28	0.08	6.5417064179999995	0.5549	0.0865	-0.8104	-1.7011	-1.3032	0.1542	53.0	90.0	0.824496109	2.207521841	289.0	0.458034024	10.0	36.0				0.0	1.0		0.84389422	-1505.85931	-110.5615	-2877.532127	1.0	1711.0	1.0	1678.0	7.838080399820094	3.870365658758403	-1.429969424622552	5.8921702507647815	4.057105780684608	0.7126097296348572	-1.9459101490553132	0.1867401219262046	2.1425791542574095	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8e2	58cfa82fe4b0c9d6adf6b8e2	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.bam	8.32		0.14	58cfa82fe4b0c9d6adf6b8e2	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A26F-01B	3B7B9C1E-A84C-47ED-983C-9E4B00CBF01A	Primary Tumor	Illumina HiSeq	4925c013-4605-47d0-9c97-2e8a69233aa4	Breast	55.0	29619D1E-E8B4-411E-BBBA-07F2CFB69E8A	A723DE1E-A9E0-487D-8D86-7AA4A062A1C2	TCGA-A7-A26F-01B-04D-A22S-26	HG19_Broad_variant	TCGA-A7-A26F	TCGA-BRCA		s6916	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	YES	T1	N0	Other  specify	Stage IA	A22S-26	False	BRCA	C2	BRCA.Basal	0.27558046199999997	0.54	0.57	3.895528995	0.5988	0.0945	0.5889	0.5332	1.6194	0.6404	10.0	8.0	0.340757222	0.908685924	80.0	0.428884304	7.0	25.0	0.897735897	3.911173905	78.0	3.8971255460000003	51.0	0.9911745609999999	2.500544692	-174.078723	1020.309576	247.5168622	0.0	738.0	0.0	738.0	5.702823110503951	7.743226334754278	-0.05254146555951489	4.747215875448184	6.031683199383023	3.093564522791026	-0.9556072350557674	-1.7115431353712545	3.1461059883505404	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8e8	58cfa82fe4b0c9d6adf6b8e8	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	346.0	1.9	0.13	58cfa82fe4b0c9d6adf6b8e8	TCGA-AA-3510-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3510-01A	35C295C2-37D1-44B2-87A3-1039645E5BAE	Primary Tumor	Illumina HiSeq	0bb810fb-0134-4ea2-a821-41bbbdbd9155	Colorectal	70.0	C71C031C-3089-44E5-A49F-5284D7D300CE	DA2A173C-BBD3-4A90-8D1D-CD35CBE750F3	TCGA-AA-3510-01A-01D-1405-02	HG18	TCGA-AA-3510	TCGA-COAD		s13666	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	True	COAD	C1	GI.HM-SNV	0.21661485600000002	0.42	0.0		0.7233	0.313	-0.0243	0.4139	-0.6395	-0.0585	1721.0	13.0	20.0772658	79.28818528	79.0	0.00017837599999999997	0.0	0.0							0.629773488	-1006.8835359999999	139.53815480000003	1417.00891	0.0	1946.0	0.0	1946.0	6.114992366721257	6.600383626736282	-0.1149964096493179	5.299955368552275	9.055789612127585	2.169221424631231	-0.8150369981689822	2.455405985391302	2.2842178342805486	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8f2	58cfa82fe4b0c9d6adf6b8f2	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted.filtered.	WGS	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted.bam	289.4	1.9	0.15	58cfa82fe4b0c9d6adf6b8f2	TCGA-50-5932-01A-11D-1751_111007_SN590_0110_C003AACXX_s_6_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5932-01A	EBCBA7F2-CE13-4BAE-97CD-91A6B1DCD465	Primary Tumor	Illumina HiSeq	a1be116a-f392-49b3-97c6-b674ac8dee93	Lung	75.0	7ECB9621-7A1F-4876-9DFB-9B77CC4CB7B4	B9ACEF1D-8029-47AB-9830-06B2FF147CDB	TCGA-50-5932-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5932	TCGA-LUAD	1235.0	s10661	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1751-02	True	LUAD	C3	LUAD.1	0.080095786	0.16	0.08		-0.5204	-0.203	-0.1375	-0.2734	0.0707	-0.1919	45.0	257.0	0.493176974	2.0960021380000002	175.0	0.9471979620000001	9.0	25.0	0.850339445	2.628435323	22.0	2.397895273	11.0	1.0	1.932722085	-537.3001275	-833.4665190000001	4168.601715999999	1.0	1235.0	1.0	1090.0	7.628656583012436	6.358239948594922	-0.367151418490437	6.07805917060127	7.291059982420288	3.206778405392974	-1.550597412411167	0.9328200338253656	3.5739298238834114	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8fa	58cfa82fe4b0c9d6adf6b8fa	TCGA-AA-3518-01A-02D-1525-10_hg19_wgs_Illumina.filtered.	WGS	TCGA-AA-3518-01A-02D-1525-10_hg19_wgs_Illumina	TCGA-AA-3518-01A-02D-1525-10_hg19_wgs_Illumina.bam	3.86	1.9	0.05	58cfa82fe4b0c9d6adf6b8fa	TCGA-AA-3518-01A-02D-1525-10_hg19_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3518-01A	C5C4A0A5-900D-483D-9282-475654D63265	Primary Tumor	Illumina HiSeq	e3929c47-b19b-4c57-9990-6448eb979647	Colorectal	81.0	BC08B757-ED0A-44C0-88CD-85496BB72A75	F4B9D98F-7B76-4EAA-9595-10B0973D5FF7	TCGA-AA-3518-01A-02D-1525-10	GRCh37-lite	TCGA-AA-3518	TCGA-COAD		s13663	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1525-10	True	COAD	C1		0.13858648099999998			9.680869515	0.9129999999999999	0.317	-0.0384	0.5628	-0.0086	-0.0856					126.0	0.002637618	0.0	0.0	0.944506849	2.557771962	15.0				0.9818750759999999	-627.3481011	572.3954312000001	121.26900570000001	0.0	31.0	0.0	31.0	4.1566077695225365	-0.3082077788708357	-0.7162443371628529	4.292739943847117	2.922994858478023	2.2026068920551802	0.13613217432458002	3.2312026373488587	2.918851229218033	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8fb	58cfa82fe4b0c9d6adf6b8fb	TCGA-AA-3518-01A-02D-1525-10_Illumina.filtered.	WGS	TCGA-AA-3518-01A-02D-1525-10_Illumina	TCGA-AA-3518-01A-02D-1525-10_Illumina.bam	3.86	1.9	0.05	58cfa82fe4b0c9d6adf6b8fb	TCGA-AA-3518-01A-02D-1525-10_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3518-01A	C5C4A0A5-900D-483D-9282-475654D63265	Primary Tumor	Illumina HiSeq	7d2638fc-9574-4f2a-baf2-495e6ba99e93	Colorectal	81.0	BC08B757-ED0A-44C0-88CD-85496BB72A75	F4B9D98F-7B76-4EAA-9595-10B0973D5FF7	TCGA-AA-3518-01A-02D-1525-10	NCBI36_BCM_variant	TCGA-AA-3518	TCGA-COAD		s13027	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1525-10	True	COAD	C1		0.13858648099999998			9.680869515	0.9129999999999999	0.317	-0.0384	0.5628	-0.0086	-0.0856					126.0	0.002637618	0.0	0.0	0.944506849	2.557771962	15.0				0.9818750759999999	-627.3481011	572.3954312000001	121.26900570000001	0.0	31.0	0.0	31.0	5.000584958242754	-0.6950570691516118	-0.7162443371628529	4.425220813339193	2.475565637394861	2.2026068920551802	-0.575364144903562	3.1706227065464727	2.918851229218033	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b8fe	58cfa82fe4b0c9d6adf6b8fe	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.filtered.	WGS	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.bam	62.7	1.9	0.15	58cfa82fe4b0c9d6adf6b8fe	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-49-6744-01A	15340DD3-84AE-49FB-989A-EB212F3E73DA	Primary Tumor	Illumina HiSeq	8290093a-0193-41fa-8e87-71960e0e640e	Lung	64.0	A9D69D7E-298C-4AB6-B64F-1EDC58832CCD	7455D0A5-45DB-461F-9026-5A0FE3D55A6A	TCGA-49-6744-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6744	TCGA-LUAD		s10656	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIA	1853-02	True	LUAD	C2	LUAD.5	0.44227676899999996	0.63	0.57	12.88451397	-0.4994	-0.0635	1.176	1.9612	1.1316	0.5446	121.0	92.0	1.7370548780000001	6.006088054	145.0	0.43959410600000004	4.0	26.0							2.595987015	447.69177069999995	-440.64682410000006	3430.434145	0.0	1683.0	0.0	1683.0	6.69601702749594	6.924438860256367	-0.07320340402329495	5.891644211825771	6.839881472228305	1.6903851882380638	-0.8043728156701695	-0.08455738802806279	1.7635885922613588	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b904	58cfa82fe4b0c9d6adf6b904	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted.bam	180.7	1.9	0.15	58cfa82fe4b0c9d6adf6b904	TCGA-49-4512-01A-21D-1853_120123_SN590_0134_AC0DJKACXX_s_6_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4512-01A	A1E65587-24C1-4B41-92A7-4E1F15FFFD78	Primary Tumor	Illumina HiSeq	bfba789d-2b84-4c34-89f9-7a38586facf6	Lung	69.0	D809A778-D1AC-4406-AB09-67CC70F1F0C2	6D2569C8-4E18-423B-852D-315DDC3AE2F7	TCGA-49-4512-01A-21D-1853-02	HG19_Broad_variant	TCGA-49-4512	TCGA-LUAD	905.0	s10780	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True	LUAD	C6	LUAD.5	0.26382911600000003	0.68	0.24	3.1995179410000003	-0.5056	-0.057999999999999996	0.6702	0.5388	0.21100000000000002	0.4196	19.0	8.0	0.40609450399999997	0.928216009	172.0	0.459929696	27.0	25.0	0.597828221	0.41438294600000003	2.0	2.13833306	9.0	0.973197315	2.64112082	-64.61513789	-1483.7952089999999	-1293.443142	1.0	905.0	1.0	905.0	6.113336434228399	7.748675703831514	0.2669986225626447	5.468198472854815	7.263167888049814	2.479557563898971	-0.6451379613735848	-0.485507815781701	2.2125589413363262	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b909	58cfa82fe4b0c9d6adf6b909	TCGA-A3-3387-01A-01D-2102-10_Illumina.filtered.	WGS	TCGA-A3-3387-01A-01D-2102-10_Illumina	TCGA-A3-3387-01A-01D-2102-10_Illumina.bam	180.4	1.9	0.14	58cfa82fe4b0c9d6adf6b909	TCGA-A3-3387-01A-01D-2102-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3387-01A	9DC7812B-C7A2-4DE4-BF6D-4C7261384A62	Primary Tumor	Illumina HiSeq	1abe0bf3-83d3-40d9-8e12-5729d760aeed	Kidney	49.0	413ED4FA-013A-4751-8F74-D54F6CF992C9	00BF0350-8C7C-4B9E-8143-13EA2DC1122F	TCGA-A3-3387-01A-01D-2102-10	GRCh37-lite	TCGA-A3-3387	TCGA-KIRC		s9302	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1a	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2102-10	False	KIRC	C3	KIRC.3	0.302846475	0.47	0.29		-0.5883	-0.1615	1.1199	0.6511	0.1999	0.3415	44.0	43.0	0.541467051	2.1057051980000003	69.0	0.302369691	2.0	4.0	0.7894477940000001	1.0944070259999998	4.0	3.536954686	37.0	0.97951678	2.199461683	237.7434518	-591.0429382	589.3058363	0.0	617.0	0.0	617.0	5.825672292265237	3.3898856976587473	-0.05621516585301922	4.887402653672307	4.339993051912172	3.2889467667138117	-0.9382696385929301	0.9501073542534249	3.345161932566831	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b90e	58cfa82fe4b0c9d6adf6b90e	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	289.2	1.9	0.14	58cfa82fe4b0c9d6adf6b90e	TCGA-49-4507-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4507-01A	50B2C647-AECD-4C81-AF22-0D8116593552	Primary Tumor	Illumina HiSeq	557606c6-d245-45ba-b9f0-adc05c6a5f4f	Lung	73.0	962F85FF-1F27-49E4-8C3D-798FACEA122F	EF299B98-6A9F-4022-8683-A9C830E7263C	TCGA-49-4507-01A-01D-1203-02	GRCh37	TCGA-49-4507	TCGA-LUAD	268.0	s11453	Harvard Medical School	Johns Hopkins	United States	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True	LUAD	C2	LUAD.6	0.438484992	0.65	0.25	11.45848763	0.5781	0.466	0.6189	1.9869999999999999	0.4011	0.1309	68.0	11.0	1.422722768	5.009169745	280.0	0.554587909	8.0	42.0	0.8463634109999999	3.258624058	47.0	3.2231488710000002	36.0	0.899436818	2.500579986	-568.9986852999999	-238.06379180000002	1373.038225	1.0	268.0	1.0	158.0	7.841127853337296	7.4705309045330885	0.52148403187595	6.6959955490342935	6.899986046065475	1.283444009191347	-1.1451323043030026	-0.5705448584676129	0.7619599773153969	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b912	58cfa82fe4b0c9d6adf6b912	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted.bam	258.2	1.9	0.13	58cfa82fe4b0c9d6adf6b912	TCGA-49-4506-01A-01D-1203_110729_SN208_0215_BD0CLPABXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4506-01A	B61ABDFD-B7A0-4E1A-B570-D1EAECAD3A9E	Primary Tumor	Illumina HiSeq	b07f7ea8-c74b-4559-97d3-987f1985f2e9	Lung	68.0	9EDEA53D-AD06-4B5D-BFF0-48E834C3684F	2270ABD6-565B-46B6-8154-505C5659A7C3	TCGA-49-4506-01A-01D-1203-02	HG19_Broad_variant	TCGA-49-4506	TCGA-LUAD	999.0	s11234	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	True	LUAD	C2	LUAD.6	0.587712484	0.75	0.02	6.709587989	0.3451	0.3275	0.528	1.9721	0.1606	-0.2181	36.0	6.0	0.881189173	3.1905125219999997	117.0	0.310806578	16.0	9.0	0.827197443	3.071857317	41.0	2.7303695119999998	32.0	0.787818111	1.661637878	-969.5455636	-172.5153813	2715.791879	1.0	999.0	1.0	692.0	8.612543774444745	6.946626280643832	1.1128441715763342	7.048568236087403	7.265080011762366	1.7464975562124077	-1.5639755383573428	0.3184537311185345	0.6336533846360735	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b914	58cfa82fe4b0c9d6adf6b914	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	129.53	1.9	0.14	58cfa82fe4b0c9d6adf6b914	TCGA-49-4505-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4505-01A	088EDF89-D2B5-40C7-B066-DF3BD383F7EA	Primary Tumor	Illumina HiSeq	af550be6-0986-458b-8206-9c7cf928c215	Lung	61.0	D1FB0862-8D9C-4BC4-AAC6-81DC4EED66C9	30B77A0C-3439-44E2-A586-5DF68C0D0002	TCGA-49-4505-01A-01D-1203-02	GRCh37	TCGA-49-4505	TCGA-LUAD	428.0	s11125	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1203-02	True	LUAD	C2	LUAD.3	0.288164733	0.55	0.51	4.537675568	-0.9028	0.1075	0.9440000000000001	1.5631	0.8547	0.4168	93.0	140.0	1.860869603	5.103293911000001	207.0	0.589915074	20.0	30.0	0.9265155190000001	3.5061104210000003	44.0	3.786768215	50.0	0.9679820920000001	2.903570849	393.9044915	-1625.359227	1529.769771	1.0	428.0	1.0	417.0	7.994564855531094	8.155409984394197	0.3431475052037266	6.559480330241772	6.902647015898829	1.9035209016229053	-1.4350845252893227	-1.252762968495368	1.5603733964191786	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b920	58cfa82fe4b0c9d6adf6b920	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina.bam	21.0		0.08	58cfa82fe4b0c9d6adf6b920	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-A4-A48D-01A	925AE8FF-3200-4564-BE76-94DB0984B027	Primary Tumor	Illumina HiSeq	ca65f407-1de9-4171-8ae5-67e4d85f5beb	Kidney	84.0	4DDC37D4-35B8-4A5D-BBF1-6DBF0548852B	5ECC88F7-8391-4168-AF11-07A6BF9B3652	TCGA-A4-A48D-01A-11D-A25F-10	GRCh37-lite	TCGA-A4-A48D	TCGA-KIRP		s11850	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True	KIRP	C3	KIRP.C2a	0.417446693	0.07	0.1		-2.1533	-0.272	0.7165	-0.1989	-0.1516	-0.6146	29.0	75.0	0.905868053	2.0781678869999998	69.0	0.15974746199999998	6.0	0.0				2.48490665	12.0	1.0	1.370946067	-886.7344701999999	-2311.0859809999997	1316.386322	0.0	379.0	0.0	379.0	7.428399211685465	0.4752298530955006	0.37224941880425644	4.478129312208232	4.252697487654518	5.639370929583813	-2.9502698994772336	3.7774676345590175	5.267121510779556	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b92a	58cfa82fe4b0c9d6adf6b92a	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.bam	349.7	1.9	0.14	58cfa82fe4b0c9d6adf6b92a	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6828-01A	9536E32D-2707-48D2-A36D-08C521665BB9	Primary Tumor	Illumina HiSeq	94e2b6af-1f25-4698-9414-f3d916d26aee	Lung	70.0	CFE0F0E4-D8BF-40CE-99F1-2BF99CECA18B	2C0D4A9F-857D-4C6F-B616-304AB5922A2F	TCGA-91-6828-01A-11D-1853-02	HG19_Broad_variant	TCGA-91-6828	TCGA-LUAD		s10802	Harvard Medical School	ABS - IUPUI	United States	NO	T1a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	True	LUAD	C3	LUAD.3	0.295857012	0.63	0.5		-0.172	-0.209	1.0955	1.3453	-0.2616	0.0634	81.0	129.0	1.5688076869999998	7.379206529	127.0	0.522942636	26.0	22.0	0.8521463979999999	3.834496604	90.0	3.065964512	23.0	0.977824962	1.298475289	-98.20389184	-187.4588777	1640.948658	0.0	323.0	0.0	323.0	7.122098314343074	8.515238902083837	0.22950725232635505	5.876161310918105	8.033400815191097	2.3161207109535664	-1.245937003424968	-0.48183808689273855	2.086613458627211	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b92e	58cfa82fe4b0c9d6adf6b92e	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina.bam	37.08		0.08	58cfa82fe4b0c9d6adf6b92e	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-A4-A57E-01A	D80F601B-1064-4FF0-9C51-7F6AFB22D1F5	Primary Tumor	Illumina HiSeq	8e29468f-f3dd-48a6-9c1a-3bd0083bae2d	Kidney	59.0	341EA198-C8A2-4675-8077-2C450E9925E1	2DEB8F9A-9E0A-46D1-BCB5-902DB3B5C8AC	TCGA-A4-A57E-01A-11D-A26P-10	GRCh37-lite	TCGA-A4-A57E	TCGA-KIRP		s11637	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2a	N0	Kidney Papillary Renal Cell Carcinoma	Stage IV	A26P-10	True	KIRP	C4	KIRP.C2a	0.10822426800000001	0.17	0.07		-0.0827	0.095	-0.0461	-1.4089	-0.3763	-0.4503	35.0	24.0	0.58020551	1.74061653	98.0	0.41656350299999995	15.0	16.0		0.0	1.0	0.0	1.0		1.975459813	-653.4441404	-1175.54226	-679.4684484	1.0	258.0	1.0	258.0	7.750471229864229	4.400068928272205	-1.0521545670735661	5.671029688184394	3.9740932857482028	2.793208009442517	-2.079441541679836	-0.4259756425240022	3.845362576516083	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b940	58cfa82fe4b0c9d6adf6b940	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	236.0	1.9	0.14	58cfa82fe4b0c9d6adf6b940	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3808-01A	4F9775F2-B663-4DAF-AA9E-50915CAE9407	Primary Tumor	Illumina HiSeq	58504a37-4eb0-44ec-bb5d-83e955521de2	Colorectal	73.0	037BA047-2228-43DE-8DF8-32920A689ECA	2B2625B5-FBDD-41C3-9BB3-71566C5FBBA4	TCGA-A6-3808-01A-01D-1167-02	HG18	TCGA-A6-3808	TCGA-COAD		s13173	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True	COAD	C1		0.291840623			4.309410234	0.7144	0.335	0.3421	0.5654	-0.018000000000000002	0.3559	72.0	14.0													1.4630763969999998	-87.16627546	525.9417179999999	-1321.568276	0.0	1014.0	0.0	1014.0	6.315874530459439	6.744362017787946	0.009452519949087579	5.894661065383135	6.538509963583797	1.1906007770842426	-0.42121346507630353	-0.20585205420414887	1.1811482571351548	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b942	58cfa82fe4b0c9d6adf6b942	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.bam	65.96	1.81	0.16	58cfa82fe4b0c9d6adf6b942	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GN-01A	A2A2DBDA-D10C-49C4-86A8-61BAF6160CDA	Primary Tumor	Illumina HiSeq	7270b44f-635f-48bf-b3c4-8042b4557613	Uterus	65.0	F6F9C40B-1E58-47A3-B518-9694FB5FF2CF	41896FDE-677E-419C-B8B9-0171D6669A4A	TCGA-A5-A0GN-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GN	TCGA-UCEC		s4589	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_HIGH	0.130554428	0.13	0.3	6.88849788	-0.3402	-0.106	0.1014	1.0135	-0.4287	0.07400000000000001	33.0	2.0	0.366305566	1.52627319	76.0	0.947197958	20.0	1.0							2.550379603	-815.8845193	-551.7319511	3039.056584	0.0	1841.0	0.0	1841.0	5.783956106655665	6.803653230381617	-1.4403045893433024	5.191452451875406	5.8741172717574415	1.6520210670654654	-0.5925036547802582	-0.9295359586241756	3.092325656408768	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b952	58cfa82fe4b0c9d6adf6b952	TCGA-AA-3534-01A-01D-1525-10_hg19_wgs_Illumina.filtered.	WGS	TCGA-AA-3534-01A-01D-1525-10_hg19_wgs_Illumina	TCGA-AA-3534-01A-01D-1525-10_hg19_wgs_Illumina.bam	84.63	1.9	0.05	58cfa82fe4b0c9d6adf6b952	TCGA-AA-3534-01A-01D-1525-10_hg19_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3534-01A	DF228C56-89AC-4122-93B3-6C0740C4EC09	Primary Tumor	Illumina HiSeq	6e533853-5822-49cf-95a8-d75c517521cc	Colorectal	78.0	ECADE2C1-9DE2-4B05-B30C-4C8B81C65AE1	66701395-5A53-41BB-866B-3BBF08BC33AB	TCGA-AA-3534-01A-01D-1525-10	GRCh37-lite	TCGA-AA-3534	TCGA-COAD		s12861	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1525-10	True	COAD	C1		0.08197274	0.22	0.0	23.41939986	0.9011	0.22399999999999998	-0.5037	-0.115	-1.0331	0.0745			1.795578307	3.2646878310000003	99.0	0.9477267359999999	14.0	4.0	0.940405191	4.2824894680000005	95.0				0.464430175	-1340.0334599999999	801.9235239	-1860.630959	0.0	882.0	0.0	882.0	2.951867459907052	3.12556994426188	-0.6931471805599452	3.932696712918778	5.19226447393255	0.8985612678965857	0.9808292530117262	2.06669452967067	1.591708448456531	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b958	58cfa82fe4b0c9d6adf6b958	TCGA-AA-3534-01A-01D-1525-10_Illumina.filtered.	WGS	TCGA-AA-3534-01A-01D-1525-10_Illumina	TCGA-AA-3534-01A-01D-1525-10_Illumina.bam	84.63	1.9	0.05	58cfa82fe4b0c9d6adf6b958	TCGA-AA-3534-01A-01D-1525-10_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3534-01A	DF228C56-89AC-4122-93B3-6C0740C4EC09	Primary Tumor	Illumina HiSeq	a3cf0d96-684b-4e42-ac5f-e1e6813123de	Colorectal	78.0	ECADE2C1-9DE2-4B05-B30C-4C8B81C65AE1	66701395-5A53-41BB-866B-3BBF08BC33AB	TCGA-AA-3534-01A-01D-1525-10	NCBI36_BCM_variant	TCGA-AA-3534	TCGA-COAD		s13509	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1525-10	True	COAD	C1		0.08197274	0.22	0.0	23.41939986	0.9011	0.22399999999999998	-0.5037	-0.115	-1.0331	0.0745			1.795578307	3.2646878310000003	99.0	0.9477267359999999	14.0	4.0	0.940405191	4.2824894680000005	95.0				0.464430175	-1340.0334599999999	801.9235239	-1860.630959	0.0	882.0	0.0	882.0	2.766625501892668	2.936891773531057	-0.6931471805599452	3.883973701618247	5.232971603251655	0.8985612678965857	1.117348199725579	2.2960798297205978	1.591708448456531	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b95e	58cfa82fe4b0c9d6adf6b95e	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	628.56	1.9	0.16	58cfa82fe4b0c9d6adf6b95e	TCGA-AA-3548-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3548-01A	2DCED66C-1F0D-4039-A5E5-54CCA77C16E9	Primary Tumor	Illumina HiSeq	362e7b19-891a-4eba-9cba-97d157a94152	Colorectal	71.0	633AFC4C-4A35-420E-9CE6-FF4670E28395	B5E87744-9963-4DBA-84C8-B61048169517	TCGA-AA-3548-01A-01D-1167-02	HG18	TCGA-AA-3548	TCGA-COAD		s13669	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1167-02	True	COAD	C1		0.13228705699999999	0.38	0.19	35.63125032	0.5993	0.294	-0.2031	0.8792	0.068	-0.0578			1.328452819	2.8229622410000004	67.0	0.435416588	12.0	9.0							0.727827566	-1375.781526	-117.2580268	83.02855327	0.0	1034.0	0.0	1034.0	6.753029433778982	4.614742545033456	0.11849771746857907	5.17405072882959	4.925591676766771	2.4940138202370896	-1.578978704949392	0.3108491317333151	2.3755161027685103	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b961	58cfa82fe4b0c9d6adf6b961	TCGA-AA-3529-01A-02D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3529-01A-02D-1554-10_wgs_Illumina	TCGA-AA-3529-01A-02D-1554-10_wgs_Illumina.bam	109.29	1.9	0.05	58cfa82fe4b0c9d6adf6b961	TCGA-AA-3529-01A-02D-1554-10_wgs_Illumina.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3529-01A	BFB07784-693B-4C25-874E-4AD6E04A5D46	Primary Tumor	Illumina HiSeq	510f1886-9023-432a-bc19-46aee37ea8a4	Colorectal	78.0	B083E3CB-0AF1-44EA-854D-85FD99B75AD5	9E5F0A23-E184-4611-B42B-E882DCF23ACD	TCGA-AA-3529-01A-02D-1554-10	GRCh37-lite	TCGA-AA-3529	TCGA-COAD	0.0	s12863	Baylor College of Medicine	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1554-10	False	COAD	C1		0.148324781	0.4	0.0	1.87309572	0.7472	0.306	-0.5797	-0.5943	-0.929	-0.0647			1.6150755019999998	1.292060402	203.0	0.18646310300000002	7.0	7.0								-1170.272449	241.5566556	-979.8185432	1.0	0.0	1.0	0.0	6.614893146488814	2.1605134695282917	-0.32706777859323455	5.327038858182176	4.727027466464123	1.5479265895459782	-1.2878542883066384	2.5665139969358313	1.8749943681392125	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b965	58cfa82fe4b0c9d6adf6b965	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole.bam	109.29	1.9	0.13	58cfa82fe4b0c9d6adf6b965	TCGA-AA-3529-01A-02D-1547-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3529-01A	BFB07784-693B-4C25-874E-4AD6E04A5D46	Primary Tumor	Illumina HiSeq	8d96c289-9e08-45f8-a5dc-8c089ca7eb93	Colorectal	78.0	B083E3CB-0AF1-44EA-854D-85FD99B75AD5	B8C9B915-BD7E-41FA-B5E1-4A28478EDC6E	TCGA-AA-3529-01A-02D-1547-02	HG18	TCGA-AA-3529	TCGA-COAD	0.0	s13364	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1547-02	False	COAD	C1		0.148324781	0.4	0.0	1.87309572	0.7472	0.306	-0.5797	-0.5943	-0.929	-0.0647			1.6150755019999998	1.292060402	203.0	0.18646310300000002	7.0	7.0								-1170.272449	241.5566556	-979.8185432	1.0	0.0	1.0	0.0	6.9784799833138464	3.6514075464789624	-0.32706777859323455	5.78889591644001	5.974332323710131	1.5479265895459782	-1.1895840668738364	2.3229247772311687	1.8749943681392125	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b96f	58cfa82fe4b0c9d6adf6b96f	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	554.96	1.9	0.17	58cfa82fe4b0c9d6adf6b96f	TCGA-AA-3666-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3666-01A	A512701F-88BB-4B05-8C94-FD285B9DD13E	Primary Tumor	Illumina HiSeq	0bc29a5e-10c6-4c45-8cb6-2284ab7be445	Colorectal	68.0	F1064663-1462-4901-8BF7-9F50DA5EE7B1	CAD86B88-04E5-400F-B3EB-43D31A2D8358	TCGA-AA-3666-01A-02D-1167-02	HG18	TCGA-AA-3666	TCGA-COAD	61.0	s13363	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	1167-02	True	COAD	C1	GI.CIN	0.077716677	0.18	0.2	0.700538586	0.9818	0.335	-0.1802	0.0178	-0.5187	-0.1893	90.0	111.0	1.036041823	4.403177748	292.0	0.80576293	20.0	17.0							0.800179761	-184.46656430000002	716.4667903	-729.7130003999999	1.0	61.0	1.0	61.0	6.6584492854069675	4.906681807698179	-0.15313301090290543	4.978393805758913	5.671185927039956	1.238865390188702	-1.680055479648054	0.764504119341777	1.3919984010916076	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b974	58cfa82fe4b0c9d6adf6b974	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	570.96	1.9	0.14	58cfa82fe4b0c9d6adf6b974	TCGA-AA-3675-01A-02D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3675-01A	41658CF8-0DE1-4A97-BB60-0F0107C84E00	Primary Tumor	Illumina HiSeq	f57af06a-9d5a-4a69-888a-8d611982b88e	Colorectal	84.0	A4CE3727-4506-493B-95F4-2F11CEB09CEB	D611373E-EF0A-46E4-8D3E-0722F221E828	TCGA-AA-3675-01A-02D-1109-02	HG18	TCGA-AA-3675	TCGA-COAD		s13672	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1109-02	True	COAD	C1			0.23	0.0	0.034848062	0.6518	0.2555	-0.6545	-0.4516	-0.7135	0.0163	49.0	59.0	1.01544533	2.030890659	74.0	0.055575908	3.0	1.0	0.9010371859999999	1.753337405	7.0	2.45831133	12.0	0.989297256	1.659074035	-1349.7967210000002	232.6718272	1657.915514	0.0	1431.0	0.0	1431.0	6.702267444156343	5.107262129785328	-0.55415659415657	5.255348461220017	6.8358426973918505	0.8937128946561921	-1.4469189829363258	1.7285805676065231	1.4478694888127621	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b976	58cfa82fe4b0c9d6adf6b976	TCGA-AA-3666-01A-02D-1981-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3666-01A-02D-1981-10_wgs_Illumina	TCGA-AA-3666-01A-02D-1981-10_wgs_Illumina.bam	554.96	1.9	0.17	58cfa82fe4b0c9d6adf6b976	TCGA-AA-3666-01A-02D-1981-10_wgs_Illumina.bam	Dead	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3666-01A	A512701F-88BB-4B05-8C94-FD285B9DD13E	Primary Tumor	Illumina HiSeq	6788c172-0c9d-4042-a664-c53d8e8a5cf9	Colorectal	68.0	F1064663-1462-4901-8BF7-9F50DA5EE7B1	6051F40A-99E5-4461-9255-0E70D757B4D5	TCGA-AA-3666-01A-02D-1981-10	GRCh37-lite	TCGA-AA-3666	TCGA-COAD	61.0	s13025	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	1981-10	False	COAD	C1	GI.CIN	0.077716677	0.18	0.2	0.700538586	0.9818	0.335	-0.1802	0.0178	-0.5187	-0.1893	90.0	111.0	1.036041823	4.403177748	292.0	0.80576293	20.0	17.0							0.800179761	-184.46656430000002	716.4667903	-729.7130003999999	1.0	61.0	1.0	61.0	6.704107935473429	3.97390214111552	-0.15313301090290543	4.95490808066417	6.015886120260456	1.238865390188702	-1.749199854809259	2.041983979144936	1.3919984010916076	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b97e	58cfa82fe4b0c9d6adf6b97e	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	353.96	1.9	0.15	58cfa82fe4b0c9d6adf6b97e	TCGA-AA-3681-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3681-01A	ABB0D53F-F74E-45DC-8FBB-40863016F3C6	Primary Tumor	Illumina HiSeq	4a7f8872-1280-4a05-8448-a62ee6de1108	Colorectal	77.0	190FECAB-1EF1-43FA-87A2-104014EB2CE2	85305E56-627C-4471-BD16-6818AD3751C2	TCGA-AA-3681-01A-01D-1637-02	HG18	TCGA-AA-3681	TCGA-COAD		s13029	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	1637-02	False	COAD	C1	GI.CIN	0.21425759100000002	0.43	0.12	2.944777764	0.7662	0.312	-0.0106	0.7538	-0.1451	-0.0225	43.0	2.0	0.856908056	2.777564043	273.0	0.33481594600000003	12.0	15.0							0.998962556	-295.970644	769.0661261	-864.9019687000001	0.0	182.0	0.0	182.0	7.093555626246554	4.635017105606214	0.11775653611349923	6.195614033040595	6.426776574834269	1.4649953080610725	-0.8979415932059585	1.7917594692280554	1.3472387719475734	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b982	58cfa82fe4b0c9d6adf6b982	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	294.0	1.9	0.15	58cfa82fe4b0c9d6adf6b982	TCGA-AA-3861-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3861-01A	5DA56982-6DE7-4994-AA9E-3B01200B2959	Primary Tumor	Illumina HiSeq	041d683a-798a-4869-a98d-b7abfe977709	Colorectal	72.0	390070D8-EF9B-46FE-93EE-9CF01A642A92	3FF478FA-97AF-4122-AC93-1BF1DD21BCB3	TCGA-AA-3861-01A-01D-1167-02	HG18	TCGA-AA-3861	TCGA-COAD		s13186	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True	COAD	C2		0.258206498			10.65966822	0.5268	0.187	-0.2323	0.8422	-0.231	-0.5671	60.0	2.0													0.804051593	-1011.166692	319.09353230000005	-22.556652399999997	0.0	914.0	0.0	914.0	7.240968241681907	6.4780657819831085	0.01935474139623672	5.9118322944019654	6.701209333297318	1.753516718840955	-1.329135947279942	0.2231435513142097	1.7341619774447183	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b98e	58cfa82fe4b0c9d6adf6b98e	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.bam	115.4	1.9	0.14	58cfa82fe4b0c9d6adf6b98e	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-50-5944-01A	1C339545-C08A-4A77-B8E9-A7E49E53853F	Primary Tumor	Illumina HiSeq	c76f3861-5117-4ed7-9ca6-eecc10e949f3	Lung	69.0	BF8FDF82-62B4-4B5D-93E7-CE153576FE49	71CD46A8-30B0-4452-860D-3ED173C461A7	TCGA-50-5944-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5944	TCGA-LUAD		s11348	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Acinar Adenocarcinoma	Stage IA	1751-02	True	LUAD	C3	LUAD.1	0.10243614699999999	0.43	0.15		-0.6587	-0.212	0.5383	-0.0123	0.1624	0.3992	32.0	19.0	0.545640989	1.515669415	315.0	0.61800592	15.0	23.0	0.422073762	0.463695421	3.0	1.9459101490000001	7.0	1.0	2.317136526	162.2438574	-461.8834396000001	1536.593854	0.0	1750.0	0.0	1750.0	6.597924973307345	6.356315972330849	-0.2700890531577623	5.408340906433509	6.684820039302886	4.843492078901367	-1.1895840668738364	0.32850406697203605	5.113581132059129	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b991	58cfa82fe4b0c9d6adf6b991	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted.bam	12.7	1.9	0.15	58cfa82fe4b0c9d6adf6b991	TCGA-50-6597-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6597-01A	0D66BF6C-EED0-4726-BD5B-3BF6D610B4E0	Primary Tumor	Illumina HiSeq	e7110ba5-6000-459a-8128-32b420e21194	Lung	79.0	C5363830-3DB9-4C0C-AA47-B32FDC888C60	84D15DBA-6689-4A93-B2CA-999BF7F97E96	TCGA-50-6597-01A-11D-1853-02	HG19_Broad_variant	TCGA-50-6597	TCGA-LUAD		s11553	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True	LUAD	C2	LUAD.5	0.274501606			4.136944194	-0.8757	-0.0845	0.5097	1.7853	1.2749	-0.309	15.0		0.38251287700000003	1.3535071019999998	301.0	0.728395692	11.0	22.0	0.929116948	1.932044378	8.0	3.3638820189999996	31.0	0.979584902	2.4943273440000002	661.8589728999999	-809.3682149	924.4797825999999	1.0	1268.0	0.0	1268.0	3.6322168133910164	7.563690837923237	-0.14371793714991965	3.014520187419625	5.809671696678029	1.5148186386076867	-0.6176966259713916	-1.754019141245208	1.6585365757576063	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b99a	58cfa82fe4b0c9d6adf6b99a	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.bam	877.7	1.9	0.15	58cfa82fe4b0c9d6adf6b99a	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5774-01A	FD3FC273-C035-40EA-A459-FF4806F5D592	Primary Tumor	Illumina HiSeq	b5b4f9c8-7044-4c76-ae48-241c8c4dd953	Lung	60.0	252C5D60-7033-44C3-8AB5-4604670A80F4	83902D13-5FD4-4640-B20F-3A8110F6D5EC	TCGA-64-5774-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5774	TCGA-LUAD		s10910	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	True	LUAD	C1	LUAD.2	0.150211297	0.24	0.09	6.1467746960000005	0.7054	0.141	-0.4666	0.5766	-0.2956	0.0864	32.0	4.0	1.1659603040000002	3.74334624	223.0	0.7998623690000001	15.0	42.0	0.807947645	3.9138495460000002	127.0	2.36938212	11.0	0.9881090920000001	5.054270572	-1184.814253	240.95402280000002	2057.424352	0.0	2676.0	1.0	246.0	2.729027249451657	6.863374609455229	-0.4760423350112498	1.770548443196418	4.40225286469067	2.9327924737801165	-0.958478806255239	-2.461121744764559	3.4088348087913665	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b9a8	58cfa82fe4b0c9d6adf6b9a8	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted.filtered.	WGS	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted.bam	292.4	1.9	0.14	58cfa82fe4b0c9d6adf6b9a8	TCGA-67-6215-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_7.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6215-01A	DBD5B0DE-94C9-45DD-AFB3-6820A7ECACA2	Primary Tumor	Illumina HiSeq	502bd59b-5e8d-4170-9a24-b18fa50a5dc1	Lung	52.0	3BA5F6B9-6458-44E2-A0AA-B5C7E5FCD632	483EF1DC-150E-4623-BA11-772ADE84E4E4	TCGA-67-6215-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6215	TCGA-LUAD		s11555	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C4	LUAD.4	0.149603136	0.31	0.07	2.8585998810000004	-0.1852	-0.059000000000000004	0.5328	-0.3554	-0.4948	-0.1715	52.0	2.0	0.79319052	2.959210788	93.0	0.633681817	7.0	10.0		0.0	1.0	2.163955657	9.0	0.984858662	1.5657511119999998	-818.1547337000001	-75.47417311	3199.572014	0.0	174.0	0.0	174.0	6.657240530871796	6.979337897625506	-0.14298305107324816	6.251775422763631	7.127757902743779	0.9928480180840354	-0.4054651081081646	0.14842000511827358	1.1358310691572835	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b9ab	58cfa82fe4b0c9d6adf6b9ab	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted.filtered.	WGS	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted.bam	36.7	1.9	0.15	58cfa82fe4b0c9d6adf6b9ab	TCGA-44-6777-01A-11D-1853_120123_SN590_0134_AC0DJKACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-44-6777-01A	349E6F38-2C67-4A69-A777-B9173A2A27CF	Primary Tumor	Illumina HiSeq	8f0fdfb5-6a7c-4e9a-9a4f-d32f9aca542d	Lung	85.0	174E4405-4848-4E5E-93CC-0CDF2795C91A	AAAAE42F-88A5-4E99-8057-A92D6759BE19	TCGA-44-6777-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6777	TCGA-LUAD	987.0	s11550	Harvard Medical School	Christiana Healthcare	United States	NO	T2	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True	LUAD	C3	LUAD.5	0.43516623200000004	0.66	0.55	4.162335541	-0.5198	-0.1915	1.6439	1.5747	0.2782	0.7154	120.0	137.0	2.821193375	9.452452029	72.0	0.438026171	17.0	12.0	0.893255067	4.592817027	171.0	3.871265198	49.0	0.994718384	2.0016224769999997	140.0493521	-419.3192523	1850.88813	1.0	987.0	0.0	987.0	6.7133979455765775	7.320394590838301	0.129507946280217	5.892417393506747	7.389387462325253	1.7917594692280547	-0.8209805520698299	0.06899287148695166	1.6622515229478378	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b9c6	58cfa82fe4b0c9d6adf6b9c6	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted.bam	150.4	1.9	0.15	58cfa82fe4b0c9d6adf6b9c6	TCGA-73-4658-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_5_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4658-01A	AFB91740-2668-46D7-BA01-BB26153AD1C7	Primary Tumor	Illumina HiSeq	9ee6d96c-98e7-4829-94dc-f41e5f078854	Lung	80.0	BFDE37F2-AB6F-4426-A33D-EF9D21772F02	6A3AFDA7-56BB-4120-AB92-6EDA217BC214	TCGA-73-4658-01A-01D-1751-02	HG19_Broad_variant	TCGA-73-4658	TCGA-LUAD	1600.0	s11130	Harvard Medical School	Roswell Park	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C6	LUAD.4	0.388598726	0.71	0.4	8.816077884	-0.4784	-0.019	1.3083	1.2308	-0.1552	0.6292	189.0	14.0	2.695768245	8.798276581	73.0	0.209710636	7.0	17.0	0.8679355559999999	3.060653682	34.0	3.4448137969999997	32.0	0.993963156	1.22232147	559.8120552	-428.96005180000003	1947.129476	1.0	1600.0	0.0	1600.0	7.066429464276663	5.959946236998546	0.2312154607840099	6.230181440076044	5.173113572361277	1.2689724737308448	-0.8362480242006187	-0.7868326646372683	1.0377570129468348	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b9c8	58cfa82fe4b0c9d6adf6b9c8	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	212.1	1.72	0.15	58cfa82fe4b0c9d6adf6b9c8	TCGA-AA-A00Q-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00Q-01A	62D39BE5-F029-4EB8-8B00-46470E06A755	Primary Tumor	Illumina HiSeq	5ccd68f8-a32c-47e2-805b-e3721dbb395d	Colorectal	66.0	89FC5DB9-EDFF-480F-8FC4-ADDD28C6D615	D458CE34-22B1-41F7-9CE7-659107AD6F77	TCGA-AA-A00Q-01A-01D-A077-02	HG18	TCGA-AA-A00Q	TCGA-COAD		s13523	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Colon Adenocarcinoma	Stage IIIB	A077-02	True	COAD	C1		0.150263944			4.506765605	0.4191	0.09300000000000001	-0.632	-0.3651	-0.6123	-0.0361					65.0	0.8288944859999999	17.0	4.0							0.6503794589999999	-1422.853088	43.86977234	-1168.525586	0.0	1278.0	0.0	1278.0	6.7439719338900375	6.738097384513553	0.04100164355185831	6.278608684200805	6.250802258157756		-0.46536324968923326	-0.48729512635579697		lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b9ca	58cfa82fe4b0c9d6adf6b9ca	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	232.95	1.72	0.15	58cfa82fe4b0c9d6adf6b9ca	TCGA-AA-A00U-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00U-01A	091E3084-04EE-4497-893C-D46226DEC78F	Primary Tumor	Illumina HiSeq	95f8b5f7-db6e-4a69-959f-dde28a98d4ed	Colorectal	50.0	2FC854D7-4F80-4C39-BD92-397E94FEE4A0	6765593B-17DC-4B0F-A20B-7F0FF67DFF64	TCGA-AA-A00U-01A-01D-A077-02	HG18	TCGA-AA-A00U	TCGA-COAD		s13682	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	A077-02	True	COAD	C1		0.135984752			19.64158436	0.9188	0.375	-0.9838	-0.4878	-0.4769	-0.1415					189.0	0.14820813	5.0	9.0							0.132611962	-1039.403677	791.2569815	-65.85221425	0.0	518.0	0.0	518.0	8.28614346853093	7.074218419841634	-1.1392774081390193	5.9835583755368855	5.760494751556578	0.2517346846434687	-2.3025850929940455	-1.3137236682850557	1.3910120927824883	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b9cc	58cfa82fe4b0c9d6adf6b9cc	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	264.6	1.73	0.15	58cfa82fe4b0c9d6adf6b9cc	TCGA-AA-A00Z-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00Z-01A	AF3A0634-4292-45BD-B948-6B6BD2D58090	Primary Tumor	Illumina HiSeq	9701e2c0-3702-4d55-9816-940f128d19e0	Colorectal	70.0	75A6A64E-11F0-41C8-9CBA-179AE3333621	DF16D4D9-DD5E-4614-AE58-465EC09F2992	TCGA-AA-A00Z-01A-01D-A077-02	HG18	TCGA-AA-A00Z	TCGA-COAD		s13198	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A077-02	True	COAD	C1		0.135171254	0.37	0.08	24.82030059	1.041	0.34	-0.6709	-0.2894	-0.0991	-0.0518	9.0	75.0	0.35562269700000004	2.48935888	205.0	0.20065555100000002	9.0	14.0							1.7956814540000001	-1944.923693	1142.249288	528.879267	0.0	669.0	0.0	669.0	5.410069178992159	5.11497203005649	-0.08280746155565066	5.1987600853249525	5.580335279745723	1.324936616652404	-0.21130909366720685	0.4653632496892337	1.4077440782080544	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b9d8	58cfa82fe4b0c9d6adf6b9d8	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted.bam	880.86	1.9	0.14	58cfa82fe4b0c9d6adf6b9d8	TCGA-AA-3947-01A-01D-1167-02_101023_SN208_0167_B80L4DABXX_s_1.rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3947-01A	654C6F5C-3E5C-49F0-B53F-87CD9797D7C9	Primary Tumor	Illumina HiSeq	2d1ad0b4-c460-4a5b-ae6d-2926bfe40052	Colorectal	60.0	5241539D-65AC-434D-8EAA-AE57F702C8CE	EE2FCBCE-108F-46EC-8C7A-12D34142820A	TCGA-AA-3947-01A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3947	TCGA-COAD		s13679	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Colon Mucinous Adenocarcinoma	Stage IIB	1167-02	True	COAD	C4	GI.HM-indel	0.135055043	0.22	0.03	15.2110802	1.1349	0.415	-0.0287	-0.9578	0.45399999999999996	-0.8001	710.0		18.47130928	57.60675088	136.0	0.02742049	0.0	0.0							0.521717388	-158.8274011	2057.929295	-1640.845208	0.0	1004.0	0.0	1004.0	4.841643850092864	4.249070043648101	-0.08274877034929695	5.056755229709809	4.464119505677336	1.171670101819695	0.2151113796169457	0.21504946202923492	1.254418872168992	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b9e0	58cfa82fe4b0c9d6adf6b9e0	TCGA-AA-3977-01A-01D-1024-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3977-01A-01D-1024-10_wgs_Illumina	TCGA-AA-3977-01A-01D-1024-10_wgs_Illumina.bam	540.0	1.9	0.15	58cfa82fe4b0c9d6adf6b9e0	TCGA-AA-3977-01A-01D-1024-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3977-01A	33E989B9-FAC4-47D8-B429-269044AC772A	Primary Tumor	Illumina HiSeq	34a6b8b6-5a24-4e03-9f20-8b51e27033c5	Colorectal	65.0	56DD63CB-CF0A-48C3-BCCC-C5094F8D8AC0	93FF786E-0165-4B02-8D27-806D422E93FC	TCGA-AA-3977-01A-01D-1024-10	GRCh37-lite	TCGA-AA-3977	TCGA-COAD		s13028	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma		1024-10	False	COAD	C1		0.180402148	0.27	0.21	12.10294459	1.1527	0.444	-0.0522	-0.2114	-0.2985	-0.1233	1864.0	41.0			176.0	0.0007730139999999999	0.0	5.0							1.8251727930000001	-1325.770384	1242.777155	-1989.8723699999998	0.0	761.0	0.0	761.0	6.8322232163697	3.6163044149931096	-0.12522062825934066	5.8912398719051735	6.511375962757094	1.1710490087780154	-0.9409833444645268	2.895071547763984	1.296269637037356	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b9e8	58cfa82fe4b0c9d6adf6b9e8	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.bam	54.22	1.93	0.16	58cfa82fe4b0c9d6adf6b9e8	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G9-01A	45D58088-D3F4-4EB0-B75C-BCB98C0981DC	Primary Tumor	Illumina HiSeq	daffebdf-d935-425e-8576-3401ef583860	Uterus	79.0	117A5B33-42C5-4A52-BABE-D9712F3E7472	0DE57B60-95AF-48E2-85CA-58135A314355	TCGA-A5-A0G9-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G9	TCGA-UCEC		s4778	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.MSI	0.112810754	0.1	0.04	2.849274522	-0.0804	0.067	-0.2616	-0.6313	-0.4057	-0.0724	149.0	181.0	2.9151461089999997	12.17680823	68.0	0.034102007999999996	1.0	4.0							2.95754294	-1410.981992	-1155.1329660000001	2112.313488	0.0	2540.0	0.0	2540.0	6.224747001782047	7.523319224883703	0.4111563530302771	5.440628043016375	6.567807779856267	3.468280217631704	-0.7841189587656721	-0.9555114450274362	3.0571238646014267	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6b9fe	58cfa82fe4b0c9d6adf6b9fe	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	756.0	1.9	0.15	58cfa82fe4b0c9d6adf6b9fe	TCGA-AA-3968-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3968-01A	CAB7BDBC-0A11-4901-97C3-26B884F79CB5	Primary Tumor	Illumina HiSeq	7c5f1648-b5c0-4e96-a5ca-38b2630f40ee	Colorectal	55.0	E950BC59-116F-4366-8524-F0731B1C9A3D	193F15A1-6BE4-4992-AC6E-EF34CBB3B57A	TCGA-AA-3968-01A-01D-1167-02	HG18	TCGA-AA-3968	TCGA-COAD		s13030	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	True	COAD	C1	GI.CIN	0.087793218	0.29	0.13	0.5097340779999999	0.9567	0.256	-0.0881	0.4383	-0.4791	0.1324	42.0	0.0	0.743706546	3.966434912	185.0	0.8187453490000001	12.0	20.0							0.410578571	-1752.068898	682.9193541	-1891.150321	0.0	669.0	0.0	669.0	6.698352121874075	6.538839826129595	-0.3427888142901059	6.063701147995738	6.002535117062619	0.8329944265449201	-0.6346509738783372	-0.5363047090669757	1.175783240835026	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba00	58cfa82fe4b0c9d6adf6ba00	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	949.56	1.9	0.13	58cfa82fe4b0c9d6adf6ba00	TCGA-AA-3555-01A-01D-1637-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3555-01A	36EAF209-C332-4321-B6AA-51A3368ECD79	Primary Tumor	Illumina HiSeq	4abf3b47-09b2-46e1-8bca-eb46790b3930	Colorectal	81.0	9F9961F0-4EE2-4471-AE4A-A0122D630A28	099EA705-3D94-4746-AF72-E21B31D0425A	TCGA-AA-3555-01A-01D-1637-02	HG18	TCGA-AA-3555	TCGA-COAD		s13513	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1637-02	False	COAD	C4		0.21071610300000002			2.260490556	1.0172	0.278	-0.2441	-1.1601	0.1498	0.1609					79.0	0.000350537	0.0	3.0							1.47107021	-1319.415918	1205.436214	-2602.9519649999997	0.0	911.0	1.0	91.0	7.291603807885378	4.9907670908795305	-2.4344917898915663	6.812030727623492	7.155730805997528	-1.8152899666382492	-0.4795730802618863	2.1649637151179983	0.6192018232533172	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba02	58cfa82fe4b0c9d6adf6ba02	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	237.83	1.78	0.15	58cfa82fe4b0c9d6adf6ba02	TCGA-AA-A01I-01A-02D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01I-01A	86D18004-9478-4E46-83B4-4FBE445CCB70	Primary Tumor	Illumina HiSeq	397e6c0b-1bf2-43ff-b659-15147ee8be30	Colorectal	76.0	FBA03796-B9C8-4042-9720-F21660CFEC28	DAED1A71-909A-42D8-87B4-6760B54D91AF	TCGA-AA-A01I-01A-02D-A077-02	HG18	TCGA-AA-A01I	TCGA-COAD		s13201	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A077-02	True	COAD	C1		0.15376109699999999	0.28	0.13	6.805528892000001	0.8765	0.29	-0.6814	-0.5725	-0.1513	-0.4438	55.0	0.0	0.754645652	3.0185826060000003	73.0	0.632541182	8.0	0.0							1.112224422	-102.6721458	1095.850858	-80.71735995	0.0	943.0	0.0	943.0	7.627165653841205	6.626864905455604	-0.1802723757490189	6.160828585047779	6.149940833365295	1.0173106304781458	-1.4663370687934267	-0.4769240720903092	1.1975830062271648	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba06	58cfa82fe4b0c9d6adf6ba06	TCGA-AA-3956-01A-02D-1981-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3956-01A-02D-1981-10_wgs_Illumina	TCGA-AA-3956-01A-02D-1981-10_wgs_Illumina.bam	282.86	1.9	0.14	58cfa82fe4b0c9d6adf6ba06	TCGA-AA-3956-01A-02D-1981-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3956-01A	7B47489F-C3CC-4388-B5D7-C7C02790A5F6	Primary Tumor	Illumina HiSeq	72141594-ac11-437d-896e-d1ae66162764	Colorectal	65.0	DC1FFDA5-5B8F-4227-BE04-321643F73731	3C019B2F-52EC-40A8-99B5-98C1423CE627	TCGA-AA-3956-01A-02D-1981-10	GRCh37-lite	TCGA-AA-3956	TCGA-COAD		s12870	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1981-10	False	COAD	C1	GI.CIN	0.204002341	0.65	0.2	50.50431578	0.4451	0.145	-0.363	0.3629	-0.3046	0.0118	84.0	13.0	1.069191462	4.276765848	149.0	0.232664444	10.0	17.0							0.524541495	-1499.029365	200.83480830000002	326.11250010000003	0.0	1035.0	0.0	1035.0	6.292915034781675	5.07514774607234	-0.39885569872049054	5.2568231030948995	6.575062805933928	1.9333412483202	-1.0360919316867756	1.4999150598615874	2.3321969470406905	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba08	58cfa82fe4b0c9d6adf6ba08	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.bam	104.46	2.03	0.15	58cfa82fe4b0c9d6adf6ba08	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G2-01A	4ABBD258-0F0C-4428-901D-625D47AD363A	Primary Tumor	Illumina HiSeq	f5289cfe-4208-4623-896c-ec78fb5f7dc5	Uterus	57.0	771811E3-740E-42FE-BE9C-FD485997EAAE	579C21E4-83BD-4DAE-B030-53E0930DEACA	TCGA-A5-A0G2-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G2	TCGA-UCEC		s4773	Harvard Medical School	Cedars Sinai	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.POLE	0.09886014300000001			8.137703979	0.757	0.188	-0.2096	0.4842	-0.8059	-0.434	11244.0		247.23629280000003	733.234354	113.0	0.43029177399999996	11.0	11.0							1.222715413	-771.8033002999999	-100.03404920000001	-1845.3733690000001	0.0	4549.0	0.0	4549.0	6.021427798293362	5.670664315108324	0.07136785611036167	5.692923731321326	6.099118941441187	2.1277398219239543	-0.32850406697203605	0.4284546263328628	2.0563719658135926	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba0c	58cfa82fe4b0c9d6adf6ba0c	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	686.66	1.9	0.15	58cfa82fe4b0c9d6adf6ba0c	TCGA-AA-3970-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3970-01A	733D8B6A-CA9D-4A69-8C9C-1F88733E8B68	Primary Tumor	Illumina HiSeq	9a7a59e0-b435-4e8b-b503-c49ce6f819e4	Colorectal	65.0	767A5260-34F4-4BED-9CDA-305BC431A402	0F57E6B4-FE51-4ACF-B65B-1FDB2CF9C6CB	TCGA-AA-3970-01A-01D-1109-02	HG18	TCGA-AA-3970	TCGA-COAD		s13190	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1109-02	True	COAD	C2					2.646720368	0.7692	0.256	-0.1113	0.6971	0.7562	-0.2725															0.9879346520000001	-1164.025809	220.3010748	868.3948221	0.0	1096.0	0.0	1096.0	6.491734656934456	5.653843924070703	-0.3864956895682874	4.757133601546349	6.417608671844602	1.607569501374073	-1.7346010553881066	0.7637647477738989	1.9940651909423603	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba10	58cfa82fe4b0c9d6adf6ba10	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	233.25	1.69	0.15	58cfa82fe4b0c9d6adf6ba10	TCGA-AA-A01G-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01G-01A	6F2B5A14-569C-4084-8C67-B1A44D787897	Primary Tumor	Illumina HiSeq	efd511ca-ff06-4cbe-afe2-2c025120233e	Colorectal	63.0	A09ABC20-4F93-4130-A23A-8413E6C32FE5	D7D83B15-9EE5-4206-805D-AC3E5914BCC6	TCGA-AA-A01G-01A-01D-A077-02	HG18	TCGA-AA-A01G	TCGA-COAD		s13205	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	A077-02	True	COAD	C1		0.164296924			30.00620925	0.9306	0.342	-1.08	-0.552	-0.4392	-0.2244					131.0	0.36773683	11.0	11.0							1.820252243	-959.7498947999999	795.1278087000001	-625.2645711	0.0	365.0	0.0	365.0	7.43901681364081	7.2555630252670955	-0.4317824164255377	5.926428727196627	6.33927229339294	1.812513900697501	-1.512588086444183	-0.9162907318741556	2.244296317123039	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba16	58cfa82fe4b0c9d6adf6ba16	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	431.56	1.9	0.17	58cfa82fe4b0c9d6adf6ba16	TCGA-AA-3549-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3549-01A	E6EC5A68-7555-4F26-BD7E-9CDB4C5F7004	Primary Tumor	Illumina HiSeq	cff80dc2-c080-4905-afce-cfd06a84f6c9	Colorectal	69.0	86158696-60A3-45B7-8351-D800F57EF23B	C5D50597-F0E1-4C34-AB95-3718566AF540	TCGA-AA-3549-01A-02D-1167-02	HG18	TCGA-AA-3549	TCGA-COAD		s13358	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	True	COAD	C1		0.199749387	0.25	0.09	12.90898275	0.5201	0.228	-0.441	0.2332	-0.6795	0.1639			0.498035664	2.822202098	199.0	0.296680205	6.0	16.0							0.416165026	-894.1997094000001	227.426418	271.3260903	0.0	639.0	0.0	639.0	6.499486243541238	7.893985101203613	-1.1455187865239476	5.957161952715877	7.912003606706292	0.15148623195619937	-0.5423242908253618	0.018018505502678472	1.297005018480147	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba1c	58cfa82fe4b0c9d6adf6ba1c	TCGA-AA-3664-01A-01D-1981-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3664-01A-01D-1981-10_wgs_Illumina	TCGA-AA-3664-01A-01D-1981-10_wgs_Illumina.bam	338.96	1.9	0.16	58cfa82fe4b0c9d6adf6ba1c	TCGA-AA-3664-01A-01D-1981-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3664-01A	A06C09A8-0951-49F4-A765-5147BBCAE109	Primary Tumor	Illumina HiSeq	c35bd7d9-ece5-492b-9d5f-dcc047684dc0	Colorectal	74.0	D448668C-90F3-40FA-9961-88407090DA31	B6B6E1D3-C592-4836-BDAD-D53AF2DBCC9A	TCGA-AA-3664-01A-01D-1981-10	GRCh37-lite	TCGA-AA-3664	TCGA-COAD		s13365	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1981-10	False	COAD	C2	GI.CIN	0.064330626	0.13	0.04	0.989274532	1.0507	0.223	-0.4502	-0.3308	0.1882	-0.255	56.0		1.180274663	3.88627023	220.0	0.255809367	4.0	35.0							1.651622201	-583.4668197000001	1323.512658	-989.4090712999999	0.0	1643.0	0.0	1643.0	6.4499436905017635	4.785659256723775	-0.6403725263426161	4.50403354144645	6.8958724570703644	1.4792323567791597	-1.9459101490553132	2.11021320034659	2.1196048831217755	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba1e	58cfa82fe4b0c9d6adf6ba1e	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted.filtered.	WGS	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted.bam	338.96	1.9	0.16	58cfa82fe4b0c9d6adf6ba1e	TCGA-AA-3664-01A-01D-1167_101023_SN208_0166_A808PFABXX_s_5_rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3664-01A	A06C09A8-0951-49F4-A765-5147BBCAE109	Primary Tumor	Illumina HiSeq	1eb3d869-c9bd-4087-80cd-7fb426eb7997	Colorectal	74.0	D448668C-90F3-40FA-9961-88407090DA31	4B4C0EDF-1012-4A6A-B01E-CDEB130FF2E6	TCGA-AA-3664-01A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3664	TCGA-COAD		s12864	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	True	COAD	C2	GI.CIN	0.064330626	0.13	0.04	0.989274532	1.0507	0.223	-0.4502	-0.3308	0.1882	-0.255	56.0		1.180274663	3.88627023	220.0	0.255809367	4.0	35.0							1.651622201	-583.4668197000001	1323.512658	-989.4090712999999	0.0	1643.0	0.0	1643.0	4.064882529491784	6.028476012084801	-0.6403725263426161	4.300196616426248	6.188106157676685	1.4792323567791597	0.2353140869344652	0.15963014559188382	2.1196048831217755	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba20	58cfa82fe4b0c9d6adf6ba20	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted.filtered.	WGS	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted.bam	338.96	1.9	0.16	58cfa82fe4b0c9d6adf6ba20	TCGA-AA-3664-01A-01D-1167_110111_SN208_0178_B818TTABXX_s_5.rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3664-01A	A06C09A8-0951-49F4-A765-5147BBCAE109	Primary Tumor	Illumina HiSeq	9caec406-c1d9-43df-a730-7226fd5880b0	Colorectal	74.0	D448668C-90F3-40FA-9961-88407090DA31	4B4C0EDF-1012-4A6A-B01E-CDEB130FF2E6	TCGA-AA-3664-01A-01D-1167-02	HG18_Broad_variant	TCGA-AA-3664	TCGA-COAD		s13024	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	True	COAD	C2	GI.CIN	0.064330626	0.13	0.04	0.989274532	1.0507	0.223	-0.4502	-0.3308	0.1882	-0.255	56.0		1.180274663	3.88627023	220.0	0.255809367	4.0	35.0							1.651622201	-583.4668197000001	1323.512658	-989.4090712999999	0.0	1643.0	0.0	1643.0	5.215286327288299	3.0616823901726278	-0.6403725263426161	2.4346654333512543	3.8014081600971643	1.4792323567791597	-2.780620893937045	0.7397257699245365	2.1196048831217755	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba25	58cfa82fe4b0c9d6adf6ba25	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina.filtered.	WGS	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina.bam	864.57	1.9	0.14	58cfa82fe4b0c9d6adf6ba25	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina.bam	Alive	MALE	ASIAN		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3363-01A	659294B9-DED9-498A-BC00-C1D4D456AA4A	Primary Tumor	Illumina HiSeq	cbce285a-a226-46dc-9f92-dfe98700c750	Kidney	50.0	605E86AC-58F6-47D4-8BDE-15EB23C857CC	0F53E757-1823-409F-A0EA-249270728E15	TCGA-A3-3363-01A-01D-2094-10	GRCh37-lite	TCGA-A3-3363	TCGA-KIRC		s9301	Baylor College of Medicine	International Genomics Consortium	None	NO	T2	N0	Kidney Clear Cell Renal Carcinoma	Stage II	2094-10	False	KIRC	C4	KIRC.4	0.09918913	0.21	0.0		-1.4183	-0.081	0.6372	-0.4259	-0.2855	-0.2793	23.0	19.0	0.25405254	1.1855785209999998	186.0	0.050961985999999994	2.0	3.0				2.67011989	15.0	0.985993498	2.1377220059999997	-480.0969987	-1462.193217	931.8942347999999	0.0	319.0	0.0	319.0	7.029360062277924	1.3080441669578846	-0.3808583803462906	6.262104909564256	4.646815142752878	2.1793487182937348	-0.7672551527136671	3.3387709757949935	2.560207098640025	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba26	58cfa82fe4b0c9d6adf6ba26	TCGA-A3-3370-01A-02D-2099-10_Illumina.filtered.	WGS	TCGA-A3-3370-01A-02D-2099-10_Illumina	TCGA-A3-3370-01A-02D-2099-10_Illumina.bam	152.4	1.9	0.14	58cfa82fe4b0c9d6adf6ba26	TCGA-A3-3370-01A-02D-2099-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3370-01A	9F632FC3-2241-469A-A14A-CD537350155F	Primary Tumor	Illumina HiSeq	2bf569a0-5698-4304-b006-f61284e72aef	Kidney	48.0	1B2DF3FD-183C-4099-A387-5908C8B44F57	D7F1DB09-8BA0-4B76-BCD2-01C14165F0D5	TCGA-A3-3370-01A-02D-2099-10	GRCh37-lite	TCGA-A3-3370	TCGA-KIRC		s9563	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2099-10	False	KIRC	C3	KIRC.1	0.283636542	0.57	0.01		-1.0158	-0.3465	1.0092	0.8426	0.46799999999999997	0.0048	19.0	5.0	0.23867341	0.924859465	71.0	0.100528771	1.0	9.0	0.98380246	0.681919901	2.0	3.71098902	62.0	0.899168448	1.267297594	187.63099069999998	-482.7723393	2994.358325	0.0	2274.0	0.0	2274.0	8.60066736749939	0.15317098127831663	-0.2307234468369791	5.406865180183305	2.8042320305585857	5.301947134598615	-3.1938021873160847	2.651061049280269	5.532670581435594	higher	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba42	58cfa82fe4b0c9d6adf6ba42	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted.filtered.	WGS	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted.bam	75.21	1.8	0.14	58cfa82fe4b0c9d6adf6ba42	TCGA-AA-A01R-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_3.rg.sorted.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01R-01A	97F6C8D3-09A0-4128-8F10-41E736648A5F	Primary Tumor	Illumina HiSeq	dc5cfaa9-514c-4e4d-b882-21df489668aa	Colorectal	47.0	73EE34E8-422D-4AB1-B0F0-DA8A5A2DD9AB	F8021A03-B35B-4E6C-B196-2948789AFCF3	TCGA-AA-A01R-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A01R	TCGA-COAD		s12876	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A079-02	True	COAD	C2	GI.HM-indel	0.291125137	0.37	0.02	11.59946136	0.5872	0.10800000000000001	0.0093	1.104	1.0544	-0.0428	804.0	431.0			150.0	0.083186977	2.0	11.0							0.813182066	-4.98278952	215.13846940000002	1202.565619	0.0	1065.0	1.0	608.0	6.877884999665216	7.303409863815197	0.40840589354528045	5.990581804664314	7.163052506120275	2.1646586743164256	-0.8873031950009032	-0.1403573576949224	1.7562527807711452	lower	flr_F1_F2
13722.58cfa82fe4b0c9d6adf6ba48	58cfa82fe4b0c9d6adf6ba48	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.bam	83.98	2.0	0.17	58cfa82fe4b0c9d6adf6ba48	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G5-01A	4806D9A6-E65D-4A82-B422-1B287980A0C6	Primary Tumor	Illumina HiSeq	db20abab-2eed-4958-a741-e31199adb617	Uterus	73.0	FA7392E8-335E-4465-9272-4A19DC99412E	EDFD99A3-38A2-4E43-A3D1-B1D19EA818E5	TCGA-A5-A0G5-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G5	TCGA-UCEC		s5382	Harvard Medical School	Cedars Sinai	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_HIGH	0.41108211	0.5	0.08	2.598140259	0.2865	0.032	0.9574	1.9628	0.1528	0.0681	48.0		0.820350184	3.3662645469999997	880.0	0.9695646170000001	11.0	62.0							0.991224452	-183.12110019999997	91.86171874	3143.508792	0.0	1126.0	0.0	1126.0	5.200319616195064	7.364316692379804	0.41053774983626057	5.99255769939924	6.626717749249025	1.733681515093428	0.7922380832041758	-0.737598943130779	1.3231437652571674	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba4a	58cfa830e4b0c9d6adf6ba4a	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina.filtered.	WGS	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina.bam	380.0	1.9	0.05	58cfa830e4b0c9d6adf6ba4a	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3807-01A	5116E3B4-2BAC-40F5-8046-B9C1783FAAA5	Primary Tumor	Illumina HiSeq	b5897ed2-6c9b-4c6e-b131-41b62e60ecb9	Colorectal	53.0	1EB2A255-6EDD-4ADB-B52D-99DCEC590C5D	F38B5D2E-5CAB-45C7-BB0A-38B2EFC5C156	TCGA-A6-3807-01A-01D-1459-10	GRCh37-lite	TCGA-A6-3807	TCGA-COAD		s13652	Baylor College of Medicine	Christiana Healthcare	None	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1459-10	False	COAD	C1	GI.CIN	0.22782604899999997	0.48	0.19	5.297474787	0.5989	0.245	-0.0674	-0.1753	0.0759	0.1453	44.0				221.0	0.48063888	12.0	20.0							1.323846415	-1247.546682	-120.7776531	-1586.448282	0.0	1054.0	0.0	1054.0	6.5018900908526325	4.8410555159332604	-0.3807326103869644	5.020285549928417	6.547260980302355	0.638151505256193	-1.4816045409242158	1.706205464369095	1.0188841156431574	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba50	58cfa830e4b0c9d6adf6ba50	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted.filtered.	WGS	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted.bam	28.83	1.9	0.15	58cfa830e4b0c9d6adf6ba50	TCGA-AA-A02K-01A-21D-A079_110401_SN177_0152_A819RJABXX_s_2.rg.sorted.bam	Dead	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02K-01A	10881458-55B2-41D1-8358-4EE6CCB8EC85	Primary Tumor	Illumina HiSeq	7942eab9-d80a-496e-b3cb-50b42bd23334	Colorectal	50.0	685DF015-1B7B-4993-BF05-E3206619DFBA	7CC17F3D-27F5-484A-8E22-C9D0B5B27836	TCGA-AA-A02K-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A02K	TCGA-COAD	426.0	s13842	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Colon Adenocarcinoma	Stage IV	A079-02	True	COAD	C2		0.232144845			5.161204723	0.8159	0.2825	-0.9163	-0.9282	0.6135	-0.3814	69.0	152.0										1.098612289	3.0	1.0	4.4440588	-1690.528792	-424.5005227	989.5328553999999	1.0	426.0	1.0	306.0	5.81166920850091	5.574828788387581	0.073829051574548	4.6195308618219775	5.7458931906569015	1.0855519814338885	-1.1921383466789326	0.1710644022693204	1.0117229298593404	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba54	58cfa830e4b0c9d6adf6ba54	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted.filtered.	WGS	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted.bam	237.45	1.73	0.15	58cfa830e4b0c9d6adf6ba54	TCGA-AA-A01Q-01A-01D-A077_110402_SN208_0200_BB02BTABXX_s_4_rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01Q-01A	4BE66108-E72A-406B-BB4B-F58FF2877336	Primary Tumor	Illumina HiSeq	f50b391c-a832-4938-86aa-0ae2e8261a9e	Colorectal	48.0	5D1D7C40-F636-46C6-9540-4DF11A466B15	D84E59D4-7777-4922-990F-622BD246A9F1	TCGA-AA-A01Q-01A-01D-A077-02	HG18_Broad_variant	TCGA-AA-A01Q	TCGA-COAD		s13032	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	A077-02	True	COAD	C1		0.13444883400000002			0.293062724	0.7121	0.151	-0.4613	-0.1074	-0.053	-0.4264					199.0	0.046231833	1.0	6.0							2.229676121	-1517.981223	547.5150168	1597.7563710000002	0.0	31.0	0.0	31.0	7.468449849901262	7.599285127391262	-0.11100722296564092	6.333469917062278	7.694179160706019	1.128088106801063	-1.1349799328389842	0.09489403331475721	1.239095329766704	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba56	58cfa830e4b0c9d6adf6ba56	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	526.89	1.9	0.15	58cfa830e4b0c9d6adf6ba56	TCGA-AA-3966-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3966-01A	BC42FE2D-1A33-428D-A601-B1871F4C8D9B	Primary Tumor	Illumina HiSeq	3a88f23b-5740-4937-be5d-a5aed2c4e962	Colorectal	89.0	8C5799BF-DB65-40F6-9A67-ABD4DA4025F2	F1E05BF6-0B98-45F8-9F97-10ABE5957C99	TCGA-AA-3966-01A-01D-1109-02	HG18	TCGA-AA-3966	TCGA-COAD		s13674	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1109-02	True	COAD	C1	GI.HM-indel	0.240714614	0.49	0.11	0.28408082100000004	0.7255	0.223	0.6312	0.752	0.0513	0.3406	356.0	1383.0	9.528103079	31.92374086	142.0	0.8709884790000001	15.0	16.0							1.5918306969999998	-297.87618310000005	353.1275463	-746.5919637000001	0.0	61.0	0.0	61.0	6.252866810539282	5.724912493822641	-0.9357239124126461	5.223247393358124	6.386310976068007	0.9771729418086152	-1.029619417181158	0.6613984822453656	1.9128968542212612	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba5d	58cfa830e4b0c9d6adf6ba5d	TCGA-AA-A00R-01A-01D-A126-10_hg19_wgs_Illumina.filtered.	WGS	TCGA-AA-A00R-01A-01D-A126-10_hg19_wgs_Illumina	TCGA-AA-A00R-01A-01D-A126-10_hg19_wgs_Illumina.bam	205.35	1.73	0.08	58cfa830e4b0c9d6adf6ba5d	TCGA-AA-A00R-01A-01D-A126-10_hg19_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00R-01A	CA22EDD4-EB7C-4677-84AA-6F0354459A19	Primary Tumor	Illumina HiSeq	6182870d-a572-4538-aaa5-06b4adad7bbe	Colorectal	64.0	F72EEAE9-F7F5-4576-A072-5021119117D6	05780D48-80E7-4D70-B00C-081F8A9519F2	TCGA-AA-A00R-01A-01D-A126-10	GRCh37-lite	TCGA-AA-A00R	TCGA-COAD		s13677	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A126-10	False	COAD	C2		0.40054602100000003			2.6955994339999996	1.125	0.41700000000000004	0.5398	1.5323	0.4167	-0.2405					96.0	0.103863096	2.0	0.0							0.457954507	-442.0228687	1637.762706	-434.6143528	0.0	30.0	0.0	30.0	3.1733338044212847	3.3938033880913734	-0.31280627762545954	4.1866485125774995	5.668657067979893	1.4469189829363254	1.0133147081562148	2.27485367988852	1.759725260561785	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba60	58cfa830e4b0c9d6adf6ba60	TCGA-A3-3372-01A-01D-2094-10_Illumina.filtered.	WGS	TCGA-A3-3372-01A-01D-2094-10_Illumina	TCGA-A3-3372-01A-01D-2094-10_Illumina.bam	595.87	1.9	0.15	58cfa830e4b0c9d6adf6ba60	TCGA-A3-3372-01A-01D-2094-10_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3372-01A	11AB53C8-6366-4BC9-B60D-23E6ED2D1CAE	Primary Tumor	Illumina HiSeq	0dc73f18-4553-49e0-b22e-8bc863c7b907	Kidney	64.0	D3280297-5674-4AE6-AB57-8D820543901E	F64E9609-D75D-400C-A92D-D77FD54D6C29	TCGA-A3-3372-01A-01D-2094-10	GRCh37-lite	TCGA-A3-3372	TCGA-KIRC		s9155	Baylor College of Medicine	International Genomics Consortium	United States	NO	T3	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2094-10	False	KIRC	C3	KIRC.2	0.257411748	0.5	0.0		-1.1013	-0.36	0.6646	0.2419	0.4225	0.0352			0.0	0.0	74.0	0.640642597	22.0	1.0				3.272249183	37.0	0.906209795	1.012621589	-357.09681969999997	-873.2838305	2696.273389	0.0	735.0	0.0	735.0	8.571556368887157	0.852738819716615	0.2726921193030897	5.473267507008074	4.003927540421588	3.7953108247732557	-3.0982888618790834	3.1511887207049734	3.522618705470166	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba6c	58cfa830e4b0c9d6adf6ba6c	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	113.85	1.65	0.15	58cfa830e4b0c9d6adf6ba6c	TCGA-AA-A010-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A010-01A	0712566E-3371-4715-95F1-5B792E72D758	Primary Tumor	Illumina HiSeq	ea0e92bb-7617-4183-82be-773e8cc15dca	Colorectal	46.0	46FB1711-E385-49A4-BF15-7990123CBE6B	30FCD977-8C62-4925-BC84-5894A12BABDB	TCGA-AA-A010-01A-01D-A077-02	HG18	TCGA-AA-A010	TCGA-COAD		s13200	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Colon Adenocarcinoma	Stage IIB	A077-02	True	COAD	C1	GI.HM-SNV	0.143919894	0.23	0.0	30.57691389	0.9199	0.256	-0.5678	-0.2652	-0.628	-0.2932	3289.0	165.0			66.0	0.005584009	0.0	2.0							0.305366795	-751.3864624	1188.086608	-645.9534123	0.0	1064.0	0.0	1064.0	7.393519472152757	4.453807418707351	0.08904313729932112	6.6203295839192755	7.184922892740557	3.13099982634131	-0.7731898882334818	2.7311154740332064	3.041956689041989	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba6e	58cfa830e4b0c9d6adf6ba6e	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	119.82	1.79	0.15	58cfa830e4b0c9d6adf6ba6e	TCGA-AA-A01D-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01D-01A	E2EDBF3F-25D8-49AA-B656-2A59C3B99AEB	Primary Tumor	Illumina HiSeq	dc156fb1-9b36-4d02-a6f0-54027775ed04	Colorectal	47.0	082DEF2F-4D99-4270-83E7-5A9A5C049C23	5BF3D0AB-D301-4EE7-84A1-83F596C29E6E	TCGA-AA-A01D-01A-01D-A077-02	HG18	TCGA-AA-A01D	TCGA-COAD		s13525	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IIIC	A077-02	True	COAD	C1		0.253386927	0.6	0.2	7.504092739	0.5786	0.08199999999999999	-0.0151	-0.6064	-0.8963	0.40399999999999997			0.0	0.0	98.0	0.410368732	18.0	12.0							0.960176044	-283.1576697	104.4606462	-846.4965762	1.0	334.0	1.0	183.0	6.969085534133743	6.147771286061589	-1.6688808811450713	5.75269020980925	6.338826522824299	3.0573103357731783	-1.2163953243244934	0.1910552367627094	4.72619121691825	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba74	58cfa830e4b0c9d6adf6ba74	TCGA-AA-3555-01A-01D-0959-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3555-01A-01D-0959-10_wgs_Illumina	TCGA-AA-3555-01A-01D-0959-10_wgs_Illumina.bam	949.56	1.9	0.13	58cfa830e4b0c9d6adf6ba74	TCGA-AA-3555-01A-01D-0959-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3555-01A	36EAF209-C332-4321-B6AA-51A3368ECD79	Primary Tumor	Illumina HiSeq	6843fb20-8f01-4121-9e2c-823e5ce9da98	Colorectal	81.0	9F9961F0-4EE2-4471-AE4A-A0122D630A28	154F80BD-984C-4792-BB89-20C4DA0C08E0	TCGA-AA-3555-01A-01D-0959-10	GRCh37-lite	TCGA-AA-3555	TCGA-COAD		s13182	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	0959-10	False	COAD	C4		0.21071610300000002			2.260490556	1.0172	0.278	-0.2441	-1.1601	0.1498	0.1609					79.0	0.000350537	0.0	3.0							1.47107021	-1319.415918	1205.436214	-2602.9519649999997	0.0	911.0	1.0	91.0	7.2543707042887515	3.5008311670963117	-2.4344917898915663	5.89106586139356	6.15023698506188	-1.8152899666382492	-1.3633048428951917	2.649405817965568	0.6192018232533172	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba75	58cfa830e4b0c9d6adf6ba75	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	270.96	1.9	0.15	58cfa830e4b0c9d6adf6ba75	TCGA-AA-3812-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3812-01A	4563E4E0-A661-46DE-AD25-9C86A621E147	Primary Tumor	Illumina HiSeq	92316171-5ae2-4812-b824-183f14adf90a	Colorectal	82.0	98AD41D5-FD77-4F30-94B5-03BF7B9C69B9	B4AA0837-42E8-41B7-B44B-F84D48155C3E	TCGA-AA-3812-01A-01D-1167-02	HG18	TCGA-AA-3812	TCGA-COAD		s13188	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True	COAD	C3	GI.CIN	0.173636016	0.58	0.0	7.73243178	-0.5463	-0.175	-0.1145	0.1661	-0.9984	0.5213	53.0	18.0	0.901842948	3.05462934	130.0	0.699529697	12.0	4.0							3.124387505	-669.4354475	-1372.2858199999998	1964.565568	0.0	1066.0	1.0	762.0	5.761942940552666	6.304593119920728	-1.790688996333683	5.632731209072661	5.241698913854697	1.9726555090307885	-0.1292117314800061	-1.062894206066031	3.7633445053644716	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba78	58cfa830e4b0c9d6adf6ba78	TCGA-AA-A03F-01A-11D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A03F-01A-11D-A17O-10_wgs_Illumina	TCGA-AA-A03F-01A-11D-A17O-10_wgs_Illumina.bam	124.44	1.85	0.09	58cfa830e4b0c9d6adf6ba78	TCGA-AA-A03F-01A-11D-A17O-10_wgs_Illumina.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A03F-01A	2A971E32-B0E7-4A3F-8C40-62D69C0307D8	Primary Tumor	Illumina HiSeq	d227eb87-8290-4223-b1d2-c241162935c9	Colorectal	90.0	8ABA8350-B5EE-4CA2-BC99-5C7922A886C4	18DD42D7-2D84-400E-9ADB-A38FAA916A9E	TCGA-AA-A03F-01A-11D-A17O-10	GRCh37-lite	TCGA-AA-A03F	TCGA-COAD	549.0	s12884	Baylor College of Medicine	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A17O-10	True	COAD	C3	GI.GS	0.209805915	0.22	0.0	1.355866356	-0.1685	-0.23	-0.9335	0.1368	-1.4081	-0.2469	48.0	13.0	1.055323209	3.422669866	73.0	3.6e-05	0.0	3.0							0.81414896	-1225.2459099999999	-593.878884	3866.731188	1.0	549.0	1.0	549.0	7.230201031370209	3.5351186997070485	-2.064543449869165	5.3976195676218985	6.611038808284079	-0.20662773090340014	-1.83258146374831	3.075920108577031	1.8579157189657647	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba7c	58cfa830e4b0c9d6adf6ba7c	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	496.0	1.9	0.14	58cfa830e4b0c9d6adf6ba7c	TCGA-AA-3509-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3509-01A	80E677B1-5EBE-4069-A1A5-1538FFEE6642	Primary Tumor	Illumina HiSeq	41b8f6a5-58f8-4e97-bbd3-a2587a70e30d	Colorectal	54.0	BA6E3333-3651-450E-A6EA-4E47CF0D18BF	ACCC21A8-D026-40E4-AA2C-C0F998A1D370	TCGA-AA-3509-01A-01D-1405-02	HG18	TCGA-AA-3509	TCGA-COAD		s13183	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1405-02	True	COAD	C1		0.078997844				0.7642	0.2945	-0.1853	0.0409	0.0806	-0.0562															1.497895995	-862.0724802000001	50.27770687	-75.60246444	0.0	1915.0	0.0	1915.0	5.6284772048310145	6.197913968072712	-1.6757894413413945	4.612556632008018	5.792448859964548	0.8919440232083005	-1.015920572822996	-0.4054651081081646	2.567733464549695	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba9b	58cfa830e4b0c9d6adf6ba9b	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.bam	92.8	2.11	0.16	58cfa830e4b0c9d6adf6ba9b	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GJ-01A	94817E78-78F5-4556-9394-610DF65605E2	Primary Tumor	Illumina HiSeq	d5b73d0f-c14a-4a54-a8e1-14bc027cfef5	Uterus	44.0	48FA5B7D-E488-4743-A7CE-ACEB9945F00B	A5D63CC4-892C-4357-B8A1-2BF50CF425DC	TCGA-A5-A0GJ-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GJ	TCGA-UCEC		s5384	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_HIGH	0.093266818	0.19	0.05	1.46415926	-0.2373	-0.071	-0.2789	0.7546	-0.0376	-0.0322	21.0	20.0	0.652056886	2.059127008	466.0	0.849487344	8.0	54.0							2.47967074	-1248.614695	-482.8791813	1972.8658920000003	0.0	2000.0	1.0	12.0	5.487599933315026	6.9277212916230155	-0.6234553964702839	5.646664627944713	5.72374848729708	4.464758032271346	0.15906469462968742	-1.203972804325936	5.08821342874163	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6ba9e	58cfa830e4b0c9d6adf6ba9e	TCGA-AA-A01X-01A-21D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A01X-01A-21D-A17O-10_wgs_Illumina	TCGA-AA-A01X-01A-21D-A17O-10_wgs_Illumina.bam	71.0	1.92	0.07	58cfa830e4b0c9d6adf6ba9e	TCGA-AA-A01X-01A-21D-A17O-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01X-01A	2E386E48-B99B-4806-A3E3-081D72A606E7	Primary Tumor	Illumina HiSeq	4b96a6ce-adbd-45b8-9c53-ea1850f0731c	Colorectal	80.0	0225A318-9BB2-4340-A34A-99FCBC563E0A	B7F2E85A-3C6A-48B7-8A4F-2DEC1D85359D	TCGA-AA-A01X-01A-21D-A17O-10	GRCh37-lite	TCGA-AA-A01X	TCGA-COAD		s12880	Baylor College of Medicine	Indivumed	Germany	NO	T2	N1	Colon Adenocarcinoma	Stage III	A17O-10	True	COAD	C1	GI.CIN	0.087045586	0.38	0.09	4.113525645	0.0492	0.040999999999999995	-0.8186	-0.1248	-0.5646	-0.0108	33.0	0.0	0.869170742	1.798284293	50.0	0.52213547	18.0	1.0				1.386294361	4.0	1.0	2.5460106330000003	-1112.5126699999998	-626.5077416	2251.569675	0.0	791.0	1.0	791.0	6.568604458155164	1.2879228401489948	-0.4967054508381319	5.512551783905851	3.679871613759639	3.1471112586388905	-1.056052674249314	2.391948773610644	3.643816709477022	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6baa2	58cfa830e4b0c9d6adf6baa2	TCGA-AA-3514-01A-02D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3514-01A-02D-1554-10_wgs_Illumina	TCGA-AA-3514-01A-02D-1554-10_wgs_Illumina.bam	263.29	1.9	0.05	58cfa830e4b0c9d6adf6baa2	TCGA-AA-3514-01A-02D-1554-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3514-01A	DDF69ED9-4C53-48B8-9F01-495BD60C3425	Primary Tumor	Illumina HiSeq	2c81df5f-0948-463a-a303-3beb5bd5205b	Colorectal	81.0	A657AFDB-5322-454F-8DD7-8397291401C5	A0F94565-9169-49EE-8E6A-21BDC43D9DE6	TCGA-AA-3514-01A-02D-1554-10	GRCh37-lite	TCGA-AA-3514	TCGA-COAD		s13667	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1554-10	False	COAD	C1		0.076714682	0.21	0.02	6.348599292	0.0514	-0.045	-0.5979	-0.1347	-1.6094	0.3792			1.2691667979999999	4.442083794	67.0	0.078219128	4.0	3.0	0.934308253	3.238065655	32.0				0.7245671779999999	-958.6218389000001	-473.7177384	751.1534154	0.0	31.0	0.0	31.0	7.108880416624341	1.0706109607014813	-1.2952220214458814	5.938809163974087	4.3919939191335065	3.1984385134440334	-1.1700712526502546	3.321382958432025	4.493660534889915	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6baa6	58cfa830e4b0c9d6adf6baa6	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	124.44	1.85	0.17	58cfa830e4b0c9d6adf6baa6	TCGA-AA-A03F-01A-11D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A03F-01A	2A971E32-B0E7-4A3F-8C40-62D69C0307D8	Primary Tumor	Illumina HiSeq	93e089c5-c259-445d-9ffa-10073ad2d336	Colorectal	90.0	8ABA8350-B5EE-4CA2-BC99-5C7922A886C4	F445E8E6-6A82-4400-8307-1DE92AC03539	TCGA-AA-A03F-01A-11D-A079-02	HG18	TCGA-AA-A03F	TCGA-COAD	549.0	s13207	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A079-02	True	COAD	C3	GI.GS	0.209805915	0.22	0.0	1.355866356	-0.1685	-0.23	-0.9335	0.1368	-1.4081	-0.2469	48.0	13.0	1.055323209	3.422669866	73.0	3.6e-05	0.0	3.0							0.81414896	-1225.2459099999999	-593.878884	3866.731188	1.0	549.0	1.0	549.0	2.1400661634962708	1.349926716949016	-2.064543449869165	-0.05715841383994835	0.5877866649021191	-0.20662773090340014	-2.197224577336219	-0.7621400520468968	1.8579157189657647	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6baaa	58cfa830e4b0c9d6adf6baaa	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.bam	96.48	1.95	0.14	58cfa830e4b0c9d6adf6baaa	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GD-01A	1486A031-B74D-4976-8B0B-4569E6978F49	Primary Tumor	Illumina HiSeq	98b5ea92-9e57-4d1f-937d-8bb0dd2a3cf2	Uterus	75.0	F449F50A-7664-4DDC-87AA-6A061EE7190C	069406A8-56D7-4E93-8570-7880A99D6C2D	TCGA-A5-A0GD-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GD	TCGA-UCEC		s4771	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.	0.177499805	0.33	0.03	1.859444104	0.7051	0.266	-0.1463	-0.1217	0.6639	-0.5657			0.0	0.0	1404.0	0.005285336999999999	0.0	0.0							1.942574094	-1305.275997	-93.33641558	-1225.783306	1.0	3423.0	0.0	3423.0	4.90416304958574	5.829707854267138	0.6263042695894018	4.108158483586086	5.296903323782372	1.9440662125677162	-0.7960045659996533	-0.532804530484766	1.3177619429783145	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6baba	58cfa830e4b0c9d6adf6baba	TCGA-AA-A01S-01A-21D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A01S-01A-21D-A17O-10_wgs_Illumina	TCGA-AA-A01S-01A-21D-A17O-10_wgs_Illumina.bam	89.57	1.8	0.07	58cfa830e4b0c9d6adf6baba	TCGA-AA-A01S-01A-21D-A17O-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01S-01A	84E34CF2-B3BB-4A1A-8FB7-6C2C604C4008	Primary Tumor	Illumina HiSeq	02f49f2b-40ad-427b-bb81-6ef0c6efc46d	Colorectal	47.0	5743700C-CBD3-4F87-8109-6349A96EB605	A64000DF-16E5-4B88-865F-5C680ADF60EB	TCGA-AA-A01S-01A-21D-A17O-10	GRCh37-lite	TCGA-AA-A01S	TCGA-COAD		s12877	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A17O-10	True	COAD	C1	GI.CIN	0.036294006000000004	0.1	0.03	1.01622772	0.4655	0.147	-1.8764	-1.5879	-1.9286	-0.5577	23.0	2.0	0.697744447	1.425825609	237.0	0.22491224199999998	7.0	19.0							0.445006699	-1982.0952280000001	-293.49188660000004	1436.6879	0.0	31.0	0.0	31.0	7.078341579557671	1.9130228130370366	-0.16276103093946115	5.861946255233178	5.342740416647607	0.6652902260569789	-1.2163953243244934	3.4297176036105705	0.82805125699644	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6babc	58cfa830e4b0c9d6adf6babc	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted.filtered.	WGS	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted.bam	80.04	2.03	0.14	58cfa830e4b0c9d6adf6babc	TCGA-AA-A01T-01A-21D-A079-02_110402_SN208_0200_BB02BTABXX_s_5.rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01T-01A	F87C6DCC-1A9E-4DF5-962C-1F946E2611F8	Primary Tumor	Illumina HiSeq	0dd44906-041d-4af2-8f42-a1bed185e1c6	Colorectal	63.0	BFC99C6D-7791-4037-9C74-A74BE68E616A	8F61B113-0E19-403E-9637-48E9D9733692	TCGA-AA-A01T-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A01T	TCGA-COAD		s13839	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	True	COAD	C1	GI.CIN	0.045102565	0.29	0.11	0.154091685	0.2623	0.095	-1.6469	-1.2234	-0.3763	-0.3073	41.0		0.6833065070000001	2.525263179	141.0	0.910212919	18.0	16.0							0.20091035399999999	-648.3558958	-530.4368972	214.07018259999998	0.0	1005.0	0.0	1005.0	6.9644191260996795	4.19353143139328	-0.9853958305089713	6.271271945539734	6.925257468180775	0.6351006464381883	-0.6931471805599454	2.731726036787495	1.6204964769471597	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bac2	58cfa830e4b0c9d6adf6bac2	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	133.2	1.9	0.14	58cfa830e4b0c9d6adf6bac2	TCGA-49-4501-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-4501-01A	0780EB43-D5B5-4C3D-9825-BEACBA5CC723	Primary Tumor	Illumina HiSeq	2df919ad-215d-40a5-8e9d-e22862898cd7	Lung	67.0	FC511A67-5383-4877-AEEF-36C0B7934B77	FA521F2B-4BB1-4A15-9101-422B2B65489A	TCGA-49-4501-01A-01D-1203-02	GRCh37	TCGA-49-4501	TCGA-LUAD	1421.0	s11003	Harvard Medical School	Johns Hopkins	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1203-02	True	LUAD	C2	LUAD.5	0.293295016	0.57	0.46	7.937631349	-0.853	0.124	0.7525	1.7852	0.882	0.2617	18.0	6.0	0.6787629909999999	1.15094594	255.0	0.5956938079999999	15.0	28.0	0.91545844	2.982651975	26.0	4.257531193	74.0	0.9891883840000001	2.3967407780000003	499.82790769999997	-1137.957224	1953.079211	1.0	1421.0	1.0	545.0	9.669125053514565	8.514331959135205	0.6184800180991957	8.369842069384303	5.281271499275048	3.579923218174555	-1.2992829841302607	-3.2330604598601576	2.961443200075359	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bad4	58cfa830e4b0c9d6adf6bad4	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted.filtered.	WGS	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted.bam	86.94	2.0	0.15	58cfa830e4b0c9d6adf6bad4	TCGA-AA-A01V-01A-23D-A079-02_110402_SN208_0200_BB02BTABXX_s_7.rg.sorted.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01V-01A	0CB0DAC8-4CE2-444A-B1AE-1550E065B4D9	Primary Tumor	Illumina HiSeq	f9fde040-dea2-4d98-8a28-05cb13efa1c2	Colorectal	59.0	8816F14D-9FBB-4033-9CA4-6CA0DB66161A	D13F4522-90DC-41C8-A274-FBD9C0CD2E60	TCGA-AA-A01V-01A-23D-A079-02	HG18_Broad_variant	TCGA-AA-A01V	TCGA-COAD		s13683	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A079-02	True	COAD	C1	GI.GS	0.10136753300000001	0.2	0.0	1.123851717	0.3243	0.084	-0.8204	-0.1163	-0.958	-0.3022	53.0		1.132780887	3.1078860230000003	55.0	0.000149704	0.0	0.0							1.842443271	-1133.990693	104.2096103	1434.598508	0.0	31.0	0.0	31.0	6.78469518622491	6.783717143994933	-1.4809090730284553	6.145615226935241	6.764668949024238	-0.6338872498528201	-0.6390799592896697	-0.019048194970694432	0.8470218231756351	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bad6	58cfa830e4b0c9d6adf6bad6	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina.filtered.	WGS	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina.bam	315.4	1.9	0.05	58cfa830e4b0c9d6adf6bad6	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-6141-01A	58FACEDB-FCB8-4ECF-8338-2BFA4947ACEF	Primary Tumor	Illumina HiSeq	6fd83764-dbd4-43ec-bab9-c2950c46cf59	Colorectal	31.0	D67FC406-7974-433E-896D-57197ECED52B	00AA769D-622C-433E-8A8A-63FB5C41EA42	TCGA-A6-6141-01A-11D-1771-10	GRCh37-lite	TCGA-A6-6141	TCGA-COAD		s13355	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1771-10	False	COAD	C1		0.308890561	0.52	0.0	21.80153829	0.4722	0.1025	-0.0996	1.2934	0.0644	0.03			0.0	0.0	69.0	0.00020983099999999998	0.0	0.0	0.921015577	2.7118741660000003	19.0	3.258096538	26.0	1.0	1.340149077	-705.4844901	424.0472761	1052.875313	0.0	255.0	0.0	255.0	6.665319684287306	4.105622578672084	-0.0820743785247533	5.47573561741347	6.023184372723142	1.993689937356721	-1.1895840668738364	1.9175617940510579	2.0757643158814743	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bada	58cfa830e4b0c9d6adf6bada	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.bam	88.7	1.9	0.15	58cfa830e4b0c9d6adf6bada	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-49-6745-01A	9C7875AD-AB71-4D48-B2E3-E4C7A46393E9	Primary Tumor	Illumina HiSeq	b4eee7d7-a56c-4927-929e-ac66abe41408	Lung	82.0	357F3EFE-E2C9-432A-A2B6-75A5FDBAE3BE	A88D69EF-BE3C-4341-AD6C-0F035685862F	TCGA-49-6745-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6745	TCGA-LUAD		s11451	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True	LUAD	C2	LUAD.4	0.33045954	0.76	0.33	7.710816212	0.2358	0.0405	0.9866	1.0438	0.9075	0.5605	52.0	5.0	0.8216590979999999	3.345326328	118.0	0.305232457	9.0	11.0	0.522689036	1.340670906	13.0	3.5956292160000003	43.0	0.955979237	1.499184444	443.0162012	153.5269825	1947.875216	0.0	522.0	0.0	522.0	7.396279519797057	9.260784844678053	-0.9744198678265424	6.1832568799512035	8.881295222973149	2.9242733095718463	-1.2130226398458537	-0.3794896217049035	3.8986931773983886	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6baf8	58cfa830e4b0c9d6adf6baf8	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted.bam	263.29	1.9	0.15	58cfa830e4b0c9d6adf6baf8	TCGA-AA-3514-01A-02D-1547_110525_SN590_0091_AC02W2ABXX_s_1.rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3514-01A	DDF69ED9-4C53-48B8-9F01-495BD60C3425	Primary Tumor	Illumina HiSeq	3737ce68-bbb0-4ecc-849f-0fd049fe4d85	Colorectal	81.0	A657AFDB-5322-454F-8DD7-8397291401C5	C0486DD0-5BE4-4B64-8A8F-3CF47BD5A330	TCGA-AA-3514-01A-02D-1547-02	HG18_Broad_variant	TCGA-AA-3514	TCGA-COAD		s13361	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1547-02	False	COAD	C1		0.076714682	0.21	0.02	6.348599292	0.0514	-0.045	-0.5979	-0.1347	-1.6094	0.3792			1.2691667979999999	4.442083794	67.0	0.078219128	4.0	3.0	0.934308253	3.238065655	32.0				0.7245671779999999	-958.6218389000001	-473.7177384	751.1534154	0.0	31.0	0.0	31.0	7.451314272364764	4.502220241620129	-1.2952220214458814	6.0967686095594535	6.502880905446851	3.1984385134440334	-1.3545456628053105	2.000660663826722	4.493660534889915	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb02	58cfa830e4b0c9d6adf6bb02	TCGA-A6-A567-01A-31D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-A6-A567-01A-31D-A28G-10_wgs_Illumina	TCGA-A6-A567-01A-31D-A28G-10_wgs_Illumina.bam	29.22		0.08	58cfa830e4b0c9d6adf6bb02	TCGA-A6-A567-01A-31D-A28G-10_wgs_Illumina.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN		Colon Adenocarcinoma	Aligned reads	TCGA-A6-A567-01A	857A5889-19E7-4208-8362-F1377C408037	Primary Tumor	Illumina HiSeq	062aa65c-624a-4bc6-97bc-6c35e7dc0ba3	Colorectal	56.0	ED37A5C0-341C-4ECC-8FB8-4B705E76E2AF	05486349-24A4-4931-BF5F-C9FEFE369AF2	TCGA-A6-A567-01A-31D-A28G-10	GRCh37-lite	TCGA-A6-A567	TCGA-COAD	1881.0	s12854	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N1	Colon Adenocarcinoma	Stage IV	A28G-10	True	COAD	C1	GI.CIN	0.123899325	0.27	0.19	1.5379137280000001	0.294	0.1725	-0.9876	-0.6853	-1.1172	-0.0045	26.0	13.0	0.44376482899999997	1.252983046	153.0	0.8339306409999999	9.0	10.0				0.0	1.0		2.4998936169999997	-1589.618577	-32.54659161	1334.546032	1.0	1881.0	1.0	612.0	7.539913187915652	3.9596109041317886	-0.24005402346252647	5.419649651715561	3.986530430045031	4.722611282848187	-2.120263536200091	0.026919525913242204	4.962665306310713	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb0a	58cfa830e4b0c9d6adf6bb0a	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.bam	55.64	2.08	0.15	58cfa830e4b0c9d6adf6bb0a	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R6-01A	39609D3C-F5D3-4BC4-B356-1403C6DD1CB5	Primary Tumor	Illumina HiSeq	7485f99f-a7fe-456f-873d-eb1be9fa04b1	Uterus	64.0	836BD487-091B-4728-BCD7-8065E5B76465	FBE6A365-A19A-42F1-9198-63549F77CD9B	TCGA-A5-A0R6-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R6	TCGA-UCEC		s4991	Harvard Medical School	Cedars Sinai	None	NO			Serous endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_HIGH	0.129028115	0.54	0.08	2.6213641180000002	0.3246	0.205	-0.7291	0.1002	0.5006	0.2284	29.0		0.35577869	1.204174028	293.0	0.8505981979999999	14.0	20.0							2.901907739	-742.6539784	-543.6751709	497.92909389999994	0.0	1153.0	1.0	961.0	6.301611142043766	6.597340576680214	-0.624604861006725	4.7123759369271845	5.407756509806378		-1.5892352051165815	-1.1895840668738367		lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb0d	58cfa830e4b0c9d6adf6bb0d	TCGA-A6-A565-01A-31D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-A6-A565-01A-31D-A28G-10_wgs_Illumina	TCGA-A6-A565-01A-31D-A28G-10_wgs_Illumina.bam	27.34		0.08	58cfa830e4b0c9d6adf6bb0d	TCGA-A6-A565-01A-31D-A28G-10_wgs_Illumina.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN		Colon Adenocarcinoma	Aligned reads	TCGA-A6-A565-01A	DD7A53EE-CB08-40C4-9935-51D1CA17E9E8	Primary Tumor	Illumina HiSeq	94ddbe0f-9753-4acc-abe8-2bfda86dd8b2	Colorectal	34.0	87A57810-8B62-4AF1-ADB9-4715A71ED632	63BC376E-5A3D-44FD-8D77-686DFC41E458	TCGA-A6-A565-01A-31D-A28G-10	GRCh37-lite	TCGA-A6-A565	TCGA-COAD	494.0	s13657	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IIIC	A28G-10	True	COAD	C3	GI.HM-indel	0.463961634	0.81	0.24	17.39195529	0.2679	-0.0015	0.573	1.9444	-0.3474	0.5221	167.0	363.0	3.42506234	8.987569599	55.0	0.008224893	0.0	9.0	0.9040213429999999	3.2395776030000003	36.0	3.573450497	36.0	0.997190348	1.6987148109999999	-474.3061303	-17.46786283	56.98616124	1.0	494.0	1.0	301.0	6.303565855845951	1.8619429421092821	0.029443751331389767	5.340128345546095	3.6281043342929173	0.6339065604956629	-0.9634375102998569	1.7661613921836352	0.6044628091642731	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb32	58cfa830e4b0c9d6adf6bb32	TCGA-AA-A00R-01A-01D-A126-10_Illumina.filtered.	WGS	TCGA-AA-A00R-01A-01D-A126-10_Illumina	TCGA-AA-A00R-01A-01D-A126-10_Illumina.bam	205.35	1.73	0.08	58cfa830e4b0c9d6adf6bb32	TCGA-AA-A00R-01A-01D-A126-10_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00R-01A	CA22EDD4-EB7C-4677-84AA-6F0354459A19	Primary Tumor	Illumina HiSeq	a3f8272c-4b21-47f7-be7c-d4fc4cbb70b0	Colorectal	64.0	F72EEAE9-F7F5-4576-A072-5021119117D6	05780D48-80E7-4D70-B00C-081F8A9519F2	TCGA-AA-A00R-01A-01D-A126-10	NCBI36_BCM_variant	TCGA-AA-A00R	TCGA-COAD		s13370	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A126-10	False	COAD	C2		0.40054602100000003			2.6955994339999996	1.125	0.41700000000000004	0.5398	1.5323	0.4167	-0.2405					96.0	0.103863096	2.0	0.0							0.457954507	-442.0228687	1637.762706	-434.6143528	0.0	30.0	0.0	30.0	2.818224403538684	2.9831898568653514	-0.31280627762545954	3.9036133590321045	5.660769800820144	1.4469189829363254	1.0853889554934204	2.6775799439547923	1.759725260561785	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb3e	58cfa830e4b0c9d6adf6bb3e	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted.filtered.	WGS	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted.bam	89.57	1.8	0.13	58cfa830e4b0c9d6adf6bb3e	TCGA-AA-A01S-01A-21D-A079_110402_SN208_0200_BB02BTABXX_s_6_rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01S-01A	84E34CF2-B3BB-4A1A-8FB7-6C2C604C4008	Primary Tumor	Illumina HiSeq	fe7c227a-1329-4956-b9bf-08bbb6fe161d	Colorectal	47.0	5743700C-CBD3-4F87-8109-6349A96EB605	DC9E606A-12D6-4AA6-9780-1D999EB72C5A	TCGA-AA-A01S-01A-21D-A079-02	HG18_Broad_variant	TCGA-AA-A01S	TCGA-COAD		s13206	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	True	COAD	C1	GI.CIN	0.036294006000000004	0.1	0.03	1.01622772	0.4655	0.147	-1.8764	-1.5879	-1.9286	-0.5577	23.0	2.0	0.697744447	1.425825609	237.0	0.22491224199999998	7.0	19.0							0.445006699	-1982.0952280000001	-293.49188660000004	1436.6879	0.0	31.0	0.0	31.0	6.92450313628336	6.555274822571537	-0.16276103093946115	6.3808876896943785	6.594495535724818	0.6652902260569789	-0.5436154465889818	0.03922071315328157	0.82805125699644	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb40	58cfa830e4b0c9d6adf6bb40	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	146.73	1.77	0.15	58cfa830e4b0c9d6adf6bb40	TCGA-AA-A02R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02R-01A	764C97C9-01D3-45CB-86BD-F8A52B5468DA	Primary Tumor	Illumina HiSeq	5affe933-9b26-4971-81d9-e380618fbfa0	Colorectal	84.0	197245F6-A310-4AF4-9231-0AFEFC547ECD	A803F2CD-F90D-4E51-8D90-1E6AF6897413	TCGA-AA-A02R-01A-01D-A077-02	HG18	TCGA-AA-A02R	TCGA-COAD	670.0	s13204	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A077-02	True	COAD	C2		0.144991299	0.34	0.08	1.498947368	0.7503	0.19899999999999998	0.4541	0.5984	1.3442	0.0221	532.0	3209.0	11.1116826	36.19818075	93.0	0.046571972	2.0	0.0							0.436724998	-62.74812668	668.4003255	-839.7556804	1.0	670.0	1.0	670.0	6.43689795210692	5.084176727730956	-0.29175539783941695	4.762921518535249	5.2941498158554205	1.5476135304257612	-1.6739764335716711	0.2099730881244648	1.8393689282651782	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb48	58cfa830e4b0c9d6adf6bb48	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	84.8	1.91	0.16	58cfa830e4b0c9d6adf6bb48	TCGA-AA-A02Y-01A-43D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02Y-01A	A435FDF4-A89A-499E-9006-CBB5693EAB26	Primary Tumor	Illumina HiSeq	faa460a7-9c39-4da6-93c1-22d5d99742f0	Colorectal	73.0	8537633B-6426-4B66-A2A3-FA942EEDF01B	CD188DB1-ED81-42A6-B550-07D4008143EE	TCGA-AA-A02Y-01A-43D-A079-02	HG18	TCGA-AA-A02Y	TCGA-COAD		s13195	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A079-02	True	COAD	C1	GI.GS	0.10199928300000001	0.25	0.0	5.554698349	0.3644	0.153	-0.9653	-0.4082	-0.4011	-0.8168	46.0	77.0	0.751741433	3.320191327	74.0	0.535476205	7.0	6.0				2.415052122	13.0	0.941559378	1.156491395	88.69404423	190.8700614	1028.7073369999998	0.0	1216.0	0.0	1216.0	6.130724691362717	5.149356189381556	-0.0033057881344992213	4.584800184650942	5.271958511473888	1.017115141061066	-1.5459245067117746	0.12260232209233202	1.0204209291955653	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb4c	58cfa830e4b0c9d6adf6bb4c	TCGA-AA-A01T-01A-21D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A01T-01A-21D-A17O-10_wgs_Illumina	TCGA-AA-A01T-01A-21D-A17O-10_wgs_Illumina.bam	80.04	2.03	0.07	58cfa830e4b0c9d6adf6bb4c	TCGA-AA-A01T-01A-21D-A17O-10_wgs_Illumina.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01T-01A	F87C6DCC-1A9E-4DF5-962C-1F946E2611F8	Primary Tumor	Illumina HiSeq	abefb6f0-6456-48a1-b9d2-3789849aaea6	Colorectal	63.0	BFC99C6D-7791-4037-9C74-A74BE68E616A	75AD15B9-8F9C-40C1-9CA6-1E8454FBD310	TCGA-AA-A01T-01A-21D-A17O-10	GRCh37-lite	TCGA-AA-A01T	TCGA-COAD		s13681	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A17O-10	True	COAD	C1	GI.CIN	0.045102565	0.29	0.11	0.154091685	0.2623	0.095	-1.6469	-1.2234	-0.3763	-0.3073	41.0		0.6833065070000001	2.525263179	141.0	0.910212919	18.0	16.0							0.20091035399999999	-648.3558958	-530.4368972	214.07018259999998	0.0	1005.0	0.0	1005.0	6.929761359244752	3.3515228923736533	-0.9853958305089713	5.2715332826412205	6.454655852541809	0.6351006464381883	-1.6582280766035324	3.103132960168156	1.6204964769471597	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb5a	58cfa830e4b0c9d6adf6bb5a	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	1010.56	1.9	0.17	58cfa830e4b0c9d6adf6bb5a	TCGA-AA-3553-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3553-01A	D181C72B-843C-4B2D-B014-2A6DD1C3C1EC	Primary Tumor	Illumina HiSeq	b8e8f766-3a6f-4c2c-aeb0-ba7b926a3b99	Colorectal	61.0	B1DCD03C-3CDD-4C23-9391-C5ADEEBFF489	2159EE82-6427-4E1F-9C6F-28B48562DF0C	TCGA-AA-3553-01A-01D-1167-02	HG18	TCGA-AA-3553	TCGA-COAD		s13362	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	1167-02	True	COAD	C1		0.199844655			4.3303929430000005	0.7874	0.41600000000000004	-0.0008	0.5221	0.0662	0.0137					96.0	0.529025464	19.0	17.0							0.630509373	-858.6087825999999	167.7008251	-936.4799969000001	0.0	730.0	0.0	730.0	6.534031056658035	2.6001496789987755	-0.2677274579222363	4.182655799494557	3.786663261952943	1.487498267973363	-2.3513752571634776	1.1865135829541673	1.7552257258955992	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb5c	58cfa830e4b0c9d6adf6bb5c	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	570.96	1.9	0.14	58cfa830e4b0c9d6adf6bb5c	TCGA-AA-3675-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3675-01A	41658CF8-0DE1-4A97-BB60-0F0107C84E00	Primary Tumor	Illumina HiSeq	971987d4-bd49-45d8-949e-4c2108a7cbc7	Colorectal	84.0	A4CE3727-4506-493B-95F4-2F11CEB09CEB	42AD4E5A-8E58-47EC-9D1F-F65D5C22DA49	TCGA-AA-3675-01A-02D-1167-02	HG18	TCGA-AA-3675	TCGA-COAD		s13372	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1167-02	True	COAD	C1			0.23	0.0	0.034848062	0.6518	0.2555	-0.6545	-0.4516	-0.7135	0.0163	49.0	59.0	1.01544533	2.030890659	74.0	0.055575908	3.0	1.0	0.9010371859999999	1.753337405	7.0	2.45831133	12.0	0.989297256	1.659074035	-1349.7967210000002	232.6718272	1657.915514	0.0	1431.0	0.0	1431.0	7.917087885735313	5.65313708743952	-0.55415659415657	6.610836232288959	6.971713274504459	0.8937128946561921	-1.3062516534463544	1.3185761870649393	1.4478694888127621	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb68	58cfa830e4b0c9d6adf6bb68	TCGA-AA-A02Y-01A-43D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A02Y-01A-43D-A17O-10_wgs_Illumina	TCGA-AA-A02Y-01A-43D-A17O-10_wgs_Illumina.bam	84.8	1.91	0.08	58cfa830e4b0c9d6adf6bb68	TCGA-AA-A02Y-01A-43D-A17O-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02Y-01A	A435FDF4-A89A-499E-9006-CBB5693EAB26	Primary Tumor	Illumina HiSeq	258e501e-d510-4eda-b9fb-9d4bf0226c16	Colorectal	73.0	8537633B-6426-4B66-A2A3-FA942EEDF01B	B2AFBCBA-D67D-43F1-BE3B-05F3A5836EC0	TCGA-AA-A02Y-01A-43D-A17O-10	GRCh37-lite	TCGA-AA-A02Y	TCGA-COAD		s13685	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A17O-10	True	COAD	C1	GI.GS	0.10199928300000001	0.25	0.0	5.554698349	0.3644	0.153	-0.9653	-0.4082	-0.4011	-0.8168	46.0	77.0	0.751741433	3.320191327	74.0	0.535476205	7.0	6.0				2.415052122	13.0	0.941559378	1.156491395	88.69404423	190.8700614	1028.7073369999998	0.0	1216.0	0.0	1216.0	7.168708291691894	3.447855243293076	-0.0033057881344992213	5.66463089491562	6.429970636342891	1.017115141061066	-1.5040773967762742	2.982115393049815	1.0204209291955653	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb6a	58cfa830e4b0c9d6adf6bb6a	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted.bam	267.4	1.9	0.15	58cfa830e4b0c9d6adf6bb6a	TCGA-75-6205-01A-11D-1751_111116_SN208_0255_D09F1ACXX_s_4_rg.sorted.bam	Dead	FEMALE			Lung Adenocarcinoma	Aligned reads	TCGA-75-6205-01A	9A63F744-4ED4-4B4D-AAC6-F9BDA66AA563	Primary Tumor	Illumina HiSeq	ccc090ad-afab-4e7d-b71b-dcd39a87e359	Lung		D845174B-1A04-4D22-B34F-C48D7AE35233	A5D194B2-0A92-49A1-9AC3-FC4C1B6ADE92	TCGA-75-6205-01A-11D-1751-02	HG19_Broad_variant	TCGA-75-6205	TCGA-LUAD		s10666	Harvard Medical School	Ontario Institute for Cancer Research (OICR)	Canada	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1751-02	True	LUAD	C2	LUAD.6	0.587876208	0.73	0.68	10.97720295	0.1197	-0.0075	1.6492	1.9619	1.4706	0.5938	24.0	1.0	0.30738627399999996	1.2910223509999998	130.0	0.18343631	20.0	10.0	0.86539583	3.483522569	56.0	3.573151553	41.0	0.962187212		136.7035957	-393.0832802	516.9971435	1.0		1.0		7.449498005382849	5.630005738765442	-0.2490654064325415	6.456246232372566	6.296950546931364	3.1965837378004474	-0.9932517730102832	0.6669448081659217	3.4456491442329886	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb72	58cfa830e4b0c9d6adf6bb72	TCGA-AA-A01V-01A-23D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A01V-01A-23D-A17O-10_wgs_Illumina	TCGA-AA-A01V-01A-23D-A17O-10_wgs_Illumina.bam	86.94	2.0	0.08	58cfa830e4b0c9d6adf6bb72	TCGA-AA-A01V-01A-23D-A17O-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01V-01A	0CB0DAC8-4CE2-444A-B1AE-1550E065B4D9	Primary Tumor	Illumina HiSeq	12678e03-e8e4-4074-91b0-68bb57767c2d	Colorectal	59.0	8816F14D-9FBB-4033-9CA4-6CA0DB66161A	31F02F48-44A4-445E-AC3D-E9BF3D8D25A2	TCGA-AA-A01V-01A-23D-A17O-10	GRCh37-lite	TCGA-AA-A01V	TCGA-COAD		s13379	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A17O-10	True	COAD	C1	GI.GS	0.10136753300000001	0.2	0.0	1.123851717	0.3243	0.084	-0.8204	-0.1163	-0.958	-0.3022	53.0		1.132780887	3.1078860230000003	55.0	0.000149704	0.0	0.0							1.842443271	-1133.990693	104.2096103	1434.598508	0.0	31.0	0.0	31.0	6.424058322604399	2.877133505143595	-1.4809090730284553	5.458977426560812	5.576479265615658	-0.6338872498528201	-0.9650808960435873	2.699345760472063	0.8470218231756351	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb79	58cfa830e4b0c9d6adf6bb79	TCGA-AA-3685-01A-02D-1981-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3685-01A-02D-1981-10_wgs_Illumina	TCGA-AA-3685-01A-02D-1981-10_wgs_Illumina.bam	417.96	1.9	0.15	58cfa830e4b0c9d6adf6bb79	TCGA-AA-3685-01A-02D-1981-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3685-01A	DCA004BF-9C14-45A1-B186-AB3759F6C7FE	Primary Tumor	Illumina HiSeq	e8516b3d-fcff-4f10-94a4-993b059ac4aa	Colorectal	69.0	A2DD99BF-3A02-42CD-9AA8-80A018584EE6	85E29049-A5E8-49FA-A576-E113C7B2C2E3	TCGA-AA-3685-01A-02D-1981-10	GRCh37-lite	TCGA-AA-3685	TCGA-COAD		s13515	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	1981-10	False	COAD	C2	GI.CIN	0.17789671399999998	0.4	0.16	8.467384716	0.8318	0.512	0.1531	1.0584	-0.0363	-0.1191	40.0	56.0	0.461921915	2.194129094	256.0	0.8285352990000001	21.0	17.0	0.869703068	3.186210804	39.0	2.582306344	15.0	0.953566645	0.91097017	-957.4611468	110.5719303	-964.7731279999999	0.0	1127.0	0.0	1127.0	6.508998389609092	3.0960094684662067	-0.03471213924013439	5.577440185604148	5.798597307176576	1.1927301970544169	-0.9315582040049435	2.702587838710369	1.2274423362945512	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb7c	58cfa830e4b0c9d6adf6bb7c	TCGA-AA-A01R-01A-21D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A01R-01A-21D-A17O-10_wgs_Illumina	TCGA-AA-A01R-01A-21D-A17O-10_wgs_Illumina.bam	75.21	1.8	0.07	58cfa830e4b0c9d6adf6bb7c	TCGA-AA-A01R-01A-21D-A17O-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01R-01A	97F6C8D3-09A0-4128-8F10-41E736648A5F	Primary Tumor	Illumina HiSeq	5b6c9797-7cfe-4bd0-a656-74dd069d72d9	Colorectal	47.0	73EE34E8-422D-4AB1-B0F0-DA8A5A2DD9AB	303ABBE5-4155-4A0D-BC3B-F8995261CA52	TCGA-AA-A01R-01A-21D-A17O-10	GRCh37-lite	TCGA-AA-A01R	TCGA-COAD		s13194	Baylor College of Medicine	Indivumed	Germany	NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage III	A17O-10	True	COAD	C2	GI.HM-indel	0.291125137	0.37	0.02	11.59946136	0.5872	0.10800000000000001	0.0093	1.104	1.0544	-0.0428	804.0	431.0			150.0	0.083186977	2.0	11.0							0.813182066	-4.98278952	215.13846940000002	1202.565619	0.0	1065.0	1.0	608.0	7.211064607319617	4.274081598492669	0.40840589354528045	5.419305138091562	7.107549557445232	2.1646586743164256	-1.791759469228055	2.8334679589525624	1.7562527807711452	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb7e	58cfa830e4b0c9d6adf6bb7e	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.bam	52.54	2.0	0.16	58cfa830e4b0c9d6adf6bb7e	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GB-01A	2F4458B6-3CAF-4E33-890E-A04722BADD1B	Primary Tumor	Illumina HiSeq	c4dd9407-812c-41b2-9953-baec8808ddbd	Uterus	65.0	130744CA-A9A2-4C99-8ABB-20FE76E0A955	A025733C-E300-4C47-B2EF-D9C978B58BFD	TCGA-A5-A0GB-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GB	TCGA-UCEC		s4585	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.POLE	0.110943666	0.19	0.0	11.86279283	1.104	0.428	-1.1936	-0.5834	-1.2668	-0.5078	311.0		5.909763157	17.98017564	63.0	0.034585255	1.0	3.0							1.787827192	-1690.632859	732.7996147000001	-2268.636418	0.0	997.0	0.0	997.0	6.835410932911509	6.901737206656575	0.651004394086566	6.168931999433726	6.170849698113782	1.3291954834928612	-0.6664789334777841	-0.7308875085427924	0.6781910894062952	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb82	58cfa830e4b0c9d6adf6bb82	TCGA-A3-3308-01A-01D-2094-10_Illumina.filtered.	WGS	TCGA-A3-3308-01A-01D-2094-10_Illumina	TCGA-A3-3308-01A-01D-2094-10_Illumina.bam	591.9	1.9	0.17	58cfa830e4b0c9d6adf6bb82	TCGA-A3-3308-01A-01D-2094-10_Illumina.bam	Alive	FEMALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3308-01A	3CBCA837-F5A7-4A87-8F02-C59EAC232D5A	Primary Tumor	Illumina HiSeq	ff863b55-b221-4580-b322-d2f1c9137279	Kidney	77.0	0B935ADB-0E19-4FCC-9BB0-B9D95872BCEF	68B7FDB1-22B5-4152-9E69-A41151640CD8	TCGA-A3-3308-01A-01D-2094-10	GRCh37-lite	TCGA-A3-3308	TCGA-KIRC		s9000	Baylor College of Medicine	International Genomics Consortium	None	NO	T3b	N0	Kidney Clear Cell Renal Carcinoma	Stage III	2094-10	False	KIRC	C3	KIRC.3	0.238993978	0.62	0.04		-0.752	-0.19699999999999998	0.634	0.1361	0.0912	0.4318	32.0	102.0	0.638632549	1.915897647	114.0	0.08464829	3.0	6.0				2.912494403	19.0	0.9891508790000001	2.061128763	2.95382005	-528.275159	568.1584542	0.0	16.0	0.0	16.0	8.622968914980977	0.5234756969560888	0.26491212670428654	5.452295191930654	2.977510430989433		-3.170673723050323	2.4540347340333444		higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bb88	58cfa830e4b0c9d6adf6bb88	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	282.86	1.9	0.14	58cfa830e4b0c9d6adf6bb88	TCGA-AA-3956-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3956-01A	7B47489F-C3CC-4388-B5D7-C7C02790A5F6	Primary Tumor	Illumina HiSeq	edcd6fc2-ca83-409b-957a-ff0199cedf0d	Colorectal	65.0	DC1FFDA5-5B8F-4227-BE04-321643F73731	63EEF7A5-A1CC-4BB6-BA02-464D2DE89E2A	TCGA-AA-3956-01A-02D-1167-02	HG18	TCGA-AA-3956	TCGA-COAD		s13519	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True	COAD	C1	GI.CIN	0.204002341	0.65	0.2	50.50431578	0.4451	0.145	-0.363	0.3629	-0.3046	0.0118	84.0	13.0	1.069191462	4.276765848	149.0	0.232664444	10.0	17.0							0.524541495	-1499.029365	200.83480830000002	326.11250010000003	0.0	1035.0	0.0	1035.0	7.56429034104535	5.26759173395385	-0.39885569872049054	5.868674732370197	5.841521364194543	1.9333412483202	-1.6956156086751526	0.5739296302406931	2.3321969470406905	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bba5	58cfa830e4b0c9d6adf6bba5	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted.filtered.	WGS	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted.bam	226.38	1.78	0.15	58cfa830e4b0c9d6adf6bba5	TCGA-AA-A02W-01A-01D-A077_110406_SN177_0153_A818P3ABXX_s_1_rg.sorted.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02W-01A	73448B56-A6C6-4C98-A153-AB704261E073	Primary Tumor	Illumina HiSeq	faf93a8d-56fb-4e28-97fa-1fcee234250c	Colorectal	73.0	B0F0EA02-B1DA-4613-A9B0-D18A07910010	4D2B2573-105C-4770-B8CF-9243B6D709EC	TCGA-AA-A02W-01A-01D-A077-02	HG18_Broad_variant	TCGA-AA-A02W	TCGA-COAD		s13532	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A077-02	True	COAD	C1		0.097505232	0.28	0.12	0.255084916	0.7017	0.228	-0.8562	-0.1844	-0.7453	-0.1142	43.0		1.0585093	2.7124300810000004	154.0	0.783444019	17.0	9.0							1.0625609109999998	-1495.676645	575.9210607000001	-1053.949427	0.0	1247.0	1.0	1005.0	7.089555866761964	4.029152232627111	-0.019527103254964207	5.091459964536081	4.722299413187057	0.8082225222543254	-1.998095902225884	0.6931471805599454	0.8277496255092897	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbac	58cfa830e4b0c9d6adf6bbac	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	107.64	2.11	0.16	58cfa830e4b0c9d6adf6bbac	TCGA-AA-A02O-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02O-01A	6FA41234-9077-4D05-A295-6820F3BEDF5B	Primary Tumor	Illumina HiSeq	e53db54a-bb1b-4c60-8214-aaa269abd153	Colorectal	82.0	2151DC9E-F76A-4CFF-8A20-B7C107D59C27	519A6BBF-68D8-4275-854A-5216FC4DFD15	TCGA-AA-A02O-01A-21D-A079-02	HG18	TCGA-AA-A02O	TCGA-COAD		s12873	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	A079-02	True	COAD	C1	GI.GS	0.068459152	0.2	0.03	0.077413761	0.4564	0.19899999999999998	-0.8117	-0.2658	-0.9057	-0.0822	86.0	3.0	1.0758405979999999	4.477823029	132.0	0.7627879809999999	11.0	6.0							1.234214295	-652.0974513	-117.4625793	-363.8310284	0.0	28.0	0.0	28.0	6.903077689431026	5.179304761721883	-0.812470978745272	5.097524898070635	5.082454935731966	0.18903793882769881	-1.8055527913603906	-0.0968498259899171	1.0015089175729708	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbb2	58cfa830e4b0c9d6adf6bbb2	TCGA-AA-A02O-01A-21D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A02O-01A-21D-A17O-10_wgs_Illumina	TCGA-AA-A02O-01A-21D-A17O-10_wgs_Illumina.bam	107.64	2.11	0.08	58cfa830e4b0c9d6adf6bbb2	TCGA-AA-A02O-01A-21D-A17O-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A02O-01A	6FA41234-9077-4D05-A295-6820F3BEDF5B	Primary Tumor	Illumina HiSeq	22eeeeaf-8aa8-45e6-ace6-b84917c3b402	Colorectal	82.0	2151DC9E-F76A-4CFF-8A20-B7C107D59C27	4019C219-C51E-479F-8A9D-CFA6816ED696	TCGA-AA-A02O-01A-21D-A17O-10	GRCh37-lite	TCGA-AA-A02O	TCGA-COAD		s12872	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Colon Adenocarcinoma	Stage II	A17O-10	True	COAD	C1	GI.GS	0.068459152	0.2	0.03	0.077413761	0.4564	0.19899999999999998	-0.8117	-0.2658	-0.9057	-0.0822	86.0	3.0	1.0758405979999999	4.477823029	132.0	0.7627879809999999	11.0	6.0							1.234214295	-652.0974513	-117.4625793	-363.8310284	0.0	28.0	0.0	28.0	6.613085889021738	2.3692007118299463	-0.812470978745272	5.443014636371483	5.386694477165451	0.18903793882769881	-1.1700712526502546	3.0174937653355043	1.0015089175729708	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbbc	58cfa830e4b0c9d6adf6bbbc	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.bam	40.68	1.8	0.14	58cfa830e4b0c9d6adf6bbbc	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0EU-01A	C0427237-B476-4AF4-B664-7BD479922EA5	Primary Tumor	Illumina HiSeq	f8f8a691-8930-46b3-9cd7-1b8ac6895baf	Breast	79.0	69DBB2AE-3F19-4C29-9C24-810AE60312F3	7F0FA628-7A18-4E52-81CC-3E213C431D3E	TCGA-A2-A0EU-01A-22D-A060-02	HG19_Broad_variant	TCGA-A2-A0EU	TCGA-BRCA		s5489	Harvard Medical School	Walter Reed	None	NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A060-02	True	BRCA	C1	BRCA.LumA	0.078253339	0.34	0.17	1.29563199	0.0983	0.0595	-0.5454	-0.6947	0.3564	0.2129	24.0	28.0	0.30227416	1.209096639	99.0	0.54533454	22.0	3.0				1.7351264569999998	6.0	0.968392514	2.7565118539999998	-750.46262	592.6762102999999	-2379.686581	0.0	1043.0	0.0	1043.0	6.524296251136588	6.473118793573693	-0.8020091475090889	4.273004452530093	5.779971613013748	1.9472601323855478	-2.251291798606495	-0.6931471805599454	2.7492692798946368	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbc0	58cfa830e4b0c9d6adf6bbc0	TCGA-AG-A002-01A-01D-A183-10_wgs_Illumina.filtered.	WGS	TCGA-AG-A002-01A-01D-A183-10_wgs_Illumina	TCGA-AG-A002-01A-01D-A183-10_wgs_Illumina.bam	228.5	1.72	0.08	58cfa830e4b0c9d6adf6bbc0	TCGA-AG-A002-01A-01D-A183-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A002-01A	CB005C69-7301-41CE-B534-C9751F1436C5	Primary Tumor	Illumina HiSeq	23b2dbcf-d83f-448a-8e6a-e3395344bc03	Colorectal	35.0	B918B56C-5C78-4CEE-85A7-7C88501E88AD	567C8810-DAEF-4FE7-AA45-E70DB20B9F01	TCGA-AG-A002-01A-01D-A183-10	GRCh37-lite	TCGA-AG-A002	TCGA-READ		s2313	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	A183-10	True	READ	C1	GI.HM-SNV	0.071644943	0.18	0.0	4.549724321	0.7217	0.171	-1.3902	-1.8246	-1.0054	-0.1468	6378.0	245.0	81.22102652	353.4896639	123.0	0.000454971	0.0	0.0							1.4268232019999998	-1488.259894	792.7846897000001	2548.476898	0.0	638.0	0.0	638.0	7.609614400144103	4.101868827976837	-0.3043445471221514	6.356851431648735	7.973787971770168	2.243322652036582	-1.252762968495368	3.871919143793331	2.5476671991587336	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbc2	58cfa830e4b0c9d6adf6bbc2	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	624.89	1.9	0.14	58cfa830e4b0c9d6adf6bbc2	TCGA-AG-4008-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4008-01A	72802851-9340-4C5F-A90B-23B7AFD7577A	Primary Tumor	Illumina HiSeq	95360a98-f3fd-40d4-b451-5973fe934b51	Colorectal	63.0	D803F092-3340-485D-9964-D6554D210E2E	CD36B70F-6819-4136-ADB5-8024E27B05A6	TCGA-AG-4008-01A-01D-1115-02	HG18	TCGA-AG-4008	TCGA-READ		s2312	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.CIN	0.12986034400000002	0.5	0.28	16.23753451	0.623	0.25	-0.1572	0.0054	-0.003	0.3494	42.0	56.0			131.0	0.312662294	10.0	18.0							1.899820099	-1245.514177	-17.50748492	236.4009461	0.0	518.0	0.0	518.0	6.3014146925404795	4.6013082491364665	-0.5468609868239894	3.847949568587298	4.881792347065921	1.9450491933413483	-2.453465123953181	0.2804840979294543	2.4919101801653376	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbc4	58cfa830e4b0c9d6adf6bbc4	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted.filtered.	WGS	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted.bam	174.93	1.72	0.15	58cfa830e4b0c9d6adf6bbc4	TCGA-AG-A008-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_7.rg.sorted.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A008-01A	E7503A51-6647-4CC2-80DD-645D0DF4DB43	Primary Tumor	Illumina HiSeq	e31d4ba3-4d48-4e50-9932-05a2978a90df	Colorectal	50.0	AC02CD55-BC05-4329-8845-E09D088E3CB4	999D82E8-B92F-4397-A9F9-9AFBFD8A249C	TCGA-AG-A008-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A008	TCGA-READ		s1995	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Mucinous Adenocarcinoma	Stage I	A077-02	True	READ	C1	GI.CIN	0.00882538	0.11	0.05	6.134869492000001	0.9087	0.275	-1.1452	-1.0824	-0.8195	-0.5186	36.0	3.0			71.0	0.947890338	16.0	4.0							0.9857982479999999	-1196.3004449999999	775.793386	322.89567289999997	0.0	424.0	0.0	424.0	7.674446071794437	4.457815487894612	-1.5688579802864315	7.108050596873635	6.955575400868347	0.4237066562657401	-0.5663954749208013	2.497759912973735	1.9925646365521716	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbc8	58cfa830e4b0c9d6adf6bbc8	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	610.89	1.9	0.14	58cfa830e4b0c9d6adf6bbc8	TCGA-AG-4015-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4015-01A	1388BBA1-02BA-40DF-93E5-C3D58B7BBAE0	Primary Tumor	Illumina HiSeq	70efc59a-8909-43e4-961b-76a7a3633927	Colorectal	85.0	3C910093-DF83-485B-86EF-26A0991D9A0B	2E183A8C-5755-4DC7-AEAB-6F7E9A9A5D1A	TCGA-AG-4015-01A-01D-1115-02	HG18	TCGA-AG-4015	TCGA-READ		s1986	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.CIN	0.05714771	0.2	0.07	11.74949326	0.7624	0.228	-0.6086	0.0398	-0.3724	-0.0693	53.0	92.0	0.848539155	2.817149995	359.0	0.669283361	19.0	25.0								-1445.9612220000001	19.50401733	1111.815253	0.0	0.0	0.0	0.0	6.559115195812683	3.908770663469581	-0.5257884964427029	5.217941269973262	4.599567666684573	2.300354194132378	-1.3411739258394206	0.6907970032149917	2.826142690575081	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbdd	58cfa830e4b0c9d6adf6bbdd	TCGA-AG-4015-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-4015-01A-01D-1989-10_wgs_Illumina	TCGA-AG-4015-01A-01D-1989-10_wgs_Illumina.bam	610.89	1.9	0.14	58cfa830e4b0c9d6adf6bbdd	TCGA-AG-4015-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4015-01A	1388BBA1-02BA-40DF-93E5-C3D58B7BBAE0	Primary Tumor	Illumina HiSeq	ba539625-e278-4166-9667-ec8f68d0b5a0	Colorectal	85.0	3C910093-DF83-485B-86EF-26A0991D9A0B	AA06AE46-2336-4666-A3AF-FC790DAF8DA4	TCGA-AG-4015-01A-01D-1989-10	GRCh37-lite	TCGA-AG-4015	TCGA-READ		s2169	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1989-10	True	READ	C1	GI.CIN	0.05714771	0.2	0.07	11.74949326	0.7624	0.228	-0.6086	0.0398	-0.3724	-0.0693	53.0	92.0	0.848539155	2.817149995	359.0	0.669283361	19.0	25.0								-1445.9612220000001	19.50401733	1111.815253	0.0	0.0	0.0	0.0	6.4682420567344	1.7139333924022768	-0.5257884964427029	5.908626268798978	4.983794772003346	2.300354194132378	-0.5596157879354227	3.2698613796010694	2.826142690575081	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbe4	58cfa830e4b0c9d6adf6bbe4	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted.bam	228.5	1.72	0.15	58cfa830e4b0c9d6adf6bbe4	TCGA-AG-A002-01A-01D-A077-02_110217_SN208_0190_B81CLKABXX_s_1.rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A002-01A	CB005C69-7301-41CE-B534-C9751F1436C5	Primary Tumor	Illumina HiSeq	90021059-77d3-4362-9cc9-f14fcfba46c9	Colorectal	35.0	B918B56C-5C78-4CEE-85A7-7C88501E88AD	901C5D59-CE0A-44AE-91AE-9C253E99B68E	TCGA-AG-A002-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A002	TCGA-READ		s1991	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	A077-02	True	READ	C1	GI.HM-SNV	0.071644943	0.18	0.0	4.549724321	0.7217	0.171	-1.3902	-1.8246	-1.0054	-0.1468	6378.0	245.0	81.22102652	353.4896639	123.0	0.000454971	0.0	0.0							1.4268232019999998	-1488.259894	792.7846897000001	2548.476898	0.0	638.0	0.0	638.0	7.81630705130011	4.798009855389801	-0.3043445471221514	7.301851659483541	4.91032008930483	2.243322652036582	-0.5144553918165693	0.11231023391502859	2.5476671991587336	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbf4	58cfa830e4b0c9d6adf6bbf4	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.bam	88.42	2.12	0.14	58cfa830e4b0c9d6adf6bbf4	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GW-01A	5B6B9D0F-787C-4AE9-AFD4-DE7CE6C57A42	Primary Tumor	Illumina HiSeq	84e2e6bd-f438-45e9-9d44-2af82246e341	Uterus	46.0	E84D0533-E892-4C1E-9415-99F92AA9A360	3DCC9DC1-990D-4053-967E-B8E4EE752C4E	TCGA-A5-A0GW-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GW	TCGA-UCEC		s4421	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.MSI	0.327124191	0.48	0.0	19.39594454	0.7474	0.355	0.3424	1.5916	0.2222	0.4807	134.0	711.0	3.441808954	8.266224923	89.0	0.050215112	2.0	0.0							1.3788076009999999	-1118.8566640000001	588.4369717999999	-2375.911927	0.0	706.0	0.0	706.0	6.208438160042196	6.746087913778233	0.1634468461302796	5.989075331567893	6.5024658311204835	0.9907233266569246	-0.21936282847430322	-0.2436220826577502	0.827276480526645	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbfa	58cfa830e4b0c9d6adf6bbfa	TCGA-AG-3593-01A-01D-1525-10_hg19_wgs_Illumina.filtered.	WGS	TCGA-AG-3593-01A-01D-1525-10_hg19_wgs_Illumina	TCGA-AG-3593-01A-01D-1525-10_hg19_wgs_Illumina.bam	495.85	1.9	0.05	58cfa830e4b0c9d6adf6bbfa	TCGA-AG-3593-01A-01D-1525-10_hg19_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3593-01A	10290E91-9784-4F94-8DAA-B5D9A8B0EFB9	Primary Tumor	Illumina HiSeq	9275573a-23ac-40aa-b792-cff9ee5bca8c	Colorectal	72.0	EFFCA0F1-E81D-47CD-8287-392A2B6AB786	FAFF4626-615B-416A-B7A6-9D177DCC94A9	TCGA-AG-3593-01A-01D-1525-10	GRCh37-lite	TCGA-AG-3593	TCGA-READ		s1953	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1525-10	True	READ	C1		0.09435855900000001			21.47919761	0.8963	0.24600000000000002	-0.0354	0.4447	-0.5132	-0.1155					240.0	0.8847177009999999	20.0	13.0							1.3550179180000002	-1925.126791	598.2607267000001	913.2091785	0.0	1035.0	0.0	1035.0	3.590709797743652	1.1558563798301815	-0.4448740742740499	4.734442521692231	3.0413233656334944	1.3326880138830612	1.1437327239485793	1.8854669858033128	1.777562088157111	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bbfe	58cfa830e4b0c9d6adf6bbfe	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	463.6	1.9	0.15	58cfa830e4b0c9d6adf6bbfe	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2684-01A	49929108-023E-4D35-B26D-50AB4D3AE581	Primary Tumor	Illumina HiSeq	1d127721-dd08-4127-af3b-0dfd623ea7bf	Colorectal	75.0	73B6994E-C9BF-41A8-A455-17D7BE309A9F	5A35E547-72DB-4B4E-8459-1264D0845506	TCGA-A6-2684-01A-01D-1405-02	HG18	TCGA-A6-2684	TCGA-COAD		s13174	Harvard Medical School	Christiana Healthcare	None	NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	True	COAD	C1		0.23007724300000001	0.37	0.01	6.343803187000001	0.6759999999999999	0.324	0.3452	0.4289	0.1098	0.3204	62.0	66.0	0.8775503109999999	2.315757764	69.0	0.130577254	6.0	7.0	0.927437925	3.184809969	31.0				1.323700665	-794.9475332000001	161.8819914	400.01001	0.0	1127.0	1.0	976.0	5.824313055103472	4.647008270612106	0.175875217079708	4.273715642692306	5.621838705394579	1.7724649870359594	-1.5505974124111668	0.974830434782473	1.5965897699562515	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc00	58cfa830e4b0c9d6adf6bc00	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	380.0	1.9	0.15	58cfa830e4b0c9d6adf6bc00	TCGA-A6-3807-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3807-01A	5116E3B4-2BAC-40F5-8046-B9C1783FAAA5	Primary Tumor	Illumina HiSeq	d5f643a5-b69b-499a-8aab-7fc6520f2e55	Colorectal	53.0	1EB2A255-6EDD-4ADB-B52D-99DCEC590C5D	3A4293C1-0860-42F9-9D64-26B7298C2CDB	TCGA-A6-3807-01A-01D-1167-02	HG18	TCGA-A6-3807	TCGA-COAD		s13505	Harvard Medical School	Christiana Healthcare	None	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1167-02	True	COAD	C1	GI.CIN	0.22782604899999997	0.48	0.19	5.297474787	0.5989	0.245	-0.0674	-0.1753	0.0759	0.1453	44.0				221.0	0.48063888	12.0	20.0							1.323846415	-1247.546682	-120.7776531	-1586.448282	0.0	1054.0	0.0	1054.0	5.654927090968718	5.505506361107633	-0.3807326103869644	4.395972152225428	5.7476464131124985	0.638151505256193	-1.2589549387432895	0.24214005200486532	1.0188841156431574	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc0a	58cfa830e4b0c9d6adf6bc0a	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.bam	42.49	2.13	0.16	58cfa830e4b0c9d6adf6bc0a	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GV-01A	5E3B981E-73FE-4CC9-8C89-B420E8E2F426	Primary Tumor	Illumina HiSeq	c99f6cb7-44cc-4045-a0f6-4fec580e964c	Uterus	67.0	339926E1-61E6-4256-A808-F931AA2C17D2	721D7961-15F0-4A52-8D2C-885278D3B579	TCGA-A5-A0GV-01A-31D-A043-02	HG19_Broad_variant	TCGA-A5-A0GV	TCGA-UCEC		s4987	Harvard Medical School	Cedars Sinai	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.05033908	0.12	0.01	2.094585882	0.4133	0.095	-1.3333	-1.4509	-1.1665	-0.3211	24.0	1.0	0.362080974	1.2069365779999999	74.0	0.895066398	7.0	1.0							3.038575967	-1238.235458	-12.19220339	1676.677375	0.0	1643.0	1.0	304.0	6.856892513913108	7.024331237207246	-0.18191792409422636	6.186734851577862	6.7189495876560645	1.5060163212809483	-0.6701576623352463	-0.30538164955118186	1.6879342453751747	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc0e	58cfa830e4b0c9d6adf6bc0e	TCGA-AG-4008-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-4008-01A-01D-1989-10_wgs_Illumina	TCGA-AG-4008-01A-01D-1989-10_wgs_Illumina.bam	624.89	1.9	0.14	58cfa830e4b0c9d6adf6bc0e	TCGA-AG-4008-01A-01D-1989-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4008-01A	72802851-9340-4C5F-A90B-23B7AFD7577A	Primary Tumor	Illumina HiSeq	673cc168-5c3a-4eec-b299-8de319725cc6	Colorectal	63.0	D803F092-3340-485D-9964-D6554D210E2E	428C100F-D7D0-4860-A8FC-2BAE6A4BBA95	TCGA-AG-4008-01A-01D-1989-10	GRCh37-lite	TCGA-AG-4008	TCGA-READ		s1990	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1989-10	True	READ	C1	GI.CIN	0.12986034400000002	0.5	0.28	16.23753451	0.623	0.25	-0.1572	0.0054	-0.003	0.3494	42.0	56.0			131.0	0.312662294	10.0	18.0							1.899820099	-1245.514177	-17.50748492	236.4009461	0.0	518.0	0.0	518.0	6.031486221457467	3.663723406078237	-0.5468609868239894	5.050656968445741	5.406242159203129	1.9450491933413483	-0.9808292530117262	1.7425187531248918	2.4919101801653376	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc11	58cfa830e4b0c9d6adf6bc11	TCGA-AG-3727-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3727-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3727-01A-01D-1989-10_wgs_Illumina.bam	489.31	1.9	0.15	58cfa830e4b0c9d6adf6bc11	TCGA-AG-3727-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3727-01A	E6827400-0D95-46B0-8874-6CE9E9D5011B	Primary Tumor	Illumina HiSeq	70d6fce9-139d-448e-8f5f-14b10832d66b	Colorectal	78.0	DA1CA84F-6C55-4536-9449-3C87E51EF85A	786FC3E4-E2BF-4914-9251-41C800EBB2FA	TCGA-AG-3727-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3727	TCGA-READ		s2142	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage III	1989-10	True	READ	C1	GI.CIN	0.04641623	0.11	0.0	0.430606161	-0.075	-0.27399999999999997	-0.9151	-0.5606	-1.8986	0.3263	58.0		0.547627348	2.403475584	163.0	0.201099754	4.0	28.0							0.399174065	-1346.321798	-1190.190994	1527.0203720000002	0.0	30.0	0.0	30.0	2.4871976015345556	2.882774251250285	-0.6447119382925427	5.232635334708386	5.442164178131672	2.1566684791904622	2.7454377331738304	2.559389926881387	2.801380417483005	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc1c	58cfa830e4b0c9d6adf6bc1c	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted.bam	125.63	1.96	0.17	58cfa830e4b0c9d6adf6bc1c	TCGA-AG-A020-01A-21D-A079-02_110409_SN590_0077_BB04EHABXX_s_1.rg.sorted.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A020-01A	19E46A3D-18C5-4927-8501-2265E2D617B8	Primary Tumor	Illumina HiSeq	1aa43549-776a-4daf-b60e-f0b8c3287077	Colorectal	57.0	EEC9C9E3-6CB3-4589-B3A8-EA2337878599	140B186D-B7EC-4A31-8FE0-A490BBDAE19B	TCGA-AG-A020-01A-21D-A079-02	HG18_Broad_variant	TCGA-AG-A020	TCGA-READ		s2003	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Mucinous Adenocarcinoma	Stage III	A079-02	True	READ	C1	GI.CIN	0.07388470400000001	0.13	0.3	4.726256426	1.1226	0.33799999999999997	-1.2969	-0.9555	-0.4903	-0.4645	32.0	4.0	0.703804695	2.026957522	161.0	0.381263736	6.0	15.0							1.423678019	-1696.5399129999998	955.4673720000001	-905.9929235	0.0	31.0	0.0	31.0	7.168719963095205	5.01569772714833	-0.6501144237232168	6.347739411025374	6.5327623194514155	1.6464850491998893	-0.8209805520698299	1.5170645923030852	2.296599472923106	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc1e	58cfa830e4b0c9d6adf6bc1e	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	100.13	2.07	0.17	58cfa830e4b0c9d6adf6bc1e	TCGA-AG-A01Y-01A-41D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01Y-01A	A91F7A8C-E0FE-403A-9EF0-F7679B2761CC	Primary Tumor	Illumina HiSeq	9b6deb45-fcab-4b6f-8c5d-225444c42154	Colorectal	49.0	28B76ABF-6A5F-4D3B-87FE-18EA7139DEDF	D295156A-3A31-4540-B295-0B620340E4DB	TCGA-AG-A01Y-01A-41D-A079-02	HG18	TCGA-AG-A01Y	TCGA-READ		s2172	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	A079-02	True	READ	C1	GI.CIN	0.139867272	0.21	0.06	7.284400486	0.9743	0.293	-0.1239	0.2842	-0.32799999999999996	0.0604	33.0	1.0	0.707354169	2.206945007	187.0	0.366270879	9.0	30.0								-1003.977082	596.9967002000001	-1210.392061	0.0	0.0	0.0	0.0	6.328356863550538	4.915881735906151	-0.7073726262334232	4.7189189511164376	4.984089985932684	1.6542116843459875	-1.6094379124341005	0.06820825002653308	2.3615843105794108	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc22	58cfa830e4b0c9d6adf6bc22	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted.filtered.	WGS	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted.bam	489.31	1.9	0.15	58cfa830e4b0c9d6adf6bc22	TCGA-AG-3727-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_3.rg.sorted.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3727-01A	E6827400-0D95-46B0-8874-6CE9E9D5011B	Primary Tumor	Illumina HiSeq	c29d4836-8104-479e-98ce-a8c435a242d7	Colorectal	78.0	DA1CA84F-6C55-4536-9449-3C87E51EF85A	D8361FC2-8AB1-4D36-9009-237D905CF899	TCGA-AG-3727-01A-01D-1167-02	HG18_Broad_variant	TCGA-AG-3727	TCGA-READ		s2141	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage III	1167-02	True	READ	C1	GI.CIN	0.04641623	0.11	0.0	0.430606161	-0.075	-0.27399999999999997	-0.9151	-0.5606	-1.8986	0.3263	58.0		0.547627348	2.403475584	163.0	0.201099754	4.0	28.0							0.399174065	-1346.321798	-1190.190994	1527.0203720000002	0.0	30.0	0.0	30.0	4.148975534329445	5.070821135714582	-0.6447119382925427	3.9548195198884875	4.804553157766618	2.1566684791904622	-0.19415601444095731	-0.2662679779479644	2.801380417483005	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc26	58cfa830e4b0c9d6adf6bc26	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	420.6	1.9	0.16	58cfa830e4b0c9d6adf6bc26	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3810-01A	B728E6E8-A0E4-496B-904C-6F07C12E901F	Primary Tumor	Illumina HiSeq	54687a8d-c693-4ae5-8451-4f4c80adca53	Colorectal	62.0	F2BD44D3-A53C-4A10-9AE1-A93E762F174C	AD4275F1-789D-471C-88DD-B6E76069D856	TCGA-A6-3810-01A-01D-1167-02	HG18	TCGA-A6-3810	TCGA-COAD		s13016	Harvard Medical School	Christiana Healthcare	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True	COAD	C1		0.24937186	0.4	0.36	4.075723831	0.5404	0.213	0.2462	0.1809	-0.1997	0.3302	70.0	24.0			97.0	0.705043912	18.0	15.0							1.037395766	-742.7106805	334.0869488	-875.2312210000001	0.0	1111.0	0.0	1111.0	7.357266270201761	5.801311499106732	-0.34370862425804605	5.926520146511036	6.895409107420314	1.3791334765220904	-1.4307461236907244	1.0940976083135823	1.7228421007801364	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc2a	58cfa830e4b0c9d6adf6bc2a	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	631.89	1.9	0.16	58cfa830e4b0c9d6adf6bc2a	TCGA-AA-3994-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3994-01A	750770DB-53CF-4021-A8C2-5E0DDB97FEF5	Primary Tumor	Illumina HiSeq	dadc0f63-410b-4eb6-b287-c05bbc274608	Colorectal	69.0	41933A62-1325-4089-80B5-06E3EBB238DA	FED1DBB6-D332-4239-A878-8587A7CE4D05	TCGA-AA-3994-01A-01D-1109-02	HG18	TCGA-AA-3994	TCGA-COAD		s13518	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Mucinous Adenocarcinoma	Stage IIIB	1109-02	True	COAD	C1	GI.CIN	0.10895039599999999	0.24	0.02	2.566144589	0.4976	0.23	-0.2875	-0.4736	-0.2791	0.1195	93.0	47.0	1.8422406709999999	4.813596592	100.0	0.21440938199999998	6.0	9.0							1.7897410630000001	-1144.988405	257.72687790000003	-2104.8989070000002	0.0	822.0	0.0	822.0	6.729425743457719	6.176986106632608	-0.5586374448147403	5.289064161067554	6.9295567076633535	1.0139371793870204	-1.440361582390166	0.752570601030746	1.5725746242017609	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc31	58cfa830e4b0c9d6adf6bc31	TCGA-AA-3994-01A-01D-1981-10_wgs_Illumina.filtered.	WGS	TCGA-AA-3994-01A-01D-1981-10_wgs_Illumina	TCGA-AA-3994-01A-01D-1981-10_wgs_Illumina.bam	631.89	1.9	0.16	58cfa830e4b0c9d6adf6bc31	TCGA-AA-3994-01A-01D-1981-10_wgs_Illumina.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-3994-01A	750770DB-53CF-4021-A8C2-5E0DDB97FEF5	Primary Tumor	Illumina HiSeq	6cc193d6-40f0-46ba-aa41-4240fe42a46c	Colorectal	69.0	41933A62-1325-4089-80B5-06E3EBB238DA	D9690A27-BB02-498E-B15C-EE76E31D16EE	TCGA-AA-3994-01A-01D-1981-10	GRCh37-lite	TCGA-AA-3994	TCGA-COAD		s12867	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Colon Mucinous Adenocarcinoma	Stage IIIB	1981-10	False	COAD	C1	GI.CIN	0.10895039599999999	0.24	0.02	2.566144589	0.4976	0.23	-0.2875	-0.4736	-0.2791	0.1195	93.0	47.0	1.8422406709999999	4.813596592	100.0	0.21440938199999998	6.0	9.0							1.7897410630000001	-1144.988405	257.72687790000003	-2104.8989070000002	0.0	822.0	0.0	822.0	6.708694398183884	5.377042308237208	-0.5586374448147403	5.003946305945458	7.044951989126641	1.0139371793870204	-1.7047480922384255	1.6679096808894336	1.5725746242017609	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc38	58cfa830e4b0c9d6adf6bc38	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	91.92	1.64	0.15	58cfa830e4b0c9d6adf6bc38	TCGA-AA-A01C-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01C-01A	80809D79-92E1-4D6C-BA2E-0A9589997792	Primary Tumor	Illumina HiSeq	a7b8c819-1f82-43d2-93aa-5c85e2710e7e	Colorectal	75.0	1E191EED-2238-450E-A384-26DF9C569FD0	77F9EF43-7202-4C9B-9556-F00F0A66D2D4	TCGA-AA-A01C-01A-01D-A077-02	HG18	TCGA-AA-A01C	TCGA-COAD		s13199	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Colon Adenocarcinoma	Stage IIIA	A077-02	True	COAD	C1		0.12431349300000001	0.4	0.33	0.7577510409999999	0.6822	0.26899999999999996	-0.7408	-0.7117	-0.3535	0.1969	37.0	103.0	0.5982889570000001	2.2672002559999997	103.0	0.428688216	13.0	10.0							1.003630686	-1511.048855	162.35327980000002	-1681.590334	0.0	457.0	0.0	457.0	7.33726238157054	5.77778198917094	-0.1177830356563837	6.158607385228894	7.316483350513262	1.2115921975953636	-1.1786549963416464	1.538701361342322	1.3293752332517474	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc3e	58cfa830e4b0c9d6adf6bc3e	TCGA-AG-3582-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3582-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3582-01A-01D-1989-10_wgs_Illumina.bam	747.21	1.9	0.15	58cfa830e4b0c9d6adf6bc3e	TCGA-AG-3582-01A-01D-1989-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3582-01A	DB1E3104-8BFD-4353-854A-C478BA1F7D07	Primary Tumor	Illumina HiSeq	f968a6d9-8eb8-436a-92a3-b7080bdf5a3e	Colorectal	75.0	1B1EF856-EA45-4857-8B4B-C4330FA930D8	D452293A-6148-4FCF-9FBC-446815016751	TCGA-AG-3582-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3582	TCGA-READ		s2135	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IV	1989-10	True	READ	C1		0.065837927			23.52186738	0.7997	0.262	-0.3103	-0.1201	-0.6781	0.0982					206.0	0.420046801	13.0	20.0							0.292375495	-1884.930789	296.879728	-287.956525	1.0	1096.0	1.0	1096.0	6.5197370844776925	3.505382294909399	-0.6208387140279106	5.490117667296534	6.912782620696163	0.9376555543718521	-1.029619417181158	3.4074003257867638	1.5584942683997627	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc46	58cfa830e4b0c9d6adf6bc46	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.bam	16.97	1.91	0.13	58cfa830e4b0c9d6adf6bc46	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JF-01A	F357FE19-5359-4662-8CE9-AA996132283B	Primary Tumor	Illumina HiSeq	031ab51d-07d0-4afe-a9dd-222889f5c32b	Breast	68.0	DDEE0B07-2771-40C7-BDDA-C1100958F0D8	BDAA1600-1B4F-4BBA-B4D6-A4D169B029D6	TCGA-AO-A0JF-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JF	TCGA-BRCA		s5491	Harvard Medical School	MSKCC	None	NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True	BRCA	C3	BRCA.LumA	0.262502852	0.58	0.01	0.176035677	-0.5981	-0.1075	0.4684	0.3551	-0.1303	0.5901	10.0	1.0	0.289704644	0.666320682	79.0	0.053613315999999994	2.0	4.0				3.538454027	40.0	0.959221918	2.019538273	-975.1847267	747.2890054999999	118.13165320000002	0.0	1980.0	0.0	1980.0	8.045428011550841	6.408646458883368	-0.6367831196349767	5.848203434214622	6.796411989892132	1.7152420156992207	-2.197224577336219	0.38776553100876354	2.3520251353341974	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc4c	58cfa830e4b0c9d6adf6bc4c	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina.bam	543.0	1.9	0.14	58cfa830e4b0c9d6adf6bc4c	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-3473-01A	A7BF785F-0539-4899-AC21-47D1FC347EE8	Primary Tumor	Illumina HiSeq	7f8267f9-4d48-48c6-aebb-a596aaf7755c	Kidney	55.0	DE88A41B-8A32-40D6-9C0B-1FE2303D8AD2	14DD86C1-DFB3-4124-A453-4D64223BC048	TCGA-AL-3473-01A-01D-1253-10	GRCh37-lite	TCGA-AL-3473	TCGA-KIRP		s11638	Baylor College of Medicine	Fox Chase	None	NO	T2	N0	Kidney Papillary Renal Cell Carcinoma	Stage II	1253-10	False	KIRP	C2	KIRP.C2a	0.51923392	0.68	0.0		-1.1451	-0.0765	1.2326	1.6986	0.8261	-0.541	16.0	24.0	0.292588297	1.199612016	110.0	0.121685396	1.0	4.0		0.0	1.0	3.7898783660000004	118.0	0.794409747	1.5418626309999999	550.6204992	-1115.555723	1001.141108	0.0	1906.0	0.0	1906.0	6.616734305264842	4.122935742505006	2.7060347486228604	4.911986213026417	3.3566662971160985	2.9162587620356373	-1.7047480922384255	-0.7662694453889074	0.21022401341277686	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc4e	58cfa830e4b0c9d6adf6bc4e	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.bam	55.61	2.3	0.14	58cfa830e4b0c9d6adf6bc4e	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A05P-01A	3CB83517-78A4-47B8-8B1E-57E765DBDD2E	Primary Tumor	Illumina HiSeq	a12cb33f-6f29-4068-a6c8-3e20520bc2e0	Uterus	54.0	F51F7B0E-3EA6-4232-9DE4-A4DD63B23BB5	E08A6886-B019-4920-ACC3-73A4CAF18E3F	TCGA-AP-A05P-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A05P	TCGA-UCEC		s5385	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.079815593	0.54	0.03	1.4425406719999998	-0.1288	0.040999999999999995	-0.4466	0.11699999999999999	-0.23	0.0745	28.0	3.0	0.434935946	1.2758121070000001	36.0	0.168812772	5.0	0.0							2.531444479	-397.94670069999995	-10.67422583	-1995.401832	0.0	636.0	0.0	636.0	7.23409700978949	4.073184764386475	0.4378503592658818	6.7922642575104515	1.730027708127384	3.2073091884967355	-0.4418327522790393	-2.3431570562590913	2.769458829230854	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc52	58cfa830e4b0c9d6adf6bc52	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted.filtered.	WGS	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted.bam	217.29	1.72	0.15	58cfa830e4b0c9d6adf6bc52	TCGA-AG-A011-01A-01D-A077-02_110409_SN590_0076_AB04G5ABXX_s_1.rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A011-01A	3BE106BC-BA42-4C70-9B50-697D89DB617D	Primary Tumor	Illumina HiSeq	af371ab1-77bf-4408-860e-ccc4386c99aa	Colorectal	80.0	B5DD8F49-26FC-48D9-A964-D8EBDCCA9E19	8C282A6C-3D47-4F9E-96C4-2C0852E7785B	TCGA-AG-A011-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A011	TCGA-READ		s2001	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	A077-02	True	READ	C1	GI.CIN	0.152210219	0.45	0.06	22.12477452	0.4651	0.046	-0.6202	0.1451	-0.5705	-0.0721	54.0	8.0			232.0	0.331239833	10.0	25.0							0.6920289040000001	-477.80809450000004	5.005204953	3006.622796	0.0	1126.0	0.0	1126.0	6.5422839964700366	5.756688307490221	-0.5446989344329014	5.401112093383131	7.090796915439541	2.308533276513807	-1.1411719030869056	1.3341086079493198	2.8532322109467083	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc5a	58cfa830e4b0c9d6adf6bc5a	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted.bam	94.43	2.0	0.16	58cfa830e4b0c9d6adf6bc5a	TCGA-AP-A0LH-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LH-01A	7DCE4215-01F6-43E9-9378-9E22C26C23A2	Primary Tumor	Illumina HiSeq	4334c333-7627-4949-90aa-55897232ec49	Uterus	60.0	4C657AD4-2C53-4EA9-82B5-52996E74E3FF	FCA1C7F5-E456-4574-9716-79770E6DAE8C	TCGA-AP-A0LH-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LH	TCGA-UCEC	1106.0	s5203	Harvard Medical School	MSKCC	None	NO			Mixed serous and endometrioid		A043-02	True	UCEC	C2	UCEC.CN_HIGH	0.073323567	0.07	0.98	17.1613425	0.838	0.28	-0.6707	-0.8716	0.4548	-0.4072	15.0	0.0	0.164682567	0.741071549	275.0	0.113158878	5.0	6.0							2.882589186	-656.4614351	222.0111136	-580.3885031000001	1.0	1106.0	1.0	302.0	5.678191124989292	7.557174460964914	-0.3585098822163302	5.7190131195095475	7.105189337221857	1.1693100901662161	0.04082199452025481	-0.45198512374305766	1.5278199723825463	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc5e	58cfa830e4b0c9d6adf6bc5e	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina.bam	543.0	1.9	0.13	58cfa830e4b0c9d6adf6bc5e	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-3472-01A	42D044AE-1416-477D-AC80-779C49BC8D35	Primary Tumor	Illumina HiSeq	8f19974d-a670-4221-82fc-60d3918c19e0	Kidney	57.0	7EEA5C2A-F1A2-432E-88A2-E96B809E15D9	63D0C49D-918D-41FB-808A-1F8001981917	TCGA-AL-3472-01A-01D-1253-10	GRCh37-lite	TCGA-AL-3472	TCGA-KIRP		s11852	Baylor College of Medicine	Fox Chase	None	NO	T2	N0	Kidney Papillary Renal Cell Carcinoma		1253-10	False	KIRP	C3	KIRP.C1	0.024497567999999997	0.11	0.0		-2.4245	-0.265	-0.5862	-0.3704	-0.7353	-0.3654	20.0	4.0	0.284075011	1.306745049	143.0	0.082042158	4.0	0.0		0.0	1.0	1.732867951	6.0	0.9671320179999999	2.301625202	-549.9041202000001	-2276.620436	2829.1656940000003	0.0	2029.0	0.0	2029.0	6.9865664594064265	1.641675136225695	-0.12054576188499022	5.357325919676146	2.073546908839953		-1.6292405397302798	0.431871772614258		lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc62	58cfa830e4b0c9d6adf6bc62	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted.filtered.	WGS	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted.bam	150.39	1.72	0.15	58cfa830e4b0c9d6adf6bc62	TCGA-AG-A00Y-01A-02D-A077-02_110405_SN590_0074_AB04EUABXX_s_7.rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A00Y-01A	C7E09161-60D6-4DFF-A840-7CEC3BB7A30A	Primary Tumor	Illumina HiSeq	2c284389-2d4d-4e3b-9b5b-a37212874f6e	Colorectal	68.0	8EC6ADED-026E-47F5-91F1-2A75F07BD8D0	27B036A3-5277-4C0F-93EE-593FDA1441DC	TCGA-AG-A00Y-01A-02D-A077-02	HG18_Broad_variant	TCGA-AG-A00Y	TCGA-READ		s1983	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	A077-02	True	READ	C2		0.16793866300000002	0.3	0.7	19.84232675	0.7965	0.196	-0.6124	0.2012	0.9409	-0.3247	142.0				1336.0	0.440865526	6.0	27.0							0.513894086	-1042.093279	340.41857830000004	-565.0084509	0.0	700.0	1.0	123.0	5.723911845951367	7.295226123718023	0.05329479344522181	4.891002723016262	6.6020789431580775	2.056659643096701	-0.8329091229351042	-0.6931471805599454	2.0033648496514793	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc6c	58cfa830e4b0c9d6adf6bc6c	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	915.89	1.9	0.16	58cfa830e4b0c9d6adf6bc6c	TCGA-AG-4007-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4007-01A	8E00E7E7-FFAF-44F0-91A7-172671F18E08	Primary Tumor	Illumina HiSeq	5f015b15-7286-4700-88d4-e7c460f68336	Colorectal	87.0	E6FC3F28-1DE1-4587-9E0E-0861323E6772	E9D7A5C4-3E98-4C98-A953-B75EA555DD7D	TCGA-AG-4007-01A-01D-1115-02	HG18	TCGA-AG-4007	TCGA-READ		s1985	Harvard Medical School	Indivumed	Germany	NO	T4	N2	Rectal Adenocarcinoma	Stage IV	1115-02	True	READ	C1		0.085002955	0.31	0.06	13.90430149	0.2916	0.138	-0.0642	0.7799	-0.4136	0.1805					420.0	0.997270488	21.0	23.0							1.557623971	-1257.6077289999998	-596.9351227999999	435.28805520000003	0.0	31.0	0.0	31.0	6.071613349948983	4.288188731194426	-0.3234562428015064	3.578122956469592	4.748404354073998	2.07244501139	-2.4934903934793913	0.46021562287957263	2.3959012541915063	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc7a	58cfa830e4b0c9d6adf6bc7a	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.bam	48.13	1.89	0.13	58cfa830e4b0c9d6adf6bc7a	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JL-01A	D5D8E76E-2F2A-49BC-BA0A-D51283611B16	Primary Tumor	Illumina HiSeq	b39a31b9-dd85-403d-ac11-d7b6dd2703a6	Breast	59.0	834D2E25-DA72-413B-BB0E-3BEB24D46472	A34C3F47-AD37-4777-A733-07AE8F4B4BFF	TCGA-AO-A0JL-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JL	TCGA-BRCA		s5639	Harvard Medical School	MSKCC	None	NO	T2	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A060-02	True	BRCA	C1	BRCA.Basal	0.06545793			1.520725499	0.6154	0.059000000000000004	-0.5355	-0.3576	-1.0403	0.1153					247.0	0.707262463	20.0	45.0	0.969703445	1.0653281209999999	3.0	0.0	1.0		3.52642544	-1279.713357	339.12283130000003	-440.7004632	0.0	1683.0	0.0	1683.0	8.301273485191349	6.279098541480954	-0.09461753202875645	5.965898569374311	6.972245722040899	1.9580806846755685	-2.3353749158170363	0.6931471805599454	2.052698216704325	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc82	58cfa830e4b0c9d6adf6bc82	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted.bam	85.32	1.85	0.15	58cfa830e4b0c9d6adf6bc82	TCGA-AP-A0LI-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_7_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LI-01A	E1E8DC66-467C-48A5-BE56-3DB4F665B9F1	Primary Tumor	Illumina HiSeq	9fe530df-5c54-45fa-a25d-65e1a7d0110b	Uterus	67.0	981D9E3B-63C5-41E9-827F-7F1D268D62F4	D80E9147-7A64-4AB0-891A-2D97D0634EAB	TCGA-AP-A0LI-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LI	TCGA-UCEC		s5387	Harvard Medical School	MSKCC	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_HIGH	0.29465461	0.57	0.14	14.41569867	0.6177	0.05	0.1909	1.7989	0.3881	-0.0891	33.0	65.0	0.7632011759999999	2.968004572	410.0	0.707326421	18.0	43.0							1.3062935359999999	316.7068643	-530.7196472	1566.45729	0.0	2972.0	0.0	2972.0	5.255269828235686	7.984710494659327	0.8707873703272615	5.2311722766566255	6.827257705968284	2.865452435671282	-0.024097551579060017	-1.1574527886910428	1.9946650653440203	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc84	58cfa830e4b0c9d6adf6bc84	TCGA-AG-A032-01A-01D-A183-10_wgs_Illumina.filtered.	WGS	TCGA-AG-A032-01A-01D-A183-10_wgs_Illumina	TCGA-AG-A032-01A-01D-A183-10_wgs_Illumina.bam	237.12	1.85	0.08	58cfa830e4b0c9d6adf6bc84	TCGA-AG-A032-01A-01D-A183-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A032-01A	0BB786EE-07CF-4853-9B49-EC95CD14E282	Primary Tumor	Illumina HiSeq	3d3bf209-70e8-4882-99c7-6e20c03cccea	Colorectal	68.0	AE3C8931-C06F-466A-B6BF-440007E13387	CD3D7559-B583-4474-81DF-4BF9232DE3C2	TCGA-AG-A032-01A-01D-A183-10	GRCh37-lite	TCGA-AG-A032	TCGA-READ		s2170	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A183-10	True	READ	C1		0.072361592			18.9495052	0.6692	0.174	-0.8102	0.0028	-0.4896	-0.0127	36.0	2.0	0.6996234859999999	2.4653399030000003	129.0	0.92073294	19.0	13.0							1.092164521	-1574.3863210000002	288.6084835	-608.016343	0.0	1157.0	1.0	792.0	6.364750756851911	2.4521168269650095	-0.8023841991203053	5.2333486453608105	5.1033446922005234	0.8750311963274489	-1.1314021114911004	2.651227865235514	1.6774153954477542	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc8a	58cfa830e4b0c9d6adf6bc8a	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted.bam	128.45	2.03	0.16	58cfa830e4b0c9d6adf6bc8a	TCGA-AP-A0L8-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_5_rg.sorted.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0L8-01A	9AA8C2B4-DB32-4899-BF0C-D578CB175E90	Primary Tumor	Illumina HiSeq	41360e8e-e9e9-402a-bd9e-a987e56c920e	Uterus	70.0	D1A7A58F-7A35-4A94-A337-051AE56DED00	2BE44D5B-CCD6-4DD5-B0C7-C7813B526B94	TCGA-AP-A0L8-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0L8	TCGA-UCEC	1484.0	s4244	Harvard Medical School	MSKCC	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_HIGH	0.04822512	0.12	0.29	0.587124083	0.9387	0.27	-1.2204	-0.7864	-1.7436	0.0664	33.0	8.0	0.48673382600000004	1.7339892559999999	351.0	0.834495291	19.0	45.0							3.3876409919999997	-1443.727041	183.8589938	-376.4867799	1.0	1484.0	1.0	1453.0	4.962345004968474	6.579659625330051	0.09455141330539907	4.854131420328241	5.675203351102899	1.3494620976961285	-0.10821358464023234	-0.9044562742271522	1.2549106843907292	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc8c	58cfa830e4b0c9d6adf6bc8c	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	913.89	1.9	0.15	58cfa830e4b0c9d6adf6bc8c	TCGA-AG-3896-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3896-01A	9AF35239-FFB9-4D4F-889E-F743DA271EEF	Primary Tumor	Illumina HiSeq	5666993b-483e-4cb2-ac08-c5f26b31b9cd	Colorectal	85.0	03B40342-3CCE-4A45-B2EC-8855AEB85100	D33D46C5-F3FD-4FD5-9CE2-06839BF33A37	TCGA-AG-3896-01A-01D-1115-02	HG18	TCGA-AG-3896	TCGA-READ		s1988	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1115-02	True	READ	C1	GI.CIN	0.07508369	0.36	0.11	8.506290998999999	0.7562	0.316	-0.376	0.0429	-1.037	0.0707	53.0	0.0			145.0	0.9009666759999999	16.0	12.0							0.809726519	-1902.6506980000001	-44.13456392	149.7527415	0.0	31.0	0.0	31.0	6.793185824239002	4.6443908991413725	-0.17583592400735648	5.070419226497898	5.563954956360496	1.461017907315827	-1.7227665977411033	0.9195640572191239	1.6368538313231835	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc8e	58cfa830e4b0c9d6adf6bc8e	TCGA-AG-3901-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3901-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3901-01A-01D-1989-10_wgs_Illumina.bam	510.89	1.9	0.15	58cfa830e4b0c9d6adf6bc8e	TCGA-AG-3901-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3901-01A	1586CB0A-081A-4364-9470-46F9D0F0167D	Primary Tumor	Illumina HiSeq	51acbe73-78d9-48e4-b937-42a159dfb5a5	Colorectal	67.0	93B755E6-5D6E-4542-8BAE-2121F44F590C	7D59205A-65EC-4341-9748-28639D82ED29	TCGA-AG-3901-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3901	TCGA-READ		s2160	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Rectal Mucinous Adenocarcinoma	Stage IIIB	1989-10	True	READ	C1	GI.CIN	0.24371406199999998	0.56	0.04	13.32631333	0.47200000000000003	0.213	0.5434	0.6764	-0.1118	0.5886	29.0	34.0			57.0	0.102987179	2.0	5.0							0.9081042559999999	-640.2876447000001	182.4189459	-575.8737787	0.0	761.0	0.0	761.0	7.067319848653476	3.7293097635439922	-1.4141711910481087	5.318119993844217	5.578639084593525	1.4025021713467443	-1.749199854809259	1.8493293210495327	2.816673362394853	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc90	58cfa830e4b0c9d6adf6bc90	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	414.02	1.9	0.15	58cfa830e4b0c9d6adf6bc90	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4308-01A	3D8FD9B2-9AA2-4C81-8843-535AE66D6140	Primary Tumor	Illumina HiSeq	562ea734-bcd1-499a-8054-f710f2de3e41	Colorectal	47.0	6F0E65B2-7CA0-4F10-8952-B64900009001	1C7E82B6-A8EB-4593-B329-5299BC05140E	TCGA-AZ-4308-01A-01D-1405-02	HG18	TCGA-AZ-4308	TCGA-COAD		s13540	Harvard Medical School	University of Pittsburgh	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1405-02	True	COAD	C1	GI.CIN	0.121125232	0.31	0.01	4.645367874	-0.0609	0.054000000000000006	-0.7556	-0.4715	-0.2222	0.3507	31.0				229.0	0.19738980399999997	6.0	14.0							0.845681896	-770.2988232999999	-1147.4909710000002	282.41545460000003	0.0	3324.0	0.0	3324.0	4.337154565983774	5.827838273378493	-1.0679179147312199	3.2667131542823604	5.936641133227292	1.5478923240224327	-1.0704414117014132	0.10880285984879912	2.6158102387536526	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bc92	58cfa830e4b0c9d6adf6bc92	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	500.89	1.9	0.14	58cfa830e4b0c9d6adf6bc92	TCGA-AG-3902-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3902-01A	BCFE4FE9-D090-49F9-85A7-2B472E0F7453	Primary Tumor	Illumina HiSeq	66b629b3-3801-4c84-966b-4b01243390f0	Colorectal	61.0	F52423C2-7780-4470-8E27-5982201CCB83	A8A88775-9775-4087-8C03-9B5BC771F983	TCGA-AG-3902-01A-01D-1115-02	HG18	TCGA-AG-3902	TCGA-READ		s2159	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C2	GI.CIN	0.271548453	0.47	0.24	30.79631182	0.6799	0.203	0.3141	1.1204	0.7188	-0.1775	53.0	0.0			139.0	0.268984715	11.0	25.0	0.847924608	3.08439882	38.0	3.4641255139999996	35.0	0.9743421609999999	1.403379951	-133.2516396	-31.06620621	-714.3013561	0.0	974.0	0.0	974.0	6.3607569238224215	6.078559253958916	0.3901377052401669	4.43766145253328	6.507371726064072	1.5777363050757105	-1.923095471289142	0.4288124721051556	1.1875985998355436	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bca2	58cfa830e4b0c9d6adf6bca2	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina.filtered.	WGS	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina.bam	171.0		0.5	58cfa830e4b0c9d6adf6bca2	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4315-01A	DE287A25-981D-49F8-81AF-FE0300E4CD31	Primary Tumor	Illumina HiSeq	707a2d43-0ea1-4012-8f29-4202690c6608	Colorectal	61.0	BA9E5603-BB1D-4AA8-93E4-40043164F143	A9D1B074-7F36-4A04-B270-A2061249FF20	TCGA-AZ-4315-01A-01W-1461-10	GRCh37-lite	TCGA-AZ-4315	TCGA-COAD		s13211	Baylor College of Medicine	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1461-10	False	COAD	C2	GI.HM-SNV	0.250854138	0.34	0.0	7.89640673	1.0292	0.5105	-0.4433	-0.0336	0.2078	-0.1211	2786.0	240.0	45.27527495	158.5655486	125.0	0.0012725219999999999	0.0	1.0		0.0	1.0	1.386294361	4.0	1.0	0.6837562909999999	-1241.59736	903.4220772	-250.25309860000002	0.0	1776.0	0.0	1776.0	2.2971439602539645	3.822626913819817	0.07488955294056965	2.8131509427619523	6.3228477985808595	1.6707372222329484	0.5160069825079878	2.5002208847610428	1.5958476692923789	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bca6	58cfa830e4b0c9d6adf6bca6	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	524.02	1.9	0.15	58cfa830e4b0c9d6adf6bca6	TCGA-AZ-4315-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4315-01A	DE287A25-981D-49F8-81AF-FE0300E4CD31	Primary Tumor	Illumina HiSeq	8b6a06d6-c15c-4491-996c-2a012440f8a2	Colorectal	61.0	BA9E5603-BB1D-4AA8-93E4-40043164F143	FBEA9F07-A969-4396-8A17-A269BF1F8A2A	TCGA-AZ-4315-01A-01D-1405-02	HG18	TCGA-AZ-4315	TCGA-COAD		s13389	Harvard Medical School	University of Pittsburgh	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	True	COAD	C2	GI.HM-SNV	0.250854138	0.34	0.0	7.89640673	1.0292	0.5105	-0.4433	-0.0336	0.2078	-0.1211	2786.0	240.0	45.27527495	158.5655486	125.0	0.0012725219999999999	0.0	1.0		0.0	1.0	1.386294361	4.0	1.0	0.6837562909999999	-1241.59736	903.4220772	-250.25309860000002	0.0	1776.0	0.0	1776.0	5.176789118784869	4.3761343089690445	0.07488955294056965	3.658143306180305	4.917419140219743	1.6707372222329484	-1.5186458126045648	0.5412848312506986	1.5958476692923789	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bcae	58cfa830e4b0c9d6adf6bcae	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	449.02	1.9	0.16	58cfa830e4b0c9d6adf6bcae	TCGA-AZ-4614-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4614-01A	3334201D-A3C0-45EC-A9ED-CF48CC8C38E8	Primary Tumor	Illumina HiSeq	50679ea1-6443-43b4-ab23-0f7542f4cb98	Colorectal	71.0	0C4DAF52-CC9F-4099-8825-33C484CED5B1	29DA0D99-6FD9-4CC0-84BE-E1670FC253E7	TCGA-AZ-4614-01A-01D-1405-02	HG18	TCGA-AZ-4614	TCGA-COAD	172.0	s12888	Harvard Medical School	University of Pittsburgh	None	NO	T4a	N1	Colon Adenocarcinoma	Stage IVA	1405-02	True	COAD	C1	GI.CIN	0.090730596	0.14	0.22	7.866044934	0.725	0.256	-1.3626	-0.5779	-0.7127	-0.386	92.0	29.0			293.0	0.574136785	6.0	23.0							2.006480019	-1064.525141	147.28631940000002	-3049.025169	1.0	172.0	1.0	172.0	4.35272211044577	2.2741115067772704	0.0346365755970498	2.1142158741362467	3.05581208467866	0.7277837561569951	-2.2385062363095236	0.7817005779013897	0.6931471805599453	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bcb2	58cfa830e4b0c9d6adf6bcb2	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	275.02	1.9	0.15	58cfa830e4b0c9d6adf6bcb2	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4684-01A	CAC80259-3A26-4A99-B0D3-13454068E6ED	Primary Tumor	Illumina HiSeq	bab439b0-f1d3-41c2-98dd-a660818851fe	Colorectal	49.0	37AD61EA-96D1-40F1-B77A-56408E4243EA	6731F782-4435-497F-9626-C0199DAE8A8A	TCGA-AZ-4684-01A-01D-1405-02	HG18	TCGA-AZ-4684	TCGA-COAD		s13391	Harvard Medical School	University of Pittsburgh	None	NO	T3	N2	Colon Adenocarcinoma	Stage IVA	1405-02	True	COAD	C1		0.249031673			0.389557186	0.7134	0.2885	-0.1128	0.5572	-0.1254	0.2528					188.0	0.558182214	18.0	20.0							0.9236013740000001	25.06041059	219.06750950000003	377.2856388	0.0	1977.0	1.0	411.0	6.144350691483453	7.440935418264912	-0.6634851178244613	5.197754610113969	7.505473939402483	0.5816452540157608	-0.9465960813694836	0.06453852113757108	1.2451303718402222	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bcb3	58cfa830e4b0c9d6adf6bcb3	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina.filtered.	WGS	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina.bam	239.4	1.9	0.15	58cfa830e4b0c9d6adf6bcb3	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B0-5695-01A	FB9BAFA5-7133-4955-8156-4EB6763DC8E1	Primary Tumor	Illumina HiSeq	a8ffeac5-01c4-4dac-92b8-413f4009f4fa	Kidney	61.0	86E4862C-7405-40B5-B73F-BE0C6C52EA6D	B6365BDB-E6D5-4615-95B3-DB12A0C2F3D9	TCGA-B0-5695-01A-11D-2103-10	GRCh37-lite	TCGA-B0-5695	TCGA-KIRC		s8833	Baylor College of Medicine	University of Pittsburgh	None	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2103-10	False	KIRC	C3	KIRC.1	0.084807997	0.22	0.03		-1.5962	-0.267	0.1019	0.3791	-0.0986	0.0543	33.0	3.0	0.439992657	1.730637786	63.0	0.061866729	1.0	5.0		0.0	1.0	3.271732977	31.0	0.9527504859999999	1.21244138	74.11152539	-1465.0599300000001	3121.023634	0.0	2150.0	0.0	2150.0	6.995242733105252	1.4281995126560947	-0.008025725262303829	6.1079395381043495	4.8109198129682	5.044231243524771	-0.8873031950009032	3.382720300312105	5.052256968787074	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bcbd	58cfa830e4b0c9d6adf6bcbd	TCGA-B0-5693-01A-11D-2103-10_Illumina.filtered.	WGS	TCGA-B0-5693-01A-11D-2103-10_Illumina	TCGA-B0-5693-01A-11D-2103-10_Illumina.bam	344.4	1.9	0.14	58cfa830e4b0c9d6adf6bcbd	TCGA-B0-5693-01A-11D-2103-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B0-5693-01A	DB058EB4-9C5E-4226-92D1-DE24AEA83630	Primary Tumor	Illumina HiSeq	4a0c2db0-f10b-41b1-8aca-fcd712b7f672	Kidney	47.0	20A21A6F-F615-47F7-9935-B330B116D51B	FB194CA3-10AA-4DC5-8D08-619DDBD6D1B6	TCGA-B0-5693-01A-11D-2103-10	GRCh37-lite	TCGA-B0-5693	TCGA-KIRC		s9937	Baylor College of Medicine	University of Pittsburgh	None	NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2103-10	False	KIRC	C3	KIRC.1	0.08923067400000001	0.27	0.02		-1.0398	-0.1835	0.0229	-0.6792	0.2442	0.1862	24.0	250.0	0.245459242	1.043201778	57.0	0.087256134	3.0	4.0		0.0	1.0	1.9459101490000001	7.0	1.0	1.055445845	-10.00308467	-903.2738593	2560.413159	0.0	4074.0	0.0	4074.0	8.897983020117142	-0.47482869828187724	0.4066488403847145	5.493932569472581	2.6517281146392833	3.7297577850754333	-3.4040504506445615	3.1265568129211605	3.323108944690719	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bcc0	58cfa830e4b0c9d6adf6bcc0	TCGA-B0-5094-01A-01D-2099-10_wgs_Illumina.filtered.	WGS	TCGA-B0-5094-01A-01D-2099-10_wgs_Illumina	TCGA-B0-5094-01A-01D-2099-10_wgs_Illumina.bam	167.4	1.9	0.15	58cfa830e4b0c9d6adf6bcc0	TCGA-B0-5094-01A-01D-2099-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B0-5094-01A	8AAA4E25-5C12-4ACE-96DC-91AAA0C4457C	Primary Tumor	Illumina HiSeq	22151e7f-a939-414f-9658-14262a84253f	Kidney	62.0	B05A7F4B-BC56-4DA6-B810-79E7C3A5395E	D429C27A-5963-42FE-B3A0-7252C20669D8	TCGA-B0-5094-01A-01D-2099-10	GRCh37-lite	TCGA-B0-5094	TCGA-KIRC	333.0	s9445	Baylor College of Medicine	University of Pittsburgh	None	NO	T3b	N0	Kidney Clear Cell Renal Carcinoma	Stage IV	2099-10	False	KIRC	C3	KIRC.3	0.188036665	0.31	0.05		-1.1135	-0.3575	0.2397	0.0979	-0.2277	-0.0849	40.0	98.0	0.37382684200000005	2.127937406	105.0	0.411574285	12.0	12.0				3.1282795610000003	24.0	0.9843381290000001	1.981572866	-260.7056223	-1611.360971	1331.48215	1.0	333.0	1.0	75.0	5.267858159063328	2.5817357303963577	-0.20443873694736225	4.374040283041231	4.2546339967476845	1.7485399669662427	-0.8938178760220965	1.6728982663513268	1.9529787039136048	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bcc4	58cfa830e4b0c9d6adf6bcc4	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	397.02	1.9	0.15	58cfa830e4b0c9d6adf6bcc4	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4313-01A	1FD75C4D-E74C-410C-A150-814722C6C1CC	Primary Tumor	Illumina HiSeq	b8e9093c-1570-45c6-8278-f686c276ee91	Colorectal	51.0	475F161C-2F7F-43A2-B187-DE6038752F39	F64D4985-D460-435C-8EC0-477D313A895A	TCGA-AZ-4313-01A-01D-1405-02	HG18	TCGA-AZ-4313	TCGA-COAD		s13212	Harvard Medical School	University of Pittsburgh	None	NO	T1	N0	Colon Adenocarcinoma	Stage I	1405-02	True	COAD	C1		0.415139966			8.805547342	1.1106	0.5485	-1.4878	-1.0082	-1.0329	-0.307					61.0	0.138133862	4.0	0.0				0.0	1.0		1.219649252	-1836.873485	916.2242054999999	1455.000147	0.0	2310.0	0.0	2310.0	5.204006687076795	3.37355874989564	-0.8573044698802615	3.7869406672901516	4.516622801134583	-0.015618538747627975	-1.417066019786644	1.1430640512389427	0.8416859311326336	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bcc6	58cfa830e4b0c9d6adf6bcc6	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted.bam	93.54	2.18	0.15	58cfa830e4b0c9d6adf6bcc6	TCGA-AP-A0L9-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0L9-01A	7B9947D5-E86B-4006-8890-EA5209584A88	Primary Tumor	Illumina HiSeq	df10c3ed-7978-4d58-b4f6-52a76db0994a	Uterus	71.0	53D0521F-10D6-4F70-9277-D99025A6B963	DAA573AF-564D-456D-8181-DF4C07B77672	TCGA-AP-A0L9-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0L9	TCGA-UCEC		s4423	Harvard Medical School	MSKCC	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_HIGH	0.088082971	0.16	0.38	11.09997891	0.7817	0.301	-0.7752	-0.9558	1.5029	-0.193	28.0	0.0	0.600819239	1.8340797830000002	465.0	0.7109751129999999	12.0	55.0							4.085954012	-1643.4935480000001	-376.9021529	-1954.864734	0.0	3815.0	0.0	3815.0	4.1195451758393995	7.827856921919775	-1.4496805209236812	4.449786862709976	7.0068763698499446	0.612345798299087	0.3302416868705764	-0.8209805520698299	2.062026319222768	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bcc8	58cfa830e4b0c9d6adf6bcc8	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted.filtered.	WGS	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted.bam	747.21	1.9	0.15	58cfa830e4b0c9d6adf6bcc8	TCGA-AG-3582-01A-01D-1167_101105_SN208_0168_A80A3BABXX_s_1_rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3582-01A	DB1E3104-8BFD-4353-854A-C478BA1F7D07	Primary Tumor	Illumina HiSeq	85a5fdbc-5a9a-4ddf-aac9-84a213ee17fd	Colorectal	75.0	1B1EF856-EA45-4857-8B4B-C4330FA930D8	CA0DD61C-D4F2-4ED9-91EF-11F7B1BE15AF	TCGA-AG-3582-01A-01D-1167-02	HG18_Broad_variant	TCGA-AG-3582	TCGA-READ		s1973	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IV	1167-02	True	READ	C1		0.065837927			23.52186738	0.7997	0.262	-0.3103	-0.1201	-0.6781	0.0982					206.0	0.420046801	13.0	20.0							0.292375495	-1884.930789	296.879728	-287.956525	1.0	1096.0	1.0	1096.0	5.262219046375558	5.677330420418898	-0.6208387140279106	4.676960827826798	4.833044610501687	0.9376555543718521	-0.5852582185487605	-0.8442858099172117	1.5584942683997627	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bcda	58cfa830e4b0c9d6adf6bcda	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	750.21	1.9	0.14	58cfa830e4b0c9d6adf6bcda	TCGA-AG-3574-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3574-01A	0EDA7373-8335-455F-B90A-8C3540F28088	Primary Tumor	Illumina HiSeq	44e4b931-5188-44b9-aea5-fdff70c4c058	Colorectal	89.0	DA897A5D-B2CC-419F-ACD7-473B4928C5D5	5DAA6B90-B302-4B0E-A44B-0A6D3159DACE	TCGA-AG-3574-01A-01D-1167-02	HG18	TCGA-AG-3574	TCGA-READ		s1955	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	1167-02	True	READ	C1		0.04333499			3.175417593	0.4391	0.207	-0.5073	-0.2912	-1.0001	-0.1569			0.648191481	1.6204787019999998	93.0	0.24083651399999997	10.0	2.0							1.177134779	-702.2939719999999	-730.6651832	-32.8054185	1.0	1096.0	1.0	1096.0	6.61616080113901	5.572470838769992	-0.14078480933874382	5.887922300767794	5.243966771797956	1.2885825320577209	-0.7282385003712157	-0.32850406697203605	1.4293673413964647	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bcfc	58cfa830e4b0c9d6adf6bcfc	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina.filtered.	WGS	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina.bam	177.7		0.05	58cfa830e4b0c9d6adf6bcfc	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AD-6964-01A	5E7074A6-5011-4DC5-950C-41365DBC6D09	Primary Tumor	Illumina HiSeq	67abf892-45e8-4468-a1fd-8446401b3f55	Colorectal	58.0	4D16E41A-B100-4080-A759-1F62E54C1C91	42D20028-0DDC-4DAC-9F05-D674F8915F21	TCGA-AD-6964-01A-11D-1924-10	GRCh37-lite	TCGA-AD-6964	TCGA-COAD		s13536	Baylor College of Medicine	International Genomics Consortium	United States	NO	T4a	N2b	Colon Adenocarcinoma		1924-10	False	COAD	C2	GI.HM-indel	0.399593254	0.5	0.0	18.93444682	0.40299999999999997	0.146	0.8749	1.5414	0.4724	0.3776	615.0	1497.0	12.004934	35.2693136	75.0	0.011102788	0.0	3.0	0.83092974	3.50611444	68.0	3.3791935719999997	32.0	0.975029162	4.609349627	-700.2847767999999	305.5953205	1377.272535	1.0	331.0	1.0	325.0	6.349676770365601	3.815714959499929	0.29598700161005975	5.736572297479192	5.405608275861059	2.363393521446418	-0.613104472886409	1.5898933163611302	2.067406519836358	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd00	58cfa830e4b0c9d6adf6bd00	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	2.0	1.9	0.15	58cfa830e4b0c9d6adf6bd00	TCGA-AF-2692-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2692-01A	71A32FCA-D48F-4EA3-8DF7-69F9DDA8FA91	Primary Tumor	Illumina HiSeq	f19d4bca-a876-4c65-a830-4d5f12eb5803	Colorectal	54.0	3CA7589A-E887-4DA2-8D59-19FE5963AC21	CC1B3C2A-43B7-43CB-85F8-383A3C255D4B	TCGA-AF-2692-01A-01D-1167-02	HG18	TCGA-AF-2692	TCGA-READ		s1972	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0		Stage IIA	1167-02	True	READ	C1		0.060004599000000006	0.26	0.1	39.93574471	0.7895	0.209	-0.4874	-0.08	-1.0094	0.2925			1.919397156	1.759447393	180.0	0.917432852	12.0	20.0	0.9575917690000001	3.082368994	25.0				1.247680761	-847.5226018	473.1060596	-277.2420522	0.0	412.0	1.0	327.0	7.448649283870163	4.516110115238317	-1.8268714991904065	5.609423277403184	6.12890373551939	-0.5847791438381638	-1.8392260064669785	1.6127936202810726	1.2420923553522427	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd2e	58cfa830e4b0c9d6adf6bd2e	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	76.48	1.86	0.16	58cfa830e4b0c9d6adf6bd2e	TCGA-AA-A01P-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A01P-01A	13AE9D83-A22F-451F-88BB-686051725CF3	Primary Tumor	Illumina HiSeq	bd44a9e2-a1a2-43a2-bfca-3a7d028fd86c	Colorectal	80.0	133C13DE-6C6B-45E2-A611-A5C5A4AEBAA6	7788130D-F341-4900-B7E0-95EAD3063A9F	TCGA-AA-A01P-01A-21D-A079-02	HG18	TCGA-AA-A01P	TCGA-COAD	1158.0	s13527	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Colon Adenocarcinoma	Stage III	A079-02	True	COAD	C2	GI.HM-indel	0.413161486	0.62	0.09	6.065449651000001	0.7284	0.2765	0.6258	1.5382	1.3757	0.3784	310.0	908.0			57.0	0.00032910800000000005	0.0	3.0							1.294181349	-174.70693319999998	604.6832397999999	-1055.053441	1.0	1158.0	1.0	762.0	6.861082870783706	6.117993538872602	-0.3088345949818251	6.13514586740077	5.975677316692346	1.739603821577334	-0.7259370033829362	-0.14231622218025564	2.048438416559159	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd38	58cfa830e4b0c9d6adf6bd38	TCGA-AA-A00N-01A-02D-A17O-10_wgs_Illumina.filtered.	WGS	TCGA-AA-A00N-01A-02D-A17O-10_wgs_Illumina	TCGA-AA-A00N-01A-02D-A17O-10_wgs_Illumina.bam	149.57	1.79	0.08	58cfa830e4b0c9d6adf6bd38	TCGA-AA-A00N-01A-02D-A17O-10_wgs_Illumina.bam	Dead	MALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00N-01A	E457344D-76FB-46BF-B362-61A6E811D131	Primary Tumor	Illumina HiSeq	d83f0731-9567-4d26-83ed-42e1c4e01ef0	Colorectal	75.0	D52F3D05-1850-473E-8E1E-AB2B4F88AF2A	6CA5C1BB-275B-4D05-948A-3C6C7D03FAB9	TCGA-AA-A00N-01A-02D-A17O-10	GRCh37-lite	TCGA-AA-A00N	TCGA-COAD	122.0	s13516	Baylor College of Medicine	Indivumed	Germany	NO	T4	N0	Colon Mucinous Adenocarcinoma	Stage IIB	A17O-10	True	COAD	C1		0.31785041399999997	0.57	0.15	9.974271525	0.5514	0.22	-0.0674	-0.4751	0.3596	0.4667	2350.0	73.0			57.0	0.000717678	0.0	0.0							1.516019446	-555.4849303999999	247.166095	-224.2835437	1.0	122.0	1.0	122.0	7.283173465738004	3.4250523637002495	-1.5798506971885398	6.00223962027594	6.657559202908611	1.1318963657949965	-1.2809338454620645	3.2325068392083613	2.7117470629835365	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd3c	58cfa830e4b0c9d6adf6bd3c	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	728.89	1.9	0.15	58cfa830e4b0c9d6adf6bd3c	TCGA-AG-3892-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3892-01A	DED3FEB2-1079-4520-A7CA-F5B5FC73D7C5	Primary Tumor	Illumina HiSeq	adde3886-c16e-4d0c-8186-1a253ffca559	Colorectal	57.0	D5B6919D-5654-486F-95B0-D89CB1893614	8B81AA70-5B77-4BE9-8438-AE0928339E21	TCGA-AG-3892-01A-01D-1115-02	HG18	TCGA-AG-3892	TCGA-READ		s1998	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Rectal Adenocarcinoma	Stage I	1115-02	True	READ	C2	GI.HM-SNV	0.262819833	0.6	0.0	10.02739726	0.7882	0.442	0.063	1.1271	0.3399	-0.1562	978.0	2.0			49.0	0.00031827900000000003	0.0	0.0							2.250650269	-436.4104398	382.5767088	159.74328880000002	0.0	396.0	0.0	396.0	5.680804440718127	5.88509455348882	0.0621257479427022	4.817758223362785	6.34350643457077	0.8833111737313653	-0.8630462173553424	0.4584118810819504	0.821185425788663	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd41	58cfa830e4b0c9d6adf6bd41	TCGA-AG-3593-01A-01D-1525-10_Illumina.filtered.	WGS	TCGA-AG-3593-01A-01D-1525-10_Illumina	TCGA-AG-3593-01A-01D-1525-10_Illumina.bam	495.85	1.9	0.05	58cfa830e4b0c9d6adf6bd41	TCGA-AG-3593-01A-01D-1525-10_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3593-01A	10290E91-9784-4F94-8DAA-B5D9A8B0EFB9	Primary Tumor	Illumina HiSeq	d2b54a0a-394a-4174-afce-c86c43e4524d	Colorectal	72.0	EFFCA0F1-E81D-47CD-8287-392A2B6AB786	FAFF4626-615B-416A-B7A6-9D177DCC94A9	TCGA-AG-3593-01A-01D-1525-10	NCBI36_BCM_variant	TCGA-AG-3593	TCGA-READ		s2130	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1525-10	True	READ	C1		0.09435855900000001			21.47919761	0.8963	0.24600000000000002	-0.0354	0.4447	-0.5132	-0.1155					240.0	0.8847177009999999	20.0	13.0							1.3550179180000002	-1925.126791	598.2607267000001	913.2091785	0.0	1035.0	0.0	1035.0	3.9072805951603105	1.1111268179755358	-0.4448740742740499	4.856361149857457	2.262778842593626	1.3326880138830612	0.9490805546971464	1.1516520246180901	1.777562088157111	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd44	58cfa830e4b0c9d6adf6bd44	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted.bam	117.13	2.03	0.16	58cfa830e4b0c9d6adf6bd44	TCGA-AP-A054-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A054-01A	D77E4DBC-B239-4742-8CB7-EFD427010D13	Primary Tumor	Illumina HiSeq	a8fe0928-3d0c-4d16-be11-a5dd077bdb2c	Uterus	64.0	DDFFB9C7-185F-402F-99B8-8058B40086D9	F5A9F85D-4E8E-4400-A109-C227D6B4C0A4	TCGA-AP-A054-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A054	TCGA-UCEC	709.0	s4590	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.POLE	0.060366710999999997	0.05	0.0	10.76817441	1.5477	0.344	-1.2537	-0.9931	-0.9224	-0.24100000000000002	560.0	1599.0	9.695997284	30.43955511	145.0	0.054539425999999995	2.0	3.0							2.658615998	-1225.725913	1558.6568220000001	-2369.203234	1.0	709.0	1.0	566.0	5.271810851142943	6.519597164232004	-0.07048748049796516	4.507870618591898	5.573254087291447	1.5308755899309983	-0.7639402325510449	-0.9463430769405567	1.6013630704289636	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd64	58cfa830e4b0c9d6adf6bd64	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	205.35	1.73	0.15	58cfa830e4b0c9d6adf6bd64	TCGA-AA-A00R-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Colon Adenocarcinoma	Aligned reads	TCGA-AA-A00R-01A	CA22EDD4-EB7C-4677-84AA-6F0354459A19	Primary Tumor	Illumina HiSeq	f8afa471-fd74-43ef-8cc5-58a4f3788e31	Colorectal	64.0	F72EEAE9-F7F5-4576-A072-5021119117D6	AC9F45EC-C004-475F-8537-8977F20B0DE8	TCGA-AA-A00R-01A-01D-A077-02	HG18	TCGA-AA-A00R	TCGA-COAD		s13517	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Colon Adenocarcinoma	Stage I	A077-02	True	COAD	C2		0.40054602100000003			2.6955994339999996	1.125	0.41700000000000004	0.5398	1.5323	0.4167	-0.2405					96.0	0.103863096	2.0	0.0							0.457954507	-442.0228687	1637.762706	-434.6143528	0.0	30.0	0.0	30.0	7.155070982267333	6.000919705878737	-0.31280627762545954	5.878777516361771	6.106280221536563	1.4469189829363254	-1.276293465905562	0.10536051565782589	1.759725260561785	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd78	58cfa830e4b0c9d6adf6bd78	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.bam	29.04	1.87	0.14	58cfa830e4b0c9d6adf6bd78	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JJ-01A	BEF7B135-A727-45E8-850A-CC4CD56C49AA	Primary Tumor	Illumina HiSeq	6d955c96-b34d-4aea-961b-378e856ae8cb	Breast	54.0	008DAFDD-A3D1-4801-8C0A-8714E2B58E48	ED24B69D-599E-42ED-BBE3-5C4F59FABED4	TCGA-AO-A0JJ-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JJ	TCGA-BRCA		s6271	Harvard Medical School	MSKCC	None	NO	T2	N1a	Infiltrating Lobular Carcinoma	Stage IIB	A060-02	True	BRCA	C6	BRCA.LumA	0.239506131	0.49	0.02	0.546225747	-0.0779	-0.071	0.7165	1.7016	0.5772	0.4762	6.0	62.0	0.123591887	0.432571604	65.0	0.20893381100000002	3.0	10.0	0.9575708959999999	2.9153460780000002	21.0	4.28566588	85.0	0.9646640329999999	1.0630364490000002	-345.7518472	533.5787058	1567.923703	0.0	1887.0	0.0	1887.0	9.173728253479451	5.876468719466484	0.31428638365692685	6.5346709238641925	6.316780558904816	7.052201883347165	-2.6390573296152584	0.4403118394383325	6.737915499690239	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd7c	58cfa830e4b0c9d6adf6bd7c	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted.bam	78.67		0.17	58cfa830e4b0c9d6adf6bd7c	TCGA-BF-A1PV-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PV-01A	EFF78AF6-0F68-49B9-866B-0D511606F2B1	Primary Tumor	Illumina HiSeq	a219d21e-e657-407a-8e8f-aba8b0190425	Skin	74.0	090DEBB2-290D-49DD-B642-7F01C99A795C	BC0B690D-7C05-4B68-B2F2-5D38EA621A02	TCGA-BF-A1PV-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PV	TCGA-SKCM		s7491	Harvard Medical School	Cureline	Russia	NO	T4b	N0		Stage IIC	A18Z-02	True	SKCM	C1	SKCM.RAS_Hotspot_Mutants	0.07230895799999999	0.08	0.03		0.4448	0.1065	-1.3462	-1.871	-0.8773	0.0167	177.0	0.0	3.59345787	7.985461934			6.0	3.0	0.952548174	1.533067144	5.0	0.693147181	2.0	1.0	2.573604574	-944.9283423	876.6266404999999	-2396.149474	0.0	14.0	0.0	14.0	5.893713891764296	4.944655985914568	-0.16279972035316315	5.537038947825565	6.262896883789443	1.3291088142875784	-0.35667494393873245	1.3182408978748752	1.4919085346407415	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd86	58cfa830e4b0c9d6adf6bd86	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.bam	65.42	2.11	0.15	58cfa830e4b0c9d6adf6bd86	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LX-01A	AC1D3946-FE6C-4BD8-B02C-638799CB0F67	Primary Tumor	Illumina HiSeq	182220ca-d437-40a2-adeb-d4cb1ce2f284	Uterus	57.0	99CDF3A0-90DC-4992-B75A-11DD41928D43	B294F25A-93D9-49A6-8FD3-6D2B0BBEF27C	TCGA-BG-A0LX-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0LX	TCGA-UCEC		s5218	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.POLE	0.134058108			8.91983712	0.6407	0.177	-0.341	0.5736	-0.9367	0.2646	211.0	1234.0	4.91634819	12.47996079	44.0	0.081141159	3.0	4.0							2.359876464	-1142.560326	298.5413017	-1976.4896899999999	0.0	614.0	0.0	614.0	6.04276855572385	7.621684998724611	-0.23223406893739806	5.860446998929895	6.389541317431979	1.3958734613392587	-0.1823215567939549	-1.2321436812926325	1.6281075302766568	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd8c	58cfa830e4b0c9d6adf6bd8c	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.bam	94.25	2.11	0.15	58cfa830e4b0c9d6adf6bd8c	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M0-01A	8BF0B156-6EB4-45E8-9CBB-0979EFBEA898	Primary Tumor	Illumina HiSeq	bedca351-a4f7-4fbd-af8e-d49f3d9b2c37	Uterus	66.0	E3F599DB-19CF-4086-8E5D-D3527119120F	78D21C64-205B-4C9C-A862-8A70348D2602	TCGA-BG-A0M0-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M0	TCGA-UCEC		s5216	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.027935897			1.136934556	0.3454	0.162	-1.4571	-1.3493	-1.1585	-0.4579	49.0	193.0	1.173556592	4.092402476	84.0	0.17323638600000002	4.0	2.0							1.811412765	-814.4981841	-153.3638985	127.5674267	0.0	588.0	0.0	588.0	6.18877733838767	7.545786076983415	-0.7137790730959978	6.049015396012511	6.5807051809398285	3.052273212845145	-0.13976194237515882	-0.9650808960435873	3.766052285941143	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd8f	58cfa830e4b0c9d6adf6bd8f	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.bam	11.7	2.0	0.14	58cfa830e4b0c9d6adf6bd8f	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4223-01A	05F01280-BF77-4682-A7A8-20DD0EAC77BD	Primary Tumor	Illumina HiSeq	e8bc6546-004a-4702-9289-b5c90582298e	Head and Neck	48.0	82DB742D-885D-4788-B509-474715AE183B	007F0F41-C370-45F9-8053-2C774ADDED49	TCGA-BB-4223-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4223	TCGA-HNSC		s15490	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Atypical	0.21168147699999998	0.26	0.17		1.1246	0.237	0.4689	1.8611	0.3363	0.0978	96.0		1.276922488	3.525416434	195.0	0.39787309600000004	11.0	10.0	0.9090664829999999	3.9369245260000003	76.0	3.841264545	59.0	0.942055002	2.065141229	-789.7089089	1145.252594	-1510.127175	0.0	3221.0	0.0	3221.0	6.903824486607304	9.488805094878355	-0.07973206827160795	5.684584210150579	8.838217528737205	1.83157255160623	-1.2192402764567243	-0.6505875661411493	1.9113046198778378	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd92	58cfa830e4b0c9d6adf6bd92	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.bam	100.95	1.92	0.15	58cfa830e4b0c9d6adf6bd92	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LW-01A	68181BC9-AA8B-44EC-8601-564B30EA0561	Primary Tumor	Illumina HiSeq	89430da6-f21d-4534-8b48-c645836813b5	Uterus	47.0	6527EC31-1D41-49C2-93FF-11615A6CBA8B	5D88ADF5-468B-4377-B3E3-DF986C613D24	TCGA-BG-A0LW-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0LW	TCGA-UCEC		s5003	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_LOW	0.059149774	0.06	0.0	2.175036955	-0.8166	-0.10400000000000001	-0.4872	-0.5873	-0.3895	-0.0202	20.0	25.0	0.20399321399999998	0.845114743	63.0	5.03e-05	0.0	0.0							2.538470225	-1038.815055	-1258.0891199999999	102.3033658	0.0	566.0	0.0	566.0	5.425209118402661	4.470688599294137	-0.09925160459067728	5.080368632110932	5.580443064515488	3.683781737042267	-0.34484048629172914	1.109754465221351	3.7830333416329447	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd9a	58cfa830e4b0c9d6adf6bd9a	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.bam	71.62	1.94	0.14	58cfa830e4b0c9d6adf6bd9a	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M6-01A	002724FA-7051-49FA-9C58-4BCB7EBA4AC6	Primary Tumor	Illumina HiSeq	0db41cb8-f118-4d04-a002-22df953a0dec	Uterus	73.0	66E4B080-E6EF-4531-9B69-1B27F15C5669	61C058D9-E5DC-4D74-B378-28B8F0A2BF78	TCGA-BG-A0M6-01A-31D-A101-02	HG19_Broad_variant	TCGA-BG-A0M6	TCGA-UCEC		s4249	Harvard Medical School	University of Pittsburgh	None	NO			Serous endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_HIGH	0.042892953	0.31	0.18	4.843023072	0.6525	0.052000000000000005	-1.6021	-1.8642	-1.0292	0.2725	17.0		0.35589972700000005	1.326535347	265.0	0.7062789070000001	18.0	42.0							2.923706328	-1484.450728	-16.11459132	-754.4244173999999	1.0	671.0	0.0	671.0	6.815340902289838	7.526178913346145	0.10048446508873721	6.2954654430039305	6.581717304505294		-0.5198754592859083	-0.9444616088408513		lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bd9b	58cfa830e4b0c9d6adf6bd9b	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.bam	101.93	1.88	0.15	58cfa830e4b0c9d6adf6bd9b	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M3-01A	8BDD4E0E-5BEC-43F2-B9FA-D6E94A72FE05	Primary Tumor	Illumina HiSeq	d3fa774f-c50e-499c-ad6e-1a5f67dd2be3	Uterus	74.0	1802CD6B-4D4A-45FA-B839-7450071E41EE	04E49830-378E-4EB2-B77C-70D6955627F7	TCGA-BG-A0M3-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M3	TCGA-UCEC		s5394	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.064079732	0.12	0.0	0.180187216	0.4007	0.147	-0.7103	-0.5798	-0.8506	-0.4059	30.0	19.0	0.539648031	1.708885431	63.0	0.160502924	6.0	2.0							3.286932222	-1527.2159609999999	64.37580557	-1099.18695	0.0	1071.0	0.0	1071.0	7.105427164322677	6.774985501017429	0.0489861081300863	6.444028682077312	6.5385967229532	4.926861912380401	-0.6613984822453651	-0.2363887780642302	4.877875804250315	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bda2	58cfa830e4b0c9d6adf6bda2	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted.bam	42.01		0.16	58cfa830e4b0c9d6adf6bda2	TCGA-BF-A1PX-01A-12D-A18Z_120518_SN1120_0142_AC0VG4ACXX_s_2_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PX-01A	197AC33E-D5DF-40DE-92F2-6EF7FE2AD6DD	Primary Tumor	Illumina HiSeq	4a62234d-e7fe-4cd1-a319-baafc27c9db8	Skin	56.0	EE2F9863-0DAE-4830-A780-E7745414BC3D	98B49A52-61EC-4A87-B2DD-EEFD6E0E028F	TCGA-BF-A1PX-01A-12D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PX	TCGA-SKCM	282.0	s7825	Harvard Medical School	Cureline	Russia	NO	T4b	N2a		Stage IIIB	A18Z-02	True	SKCM	C2	SKCM.BRAF_Hotspot_Mutants	0.538046201	0.75	0.06		0.3343	0.1005	0.8836	1.7737	0.8158	0.5997	115.0		4.9298358780000004	8.247398387999999			8.0	6.0	0.909331863	4.050479927	86.0	4.028032069	78.0	0.924558475	2.546182904	613.6556135	758.0904780000001	-2127.8766	1.0	282.0	0.0	282.0	6.4790087495846045	5.729577441509361	0.43930975916076864	6.556970291054316	8.94322221696001	1.6648506173640256	0.0779615414697119	3.213644775450648	1.225540858203257	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bda8	58cfa830e4b0c9d6adf6bda8	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted.bam	66.95		0.16	58cfa830e4b0c9d6adf6bda8	TCGA-BF-A1Q0-01A-21D-A18Z_120520_SN590_0158_AC0J99ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1Q0-01A	633DDC04-C424-42C8-8E54-673968B130A7	Primary Tumor	Illumina HiSeq	44801af7-d042-441d-afc9-4c0d7b493b01	Skin	80.0	B68CFB6B-4249-4855-8278-B18C0F561EFD	C94F7E24-8073-4786-BFC0-C45A37D85B2F	TCGA-BF-A1Q0-01A-21D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1Q0	TCGA-SKCM		s7320	Harvard Medical School	Cureline	Russia	NO	T4b	N0		Stage IIC	A18Z-02	True	SKCM	C1	SKCM.Triple_WT	0.318470044	0.6	0.33		1.0546	0.373	0.0017	0.3759	0.0528	0.2309	386.0	18.0	9.500260447	17.31850757			18.0	44.0	0.885353435	2.45472095	16.0	2.8647385119999997	19.0	0.972931867	5.519405872	272.47218010000006	926.7188249	-2578.082887	0.0	831.0	0.0	831.0	5.760340869551376	6.992427255039335	0.7208251045040441	5.014271287537088	6.684942555291374	2.4927819464359193	-0.7460695820142877	-0.307484699747961	1.7719568419318752	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bdad	58cfa830e4b0c9d6adf6bdad	TCGA-AG-3574-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3574-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3574-01A-01D-1989-10_wgs_Illumina.bam	750.21	1.9	0.14	58cfa830e4b0c9d6adf6bdad	TCGA-AG-3574-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3574-01A	0EDA7373-8335-455F-B90A-8C3540F28088	Primary Tumor	Illumina HiSeq	b41b6882-7cf8-49c6-aa56-8418d77c24cb	Colorectal	89.0	DA897A5D-B2CC-419F-ACD7-473B4928C5D5	ECF4E05A-0912-4B93-AD66-323002F0C845	TCGA-AG-3574-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3574	TCGA-READ		s2309	Baylor College of Medicine	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	1989-10	True	READ	C1		0.04333499			3.175417593	0.4391	0.207	-0.5073	-0.2912	-1.0001	-0.1569			0.648191481	1.6204787019999998	93.0	0.24083651399999997	10.0	2.0							1.177134779	-702.2939719999999	-730.6651832	-32.8054185	1.0	1096.0	1.0	1096.0	7.75505313936934	1.3826165342453027	-0.14078480933874382	5.634789603169249	4.598071881798671	1.2885825320577209	-2.120263536200091	3.2154553475533687	1.4293673413964647	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bdb3	58cfa830e4b0c9d6adf6bdb3	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.bam	57.94	1.87	0.14	58cfa830e4b0c9d6adf6bdb3	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MG-01A	9CDE90C8-2BE0-4328-A032-FF1DC19E66FD	Primary Tumor	Illumina HiSeq	30b3e5f5-4066-401d-9cf3-5ee64b9014ef	Uterus	73.0	96B6826D-8A4C-45F5-8CD3-B5988AA5FD0E	755BD772-9331-402B-832B-2933AAECFC71	TCGA-BG-A0MG-01A-21D-A101-02	HG19_Broad_variant	TCGA-BG-A0MG	TCGA-UCEC		s4248	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.134104119	0.24	0.0	12.12363915	0.7344	0.221	-0.5229	-1.1506	-0.1201	-0.2003	48.0		1.037517085	2.412227222	84.0	0.093795957	4.0	6.0							2.510679504	-1056.6364839999999	131.2332118	38.05707878	0.0	1477.0	0.0	1477.0	7.929414526482119	7.683812846362317	-0.05603078686244156	6.40335822298707	6.9365984445320965	1.3969549487561213	-1.5260563034950492	-0.7472144018302207	1.452985735618563	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bdc0	58cfa830e4b0c9d6adf6bdc0	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.bam	79.77	1.93	0.17	58cfa830e4b0c9d6adf6bdc0	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A186-01A	FE4DB898-3A9F-4DFF-ADCB-7B8C30137350	Primary Tumor	Illumina HiSeq	f65268ef-b937-4d49-922e-a5e3ebc0eab8	Uterus	61.0	B1645A83-57B7-4357-B977-63A5B6AEE39E	ECF410AD-B160-4F00-A165-38529FAE974B	TCGA-BG-A186-01A-11D-A12F-02	HG19_Broad_variant	TCGA-BG-A186	TCGA-UCEC		s4792	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C3	UCEC.CN_LOW	0.145743423	0.18	0.0	6.600332262999999	-0.18600000000000003	-0.11800000000000001	-0.113	0.5196	-0.4062	0.0142	17.0	8.0	0.24228122300000002	0.807604077	69.0	0.049554182	2.0	3.0							2.297214664	-1080.09172	-179.07782759999998	-171.5410928	0.0	419.0	0.0	419.0	5.9909209211092715	7.545691727569727	-0.3504288274417797	5.388745518755053	6.5471628974586	2.6453034461122114	-0.6021754023542183	-0.9985288301111273	2.9957322735539913	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bdc4	58cfa830e4b0c9d6adf6bdc4	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.bam	21.93	1.96	0.17	58cfa830e4b0c9d6adf6bdc4	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A18A-01A	FEB3E930-3638-44B4-AC0F-A5DCB01FED76	Primary Tumor	Illumina HiSeq	cf06b397-1811-4a38-93b4-05f1457e9882	Uterus	74.0	8FD0971D-40BA-46C2-B3C4-8E48A3E6C122	518AFA21-9E19-49DE-A2A6-387828A10837	TCGA-BG-A18A-01A-21D-A12F-02	HG19_Broad_variant	TCGA-BG-A18A	TCGA-UCEC		s4789	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C3	UCEC.POLE	0.132474538			0.654568547	-0.3674	-0.18100000000000002	-0.4874	0.1368	0.042	0.2705	33.0		0.648015156	1.408728601	49.0	0.046416655999999994	2.0	0.0							2.398418193	-892.6312488	-1308.594014	-940.4675377	0.0	426.0	0.0	426.0	7.3658760863161	8.840332034135514	-1.0345652138329755	6.26726379764799	7.790509909636837		-1.0986122886681096	-1.0498221244986776		higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bdcc	58cfa830e4b0c9d6adf6bdcc	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.bam	71.16	2.03	0.15	58cfa830e4b0c9d6adf6bdcc	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0H6-01A	AEB6A3A6-B57A-4C53-90E6-E833777DD2A1	Primary Tumor	Illumina HiSeq	9c69c17b-33de-4bb8-be9f-7e0dcde9db0a	Breast	82.0	B2921C9D-C655-46F3-86E5-2FC2BED1ED33	57D73BC9-950E-42A3-B9FB-6045117112B7	TCGA-BH-A0H6-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0H6	TCGA-BRCA		s5963	Harvard Medical School	University of Pittsburgh	None	NO	T1b	NX	Infiltrating Ductal Carcinoma	Stage I	A060-02	True	BRCA	C1	BRCA.LumA	0.064488516	0.29	0.96	1.066692816	-0.5622	-0.1035	-0.5143	-1.5154	-0.29100000000000004	0.512	6.0	56.0	0.172825082	0.460866885	94.0	0.098181046	3.0	9.0				0.693147181	2.0	1.0	1.109805256	-555.7239907000001	340.5538874	1101.190057	0.0	747.0	0.0	747.0	8.891786635857315	6.957356401713723	0.30740001737736833	6.58920154286327	6.9209887575428475	3.5366461269099907	-2.3025850929940455	-0.03636764417087468	3.2292461095326224	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bdd4	58cfa830e4b0c9d6adf6bdd4	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.bam	18.62	1.9	0.15	58cfa830e4b0c9d6adf6bdd4	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0BM-01A	C2AEEE6C-BA10-4CF9-B560-C739580F7BF3	Primary Tumor	Illumina HiSeq	46f039c4-a705-4933-bf85-0e96e80e5024	Breast	54.0	5423B7F8-D2BB-47C8-9AF8-3D3E1276888C	FA99DD38-37F1-4B24-960E-617F92CDADD0	TCGA-BH-A0BM-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0BM	TCGA-BRCA		s6772	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True	BRCA	C3	BRCA.Normal	0.101749361	0.4	0.01	0.69456749	-1.595	-0.147	-0.3096	0.2591	-0.5683	0.2428	15.0	16.0	0.283521405	0.56704281	53.0	0.09363184599999999	4.0	8.0				2.022808529	8.0	0.972765278	1.669469976	-774.8854727	-514.3070882000001	1499.309232	0.0	1876.0	0.0	1876.0	8.628108251987392	6.277013664609621	-0.350927083555725	6.325523158993347	7.247792581767845	2.6378121545072957	-2.3025850929940455	0.9707789171582246	2.9887392380630207	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bdd6	58cfa830e4b0c9d6adf6bdd6	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.bam	84.24	2.08	0.16	58cfa830e4b0c9d6adf6bdd6	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MC-01A	884FD57D-BD8E-40E7-82F6-0BA1C71101A9	Primary Tumor	Illumina HiSeq	db9c9c51-2c42-4a56-a87d-9c01038c4e6f	Uterus	74.0	46B48BF8-346B-4F25-916E-26A3CDDFA00D	9376C8CD-BD9D-4576-BBE3-7D771914AFA3	TCGA-BG-A0MC-01A-21D-A043-02	HG19_Broad_variant	TCGA-BG-A0MC	TCGA-UCEC		s4601	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_LOW	0.188808925	0.36	0.0	4.438969912	-0.6959	-0.233	-0.1293	1.0501	-0.8668	-0.0834	28.0	10.0	0.436254252	1.4250972240000002	59.0	0.029636922000000003	0.0	7.0							2.607272996	-1125.632233	-1739.3831109999999	-34.8488741	0.0	1263.0	0.0	1263.0	7.287332616138174	7.73902053943808	-0.5453240954637477	6.869597415438196	6.891722679050877	2.7374974024285113	-0.4177352006999788	-0.8472978603872034	3.2828214978922587	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bde2	58cfa830e4b0c9d6adf6bde2	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted.filtered.	WGS	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted.bam	237.59	1.78	0.15	58cfa830e4b0c9d6adf6bde2	TCGA-AG-A01N-01A-01D-A077_110406_SN177_0154_B818URABXX_s_3.rg.sorted.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01N-01A	1118490D-75AA-43CC-B2A2-C2AF61829FFC	Primary Tumor	Illumina HiSeq	1e5467f7-e974-4244-b9fb-2afff5ed40b4	Colorectal	68.0	0350E0DE-7B86-485A-A057-50E77D899ED9	49977602-A81B-4DDD-9354-8949BC3208CF	TCGA-AG-A01N-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A01N	TCGA-READ		s2007	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage IV	A077-02	True	READ	C1	GI.CIN	0.12512737	0.41	0.28	17.296726500000002	0.7508	0.237	-1.1971	-1.2203	-0.048	-0.1425	51.0		0.784290832	3.375860538	75.0	0.927395676	21.0	13.0							1.39153088	-1954.639823	1.230471514	-345.2454112	0.0	943.0	0.0	943.0	6.23793392372569	4.7909692956371694	-1.9681258947641562	4.889860775425996	5.06239084721717	-0.22952615229470696	-1.3480731482996933	0.2714215515800005	1.7385997424694493	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bded	58cfa830e4b0c9d6adf6bded	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.bam	43.73	2.05	0.16	58cfa830e4b0c9d6adf6bded	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0DK-01A	F2BBFA9D-9A9D-4F46-9FDE-378E4C44E2AD	Primary Tumor	Illumina HiSeq	71acb20b-f186-44d4-a92e-a2751f845fe3	Breast	49.0	1ACAE6E0-3100-4DE8-A436-E15CDBE1322B	92245807-8B1B-4E96-8567-6CFE5E70ADE4	TCGA-BH-A0DK-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0DK	TCGA-BRCA		s5493	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True	BRCA	C2	BRCA.LumA	0.314561435	0.48	0.01	0.8058527190000001	0.21	0.0655	0.7502	1.8828	1.6852	0.6667	41.0	56.0	0.49974637899999996	2.38114451	180.0	0.22289701399999998	6.0	16.0	0.7232843659999999	2.9368549489999998	58.0	4.725641556	123.0	0.9820159009999999	2.56356427	214.0376674	474.5170661	1063.839284	0.0	423.0	0.0	423.0	7.328218462667736	6.27786862936502	-0.10763513279706594	5.431098477781855	6.368840407570747	2.580173038127275	-1.897119984885881	0.09097177820572666	2.687808170924341	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bdf1	58cfa830e4b0c9d6adf6bdf1	TCGA-AK-3428-01A-02D-2096-10_Illumina.filtered.	WGS	TCGA-AK-3428-01A-02D-2096-10_Illumina	TCGA-AK-3428-01A-02D-2096-10_Illumina.bam	23.4	1.9	0.14	58cfa830e4b0c9d6adf6bdf1	TCGA-AK-3428-01A-02D-2096-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-AK-3428-01A	9DA334ED-314C-4445-BA29-FFD9BB42403C	Primary Tumor	Illumina HiSeq	46d21c8f-8493-4886-82f4-91fd488b4364	Kidney	62.0	0B96A41E-6A0C-4FC6-8F21-8E5F992CE5D1	D01710F9-EFC8-4B5F-9E53-300B30F9219F	TCGA-AK-3428-01A-02D-2096-10	GRCh37-lite	TCGA-AK-3428	TCGA-KIRC		s9303	Baylor College of Medicine	Fox Chase	None	NO	T3b	N0	Kidney Clear Cell Renal Carcinoma	Stage III	2096-10	False	KIRC	C3	KIRC.4	0.11381819900000001				-1.5454	-0.2025	0.4208	-0.3233	0.1646	-0.0196					49.0	0.072729068	0.0	2.0				0.0	1.0		1.812582766	-289.3513585	-731.0425541000001	2331.118498	0.0	3728.0	0.0	3728.0	8.125096025200348	0.8574774456976275	1.7399223397285144	5.475109625052899	3.962385984067601	1.8887959624549289	-2.6499864001474487	3.1049085383699735	0.14887362272641447	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bdf5	58cfa830e4b0c9d6adf6bdf5	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	140.75	2.0	0.15	58cfa830e4b0c9d6adf6bdf5	TCGA-AG-A01W-01A-21D-A079-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01W-01A	74543FA4-CE73-46E4-9C59-224E8242B4A2	Primary Tumor	Illumina HiSeq	66ffc729-68c6-4bd6-b4d2-e68e3989e252	Colorectal	67.0	C481ABBB-21EB-4393-AB8D-C27E3DA1B8F7	BC3C3340-5E36-4754-AF22-F08EF550BD07	TCGA-AG-A01W-01A-21D-A079-02	HG18	TCGA-AG-A01W	TCGA-READ		s2171	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage II	A079-02	True	READ	C2	GI.CIN	0.187136672	0.39	0.12	14.97478291	1.1471	0.426	-0.5799	0.1669	0.2249	-0.2872	74.0	34.0	1.088335558	3.5227703569999997	199.0	0.542209834	15.0	28.0								-1632.03746	713.4304784	660.567984	0.0	0.0	0.0	0.0	6.395556163388334	5.049341471606594	-0.1222979489643391	4.4496460143330205	5.551970328168405	1.6263357564178216	-1.9459101490553135	0.5026288565618113	1.7486337053821606	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bdf8	58cfa830e4b0c9d6adf6bdf8	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina.filtered.	WGS	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina.bam	28.07	1.9	0.15	58cfa830e4b0c9d6adf6bdf8	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-AK-3454-01A	28E9B6F9-AB6A-400B-A6A9-79095A443591	Primary Tumor	Illumina HiSeq	54d1e202-1017-4494-af06-5b5747b7201c	Kidney	84.0	74741322-3B24-43E6-9CE1-F267B0555F62	FD74DE4D-6973-4597-A541-E8A13D80AD55	TCGA-AK-3454-01A-02D-2096-10	GRCh37-lite	TCGA-AK-3454	TCGA-KIRC		s9731	Baylor College of Medicine	Fox Chase	United States	NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2096-10	False	KIRC	C3	KIRC.1	0.169385125				-1.2809	-0.2385	0.3106	0.1118	0.1941	-0.0387					95.0	0.120049713	1.0	11.0				1.71049323	6.0	0.9546444479999999	1.2612456140000001	927.5326691	-1207.295069	3127.4585260000003	0.0	874.0	0.0	874.0	8.688050054233521	-0.2570958976007116	0.7634394067439164	5.454400184094013	2.846771664320374		-3.2336498701395087	3.103867561921086		higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be04	58cfa830e4b0c9d6adf6be04	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.bam	133.79	2.0	0.17	58cfa830e4b0c9d6adf6be04	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M9-01A	4FD1CB59-6C50-4355-9D37-A341E1F4FAD9	Primary Tumor	Illumina HiSeq	633f3cff-14c3-45f7-b568-caa86760d863	Uterus	73.0	DC487BBF-555B-423B-B7C0-3E92DEFA5A79	3D712314-6FDC-41C7-9CE1-5F9BB85929EE	TCGA-BG-A0M9-01A-21D-A101-02	HG19_Broad_variant	TCGA-BG-A0M9	TCGA-UCEC		s4603	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.072580584			0.917571885	-0.1953	0.063	-0.8322	-1.1941	-1.1606	-0.113	26.0		0.362567142	1.63155214	119.0	0.049821577									4.183850517	-990.4722621	-1035.578023	-889.9575833999999	0.0	2270.0	0.0	2270.0	7.037261916468042	7.409186917106259	-1.0668860758560026	6.941951736663718	6.716039736546314	1.2887434329558176	-0.09531017980432477	-0.6931471805599454	2.35562950881182	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be06	58cfa830e4b0c9d6adf6be06	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.bam	87.16	2.0	0.14	58cfa830e4b0c9d6adf6be06	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MQ-01A	12D36A1D-9922-4311-BBDA-71F32AC2C03B	Primary Tumor	Illumina HiSeq	d1e9cdb8-f8a6-43da-9afb-28a6e6d72b6a	Uterus	71.0	3D1FA321-D2E8-4460-AE87-356AB1CA6281	08F01B17-0386-4C7E-B926-1736CEC043D2	TCGA-BG-A0MQ-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MQ	TCGA-UCEC		s4253	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.056270479000000005	0.15	0.0	10.25845071	0.2858	0.098	-0.9543	-1.4031	-1.1404	-0.2984	143.0		5.108797837	15.4328268	69.0	0.049252434000000005	2.0	2.0							1.7620417000000002	-1110.6693599999999	-58.79649531	2396.1888989999998	0.0	1817.0	0.0	1817.0	7.321655301205362	7.729999032876493	-1.6717718913236395	6.41719902697821	7.199370781814323	2.4702799979290617	-0.9044562742271522	-0.5306282510621703	4.142051889252701	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be10	58cfa830e4b0c9d6adf6be10	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.bam	19.84	1.95	0.16	58cfa830e4b0c9d6adf6be10	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HX-01A	3B01D064-8C00-4972-9F07-407EAC8E7534	Primary Tumor	Illumina HiSeq	06f7db86-540c-401d-bbd9-0b88698c5f36	Breast	54.0	989C2DF5-5183-4DAA-A8DA-FC9AB18A437C	11821020-0E93-4479-85F8-306976DE6722	TCGA-BH-A0HX-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0HX	TCGA-BRCA		s6126	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True	BRCA	C1	BRCA.LumA	0.147624926	0.4	0.44		0.1575	0.069	-0.1506	-0.2522	-0.1606	0.4108	26.0	0.0	0.5878101689999999	1.70464949	278.0	0.605404901	16.0	44.0		0.0	1.0	2.94700477	20.0	0.98373436	3.9100396660000003	-467.21010650000005	793.4465865	-37.15866052	0.0	829.0	0.0	829.0	8.22817689595132	7.030604823259798	-0.4785270550619065	5.830281623152949	6.897073430635276		-2.3978952727983707	-0.13353139262452274		higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be13	58cfa830e4b0c9d6adf6be13	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.bam	55.92	1.91	0.16	58cfa830e4b0c9d6adf6be13	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0W5-01A	DA9C10EA-C13F-4D88-8B94-A0CBC106D036	Primary Tumor	Illumina HiSeq	eeccc516-2d3d-4f41-a324-c90f92a6f944	Breast	77.0	050E66BB-438A-49D5-A005-7967A006B3F0	6C8B3A70-CD58-4BFC-9418-54182588CFCB	TCGA-BH-A0W5-01A-11D-A106-02	HG19_Broad_variant	TCGA-BH-A0W5	TCGA-BRCA		s5803	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A106-02	False	BRCA	C3	BRCA.LumA	0.46683243700000004	0.67	0.05	2.232300791	-0.4587	-0.1205	0.7806	2.2521	-0.1723	0.4202	2.0	0.0	0.082612459	0.633362188	47.0	0.10814992699999999	5.0	5.0	0.874063502	3.6486795539999997	65.0	4.759145088	136.0	0.968752171	1.4578462859999999	-564.1030262	305.634995	94.70566613	0.0	1288.0	0.0	1288.0	8.08193875449732	6.404401670054847	-0.283805740879026	5.830646955890826	6.21024565561389	2.0539763606203403	-2.251291798606495	-0.19415601444095776	2.337782101499366	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be18	58cfa830e4b0c9d6adf6be18	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	361.02	1.9	0.15	58cfa830e4b0c9d6adf6be18	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4615-01A	BF69A4CE-EC7E-4752-A86D-DCC80E3C9A57	Primary Tumor	Illumina HiSeq	82dc215a-4234-4f8b-a4c0-50c8103dda6e	Colorectal	84.0	89811300-8202-4A82-8353-5B2B2B2ECFD4	90D11094-F492-4B05-81AB-E637AEC8F953	TCGA-AZ-4615-01A-01D-1405-02	HG18	TCGA-AZ-4615	TCGA-COAD		s13216	Harvard Medical School	University of Pittsburgh	None	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1405-02	True	COAD	C2	GI.HM-indel	0.22896406100000002	0.35	0.0	16.07671708	0.6597	0.2075	0.2953	0.4828	1.4096	0.0864	217.0	1371.0	8.163128215	24.52054162	100.0	0.058709582999999996	2.0	1.0							0.8662784579999999	-588.1257283	408.7878023	-2058.379225	0.0	1002.0	1.0	688.0	4.925238774139026	4.727955977487415	0.41422320005343616	3.8082773468027193	5.229649117690133	1.636708055506746	-1.1169614273363067	0.5016931402027183	1.2224848554533096	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be22	58cfa830e4b0c9d6adf6be22	TCGA-B9-4113-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4113-01A-01D-1253-10_wgs_Illumina	TCGA-B9-4113-01A-01D-1253-10_wgs_Illumina.bam	0.0	1.9	0.15	58cfa830e4b0c9d6adf6be22	TCGA-B9-4113-01A-01D-1253-10_wgs_Illumina.bam	Dead	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4113-01A	5C9A6C40-982E-45C7-98D3-AEB6CAD16986	Primary Tumor	Illumina HiSeq	946b3469-d936-4438-8fc4-3075da99cd4d	Kidney	64.0	DDDC5575-D88F-4F4E-B591-96F11403184B	F03330DD-C616-4AD5-ABC3-6D6B0445E9E9	TCGA-B9-4113-01A-01D-1253-10	GRCh37-lite	TCGA-B9-4113	TCGA-KIRP	1536.0	s11585	Baylor College of Medicine	UNC	None	NO	T1	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1253-10	False	KIRP	C3	KIRP.C1	0.149588568	0.3	0.0		-2.0969	-0.313	0.7138	0.1198	-0.2456	-0.3152	24.0	209.0	0.536051948	1.4953028030000002	255.0	0.132563989	6.0	0.0	0.946290698	1.0396065890000001	3.0	3.39691442	31.0	0.989204158	2.361942134	-691.0374095	-1670.987957	1306.36679	1.0	1536.0	0.0	1536.0	6.14173013872367	2.548381680449924	0.5719479600355871	5.043117850055561	2.764745544778755	4.997212273764115	-1.0986122886681098	0.21636386432883103	4.425264313728528	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be2a	58cfa830e4b0c9d6adf6be2a	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted.bam	65.55	2.08	0.15	58cfa830e4b0c9d6adf6be2a	TCGA-B6-A0X4-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0X4-01A	4E42FDC5-2A8B-49E9-87EF-6DB7A6692D08	Primary Tumor	Illumina HiSeq	1973be6c-c5a9-40d1-bdd2-a752dd33d6d1	Breast	62.0	45C3BD72-D260-4663-9091-5058E58F352D	062A41CC-4B23-49E2-AFF8-3CFE34DE9A36	TCGA-B6-A0X4-01A-11D-A106-02	HG19_Broad_variant	TCGA-B6-A0X4	TCGA-BRCA	860.0	s6462	Harvard Medical School	Duke	United States	NO	T2	N1b	Infiltrating Ductal Carcinoma	Stage IIB	A106-02	False	BRCA	C4	BRCA.LumA	0.053161753			1.2612446290000001	-0.9085	-0.1465	-1.4458	-2.5987	0.08800000000000001	-0.326	7.0	15.0	0.122748814	0.5523696610000001	53.0	0.030510977999999998	0.0	1.0					0.0		1.95250742	-1039.717813	447.67878360000003	2729.8853059999997	1.0	860.0	1.0	716.0	7.734704648831211	6.6174029779744785	0.2300513398553713	5.788794499775898	6.2379133562695745	1.4705302306251218	-1.9459101490553132	-0.3794896217049035	1.2404788907697506	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be38	58cfa830e4b0c9d6adf6be38	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.bam	80.24	1.95	0.16	58cfa830e4b0c9d6adf6be38	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JY-01A	61935424-44D0-4211-81C1-C925E436EAC5	Primary Tumor	Illumina HiSeq	e463dbb2-091a-4183-98b6-a90c2e55ffae	Uterus	50.0	95F418CE-FCD9-4402-BC24-1520F45CB6B7	88CE0037-F3F9-4F45-BF14-36A58FF61A3D	TCGA-B5-A0JY-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JY	TCGA-UCEC		s4784	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.POLE	0.1447737	0.4	0.0	8.243563297	0.5635	0.247	-0.3913	0.1238	-0.9981	0.1752	4625.0	61.0	62.32319203	253.5817898	65.0	0.00030883099999999997	0.0	0.0							2.75032741	-2227.999312	385.1045972	-2786.977451	0.0	2107.0	0.0	2107.0	6.642949326341339	5.958014453444114	-0.1218754120196679	5.9660626666531735	6.965654963906497	2.6964742282189693	-0.6768866596881651	1.007640510462383	2.8183496402386377	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be3a	58cfa830e4b0c9d6adf6be3a	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.bam	45.3	1.98	0.17	58cfa830e4b0c9d6adf6be3a	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A18Z-01A	0D497FAF-2C1C-4173-A5FE-770CCA73323C	Primary Tumor	Illumina HiSeq	a740c90f-9cbc-4ff1-8cad-c78d4dbb92cf	Thyroid	58.0	19DEE039-9C98-4D4A-8BAF-EEA1B6DDA8EB	815C53C3-8ADD-4612-B93C-3ED4BFA530AA	TCGA-BJ-A18Z-01A-21D-A13U-02	HG19_Broad_variant	TCGA-BJ-A18Z	TCGA-THCA		s12354	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A13U-02	True	THCA	C3	THCA.4	0.190872515	0.67	0.0		-1.6356	-0.253	-0.0298	-0.4102	-0.0701	0.5091	16.0		0.029045427000000002	0.464726827	37.0	1.4400000000000001e-05	0.0	0.0				1.9459101490000001	7.0	1.0	1.6103323840000001	281.16050989999997	-1225.680656	1857.156645	0.0	1263.0	0.0	1263.0	5.694853843911899	8.545888622138577	-0.4545297232590616	4.665234426730741	7.246605638008317	0.9011994556736966	-1.029619417181158	-1.2992829841302607	1.3557291789327581	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be3c	58cfa830e4b0c9d6adf6be3c	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.bam	77.56	2.0	0.18	58cfa830e4b0c9d6adf6be3c	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A18Y-01A	ACB3B9DB-16E9-40F5-87A9-9DF9D4CEEE54	Primary Tumor	Illumina HiSeq	0074a697-0800-4872-9a48-48945f46d18d	Thyroid	29.0	5D1D84D0-9A03-4381-9CF1-E460B3617AAA	56D2A069-7969-40F1-A237-E4FE7E62C84C	TCGA-BJ-A18Y-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A18Y	TCGA-THCA		s12351	Harvard Medical School	University of Pittsburgh	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True	THCA	C3	THCA.1	0.061199582	0.4	0.0		-2.1359	-0.3495	-0.5921	-1.5621	-0.8101	-0.2703	6.0		0.060061802000000004	0.150154506	53.0	0.011083262	0.0	0.0				0.693147181	2.0	1.0	1.818513285	-1063.0899960000002	-1055.9526779999999	2119.803652	0.0	1563.0	0.0	1563.0	6.568545966651039	7.268257888055196	-1.0853595922356625	5.339880549734731	6.931785651433982	1.4204857258681696	-1.2286654169163076	-0.33647223662121295	2.505845318103832	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be44	58cfa830e4b0c9d6adf6be44	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	406.94	1.9	0.15	58cfa830e4b0c9d6adf6be44	TCGA-AF-2691-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2691-01A	830FD359-ABD4-4C99-89E4-2D6BB9CE5637	Primary Tumor	Illumina HiSeq	92f1a7a8-08ff-487e-bd7d-8146bc0109c6	Colorectal	48.0	CE252C3D-5CF3-46BC-A181-3714D1C65E4E	64EDFE90-619C-42A0-BBE1-EB78B4D5C26D	TCGA-AF-2691-01A-01D-1167-02	HG18	TCGA-AF-2691	TCGA-READ		s2131	Harvard Medical School	Christiana Healthcare	None	NO	T1	N0	Rectal Adenocarcinoma	Stage I	1167-02	True	READ	C1		0.121589793	0.57	0.26	11.192712599999998	0.3274	0.177	-0.0041	0.6225	0.0057	-0.0484			1.171023851	5.353251891	129.0	0.458679751	9.0	17.0	0.9350018659999999	3.449109172	40.0				1.345116664	-403.68021380000005	-99.26833894	1850.7353649999998	0.0	1309.0	0.0	1309.0	7.753103872361171	4.573431490124112	-0.3977332369495312	5.979043980232517	5.0765350677961925	0.829901074874563	-1.774059892128654	0.5031035776720802	1.2276343118240942	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be46	58cfa830e4b0c9d6adf6be46	TCGA-AF-2691-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AF-2691-01A-01D-1989-10_wgs_Illumina	TCGA-AF-2691-01A-01D-1989-10_wgs_Illumina.bam	406.94	1.9	0.15	58cfa830e4b0c9d6adf6be46	TCGA-AF-2691-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Rectum Adenocarcinoma	Aligned reads	TCGA-AF-2691-01A	830FD359-ABD4-4C99-89E4-2D6BB9CE5637	Primary Tumor	Illumina HiSeq	51fe9202-95ee-418b-a143-fe84f4b20380	Colorectal	48.0	CE252C3D-5CF3-46BC-A181-3714D1C65E4E	81B1E78C-6032-4FF4-B52A-83456B9450EA	TCGA-AF-2691-01A-01D-1989-10	GRCh37-lite	TCGA-AF-2691	TCGA-READ		s1956	Baylor College of Medicine	Christiana Healthcare	None	NO	T1	N0	Rectal Adenocarcinoma	Stage I	1989-10	True	READ	C1		0.121589793	0.57	0.26	11.192712599999998	0.3274	0.177	-0.0041	0.6225	0.0057	-0.0484			1.171023851	5.353251891	129.0	0.458679751	9.0	17.0	0.9350018659999999	3.449109172	40.0				1.345116664	-403.68021380000005	-99.26833894	1850.7353649999998	0.0	1309.0	0.0	1309.0	7.138708257187829	0.6006397222664219	-0.3977332369495312	6.183196812160393	3.9143061114427145	0.829901074874563	-0.9555114450274362	3.3136663891762925	1.2276343118240942	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be4c	58cfa830e4b0c9d6adf6be4c	TCGA-AG-3890-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3890-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3890-01A-01D-1989-10_wgs_Illumina.bam	614.89	1.9	0.15	58cfa830e4b0c9d6adf6be4c	TCGA-AG-3890-01A-01D-1989-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3890-01A	E2D395F8-BF13-4FE4-8031-683B0EEDD875	Primary Tumor	Illumina HiSeq	8df564e5-cdec-4714-b522-5f7356be8d5d	Colorectal	62.0	DB70A6DD-DE09-4ED7-916C-708B21734500	03CFF38D-7E29-4409-A508-749BDDB1B3DF	TCGA-AG-3890-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3890	TCGA-READ		s1975	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1989-10	True	READ	C1	GI.CIN	0.184366589	0.29	0.54	14.40303525	0.3755	0.023	-0.1392	1.0402	-0.5787	0.0309	55.0	63.0			185.0	0.501152942	7.0	26.0							0.995981417	-1458.486919	-396.9077121	-441.5665663	0.0	518.0	0.0	518.0	6.831818712892197	3.2401262589903235	-0.5216039371399058	5.692384429703832	4.797963042649341	2.098144268754017	-1.1394342831883648	1.5578367836590177	2.6197482058939223	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be55	58cfa830e4b0c9d6adf6be55	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.bam	118.49	2.07	0.17	58cfa830e4b0c9d6adf6be55	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LT-01A	43714E9A-E9C4-4206-AF92-1D00D2A8AE35	Primary Tumor	Illumina HiSeq	42ca121f-f3b0-4b47-acb4-f1294f88eb39	Uterus	57.0	C94DD7A5-DD58-4702-A7D1-8199D3F8C9CC	B057AD28-5D99-48BC-B642-7E548914F1B1	TCGA-AP-A0LT-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LT	TCGA-UCEC		s4242	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.MSI	0.123158925	0.11	0.0	9.665798896	1.0328	0.395	-1.2906	-0.5331	-1.6369999999999998	-0.511	200.0		5.50002095	17.97856311	47.0	3.37e-06	0.0	0.0							1.919688869	-1530.135765	561.6855283	-705.4964139	0.0	1497.0	0.0	1497.0	5.6958724851327105	6.626623137394088	-0.7257771145668184	5.478807979894882	6.007583928987865	0.2923951567764178	-0.21706450523782772	-0.6190392084062237	1.0181722713432362	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be66	58cfa830e4b0c9d6adf6be66	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.bam	17.47		0.15	58cfa830e4b0c9d6adf6be66	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A3PT-01A	29C4319C-3EAD-42B1-810D-418DA8D515C4	Primary Tumor	Illumina HiSeq	0d7263bd-8ffa-4ba1-93c4-0444afd9b56e	Thyroid	51.0	8C112A5F-AE83-4B13-8E00-802382729344	EC6A8D75-A25A-4179-BAF4-53607841AC09	TCGA-BJ-A3PT-01A-12D-A221-26	HG19_Broad_variant	TCGA-BJ-A3PT	TCGA-THCA		s12747	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	True	THCA	C3	THCA.1	0.194264176	0.33	0.01		-1.9385	-0.1485	0.1039	0.4766	-0.627	-0.1797	11.0		0.029047051	0.319517559	57.0	0.011020303	0.0	0.0				2.404244448	17.0	0.8485928009999999	1.835905792	-245.367993	-1279.9870640000001	1487.1961119999999	0.0	709.0	0.0	709.0	6.61463911371722	8.248856125228233	-0.2355366903980195	6.411040158475981	7.383858687741629	2.17161528399403	-0.2035989552412394	-0.8649974374866045	2.40715197439205	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be68	58cfa830e4b0c9d6adf6be68	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.bam	46.06	1.81	0.15	58cfa830e4b0c9d6adf6be68	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28Z-01A	6BA76174-620E-4851-857A-D0ADBFD6F3E6	Primary Tumor	Illumina HiSeq	3d2be877-3825-44b4-99b1-b3c314e68c0c	Thyroid	46.0	D9689254-AFE2-4544-AF54-E02670BD5EBD	F353E9F5-A869-4BE1-ACC4-A832D77285D4	TCGA-BJ-A28Z-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28Z	TCGA-THCA		s12508	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	True	THCA	C3	THCA.2	0.43958029600000004				-1.2609	-0.3135	1.2212	2.3451	0.6455	0.2293	6.0		0.31345745199999997	0.37044971600000004	61.0	0.005854447			0.729885363	2.728070348	42.0	4.123460637	68.0	0.9772373759999999	1.7612990990000001	1348.67525	-575.8263492000001	1107.6120210000001	0.0	337.0	0.0	337.0	6.732267461766748	8.26547868311399	0.6464640726960358	6.342802695005024	7.418180822726788	2.231908216437371	-0.38946476676172326	-0.8472978603872034	1.585444143741335	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be6c	58cfa830e4b0c9d6adf6be6c	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted.bam	57.46	1.9	0.15	58cfa830e4b0c9d6adf6be6c	TCGA-BL-A13J-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_8_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A13J-01A	556FCBC8-172A-4AF1-8822-AE036E8D68E8	Primary Tumor	Illumina HiSeq	58daf5d5-0c54-4a8c-b756-35565cdc9671	Bladder	65.0	CF23846D-A7D2-40A9-8B51-49A27967D101	782CEFE1-C28F-40BA-93A2-66279184EEF6	TCGA-BL-A13J-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BL-A13J	TCGA-BLCA	81.0	s3080	Harvard Medical School	Christiana Healthcare	United States	NO	T4	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	True	BLCA	C1	BLCA.2	0.157691052	0.44	0.21	2.3099850969999998	0.5812	0.0015	-0.6311	-0.9139	-0.6015	0.3095	25.0	32.0	0.9475945659999999	2.628810732	209.0	0.736032885	17.0	43.0	0.9269905629999999	1.2850817909999999	4.0	0.693147181	2.0	1.0	1.7907422419999999	-1295.047718	636.5785716	-3493.2627409999996	1.0	81.0	1.0	81.0	5.533866409193041	6.4036688008391955	-0.3153379245472394	4.624496120163459	5.848142998155297	1.0628656178929559	-0.9093702890295816	-0.5555258026838978	1.378203542440195	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be6e	58cfa830e4b0c9d6adf6be6e	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.bam	53.09	1.95	0.16	58cfa830e4b0c9d6adf6be6e	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A190-01A	04FFF86A-B6F5-4900-9E37-C1F0B881B160	Primary Tumor	Illumina HiSeq	a9f1f6de-8f02-48c6-a9e2-6cef21cd8438	Thyroid	55.0	2EB89D79-861E-41C2-BDD5-6F16D2A84B25	42FE4D84-B54D-42B8-81F8-92191723D057	TCGA-BJ-A190-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A190	TCGA-THCA		s12234	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A13U-02	True	THCA	C3	THCA.1	0.036559572				-2.1637	-0.315	-1.7482	-2.63	-1.0206	-0.6747					69.0	0.9230235940000001						0.693147181	2.0	1.0	1.502920667	-842.5599526000001	-687.8511679999999	2503.5107329999996	0.0	626.0	0.0	626.0	6.226371965342435	8.823950072188646	-0.6924820658031346	4.983178447863217	7.491722932339031	1.1214781134051126	-1.2431935174792175	-1.332227139849615	1.8139601792082471	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be70	58cfa830e4b0c9d6adf6be70	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.bam	82.3	2.03	0.16	58cfa830e4b0c9d6adf6be70	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28R-01A	524A39EE-8FA3-418E-98A2-A6A90E9C8064	Primary Tumor	Illumina HiSeq	122e0c7e-da24-4121-907e-8b913b4e4147	Thyroid	38.0	F4906B86-3971-4ED3-AC3C-69635311FB45	A5170F7D-F298-4330-8272-8DACFF7775A1	TCGA-BJ-A28R-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28R	TCGA-THCA		s11987	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.4	0.164744426	0.25	0.0		-1.756	-0.2855	0.1764	0.9106	-0.2336	-0.1075	1.0		0.057967849	0.144919622	35.0	2.68e-05	0.0	0.0	0.614723117	2.84907505	103.0	3.717941795	44.0	0.98249352	1.263738211	40.45623521	-986.6245582	2590.319727	0.0	1282.0	0.0	1282.0	7.418480897747795	5.86220971125072	-0.29031599024048294	0.5881467657342432	5.120272366521343	2.1474535401111954	-6.830334132013552	-0.7419373447293771	2.4377695303516784	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be71	58cfa830e4b0c9d6adf6be71	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina.bam	109.0	1.9	0.14	58cfa830e4b0c9d6adf6be71	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4326-01A	7664C241-B369-4D76-9CD1-7F2BDC1D267F	Primary Tumor	Illumina HiSeq	8d64ee9c-1973-46e9-8ad7-1d9c3a96a47c	Kidney	53.0	068BFE4D-341C-49F7-B7A9-5D070DE00AB3	54842328-9432-4820-8976-7964BF9BF147	TCGA-BP-4326-01A-01D-2097-10	GRCh37-lite	TCGA-BP-4326	TCGA-KIRC		s9163	Baylor College of Medicine	MSKCC	None	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2097-10	False	KIRC	C3	KIRC.3	0.09398661800000001				-1.1505	-0.19	0.3015	-0.1892	-0.0506	0.5279					87.0	0.035486317999999996	1.0	10.0				2.397895273	11.0	1.0	1.830947681	39.18644695	-431.26181349999996	1387.235129	1.0	1625.0	1.0	958.0	7.5011323490156645	1.553668771540801	-0.7083861630680768	6.161358003530667	5.120804230746388	2.2720318755128717	-1.3397743454849977	3.567135459205587	2.9804180385809484	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be78	58cfa830e4b0c9d6adf6be78	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted.bam	24.07		0.16	58cfa830e4b0c9d6adf6be78	TCGA-BL-A3JM-01A-12D-A21C_120914_SN590_0180_BC19KDACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A3JM-01A	0F4FB205-B13C-4A85-97B3-779429E6CCDD	Primary Tumor	Illumina HiSeq	5cd881b7-caa0-43ad-9ba8-f9696fdf7403	Bladder	62.0	110ACEE1-915F-43A2-B382-5D0AF1FC167F	6ABBBA00-C322-4EDE-91A4-85D0D3E886F9	TCGA-BL-A3JM-01A-12D-A21C-26	HG19_Broad_variant	TCGA-BL-A3JM	TCGA-BLCA	205.0	s2691	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A21C-26	True	BLCA	C2	BLCA.4	0.150053419	0.24	0.12	6.926086497000001	1.2142	0.45	-0.5119	-0.5683	0.1278	-0.2622	57.0	74.0	2.067980416	5.200362517	110.0	0.940040412	17.0	7.0				1.992798144	9.0	0.9069615209999999	2.639992611	-1492.3495619999999	1121.514171	-3705.0976299999998	1.0	205.0	1.0	111.0	6.805353345364056	9.731674226745687	-1.1502779939825576	5.576687928447748	8.910693674675857	1.4983968047036498	-1.2286654169163076	-0.8209805520698299	2.6486747986862076	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be7e	58cfa830e4b0c9d6adf6be7e	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.bam	32.81	2.02	0.17	58cfa830e4b0c9d6adf6be7e	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-BJ-A192-01A	B55375C3-9EF2-4D2F-9C29-224E746931C4	Primary Tumor	Illumina HiSeq	9218178e-761c-40ac-b3ca-044bf37f8686	Thyroid	54.0	582C3030-1F23-4535-9C8B-6B594E656AF4	6D770754-E14D-4E47-AE33-BE0FC9B40CE9	TCGA-BJ-A192-01A-31D-A13U-02	HG19_Broad_variant	TCGA-BJ-A192	TCGA-THCA		s12235	Harvard Medical School	University of Pittsburgh	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A13U-02	True	THCA	C4	THCA.1	0.106448866				-2.4739	-0.209	-0.4268	-1.9371	-0.4196	-0.6	3.0	0.0	0.059633705999999995	0.208717971	70.0	0.076602723						0.0	1.0		1.836146488	-1469.982573	-1348.646028	3257.970522	0.0	1349.0	0.0	1349.0	7.2832519771614574	8.423678898042093	-1.0121246455638127	6.115646817006397	7.4585980019985065	2.409098789636864	-1.1676051601550612	-0.9650808960435873	3.4212234352006767	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be84	58cfa830e4b0c9d6adf6be84	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted.bam	110.16	1.93	0.17	58cfa830e4b0c9d6adf6be84	TCGA-BJ-A191-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A191-01A	2501EE46-8D38-448B-8765-E9C9706CBBE8	Primary Tumor	Illumina HiSeq	fb73296b-b8ef-4ff9-a954-fab7d29ab101	Thyroid	49.0	C92FC4E3-7A96-4000-A969-AA894CA58A33	B3EDF2BC-5E8F-435A-ADA1-F292722EDD9C	TCGA-BJ-A191-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A191	TCGA-THCA		s12237	Harvard Medical School	University of Pittsburgh	United States	NO	T1b	N0	Other  specify	Stage I	A13U-02	True	THCA	C3	THCA.1	0.048944620999999994	0.64	0.0		-1.6826	-0.3945	-0.5602	0.6797	-0.5778	-0.5002	6.0	1.0	0.232515124	0.465030249	55.0	2.24e-05	0.0	0.0	0.855526282	3.820701769	87.0	2.599301927	14.0	0.9849357559999999	1.96319774	-1508.9667949999998	-1187.604247	1847.246869	0.0	147.0	0.0	147.0	6.400465064950385	7.444281137597941	0.4947617461648748	5.666495889870184	6.967357065507631	1.5599202109462915	-0.7339691750802002	-0.4769240720903096	1.0651584647814167	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be88	58cfa830e4b0c9d6adf6be88	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.bam	30.94	1.89	0.15	58cfa830e4b0c9d6adf6be88	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A291-01A	D4C68C1C-A3F3-4E0C-B555-D457378A1D24	Primary Tumor	Illumina HiSeq	bb0bf0e4-e29d-422a-879e-b8dc7f5c720b	Thyroid	56.0	D1612961-A709-487B-A4D1-CE42F0B9AA54	E28A1E8B-41A3-44C0-ADBC-6A203C92DDF5	TCGA-BJ-A291-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A291	TCGA-THCA		s11990	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.1	0.066797418				-2.6085	-0.2605	-1.035	-1.3556	-0.1485	-0.2704					35.0	0.000227875	0.0	0.0				0.0	1.0		1.6136904090000002	-531.4698621	-862.5013011	2018.660925	0.0	696.0	0.0	696.0	7.206711063657295	8.659444785657811	-1.0624897629642163	6.591525424567061	7.59857282497255	2.548016485866304	-0.6151856390902335	-1.0608719606852626	3.6105062488305206	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be8d	58cfa830e4b0c9d6adf6be8d	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.bam	79.7	1.9	0.16	58cfa830e4b0c9d6adf6be8d	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BK-A0CB-01A	59E9029A-8DDD-4447-B35A-72BC39F82A30	Primary Tumor	Illumina HiSeq	2c466122-c49e-4866-b9d4-faf31dde999c	Uterus	60.0	7678C70D-A298-4472-89A0-427AF1E93D28	F186159C-DCE6-467C-AAAF-BB08FBAE6827	TCGA-BK-A0CB-01A-32D-A101-02	HG19_Broad_variant	TCGA-BK-A0CB	TCGA-UCEC		s5006	Harvard Medical School	Christiana Healthcare	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.120724741	0.33	0.05	1.4426516180000002	-0.4308	-0.113	-0.0945	-0.1206	-0.7479	0.6436	21.0	41.0	0.581325258	1.328743448	53.0	0.049984144	0.0	0.0							2.45743179	-899.1807367999999	-754.3778766	-705.3037774000001	0.0	1092.0	0.0	1092.0	5.978366318100272	6.574300706850244	-0.6306268235786113	5.564390520324198	6.245796639878208	3.3534067178258073	-0.4139757977760734	-0.32850406697203605	3.9840335414044183	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be90	58cfa830e4b0c9d6adf6be90	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted.bam	92.87	2.0	0.15	58cfa830e4b0c9d6adf6be90	TCGA-BL-A13I-01A-11D-A13U_121005_SN1120_0195_AC13RHACXX_s_4_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A13I-01A	EBC094A6-CDC9-4C02-B8EC-A181B25A364D	Primary Tumor	Illumina HiSeq	b7cfe609-703a-4750-b9e7-5bda8e948cc4	Bladder	57.0	62C2BA8F-02E3-4100-86BC-5958038B4983	7C09CFF3-3162-4952-93AD-8A7D89F07266	TCGA-BL-A13I-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BL-A13I	TCGA-BLCA	223.0	s2689	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True	BLCA	C4	BLCA.4	0.494772514	0.67	0.13	12.79047019	0.7346	0.3435	1.192	0.3819	0.0129	0.2083	48.0	66.0			86.0	0.070601795	2.0	5.0				3.3988230710000003	34.0	0.963833121	5.851954332999999	-301.1959584	881.7584521	-1246.029291	1.0	223.0	1.0	216.0	5.579876837967964	6.212241664260604	0.6884103698084436	5.934698213257374	5.776923593002758	3.5317356431400033	0.3548213752894096	-0.4353180712578455	2.8433252733315597	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be92	58cfa830e4b0c9d6adf6be92	TCGA-AG-4007-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-4007-01A-01D-1989-10_wgs_Illumina	TCGA-AG-4007-01A-01D-1989-10_wgs_Illumina.bam	915.89	1.9	0.16	58cfa830e4b0c9d6adf6be92	TCGA-AG-4007-01A-01D-1989-10_wgs_Illumina.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4007-01A	8E00E7E7-FFAF-44F0-91A7-172671F18E08	Primary Tumor	Illumina HiSeq	16ef1919-094b-44db-a49b-966c6bf84f33	Colorectal	87.0	E6FC3F28-1DE1-4587-9E0E-0861323E6772	8DA641E4-9B12-4163-BD1E-9D5AF91E5186	TCGA-AG-4007-01A-01D-1989-10	GRCh37-lite	TCGA-AG-4007	TCGA-READ		s1981	Baylor College of Medicine	Indivumed	Germany	NO	T4	N2	Rectal Adenocarcinoma	Stage IV	1989-10	True	READ	C1		0.085002955	0.31	0.06	13.90430149	0.2916	0.138	-0.0642	0.7799	-0.4136	0.1805					420.0	0.997270488	21.0	23.0							1.557623971	-1257.6077289999998	-596.9351227999999	435.28805520000003	0.0	31.0	0.0	31.0	7.35171968624091	1.8212076742152092	-0.3234562428015064	5.96542532512102	5.002143350938043	2.07244501139	-1.3862943611198908	3.180935676722834	2.3959012541915063	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6be9f	58cfa830e4b0c9d6adf6be9f	TCGA-AG-3896-01A-01D-1989-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3896-01A-01D-1989-10_wgs_Illumina	TCGA-AG-3896-01A-01D-1989-10_wgs_Illumina.bam	913.89	1.9	0.15	58cfa830e4b0c9d6adf6be9f	TCGA-AG-3896-01A-01D-1989-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3896-01A	9AF35239-FFB9-4D4F-889E-F743DA271EEF	Primary Tumor	Illumina HiSeq	a9406c81-5dd3-4c50-8984-c81a85f67723	Colorectal	85.0	03B40342-3CCE-4A45-B2EC-8855AEB85100	14334AEA-2DAE-428C-9D4A-1A37878DFC3F	TCGA-AG-3896-01A-01D-1989-10	GRCh37-lite	TCGA-AG-3896	TCGA-READ		s1992	Baylor College of Medicine	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1989-10	True	READ	C1	GI.CIN	0.07508369	0.36	0.11	8.506290998999999	0.7562	0.316	-0.376	0.0429	-1.037	0.0707	53.0	0.0			145.0	0.9009666759999999	16.0	12.0							0.809726519	-1902.6506980000001	-44.13456392	149.7527415	0.0	31.0	0.0	31.0	8.033442164909529	1.496514698674103	-0.17583592400735648	6.018539144367264	4.7347896158667035	1.461017907315827	-2.0149030205422647	3.2382749171926006	1.6368538313231835	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bea4	58cfa830e4b0c9d6adf6bea4	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	722.89	1.9	0.15	58cfa830e4b0c9d6adf6bea4	TCGA-AG-3898-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3898-01A	5A7D19F9-6BE2-45AC-9FFC-11E28594EEEE	Primary Tumor	Illumina HiSeq	846bcf47-2650-4479-be12-96589e587f3a	Colorectal	61.0	C782D6BF-AA57-4184-8276-E08D6B64E6B2	AA49029D-0F51-4836-BD7B-74CC0C2F9576	TCGA-AG-3898-01A-01D-1115-02	HG18	TCGA-AG-3898	TCGA-READ		s2314	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.CIN	0.22200247	0.47	0.29	12.67047392	1.0628	0.39	-0.1724	-0.3199	0.1193	0.0561	41.0	20.0			216.0	0.43219339799999995	16.0	17.0							1.3474514709999998	-1446.706422	534.5420848	-1070.1509740000001	0.0	1461.0	0.0	1461.0	4.674074164635302	4.972055452981691	-0.2746244563632865	3.8267763042480984	5.392788033220644	0.48602099346240313	-0.8472978603872039	0.420732580238953	0.7606454498256896	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bea9	58cfa830e4b0c9d6adf6bea9	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	208.89	1.9	0.14	58cfa830e4b0c9d6adf6bea9	TCGA-AG-3909-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3909-01A	769880AE-34D9-405E-8EA7-33BA47CF2DD2	Primary Tumor	Illumina HiSeq	f11e5abe-82c7-4b53-bc65-7bde2dbc2bb1	Colorectal	69.0	12A43BEB-EDB6-4ABC-8322-CA8246D64B3F	F168205F-B2ED-4563-A211-DA59223830AB	TCGA-AG-3909-01A-01D-1115-02	HG18	TCGA-AG-3909	TCGA-READ		s1987	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	True	READ	C1	GI.CIN	0.081166317	0.44	0.0	16.96628451	0.1611	0.077	-0.4147	0.3462	-0.9587	-0.0405	30.0	25.0	0.543188308	2.4103981180000003	131.0	0.457828859	16.0	12.0							0.652135798	-1365.976745	-547.4250194	1593.212357	0.0	608.0	0.0	608.0	5.907455651164566	5.021826913921245	-0.25341317644444605	4.447053317890954	5.44355254290119	2.2530885290413396	-1.460402333273612	0.4217256289799449	2.506501705485786	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bead	58cfa830e4b0c9d6adf6bead	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	510.89	1.9	0.15	58cfa830e4b0c9d6adf6bead	TCGA-AG-3901-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3901-01A	1586CB0A-081A-4364-9470-46F9D0F0167D	Primary Tumor	Illumina HiSeq	c8ff4c94-25ea-4468-8ae0-06cb92ffa025	Colorectal	67.0	93B755E6-5D6E-4542-8BAE-2121F44F590C	F5D4395A-5E00-4616-A402-CDCAD8702E1B	TCGA-AG-3901-01A-01D-1115-02	HG18	TCGA-AG-3901	TCGA-READ		s2148	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Mucinous Adenocarcinoma	Stage IIIB	1115-02	True	READ	C1	GI.CIN	0.24371406199999998	0.56	0.04	13.32631333	0.47200000000000003	0.213	0.5434	0.6764	-0.1118	0.5886	29.0	34.0			57.0	0.102987179	2.0	5.0							0.9081042559999999	-640.2876447000001	182.4189459	-575.8737787	0.0	761.0	0.0	761.0	6.254941552573401	5.192638328829865	-1.4141711910481087	4.699570861409576	5.576055299716267	1.4025021713467443	-1.5553706911638248	0.3834169708864019	2.816673362394853	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bec0	58cfa830e4b0c9d6adf6bec0	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted.bam	73.2	1.9	0.15	58cfa830e4b0c9d6adf6bec0	TCGA-AR-A0TU-01A-31D-A106_130719_SN1120_0270_AC2CVRACXX_s_5_rg.sorted.bam	Alive	FEMALE			Breast Invasive Carcinoma	Aligned reads	TCGA-AR-A0TU-01A	DFE6DB17-CF45-488E-BD3C-B8433D7343CA	Primary Tumor	Illumina HiSeq	fb34c291-904a-4613-80cd-9788ff446157	Breast	35.0	1E629A73-68CD-449D-A1C0-B856BE4143E6	E00819A1-4A65-4289-9DDE-0800FC6C69F6	TCGA-AR-A0TU-01A-31D-A106-02	HG19_Broad_variant	TCGA-AR-A0TU	TCGA-BRCA		s6630	Harvard Medical School	Mayo	None	NO	T2	N0	Infiltrating Ductal Carcinoma	Stage IIA	A106-02	False	BRCA	C2	BRCA.Basal	0.246029035			6.1658864179999995	1.4047	0.4095	0.3189	0.4111	1.1035	-0.4503	25.0	34.0	0.722646442	1.759486989					0.823042045	1.4746933780000002	6.0	3.340656682	35.0	0.939614525	2.554081988	-362.6219135	1995.743352	-3296.2924359999997	0.0	709.0	0.0	709.0	8.301521654940728	6.799655973526075	0.29693800668648096	6.050229856334234	6.59201660874783	1.4041501871098871	-2.251291798606495	-0.2076393647782444	1.1072121804234063	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bec5	58cfa830e4b0c9d6adf6bec5	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	237.12	1.85	0.15	58cfa830e4b0c9d6adf6bec5	TCGA-AG-A032-01A-01D-A077-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A032-01A	0BB786EE-07CF-4853-9B49-EC95CD14E282	Primary Tumor	Illumina HiSeq	16a2716c-9563-4403-9a4b-8d4856022741	Colorectal	68.0	AE3C8931-C06F-466A-B6BF-440007E13387	AF7D94D6-C414-4812-A329-8856C086087E	TCGA-AG-A032-01A-01D-A077-02	HG18	TCGA-AG-A032	TCGA-READ		s2175	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A077-02	True	READ	C1		0.072361592			18.9495052	0.6692	0.174	-0.8102	0.0028	-0.4896	-0.0127	36.0	2.0	0.6996234859999999	2.4653399030000003	129.0	0.92073294	19.0	13.0							1.092164521	-1574.3863210000002	288.6084835	-608.016343	0.0	1157.0	1.0	792.0	7.570052133988066	5.640057007713855	-0.8023841991203053	7.015374627693226	5.9819493118044065	0.8750311963274489	-0.5546775062948406	0.3418923040905515	1.6774153954477542	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bec7	58cfa830e4b0c9d6adf6bec7	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.bam	83.32	2.09	0.15	58cfa830e4b0c9d6adf6bec7	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LJ-01A	B4A520AE-F259-48C8-823E-C10B9B8A133A	Primary Tumor	Illumina HiSeq	c3705d55-9194-4d83-9162-41aae551e016	Uterus	42.0	BE3ED392-4D9F-4EAF-8A56-D251846DF4DA	2A88E054-E64F-4C5F-97F0-53F95D64FC04	TCGA-AP-A0LJ-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LJ	TCGA-UCEC		s4996	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.CN_LOW	0.209274364	0.39	0.02	24.15658012	-0.4587	-0.08800000000000001	-0.2316	0.21100000000000002	-0.18	-0.0791	12.0	26.0	0.34863861700000004	1.074969069	81.0	0.046862077	2.0	0.0							2.536446741	-431.33559	-1401.252785	-804.8210573	0.0	1421.0	0.0	1421.0	7.110139381756317	7.0921260168210285	-0.39018535767742935	6.537620188984987	6.7667036163864	1.6981194056308344	-0.5725191927713302	-0.3254224004346278	2.0883047633082636	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bec9	58cfa830e4b0c9d6adf6bec9	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.bam	109.58	1.91	0.16	58cfa830e4b0c9d6adf6bec9	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LP-01A	EFAE3940-D3CC-4988-BDB4-FA05D977AFF5	Primary Tumor	Illumina HiSeq	369f32c0-ebb9-490e-baa4-0735e0efa092	Uterus	76.0	D67450C1-8848-4B28-9C16-83AA7132E8C8	C7A70C11-A05E-473D-929E-59A260FFBD97	TCGA-AP-A0LP-01A-12D-A101-02	HG19_Broad_variant	TCGA-AP-A0LP	TCGA-UCEC		s5202	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.MSI	0.106223321	0.19	0.0	9.414800176	-0.0138	0.035	0.0388	0.1119	0.4161	-0.318	117.0		2.28887839	8.35291984	69.0	2.59e-05	0.0	0.0							3.110740171	-1901.3367239999998	-1072.474661	-1269.463368	0.0	1875.0	0.0	1875.0	6.55208512108209	7.220081182346678	-0.21644999446039936	5.935898981658273	6.578227296174283	3.57876510946957	-0.6161861394238168	-0.6418538861723944	3.7952151039299693	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bed5	58cfa830e4b0c9d6adf6bed5	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina.bam	133.0	1.9	0.14	58cfa830e4b0c9d6adf6bed5	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina.bam	Alive	FEMALE	ASIAN		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4756-01A	9ECDDE9C-2179-4830-BD10-C4FA40F26066	Primary Tumor	Illumina HiSeq	21f5c572-343f-4923-af48-99ee2a4ccbdf	Kidney	62.0	98D425BE-4D70-4260-8C4F-B0EB89E0E4A6	DB4592FB-13C2-4D61-9DC3-A5D43DEF8D4B	TCGA-BP-4756-01A-01D-2097-10	GRCh37-lite	TCGA-BP-4756	TCGA-KIRC		s9164	Baylor College of Medicine	MSKCC	None	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2097-10	False	KIRC	C3	KIRC.1	0.09510768800000001				-1.3715	-0.3105	0.3629	0.4091	-0.23600000000000002	-0.6222					101.0	0.328981946	9.0	2.0	0.88624812	0.9736430759999999	3.0	3.340439622	32.0	0.9638471359999999	2.191520408	-753.6733227999999	-2046.4290239999998	3893.019923	0.0	374.0	0.0	374.0	5.497782790507669	1.9539403051294837	0.3125692220888092	4.7799429973573515	3.188354134956655	3.29796113658541	-0.7178397931503171	1.2344138298271714	2.9853919144966006	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bee2	58cfa830e4b0c9d6adf6bee2	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted.bam	90.97	2.13	0.17	58cfa830e4b0c9d6adf6bee2	TCGA-AP-A0LO-01A-11D-A043_120318_SN590_0147_BD0U3RACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LO-01A	A081DA6F-51F3-4555-A6B8-736F8C6CDA39	Primary Tumor	Illumina HiSeq	4726575a-1ad0-471a-8a8e-26eb668681f2	Uterus	45.0	9846D8F3-5B22-48E9-B972-A0FE9F509FB4	A91FCC79-7AE0-4BD1-BCAE-543E49E2D62E	TCGA-AP-A0LO-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LO	TCGA-UCEC	1016.0	s4243	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.12904304800000002	0.4	0.24	2.326440467	0.3136	0.266	-0.8159	-0.5296	-1.196	-0.33399999999999996	22.0		0.236823924	0.799280742	62.0	0.738030608	11.0	1.0							1.617192314	-1509.9898699999999	89.43753034	658.1189293	1.0	1016.0	1.0	516.0	7.1521039823666115	7.680221828746338	-0.2941561107193228	6.600035400066572	6.763931096872183	3.920085652851497	-0.55206858230004	-0.9162907318741547	4.21424176357082	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bee6	58cfa830e4b0c9d6adf6bee6	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.bam	117.75	2.28	0.16	58cfa830e4b0c9d6adf6bee6	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0IU-01A	7E64EA6C-A3DB-48EB-91BE-131361510A92	Primary Tumor	Illumina HiSeq	927c6e80-e2e3-4198-98a4-77a79159fb8a	Uterus	79.0	DC4B3695-CE62-48D5-9F1D-7DD70D049C97	24746F36-88BC-44B0-955A-55A2CC98E17C	TCGA-AX-A0IU-01A-11D-A101-02	HG19_Broad_variant	TCGA-AX-A0IU	TCGA-UCEC		s4999	Harvard Medical School	Gynecologic Oncology Group	None	NO			Serous endometrial adenocarcinoma		A101-02	True	UCEC	C4	UCEC.CN_HIGH	0.080913256	0.21	0.06	3.3678039089999996	0.5502	0.049	-1.2027	-0.2842	0.5097	-0.2693	20.0	7.0	0.416791785	1.305947594	336.0	0.222581009	9.0	24.0							2.7475192410000004	-954.1049666000001	-326.7745966	-3021.829863	0.0	1087.0	0.0	1087.0	6.281189985011348	6.651115773239744	0.11036751639691844	5.202986567974445	5.928981055806547	2.9916542020706123	-1.0782034170369026	-0.7221347174331973	2.881286685673694	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6beea	58cfa830e4b0c9d6adf6beea	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.bam	106.84	1.77	0.15	58cfa830e4b0c9d6adf6beea	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LL-01A	D17668C4-5D66-4E16-8B70-B54616581AAE	Primary Tumor	Illumina HiSeq	0ea2fbb0-cc11-44d9-9706-2523b9d268be	Uterus	56.0	488A7462-8348-422C-91D3-7D9F0C39D25E	0D29C555-7C7C-4BBB-A4C6-E554CC758CA7	TCGA-AP-A0LL-01A-12D-A101-02	HG19_Broad_variant	TCGA-AP-A0LL	TCGA-UCEC		s4595	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.CN_LOW	0.0307981	0.06	0.02	2.834476004	-0.5135	-0.18600000000000003	-0.6288	-0.0071	-0.6733	-0.129	18.0	7.0	0.25674124800000003	1.255179434	74.0	0.034401083	1.0	1.0							2.7695412910000003	-1632.699827	-1273.1567890000001	2125.34047	0.0	2554.0	1.0	790.0	6.697587521572453	7.600044949127954	-0.2565036529868774	6.214735749848869	6.6555833402871025	1.6169379475906474	-0.4828517717235843	-0.9444616088408513	1.8734416005775247	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bef0	58cfa830e4b0c9d6adf6bef0	TCGA-BP-4327-01A-01D-1995-10_Illumina.filtered.	WGS	TCGA-BP-4327-01A-01D-1995-10_Illumina	TCGA-BP-4327-01A-01D-1995-10_Illumina.bam	119.0	1.9	0.14	58cfa830e4b0c9d6adf6bef0	TCGA-BP-4327-01A-01D-1995-10_Illumina.bam	Dead	FEMALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4327-01A	9B84D013-713B-4571-888C-12863FDD4A52	Primary Tumor	Illumina HiSeq	02674510-9972-4120-8940-18449f4623e8	Kidney	75.0	45CC1D31-9B81-4268-B83A-5D4C740BD2B6	85448D11-9F84-44B7-8AE3-A115F24BDB76	TCGA-BP-4327-01A-01D-1995-10	GRCh37-lite	TCGA-BP-4327	TCGA-KIRC	109.0	s9565	Baylor College of Medicine	MSKCC	None	NO	T2	N0	Kidney Clear Cell Renal Carcinoma	Stage II	1995-10	False	KIRC	C3	KIRC.2	0.113321639				-1.5557	-0.268	0.3237	0.2879	0.1435	0.1264					73.0	0.29177806100000003	4.0	4.0	0.829584813	1.335165249	5.0	2.7759755530000003	17.0	0.979797571	1.213678098	350.4260198	-1771.9378609999999	2591.3309289999997	1.0	109.0	0.0	109.0	8.859333855911183	-0.5829134414146759	0.23136189019681908	5.433443861658656	2.378434405277484	3.0795217992836745	-3.4258899942525267	2.96134784669216	2.8481599090868555	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bef8	58cfa830e4b0c9d6adf6bef8	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.bam	59.66	1.88	0.17	58cfa830e4b0c9d6adf6bef8	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28W-01A	A6D37F61-BECA-46EA-A59A-62257475AC77	Primary Tumor	Illumina HiSeq	32effbdc-7d3b-4ad8-9245-1a253cbe1ff3	Thyroid	32.0	32AEF736-82A4-4813-A272-86EF160E7D56	229AD821-4BB0-4046-B5E6-6193005D3C8A	TCGA-BJ-A28W-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28W	TCGA-THCA		s12507	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C2	THCA.	0.620685803				-0.3754	-0.016	1.3434	3.705	0.2004	-0.5439					55.0	2.18e-05			0.9680495929999999	3.153999029	26.0	4.85149484	130.0	0.996704777	1.61696903	-0.993661027	-941.9068273	1159.888053	0.0	344.0	0.0	344.0	7.265954061289213	7.956520595255665	0.6227451395208221	6.7353258102270415	6.6019749324503545	1.2488501376239272	-0.5306282510621707	-1.3545456628053105	0.626104998103105	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf00	58cfa830e4b0c9d6adf6bf00	TCGA-BP-5168-01A-01D-2099-10_Illumina.filtered.	WGS	TCGA-BP-5168-01A-01D-2099-10_Illumina	TCGA-BP-5168-01A-01D-2099-10_Illumina.bam	129.4	1.9	0.15	58cfa830e4b0c9d6adf6bf00	TCGA-BP-5168-01A-01D-2099-10_Illumina.bam	Dead	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-5168-01A	781ACAFA-A58B-4180-BBCA-C5B675D51B17	Primary Tumor	Illumina HiSeq	a353f21b-796e-4d66-a273-83755c9b0525	Kidney	75.0	233C6672-A850-48E0-99FD-024CF1A76B4C	D991F23A-DC1B-427A-B798-BD4187D3AA02	TCGA-BP-5168-01A-01D-2099-10	GRCh37-lite	TCGA-BP-5168	TCGA-KIRC	1463.0	s8837	Baylor College of Medicine	MSKCC	None	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2099-10	False	KIRC	C3	KIRC.1	0.119398155				-1.4226	-0.262	0.2711	0.23199999999999998	0.4094	0.0341	33.0	122.0	1.015461165	2.470040671	54.0	0.09893382	3.0	2.0				3.260918854	28.0	0.9786070590000001	1.2626867309999998	180.6152017	-1153.277531	3244.770802	1.0	1463.0	0.0	1463.0	8.579312121035041	0.9653880685233478	0.0801253994565011	5.4365976571324035	3.777102432035206	2.7851700165013638	-3.142714463902637	2.811714363511858	2.7050446170448628	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf02	58cfa830e4b0c9d6adf6bf02	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina.bam	68.77	1.9	0.14	58cfa830e4b0c9d6adf6bf02	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4968-01A	1E417B93-837D-4110-9090-239EB82C3E20	Primary Tumor	Illumina HiSeq	e2ce6973-54d1-4e7b-88f1-cb684419ff11	Kidney	40.0	8CD2BBCD-3CE9-4B57-99DA-895B82300AF8	AAD8C8D6-D828-4AAC-9CFB-CEE893E36850	TCGA-BP-4968-01A-01D-2100-10	GRCh37-lite	TCGA-BP-4968	TCGA-KIRC		s9162	Baylor College of Medicine	MSKCC	None	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2100-10	False	KIRC	C3	KIRC.4	0.22849461199999999	0.36	0.23		-0.8249	-0.0585	0.8049	1.3419	0.4518	0.1935	18.0	3.0	0.373889641	1.06414744	77.0	0.270653949	0.0	5.0				3.420374752	69.0	0.8078150009999999	1.816854978	680.2056943	-987.6559996	193.3231144	0.0	1746.0	0.0	1746.0	8.866762953224923	0.3454485316185245	0.8723065188468163	5.445762944266587	3.454871018355865	3.356170959056373	-3.4210000089583352	3.1094224867373406	2.4838644402095564	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf14	58cfa830e4b0c9d6adf6bf14	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.bam	265.9	1.9	0.13	58cfa830e4b0c9d6adf6bf14	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4267-01A	0D0F0200-25B8-483B-B04A-82A7833B4D30	Primary Tumor	Illumina HiSeq	cd48e485-3a3f-4eec-92e7-f1c52c0866f1	Stomach	51.0	32D28ED3-2E33-4D83-8DE6-82E156B33211	F0DB5AF5-091F-4CDC-9917-BEFD658BF454	TCGA-BR-4267-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4267	TCGA-STAD		s15044	Harvard Medical School	Asterand	None	NO	T2a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1128-02	True	STAD	C1	GI.CIN	0.131743479	0.25	0.11		0.2313	0.122	0.2592	0.3188	0.0	0.1069			0.65404763	2.1999783930000003	188.0	0.314047427	5.0	53.0	0.867851921	4.30092403	142.0	4.390203436	90.0	0.9756420290000001	0.47408961	200.51691830000001	255.40767689999998	1270.458936	1.0	188.0	0.0	188.0	6.9825209295548305	4.524533961800474	-0.3549795997794174	6.9825209295548305	8.568116720479319	0.6063834815901574	0.0	4.043582758678845	0.9613630813695748	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf16	58cfa830e4b0c9d6adf6bf16	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.bam	106.9	1.9	0.16	58cfa830e4b0c9d6adf6bf16	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4257-01A	DA112431-5579-4FD1-A230-9144B359B0E9	Primary Tumor	Illumina HiSeq	5e38d8b4-97fb-407a-ab06-2f002456472d	Stomach	79.0	97B44B05-97EB-486C-94DB-42838831DE0B	465E5E4D-A801-4BBC-9E1C-004C7718571F	TCGA-BR-4257-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4257	TCGA-STAD		s15048	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True	STAD	C4	GI.HM-indel	0.234499542	0.46	0.08		0.8403	0.265	0.8042	0.2381	0.111	0.4142			11.88986578	29.01505708	169.0	0.858750955	20.0	2.0	0.9021383690000001	2.903871386	25.0	4.334255996	152.0	0.862730707	0.7464722509999999	-494.1063647	752.6595844999999	1572.1452060000001	1.0	294.0	0.0	294.0	8.966356154790121	7.212171550425083	0.07469371726485385	6.663771061796076	6.806706442316918	0.9708065992022686	-2.3025850929940455	-0.40546510810816416	0.8961128819374148	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf19	58cfa830e4b0c9d6adf6bf19	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina.bam	62.42		0.07	58cfa830e4b0c9d6adf6bf19	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Colon Adenocarcinoma	Aligned reads	TCGA-AY-A54L-01A	D8E9EA52-FF28-4626-BAA3-71350FD53DDF	Primary Tumor	Illumina HiSeq	709d8bea-f505-4558-b12a-7bd4322e75ea	Colorectal	74.0	52EFBEB4-7B23-4C49-92F9-931A3EB99055	080ECC31-756A-4A1B-A51E-D632AC8219F7	TCGA-AY-A54L-01A-11D-A28G-10	GRCh37-lite	TCGA-AY-A54L	TCGA-COAD		s13542	Baylor College of Medicine	UNC	United States	NO	T2	N0	Colon Adenocarcinoma	Stage I	A28G-10	True	COAD	C1	GI.CIN	0.12693058599999998	0.56	0.49	7.774961837	0.8727	0.433	-1.6172	-1.1304	-1.1903	-0.5731	68.0	30.0	1.011558692	3.4756119169999997	70.0	0.692071697	23.0	24.0	0.9999585999999999	0.6931184840000001	2.0	0.693147181	2.0	1.0	3.663768449	-805.5525665	398.5673332	-1185.241019	0.0	525.0	1.0	396.0	6.42722982227682	4.049966602060097	-1.9529869341692216	5.867614034341397	6.523785253127275	-0.4124514813961444	-0.5596157879354227	2.4738186510671776	1.5405354527730772	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf21	58cfa830e4b0c9d6adf6bf21	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.bam	7.9	1.9	0.16	58cfa830e4b0c9d6adf6bf21	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4279-01A	117EB38B-0C62-4336-A866-FA5BD013256A	Primary Tumor	Illumina HiSeq	0fa8a7d6-6636-4135-82f6-21c9df279b16	Stomach	43.0	84AD647D-76B8-4EDA-8603-40220089BE34	01DC88B7-45FC-464C-A613-9793CD0C068B	TCGA-BR-4279-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4279	TCGA-STAD		s14814	Harvard Medical School	Asterand	Russia	NO	T2a	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1128-02	True	STAD	C2	GI.CIN	0.240371117	0.66	0.03		-0.0561	0.06	0.9621	1.3563	0.7199	0.3548			0.691316405	1.08206046	72.0	0.194011452	5.0	14.0	0.9317356170000001	4.271977504	98.0	2.998822118	22.0	0.9701652959999999	0.803881022	561.6231215	238.18675180000002	-2681.2273210000003	1.0	291.0	0.0	291.0	8.188633567345379	8.368958312018282	-0.23374229653948053	6.753549042056056	7.147285930592946	1.2517438601269113	-1.4350845252893227	-1.221672381425337	1.4854861566663917	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf30	58cfa830e4b0c9d6adf6bf30	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.bam	266.9	1.9	0.15	58cfa830e4b0c9d6adf6bf30	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4191-01A	74F859CF-6DF5-4E96-AE6B-CFAAB691D5FD	Primary Tumor	Illumina HiSeq	d71fa3ea-a7fb-40af-a7b9-64ceca39e135	Stomach	72.0	E5A1A598-5896-46F9-8DCA-BA19AC138D14	125C563B-A1CE-4FFC-8D8D-19C7CA2E1049	TCGA-BR-4191-01A-02D-1128-02	HG19_Broad_variant	TCGA-BR-4191	TCGA-STAD		s14608	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True	STAD	C2	GI.CIN	0.26734475	0.49	0.19		0.4411	0.184	1.2678	1.6027	0.6105	0.2261			1.692164553	5.651191056	319.0	0.44107908100000004	4.0	66.0	0.612564648	2.9576543039999996	125.0	3.540255555	39.0	0.9663425640000001	1.121097636	474.4271181	382.8697204	-718.0618772999999	1.0	558.0	0.0	558.0	6.789604988395917	6.202535517187922	0.11583181552512167	5.484656266729979	7.778071877946341	1.3862943611198904	-1.3049487216659386	1.5755363607584192	1.2704625455947687	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf3c	58cfa830e4b0c9d6adf6bf3c	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.bam	67.9	1.9	0.15	58cfa830e4b0c9d6adf6bf3c	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4256-01A	7B0D69CA-13A6-46E0-839C-E433BBEDE3AD	Primary Tumor	Illumina HiSeq	6e990147-2463-4d38-a785-6c76ae1dbc25	Stomach	80.0	61C7AAB0-51D9-4706-A37C-D5058007DAF1	30AF7950-11F7-43BF-9A1D-98A57F416397	TCGA-BR-4256-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4256	TCGA-STAD		s14396	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True	STAD	C2	GI.HM-indel	0.42206694200000006	0.65	0.63		0.5927	0.22399999999999998	1.2664	1.1592	1.7793	0.4906			9.724516057999999	26.94315458	91.0	0.049847394	4.0	3.0	0.81753726	4.398266543	217.0	5.09476292	264.0	0.913703268	1.041331683	491.4392056	665.8963431	-95.54220466	1.0	284.0	0.0	284.0	7.461257177028564	7.5572601335987795	0.2880666138908591	6.208494208533196	7.7620545462447925	1.7566283777063973	-1.252762968495368	0.20479441264601306	1.4685617638155382	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf3d	58cfa830e4b0c9d6adf6bf3d	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.bam	138.9	1.9	0.15	58cfa830e4b0c9d6adf6bf3d	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4187-01A	12071070-D06B-4C7B-A7B1-77C84963ABE6	Primary Tumor	Illumina HiSeq	1da3a244-39ae-4b4d-baed-e4d9b312f777	Stomach	56.0	144FB4ED-63BB-4908-B678-6026E09566A3	57CF858D-FF3F-4528-96DB-5A820C9B78DE	TCGA-BR-4187-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4187	TCGA-STAD		s15046	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True	STAD	C2	GI.GS	0.43923428	0.7	0.22		-0.0943	-0.006	1.1346	1.2958	1.5778	0.6093			0.298779611	0.7170710659999999	66.0	0.004903066	4.0	0.0	0.7927208990000001	2.245947429	17.0	4.670585234	131.0	0.9580299879999999	2.2592292869999997	166.27277769999998	541.212935	-1487.747203	1.0	141.0	0.0	141.0	7.123715194924921	8.056668306125045	-0.12018733925052894	6.3069540583978	7.272549347359373	1.8816567312696377	-0.8167611365271221	-0.7841189587656721	2.0018440705201668	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf40	58cfa830e4b0c9d6adf6bf40	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.bam	100.97	1.91	0.17	58cfa830e4b0c9d6adf6bf40	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A1CJ-01A	ABAF757B-F79F-40BD-96E3-E2C0F63061F0	Primary Tumor	Illumina HiSeq	f42806a5-e473-4ae8-bb1a-aa11fe2dde53	Uterus	59.0	72D06DDF-9FB2-4577-BFDB-B0E463105B4A	A4EE1BB7-59FF-4034-ABA1-9AF4F62B42B0	TCGA-AX-A1CJ-01A-11D-A133-02	HG19_Broad_variant	TCGA-AX-A1CJ	TCGA-UCEC		s5388	Harvard Medical School	Gynecologic Oncology Group	None	NO			Endometrioid endometrial adenocarcinoma		A133-02	False	UCEC	C2	UCEC.CN_LOW	0.172377804	0.27	0.01	5.23783572	-0.0155	0.036000000000000004	0.0386	0.8479	-0.2263	-0.4439	13.0		0.52382935	1.0476587	114.0	0.08111581400000001	3.0	1.0							2.984653867	-641.8685085	-179.73680369999997	-789.4798668	0.0	2233.0	0.0	2233.0	4.394646350547741	6.7626289741078285	0.010396587376933275	3.1579867896189517	4.688637037195557	3.25627301406364	-1.2366595609287891	-2.0739919369122717	3.2458764266867064	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf44	58cfa830e4b0c9d6adf6bf44	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.bam	115.02	1.84	0.16	58cfa830e4b0c9d6adf6bf44	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A2HD-01A	A8DEF1A0-A136-47F4-9AD9-60EBCF9B726B	Primary Tumor	Illumina HiSeq	b9d10df5-eb11-4976-b3dd-10e970fc715d	Uterus	69.0	5A2EDE97-0CF7-44D7-A789-92EE9BDA3D6C	C24E7F27-2155-4727-B6D8-8E5BC16D9197	TCGA-AX-A2HD-01A-21D-A17E-02	HG19_Broad_variant	TCGA-AX-A2HD	TCGA-UCEC		s4428	Harvard Medical School	Gynecologic Oncology Group	United States	NO			Endometrioid endometrial adenocarcinoma		A17E-02	True	UCEC	C1	UCEC.POLE	0.11195608	0.13	0.01		0.7555	0.126	-0.5729	-0.3078	-0.3808	-0.0276	4043.0	1835.0	64.12421966	164.39742230000002	99.0	0.029972197000000003	0.0	7.0		0.0	1.0				2.698888119	-1405.109501	829.990518	439.1317302	0.0	1414.0	0.0	1414.0	5.57916873030469	8.605997404758346	0.21228043905683858	4.322552192493332	6.692348117921255	2.0144177014354323	-1.2566165378113574	-1.9136492868370918	1.802137262378594	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf52	58cfa830e4b0c9d6adf6bf52	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted.bam	252.9	1.9	0.14	58cfa830e4b0c9d6adf6bf52	TCGA-BR-4280-01A-01D-1128_121127_SN208_0440_AC1F4LACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4280-01A	E0916597-E489-45EF-A8F7-653A3C6591EF	Primary Tumor	Illumina HiSeq	418e722c-d444-43fe-87b1-6d8ce0ce5359	Stomach	78.0	797D2D3A-F01C-4985-B27C-4E4C2838D34D	7F073E1B-E936-44FF-B3C0-8F4C26ECC3A9	TCGA-BR-4280-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4280	TCGA-STAD		s14880	Harvard Medical School	Asterand	Russia	NO	T2b	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage III	1128-02	True	STAD	C2	GI.HM-indel	0.107561025	0.24	0.02		0.71	0.259	0.2414	0.6074	-0.0506	-0.27399999999999997			5.515588298	19.89763305	77.0	0.05854168	2.0	0.0	0.7354327709999999	4.005709157	232.0	3.9849217169999998	132.0	0.8161137359999999	0.9888676270000001	-70.23232587	746.3912173	-34.97269652	1.0	201.0	0.0	201.0	7.5508114496396015	7.274770129747876	-0.04154019575995427	6.894031913250531	5.888475768627985	2.1104296271410714	-0.6567795363890707	-1.3862943611198908	2.151969822901026	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf60	58cfa830e4b0c9d6adf6bf60	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.bam	197.2	1.9	0.16	58cfa830e4b0c9d6adf6bf60	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4357-01A	BEC83DFF-2BBA-4467-92AA-5DC3DB9E0EAF	Primary Tumor	Illumina HiSeq	4bc9f55b-1edb-49c9-be1a-1d00a108b99b	Stomach	58.0	81C87C27-47C7-4DC7-BF92-E0037433DF30	93F60FA6-0D34-441E-8F61-80306E10D046	TCGA-BR-4357-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4357	TCGA-STAD		s15301	Harvard Medical School	Asterand	Russia	NO	T3	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True	STAD	C2	GI.CIN	0.28910268699999997	0.56	0.13		1.0819	0.249	1.0296	1.2819	0.87	0.2841			1.7191263719999998	5.974668701000001	1032.0	0.8756358909999999	19.0	45.0	0.693673867	3.956564846	300.0	3.0897556539999997	24.0	0.9722162740000001		647.066367	544.0487472	512.7046729	0.0	0.0	0.0	0.0	9.156587915976937	6.891533505496776	-0.08247714508254622	7.16415775128673	6.139545824913896	2.0413976102499887	-1.9924301646902063	-0.7519876805828791	2.123874755332535	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf6a	58cfa830e4b0c9d6adf6bf6a	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted.bam	409.4	1.9	0.16	58cfa830e4b0c9d6adf6bf6a	TCGA-BR-6452-01A-12D-1798_130115_SN1222_0169_BD1K2PACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6452-01A	27988B3E-CDE1-4F4B-82A1-6D8AD08DB8E9	Primary Tumor	Illumina HiSeq	cfd9aa7a-7f3d-4b70-9359-2c93f0238361	Stomach	78.0	76144F2F-2498-430D-B33C-F000394C427E	460DE564-5AAB-46B0-8174-36AF18D2DF4C	TCGA-BR-6452-01A-12D-1798-02	HG19_Broad_variant	TCGA-BR-6452	TCGA-STAD		s14744	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True	STAD	C1	GI.HM-indel	0.240214782	0.53	0.12	17.57870195	0.8142	0.19899999999999998	0.3409	0.8682	-0.0851	0.28600000000000003			45.55028334	136.38805990000003	51.0	0.050651244000000005	2.0	0.0	0.6849360409999999	4.023951798	356.0	3.5846819180000002	144.0	0.721291063	2.298592501	-689.4325947000001	807.3589946000001	-117.00123959999999	0.0	1055.0	0.0	1055.0	7.786274913169293	7.420151097917644	-0.46416384347593953	5.84036476411398	6.475689489076793	1.7995071560188807	-1.9459101490553132	-0.9444616088408513	2.26367099949482	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf72	58cfa830e4b0c9d6adf6bf72	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.bam	264.2	1.9	0.15	58cfa830e4b0c9d6adf6bf72	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4363-01A	66BCA2F8-F269-454D-ABE2-CE51A0704645	Primary Tumor	Illumina HiSeq	ab5af808-6239-48fa-ba17-b80aa3fc5e14	Stomach	60.0	06EC6231-EE0E-4C15-AF9F-5B9E5BF557B8	D62228AE-B0AB-4C31-9FD7-F9D48B140CDC	TCGA-BR-4363-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4363	TCGA-STAD		s14528	Harvard Medical School	Asterand	Russia	NO	T3	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True	STAD	C2	GI.HM-indel	0.200073652	0.37	0.01		0.8644	0.18	0.7488	0.9848	0.47100000000000003	0.358			4.4749399489999995	14.94515201	175.0	0.09018887699999999	2.0	5.0	0.90488552	5.007084026	253.0	3.4698571410000003	36.0	0.968282072		-679.5446234	1242.129007	-2332.696856	0.0	0.0	0.0	0.0	8.152198015861787	5.607453688393119	0.029531781197345897	5.849612922867742	7.522827113588351	2.2286849994399707	-2.3025850929940455	1.9153734251952317	2.1991532182426248	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf74	58cfa830e4b0c9d6adf6bf74	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted.bam	84.77	1.86	0.16	58cfa830e4b0c9d6adf6bf74	TCGA-AP-A0LD-01A-11D-A043_120330_SN1120_0128_AC0L52ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LD-01A	1200C8B7-A058-4C01-BBE2-04EC09A65245	Primary Tumor	Illumina HiSeq	aa90984a-1483-43a2-8b20-f1654e3f601e	Uterus	63.0	649DADDA-5823-4B0D-B5A2-49F501ADC029	3D587F43-D9C5-4E3B-B245-60BB0AE92808	TCGA-AP-A0LD-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LD	TCGA-UCEC		s5199	Harvard Medical School	MSKCC	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.MSI	0.07119687	0.2	0.03	6.02712248	0.6286	0.152	-1.3244	-0.9166	0.5964	-0.0495	176.0	594.0	4.288222192	12.51697289	38.0	0.130012084	5.0	2.0							2.875513958	-1339.176737	452.51787249999995	-1216.62567	0.0	3589.0	0.0	3589.0	5.139204394890964	7.438710274043293	-1.0897635839509348	5.080935486766988	6.417059026511312	-0.7759754711116351	-0.058268908123976004	-1.021651247531981	0.31378811283929964	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf7e	58cfa830e4b0c9d6adf6bf7e	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.bam	90.33	1.92	0.15	58cfa830e4b0c9d6adf6bf7e	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JV-01A	233E947A-D5E2-48E5-A8CE-5DA1ABB20681	Primary Tumor	Illumina HiSeq	2c99d5d5-1f92-452e-9370-59486a6d7bce	Uterus	63.0	42199E5A-9F4F-4445-9E6E-114D47BA67FA	7132C5C6-9DC5-42A8-863F-D82280266427	TCGA-B5-A0JV-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JV	TCGA-UCEC		s4783	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.MSI	0.069220966	0.15	0.01	11.29573551	0.6032	0.212	-0.9676	-0.6899	0.2586	-0.5503	174.0	743.0	2.730732118	8.437962245	172.0	0.035947175	1.0	2.0							1.747964104	-953.4197849	-253.3427955	1090.632869	0.0	2616.0	1.0	698.0	6.912168602848917	7.551291958988748	0.23562013851831654	6.532678981144013	7.020663707926578	2.0230096080752533	-0.3794896217049035	-0.5306282510621703	1.7873894695569368	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf80	58cfa830e4b0c9d6adf6bf80	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.bam	324.7	1.9	0.15	58cfa830e4b0c9d6adf6bf80	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6455-01A	75A29059-4705-4A55-BC3D-F5923B24B358	Primary Tumor	Illumina HiSeq	719ee3a5-cfe9-48cb-9e48-e11e49bd217c	Stomach	59.0	59BD0192-A50B-4672-A17F-4DF138F58988	6C038E7C-8B03-4AB6-A31A-00C3C6CE6204	TCGA-BR-6455-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6455	TCGA-STAD		s14470	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True	STAD	C1	GI.EBV	0.196753383	0.34	0.0	15.85250697	0.9551	0.3135	0.4286	1.1679	-0.0988	0.0972			1.100960098	2.028084391	75.0	0.11804980400000001	6.0	0.0	0.7294279220000001	3.711034821	162.0	4.295376223	139.0	0.870483111	2.6978569080000003	-642.3476883999999	1018.210641	-2450.565048	1.0	422.0	1.0	385.0	7.813187267521416	8.51271651938916	0.49665969995595904	5.561895468914921	7.596425787515004	2.0855248141113463	-2.251291798606495	-0.9162907318741551	1.5888651141553871	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf83	58cfa830e4b0c9d6adf6bf83	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.bam	93.7	1.9	0.15	58cfa830e4b0c9d6adf6bf83	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6453-01A	AE633E83-303F-4A90-AC3B-34458FD9BEEF	Primary Tumor	Illumina HiSeq	e92977c9-6880-4f84-842a-9152e558d0b1	Stomach	54.0	A8F3B148-5929-4025-81A1-6595D49F2279	EE3446DC-7278-47AF-8F65-F63A1D423644	TCGA-BR-6453-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6453	TCGA-STAD		s15305	Harvard Medical School	Asterand	Russia	NO	T2	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True	STAD	C2	GI.GS	0.568008509	0.81	0.08	25.76105777	0.131	0.0695	1.146	2.9802	0.0837	0.1698			1.5066073130000002	4.345982635	50.0	0.09672275300000001	4.0	3.0	0.82873913	4.524572147	235.0	5.801951814	434.0	0.955361315	1.522569199	588.1166622999999	-194.20330719999998	-535.0120747	0.0	485.0	0.0	485.0	8.460199469896118	7.878912912297132	0.9631429970789931	6.157614376902073	6.404511283666974	3.173508367976271	-2.3025850929940455	-1.474401628630158	2.2103653708972777	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf87	58cfa830e4b0c9d6adf6bf87	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.bam	45.84		0.15	58cfa830e4b0c9d6adf6bf87	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A3PR-01A	FD036EC5-3FFB-40B1-8002-943BE0E2532E	Primary Tumor	Illumina HiSeq	c8c8646f-54e4-4440-bf91-d2cd90083c44	Thyroid	69.0	E058A8E1-ED00-48A5-A46B-77538D7B73F1	57FD6BDA-C7B4-4B74-B21A-B7FF5D1C87EE	TCGA-BJ-A3PR-01A-11D-A221-26	HG19_Broad_variant	TCGA-BJ-A3PR	TCGA-THCA		s12358	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T1a	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True	THCA	C2	THCA.4	0.620774311	0.54	0.0		-0.1548	-0.076	1.2973	3.2449	0.4329	-0.0634	5.0		0.05814382	0.145359549	35.0	6.64e-05	0.0	0.0	0.8883753059999999	4.8349095	231.0	5.221741509	211.0	0.97568758	1.622303111	1004.923635	-662.6023018999999	-668.4881095	0.0	1107.0	0.0	1107.0	6.342601457133442	8.403884505909236	0.3627516812101407	6.312748493983761	7.650112703532856	1.622203637856305	-0.029852963149681333	-0.7537718023763804	1.2594519566461642	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf8f	58cfa830e4b0c9d6adf6bf8f	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted.bam	106.93	1.95	0.16	58cfa830e4b0c9d6adf6bf8f	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0113_AC0DKVACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K0-01A	29C8F468-5AC1-4D6C-8376-E36E6D246926	Primary Tumor	Illumina HiSeq	5de016ca-e694-4ebc-b06f-5d07f7523fda	Uterus	48.0	11C43948-E7C9-4436-A654-82FA8033B625	3296C785-7C20-487D-BAEC-C66022E77E53	TCGA-B5-A0K0-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K0	TCGA-UCEC		s5204	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.190545054			22.46429525	-0.1344	-0.054000000000000006	0.2164	0.2847	-0.1471	0.3718	9.0	0.0	0.14607725300000002	0.525878111	58.0	0.088807446	3.0	1.0							2.269278766	-791.8938086	-472.3800669	-1945.3798370000002	0.0	1478.0	0.0	1478.0	5.840515259092246	6.513344233594314	-0.7488803103501094	5.643804964846192	6.404144941629321	1.8934255332209804	-0.19671029424605457	-0.109199291964992	2.6423058435710898	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf95	58cfa830e4b0c9d6adf6bf95	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted.bam	29.7	1.9	0.13	58cfa830e4b0c9d6adf6bf95	TCGA-BR-6564-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6564-01A	AF1086CC-B330-4AD6-AE1C-3B5C7259949A	Primary Tumor	Illumina HiSeq	6ee5a220-be0b-4909-bd37-5a6d8c53177d	Stomach	46.0	B8355E52-D7A7-4711-BBA7-BC4D201741F2	62E2C436-03DA-4B32-B43A-DF7AC992DD7C	TCGA-BR-6564-01A-12D-1880-02	HG19_Broad_variant	TCGA-BR-6564	TCGA-STAD		s15051	Harvard Medical School	Asterand	Russia	NO	T3	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1880-02	True	STAD	C2	GI.CIN	0.274202253	0.78	0.14	12.61669024	-1.0592	-0.237	0.4319	1.2336	1.5673	0.5685			0.34231179100000003	0.798727513	84.0	0.290098573	8.0	21.0	0.969895556	1.7378195459999999	6.0	4.845365714	140.0	0.980517265	1.762194441	-249.8457508	-713.95088	-1297.425989	1.0	794.0	0.0	794.0	7.693253720606268	7.243512974665482	0.4861450399725593	5.496029143270049	6.327222242791326	3.5314697240286206	-2.197224577336219	-0.9162907318741551	3.045324684056061	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bf9f	58cfa830e4b0c9d6adf6bf9f	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.bam	306.4	1.9	0.15	58cfa830e4b0c9d6adf6bf9f	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6458-01A	E516880B-C4E5-43CD-A358-BE0DB88564D7	Primary Tumor	Illumina HiSeq	545acf44-8e16-46b9-b35a-c860c08b416b	Stomach	57.0	A30B45F5-C6E4-4975-A912-8313D93DFD27	2DD3E59B-4DBB-49B4-9DC4-A949FE48AA17	TCGA-BR-6458-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6458	TCGA-STAD		s14613	Harvard Medical School	Asterand	Ukraine	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True	STAD	C2	GI.CIN	0.287551892	0.55	0.16	9.686403627	0.6554	0.129	0.7929	1.1067	0.5419	0.4094			2.416486025	7.278572362999999	249.0	0.58492169	10.0	53.0	0.8027486859999999	4.774777275	383.0	5.3958935839999995	291.0	0.9510992640000001	4.459754351	-696.8968999	510.26480639999994	-832.6829815000001	1.0	588.0	1.0	574.0	8.28488275227721	7.818671594518837	-0.06653684973225926	6.675444839843111	7.348667965273101	2.2196825885742744	-1.6094379124341003	-0.47000362924573524	2.2862194383065337	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bfa4	58cfa830e4b0c9d6adf6bfa4	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.bam	77.4	1.9	0.15	58cfa830e4b0c9d6adf6bfa4	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6457-01A	05CE16D4-A999-491A-91AD-9449A57228FF	Primary Tumor	Illumina HiSeq	695f7145-7735-48f7-98e8-99b86bb936f4	Stomach	69.0	BADB9AE0-9C44-41D4-848B-EE03B6FCA503	85EEEBBE-BDBB-4FE7-8CCD-401E818EEB29	TCGA-BR-6457-01A-21D-1798-02	HG19_Broad_variant	TCGA-BR-6457	TCGA-STAD		s14618	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True	STAD	C3	GI.GS	0.42500251899999997	0.77	0.45	9.694220652	-0.3455	-0.0985	0.5359	1.7006	-0.1518	0.762			0.924417782	2.773253347	90.0	0.166781705	8.0	14.0	0.7980269190000001	4.850122117	436.0	4.422367536	119.0	0.9253511740000001	2.119165064	-217.6824353	-269.2042361	328.8282373	0.0	416.0	0.0	416.0	8.1084727905874	9.266752210902125	0.3563000610852324	6.1989302857029625	8.013989242406756	3.0054026785856736	-1.9095425048844386	-1.252762968495368	2.649102617500441	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bfa8	58cfa830e4b0c9d6adf6bfa8	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.bam	478.4	1.9	0.14	58cfa830e4b0c9d6adf6bfa8	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6454-01A	AC2CBCE4-4BA8-42C9-AC61-70F42995588E	Primary Tumor	Illumina HiSeq	e344c34d-da8c-4145-8a02-b9ae248ca3a3	Stomach	58.0	E7D94421-7A3B-4100-9CBF-1B1F2EC07737	6F5506E4-8375-4F62-8B85-64FD729C6136	TCGA-BR-6454-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6454	TCGA-STAD		s14619	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True	STAD	C2	GI.CIN	0.38438392	0.63	0.18	50.97562736	0.5009	0.0465	0.5864	2.0149	0.8170000000000001	0.0163			1.2473432309999999	3.5099658369999998	113.0	0.540212271	20.0	34.0	0.795346695	4.807874996000001	422.0	4.741883045	273.0	0.845335037		336.29564980000004	546.0980927999999	1923.091708	0.0	0.0	0.0	0.0	7.49517150490984	7.780720886117919	0.32474860271689265	5.59805152002396	6.7392670112897575	2.275215721683333	-1.897119984885881	-1.0414538748281612	1.95046711896644	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bfa9	58cfa830e4b0c9d6adf6bfa9	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted.bam	282.7	1.9	0.15	58cfa830e4b0c9d6adf6bfa9	TCGA-BR-6456-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6456-01A	1CA3C5E0-32B0-4467-8EC0-CA212E35D2B3	Primary Tumor	Illumina HiSeq	a772744a-8f77-4f03-adaf-cbd5db4ba399	Stomach	74.0	53369A25-3BC4-48CB-9004-DA3507C4D478	B2D5157F-5D0A-451C-8E78-AFFFC67B2F68	TCGA-BR-6456-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6456	TCGA-STAD		s14399	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True	STAD	C2	GI.CIN	0.218351293	0.7	0.15	9.410818419	0.5509	0.005	0.4635	0.8189	0.8378	0.7137			0.352767449	0.91131591	257.0	0.549682656	20.0	43.0	0.83278864	4.205462719	156.0	5.08687235	206.0	0.9547654990000001	4.737923747	-103.1117772	523.6502498	-2155.092206	1.0	526.0	0.0	526.0	7.187405179736653	7.359891906399449	-0.4121362469251866	5.341578489238323	6.443601174525293	7.5968944381445445	-1.8458266904983305	-0.9162907318741551	8.009030685069732	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bfc0	58cfa830e4b0c9d6adf6bfc0	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.bam	61.49	1.87	0.17	58cfa830e4b0c9d6adf6bfc0	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JS-01A	0DA7BBD4-ED8D-474B-B494-CB93C5FA811E	Primary Tumor	Illumina HiSeq	06607d3e-b9f0-4332-aee8-7001d26e7d12	Uterus	54.0	D0B88B1C-150D-4ABC-9F9E-8C51CB208EFA	D2DD7ED4-03F6-463E-94BD-6CF98D80E8FD	TCGA-B5-A0JS-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JS	TCGA-UCEC		s5208	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.CN_LOW	0.13496497	0.35	0.0	8.16971582	-0.4385	-0.035	-0.0746	0.5732	-0.6277	0.1189	10.0	0.0	0.17085335199999999	0.768840085	88.0	0.019541054	1.0	1.0							2.606778053	-864.1903812999999	-881.8012197999999	-966.7605751	0.0	2627.0	0.0	2627.0	6.170371188801868	7.328656195220139	-0.3463586924862505	5.547841575455876	6.307004947688158	7.230080294877457	-0.6225296133459919	-1.021651247531981	7.576438987363708	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bfd6	58cfa830e4b0c9d6adf6bfd6	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	650.31	1.9	0.14	58cfa830e4b0c9d6adf6bfd6	TCGA-AG-3728-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3728-01A	856A490C-C6DA-48FE-88B5-9FDE0F481365	Primary Tumor	Illumina HiSeq	d36f782a-483a-478d-a9a6-22f626b032bb	Colorectal	73.0	019EB82B-4A2D-4E67-99A6-FE10B0ABCB70	DF699DEA-C800-47D0-A526-A6C7A610041A	TCGA-AG-3728-01A-01D-1115-02	HG18	TCGA-AG-3728	TCGA-READ		s2137	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	True	READ	C3					25.21544635	-0.3585	-0.14400000000000002	0.0299	1.3328	-0.5501	0.3684					130.0	0.504954669	16.0	14.0							0.962070918	-1225.494557	-1056.0460970000001	2841.575206	0.0	912.0	0.0	912.0	5.131541021089544	6.162286706801442	-0.06117559613660439	4.540672689650017	6.40344876361833	3.955207424615784	-0.5908683314395269	0.24116205681688818	4.0163830207523885	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bfdf	58cfa830e4b0c9d6adf6bfdf	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.bam	172.7	1.9	0.15	58cfa830e4b0c9d6adf6bfdf	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6801-01A	24FED326-BDCF-4C20-A06E-7C1C3D6C9CC5	Primary Tumor	Illumina HiSeq	48843aff-35a1-472b-a298-6489ad1b7de7	Stomach	70.0	713F11EE-D285-4A3B-B421-1D416E5F8E52	FDD2EE8C-C74B-49B8-A530-8CC171C34804	TCGA-BR-6801-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6801	TCGA-STAD		s15450	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	True	STAD	C1	GI.CIN	0.181032759	0.32	0.55	3.9912430939999997	0.0997	0.0375	-0.4268	-1.0729	-0.3676	0.4925			0.52116369	1.013373842	156.0	0.853433784	6.0	9.0				2.479955521	13.0	0.966863347	1.883567325	-1040.254543	-511.3075627	-751.8282264	0.0	1223.0	0.0	1223.0	7.974532844130229	7.33474464501743	-0.8666067459239402	5.77730826679401	6.436803051811472	1.9762642023530659	-2.197224577336219	-0.8979415932059585	2.842870948277006	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bfe8	58cfa830e4b0c9d6adf6bfe8	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.bam	338.7	1.9	0.14	58cfa830e4b0c9d6adf6bfe8	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6565-01A	DAECEA36-B379-46CE-8AE9-A38D22556CE2	Primary Tumor	Illumina HiSeq	8cfafa49-f561-4e59-98c5-b9a816534417	Stomach	67.0	1D7AAE07-2453-4DC3-A26D-D67161172648	E5F188AD-28C2-4AD0-89DD-C13493CE4B03	TCGA-BR-6565-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6565	TCGA-STAD		s14881	Harvard Medical School	Asterand	Russia	NO	T4a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True	STAD	C2	GI.CIN	0.28470665100000003	0.68	0.42	8.727746417999999	0.8485	0.156	0.5588	1.1911	0.6176	0.2743			0.989183655	3.6076109769999998	214.0	0.663876794	23.0	33.0	0.8724122059999999	5.149529369	366.0	4.359274736000001	202.0	0.821223605	3.171869879	-46.83260304	628.7790457000001	-2314.7882050000003	1.0	279.0	1.0	279.0	7.483806687665835	8.185536010452793	-0.9657298624918946	5.085911414867464	6.393776541224738	0.9599317857592513	-2.3978952727983707	-1.791759469228055	1.925661648251146	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bfea	58cfa830e4b0c9d6adf6bfea	TCGA-AG-3885-01A-01D-0967-10_wgs_Illumina.filtered.	WGS	TCGA-AG-3885-01A-01D-0967-10_wgs_Illumina	TCGA-AG-3885-01A-01D-0967-10_wgs_Illumina.bam	688.31	1.9	0.15	58cfa830e4b0c9d6adf6bfea	TCGA-AG-3885-01A-01D-0967-10_wgs_Illumina.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3885-01A	E5E4AA9F-6015-4D62-A088-69920D7F2500	Primary Tumor	Illumina HiSeq	f75ec564-baa7-4aeb-8c4e-21e77d60669d	Colorectal	71.0	7764DB67-5D9E-4421-86C6-7151ACA688D1	BB6150F7-23E4-40F2-B466-6B6EDD19C502	TCGA-AG-3885-01A-01D-0967-10	GRCh37-lite	TCGA-AG-3885	TCGA-READ		s1964	Baylor College of Medicine	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	0967-10	False	READ	C3	GI.CIN	0.06986483	0.24	0.21	7.907829275	-0.0273	-0.066	-0.569	0.3689	-1.2481	0.0306	48.0	39.0	0.7157878240000001	2.614181618	228.0	0.47968001299999996	13.0	12.0							0.64494896	-1168.0736650000001	-1027.482191	2265.873325	0.0	546.0	0.0	546.0	7.087740775978543	4.3598605087099	-0.4512104303537641	5.606136235054327	7.2163307149303835	4.500842728273378	-1.4816045409242158	2.856470206220483	4.952053158627143	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bff8	58cfa830e4b0c9d6adf6bff8	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	745.89	1.9	0.15	58cfa830e4b0c9d6adf6bff8	TCGA-AG-3887-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3887-01A	8C7CCDB0-7653-4A8D-86B6-DE39AFC40765	Primary Tumor	Illumina HiSeq	0041b462-7ad7-4a4d-8fea-1942532341ed	Colorectal	68.0	7F10DD13-E2C3-4F27-8673-FF5CD1632B2B	5986038D-2696-4F89-A5F5-C8173BA7D70F	TCGA-AG-3887-01A-01D-1115-02	HG18	TCGA-AG-3887	TCGA-READ		s2136	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Mucinous Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.CIN	0.055162540999999995	0.17	0.0	7.242231179	0.986	0.331	-0.5292	0.4802	-0.8756	0.0352	43.0		0.6137172470000001	1.84115174	98.0	0.18545603	8.0	8.0							0.8071641409999999	-1376.54102	191.0762671	-518.8277003000001	0.0	1124.0	1.0	1064.0	6.153498358955215	4.954336886291962	0.2895594431830354	4.977925029150977	6.99174889572815	0.689328238481744	-1.1755733298042386	2.0374120094361876	0.39976879529870857	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bffa	58cfa830e4b0c9d6adf6bffa	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	360.61	1.9	0.15	58cfa830e4b0c9d6adf6bffa	TCGA-AG-3878-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3878-01A	FDEEFF8E-1328-42A4-ACA0-A03B97421F1E	Primary Tumor	Illumina HiSeq	df3192f9-1041-4ef9-80aa-2f3e263fa968	Colorectal	64.0	D2F28259-87A7-4BD8-84BC-832E551C1ACE	8F233F73-550A-4708-9C2C-BEA9347969F7	TCGA-AG-3878-01A-02D-1167-02	HG18	TCGA-AG-3878	TCGA-READ		s2127	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1167-02	True	READ	C3	GI.GS	0.23450769300000002	0.58	0.09	11.25956674	-0.2171	-0.217	-0.0127	1.0186	-0.544	0.5987	50.0	13.0	0.512378322	2.682451214	43.0	0.144047023	8.0	0.0							0.682635164	-1239.611365	-1140.246106	1878.909323	0.0	30.0	0.0	30.0	8.422314585137327	6.263295297187908	0.012312500288817807	6.070939327973849	5.151259988187658	1.8369922072769058	-2.3513752571634776	-1.11203530900025	1.8246797069880882	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6bffc	58cfa830e4b0c9d6adf6bffc	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	614.89	1.9	0.15	58cfa830e4b0c9d6adf6bffc	TCGA-AG-3890-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3890-01A	E2D395F8-BF13-4FE4-8031-683B0EEDD875	Primary Tumor	Illumina HiSeq	b4bf7544-0816-4940-aa9f-d770f09f35f3	Colorectal	62.0	DB70A6DD-DE09-4ED7-916C-708B21734500	12064771-AE96-441D-BE8B-EE49B63F1E4E	TCGA-AG-3890-01A-01D-1115-02	HG18	TCGA-AG-3890	TCGA-READ		s2145	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Rectal Adenocarcinoma	Stage I	1115-02	True	READ	C1	GI.CIN	0.184366589	0.29	0.54	14.40303525	0.3755	0.023	-0.1392	1.0402	-0.5787	0.0309	55.0	63.0			185.0	0.501152942	7.0	26.0							0.995981417	-1458.486919	-396.9077121	-441.5665663	0.0	518.0	0.0	518.0	6.519080243590533	5.958240106042641	-0.5216039371399058	5.420467954922424	6.4339744099973615	2.098144268754017	-1.0986122886681091	0.47573430395472016	2.6197482058939223	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c005	58cfa830e4b0c9d6adf6c005	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina.bam	216.07	1.9	0.05	58cfa830e4b0c9d6adf6c005	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B3-4103-01A	1A726069-0B44-42AD-9A20-0EE90B31796B	Primary Tumor	Illumina HiSeq	e00b0cfe-8b23-4f21-998f-957efbc26955	Kidney	56.0	3829FA12-FDD5-4829-8F00-BDFBB057F23E	1DA96C26-20A5-435A-8CA3-9F698B8652A2	TCGA-B3-4103-01A-02D-1402-10	GRCh37-lite	TCGA-B3-4103	TCGA-KIRP		s11853	Baylor College of Medicine	Christiana Healthcare	None	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1402-10	False	KIRP	C3	KIRP.C1	0.224020351				-1.6363	-0.2765	0.1917	-0.6742	-0.5046	-0.2577	25.0	1.0	0.388620762	1.138103661	61.0	0.8488251520000001	12.0	0.0				2.441015278	12.0	0.982336813	2.231070046	-561.4163442	-1538.168111	-505.5333297	0.0	930.0	0.0	930.0	6.827629234502852	3.16471276192829	0.026828435891713576	4.370893461681549	2.5647217484927607	6.226931848111024	-2.456735772821304	-0.5999910134355293	6.20010341221931	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c00e	58cfa830e4b0c9d6adf6c00e	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina.bam	191.07	1.9	0.05	58cfa830e4b0c9d6adf6c00e	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B3-3926-01A	2666AB3E-F2B9-4B3D-BFCE-AAC2A4BAFE62	Primary Tumor	Illumina HiSeq	7825c6ac-6e33-4e1d-82cc-35cf60c16253	Kidney	59.0	3BB75DF9-E710-4F3D-B1B1-A4D459EB376F	72293A70-9DC8-4E4A-ACDC-C74587A90420	TCGA-B3-3926-01A-02D-1402-10	GRCh37-lite	TCGA-B3-3926	TCGA-KIRP		s11582	Baylor College of Medicine	Christiana Healthcare	None	NO	T1	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1402-10	False	KIRP	C3	KIRP.C1	0.07384742400000001	0.06	0.77		-1.4903	-0.2605	0.1008	-1.0384	-0.4803	-0.2944	4.0	15.0	0.0	0.31248711	83.0	0.947733499	12.0	0.0				2.25385759	10.0	0.9788379140000001	2.018040699	-1149.997538	-1125.382524	-43.57368885	0.0	883.0	0.0	883.0	5.786432502924047	1.9291561507241397	0.05367583183279423	5.786432502924047	3.419527481596046	4.68861136762074	0.0	1.4903713308719064	4.634935535787945	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c010	58cfa830e4b0c9d6adf6c010	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.bam	106.93	1.95	0.16	58cfa830e4b0c9d6adf6c010	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K0-01A	29C8F468-5AC1-4D6C-8376-E36E6D246926	Primary Tumor	Illumina HiSeq	e5550bf6-3edf-480e-9dc5-6d590e837e5e	Uterus	48.0	11C43948-E7C9-4436-A654-82FA8033B625	3296C785-7C20-487D-BAEC-C66022E77E53	TCGA-B5-A0K0-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K0	TCGA-UCEC		s4598	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.190545054			22.46429525	-0.1344	-0.054000000000000006	0.2164	0.2847	-0.1471	0.3718	9.0	0.0	0.14607725300000002	0.525878111	58.0	0.088807446	3.0	1.0							2.269278766	-791.8938086	-472.3800669	-1945.3798370000002	0.0	1478.0	0.0	1478.0	4.46497210200538	6.584607213363187	-0.7488803103501094	3.8888814768664517	5.267305723730248	1.8934255332209804	-0.576090625138928	-1.3173014896329396	2.6423058435710898	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c01c	58cfa830e4b0c9d6adf6c01c	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.bam	106.4	2.0	0.15	58cfa830e4b0c9d6adf6c01c	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K7-01A	2F0640BC-598C-4714-9E9B-7E0F2CA4567F	Primary Tumor	Illumina HiSeq	b1ac8e27-775c-4d91-8a4d-9d096cde589d	Uterus	64.0	51E8577D-6849-422E-8F37-2EA8C400BBE5	ED30E619-1EBE-4CCE-B7FD-93B552953B65	TCGA-B5-A0K7-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0K7	TCGA-UCEC		s5390	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.CN_LOW	0.164332805	0.27	0.0	10.72851227	-0.1906	-0.015	0.1754	1.0059	-0.0122	-0.1316	24.0	1.0	0.450079925	1.200213134	56.0	0.118320219	3.0	1.0							2.732431762	-1086.596179	89.98286378	934.8215256000001	0.0	1933.0	1.0	322.0	6.344359629087981	7.657459998448395	0.18273728650005006	5.889623471973033	6.5180257152600305	2.877046985352583	-0.4547361571149473	-1.1394342831883648	2.694309698852533	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c01e	58cfa830e4b0c9d6adf6c01e	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted.bam	89.84	1.92	0.14	58cfa830e4b0c9d6adf6c01e	TCGA-BJ-A0Z2-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_1_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z2-01A	F9CEFFC0-D544-418D-B4A9-BD3C84E37026	Primary Tumor	Illumina HiSeq	9493c81d-440a-4066-975b-c6265b7641a6	Thyroid	57.0	B06B7493-F38A-493F-8B47-61E0FA4D111F	D8B6F131-76CA-45D3-8934-A6CDEA8153AD	TCGA-BJ-A0Z2-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z2	TCGA-THCA		s12353	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage IVC	A10R-02	True	THCA	C3	THCA.1	0.019618853999999998	0.03	0.0		-0.8832	-0.3535	-0.922	-1.1556	-0.925	-0.4405	8.0	3.0	0.169364602	0.39518407200000005	61.0	0.011035305	0.0	0.0				1.791759469	6.0	1.0	1.45546468	-1399.837385	-631.9459477	1818.829332	0.0	1514.0	1.0	158.0	7.4353537347624545	8.430654429998999	-1.3008881966934387	6.410849418248067	7.251999433657353	0.6454466108720429	-1.024504316514388	-1.1786549963416464	1.9463348075654816	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c022	58cfa830e4b0c9d6adf6c022	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.bam	36.9	2.03	0.15	58cfa830e4b0c9d6adf6c022	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZE-01A	AB8C9101-ADEB-4C43-A8BB-B089EBD711F6	Primary Tumor	Illumina HiSeq	b215d9c2-6a64-45cf-8e4b-0e2b87207119	Thyroid	63.0	695C5627-F442-4A86-9702-EF35DEFD8C8C	ED0B1C86-A516-422F-92C4-7C535E709989	TCGA-BJ-A0ZE-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZE	TCGA-THCA		s12231	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	True	THCA	C3	THCA.1	0.04604256	0.27	0.0		-1.6713	-0.244	-1.1628	-1.4041	-1.0973	-0.9057	8.0	0.0	0.084361534	0.337446136	37.0	2.46e-05	0.0	0.0				0.0	1.0		0.921170597	-573.37163	-1265.5602939999999	796.3313831	0.0	509.0	0.0	509.0	7.628335216943322	8.08397654697723	-0.06787596891365733	6.1814162340069965	7.167685815103074	1.3633048428951917	-1.4469189829363258	-0.9162907318741547	1.4311808118088492	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c024	58cfa830e4b0c9d6adf6c024	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted.bam	87.89	1.88	0.15	58cfa830e4b0c9d6adf6c024	TCGA-AX-A0J1-01A-11D-A043_120403_SN1222_0094_BD0UKBACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0J1-01A	EC7A9D74-8B3F-4747-8926-1739A016AB2B	Primary Tumor	Illumina HiSeq	7bce686e-1ac7-49b4-9b2f-c76eec80a77c	Uterus	80.0	AC14E378-2DE1-458A-B8CD-7C60131AA927	3612DB54-D93C-47FB-A5E7-3BA3CE404A3C	TCGA-AX-A0J1-01A-11D-A043-02	HG19_Broad_variant	TCGA-AX-A0J1	TCGA-UCEC		s4594	Harvard Medical School	Gynecologic Oncology Group	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.POLE	0.165305218	0.22	0.02	2.831382365	0.7809999999999999	0.304	-0.3665	0.2969	-1.0899	-0.2345	2620.0	2991.0	54.62686897	149.3293449	56.0	0.034093745	1.0	2.0							2.785401515	-1246.3692	447.9276438999999	2811.601453	0.0	2354.0	0.0	2354.0	5.233919186439395	5.393843973146843	0.3248590201380367	4.056614629195621	5.93966643894993	1.162906639373507	-1.1773045572437741	0.545822465803087	0.8380476192354702	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c026	58cfa830e4b0c9d6adf6c026	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted.bam	79.63	2.0	0.16	58cfa830e4b0c9d6adf6c026	TCGA-BJ-A0ZB-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZB-01A	DC4D8468-6F34-40CB-A826-8D582CD86FDE	Primary Tumor	Illumina HiSeq	72ce31c8-5889-450a-ac21-159c97d9b125	Thyroid	66.0	145A474E-D262-468A-8DB7-EE9F1B7CE0A7	EBAA6AE4-66C0-49A7-938C-620E24564846	TCGA-BJ-A0ZB-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZB	TCGA-THCA		s12097	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A10R-02	True	THCA	C3	THCA.4	0.051433805	0.33	0.01		-1.535	-0.29	-0.5715	-0.6734	-0.6039	-0.0314	18.0	1.0	0.226859308	0.9074372340000001	57.0	0.018293262	0.0	0.0				2.582306344	14.0	0.978495736	0.8373336570000001	-292.7745836	-929.1002110999999	2210.018689	0.0	122.0	0.0	122.0	6.732841510763575	8.331396128356953	-0.2910428255928812	5.828385236536423	7.692316169067284	3.7159372522912877	-0.9044562742271518	-0.6390799592896697	4.006980077884169	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c02a	58cfa830e4b0c9d6adf6c02a	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.bam	112.67	1.79	0.14	58cfa830e4b0c9d6adf6c02a	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0IW-01A	DB21FCCF-40CB-4235-A34D-336A03B8C8F4	Primary Tumor	Illumina HiSeq	26dfa889-ba7c-4cc0-8adc-59d5eb4e4026	Uterus	67.0	874A1C5C-229B-4BCE-B612-55EFF238D533	CFB35E8C-470B-4F9E-B7C1-63FCAA162F3C	TCGA-AX-A0IW-01A-11D-A043-02	HG19_Broad_variant	TCGA-AX-A0IW	TCGA-UCEC		s4422	Harvard Medical School	Gynecologic Oncology Group	None	NO			Serous endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_HIGH	0.089105368	0.18	0.29	0.08194242	0.5402	0.20800000000000002	-0.8825	-0.4751	1.4811	0.0287	31.0		0.486116734	1.519114794	402.0	0.9176000959999999	14.0	41.0							3.2213989389999997	-1759.447177	-294.2454894	480.5656004	0.0	1149.0	0.0	1149.0	4.353406677293833	6.139884552226254	0.3741305096298281	3.848311728236827	3.9914501390594674	3.420655952529687	-0.5050949490570056	-2.148434413166787	3.046525442899859	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c02c	58cfa830e4b0c9d6adf6c02c	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.bam	26.88	1.91	0.16	58cfa830e4b0c9d6adf6c02c	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZC-01A	6675C581-297D-44CD-B80F-AE7E53D48228	Primary Tumor	Illumina HiSeq	a470b305-96a5-43a8-b1f4-db15c7b0b4d5	Thyroid	55.0	1F945AFF-7BC2-40F5-87DB-92313E541243	0E4A0528-883D-47A5-B399-57B1B15EC412	TCGA-BJ-A0ZC-01A-12D-A13U-02	HG19_Broad_variant	TCGA-BJ-A0ZC	TCGA-THCA		s12232	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True	THCA	C3	THCA.1	0.078934457	0.24	0.0		-2.4381	-0.396	-0.986	-0.8714	-0.3386	-0.622	6.0		0.057987612	0.086981419	41.0	0.014757171000000001	0.0	2.0		0.0	1.0	1.098612289	3.0	1.0	1.4129880769999998	-1286.6066759999999	-780.5237093999999	2631.941823	0.0	352.0	0.0	352.0	6.750772467453286	9.52316711242439	0.22252209182053695	6.089373985207922	8.686919088223771	2.1850571268454857	-0.6613984822453651	-0.8362480242006187	1.9625350350249489	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c032	58cfa830e4b0c9d6adf6c032	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.bam	385.7	1.9	0.15	58cfa830e4b0c9d6adf6c032	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6852-01A	44799C67-61CD-4F3E-BDBC-423E2E0FD2E8	Primary Tumor	Illumina HiSeq	bff2f642-516a-4072-95aa-f213a4555f79	Stomach	64.0	F230ED0B-8D08-4546-9762-923097B4BF02	20F8131D-3F7E-47C5-AE84-A3886A387514	TCGA-BR-6852-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6852	TCGA-STAD		s15387	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	True	STAD	C2	GI.HM-indel	0.480599899	0.65	0.07	24.31713101	0.72	0.2155	1.0306	2.0896	1.6480000000000001	0.4021			8.842388897000001	25.92427654	91.0	0.057290959	2.0	2.0	0.771513608	4.4527453669999995	321.0	5.074082466	251.0	0.918310684	1.800259655	265.4824338	669.3868249	-132.14565430000002	0.0	1367.0	0.0	1367.0	6.124683390894204	5.5847486570981655	0.018174259100801615	3.927458813557985	4.6684579252240095	1.5400790489216898	-2.197224577336219	-0.9162907318741551	1.521904789820888	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c03c	58cfa830e4b0c9d6adf6c03c	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	420.89	1.9	0.15	58cfa830e4b0c9d6adf6c03c	TCGA-AG-4001-01A-02D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4001-01A	D846228F-67AF-4B3B-9796-DBC263C2054C	Primary Tumor	Illumina HiSeq	53c6af7e-4876-4559-b1b1-d7dc58c2b702	Colorectal	74.0	6160C363-B050-4B3B-9909-4EBC33ED3A1A	05B6BA78-DDE8-4E68-9622-7B618A083CC8	TCGA-AG-4001-01A-02D-1115-02	HG18	TCGA-AG-4001	TCGA-READ		s2164	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.CIN	0.167939737	0.52	0.24	27.79547868	0.4129	0.084	0.0615	-0.1642	-0.154	0.4604	52.0	28.0	1.095867381	3.190907962	126.0	0.695696236	17.0	20.0							2.612913858	-1522.091483	-438.30870130000005	142.1427802	0.0	1096.0	0.0	1096.0	5.946153324397979	5.275453809382159	-0.6888767114364929	4.665219478935915	5.680918917490324	1.8012742888693938	-1.2809338454620645	0.4054651081081646	2.490151000305887	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c044	58cfa830e4b0c9d6adf6c044	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	551.89	1.9	0.15	58cfa830e4b0c9d6adf6c044	TCGA-AG-3893-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3893-01A	ADD567B7-29EF-4122-8A54-57D36F735E78	Primary Tumor	Illumina HiSeq	d98305fc-80c0-4336-b35c-0c47d8c297b8	Colorectal	74.0	7E16AFE9-DA05-451B-BD8C-86D75C8E475C	5815181B-A53B-4AAF-9817-168AC41DAD2A	TCGA-AG-3893-01A-01D-1115-02	HG18	TCGA-AG-3893	TCGA-READ		s2152	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	1115-02	True	READ	C1	GI.CIN	0.08262618599999999	0.28	0.13	12.68272163	0.4622	0.11199999999999999	-0.2597	-0.5781	-0.5741	0.2672	60.0	12.0			156.0	0.326965353	9.0	23.0							2.803122058	-1123.424109	-277.5146727	1347.814058	0.0	1065.0	0.0	1065.0	5.89057431158106	5.3523195354363375	-0.18012874520184463	4.06187132716132	5.592460663119119	1.8973546991223773	-1.8287029844197393	0.24014112768278117	2.077483444324222	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c046	58cfa830e4b0c9d6adf6c046	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina.filtered.	WGS	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina.bam	142.77	1.9	0.16	58cfa830e4b0c9d6adf6c046	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B2-4102-01A	BBBCE1BA-C739-43BA-B9CF-A4F746491AE3	Primary Tumor	Illumina HiSeq	08200438-3da7-446b-99d7-c23e7cbfb2b5	Kidney	61.0	0A187E9E-FAE3-4B9F-B6ED-23CF0FFCB39E	39C55051-E1BC-4081-962A-17205645DE45	TCGA-B2-4102-01A-02D-2095-10	GRCh37-lite	TCGA-B2-4102	TCGA-KIRC		s9734	Baylor College of Medicine	Christiana Healthcare	None	NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2095-10	False	KIRC	C3	KIRC.1	0.293631595	0.51	0.03		-1.4223	-0.3405	1.0291	0.594	0.7401	-0.0678	25.0	103.0	0.551147144	1.405425217	121.0	0.081844032	0.0	4.0	0.9171479379999999	1.9071555230000001	8.0	3.626656184	40.0	0.9831322029999999	1.7170155580000002	314.5913329	-831.4660703	3783.7470049999997	0.0	952.0	0.0	952.0	8.310628833894864	1.8708379374068116	0.34859276000807315	5.386415912619785	4.7700263003963155	4.559383702969763	-2.924212921275079	2.899188362989504	4.210790942961689	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c048	58cfa830e4b0c9d6adf6c048	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina.bam	241.07	1.9	0.05	58cfa830e4b0c9d6adf6c048	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B3-3925-01A	75A53BFF-BF0F-4AD8-9B8E-14A27914D4F2	Primary Tumor	Illumina HiSeq	9130f58c-9250-4f4f-a60d-028366b76852	Kidney	52.0	16223531-33C3-4D2C-8715-FA9899CEE168	42F88B95-FA12-47C7-93F1-CF72F207291C	TCGA-B3-3925-01A-02D-1402-10	GRCh37-lite	TCGA-B3-3925	TCGA-KIRP		s11770	Baylor College of Medicine	Christiana Healthcare	None	NO	T3a	NX	Kidney Papillary Renal Cell Carcinoma	Stage III	1402-10	False	KIRP	C3	KIRP.C1	0.17334782899999998	0.28	0.01		-1.8408	-0.3535	0.627	-0.0354	-0.0395	-0.2442	25.0	17.0	0.5795256089999999	1.655787453	59.0	0.17085177699999998	8.0	0.0				3.193148395	25.0	0.992007324	1.8829260419999998	-330.2548045	-1405.8251599999999	1187.468567	0.0	1029.0	0.0	1029.0	5.375187626512117	2.1389354968416825	0.2166948877876762	5.780652734620282	3.628551780245293	3.140683256482826	0.40546510810816416	1.4896162834036106	2.9239883686951496	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c050	58cfa830e4b0c9d6adf6c050	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.bam	110.74	2.06	0.14	58cfa830e4b0c9d6adf6c050	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K6-01A	5CBA9441-6812-49C0-A0F6-7928ED4E5B81	Primary Tumor	Illumina HiSeq	06cd1c7f-2531-4a07-bf4f-c086f7a954a0	Uterus	58.0	69BF0D3A-B7AE-4EE1-B7D1-18A32FCFA67C	A4364F57-81A8-4B96-BA31-1D8B1CC78C5D	TCGA-B5-A0K6-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K6	TCGA-UCEC		s4247	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C3	UCEC.MSI	0.10440606	0.23	0.01	4.447968886	-0.3936	-0.157	-0.1888	0.0578	0.0771	-0.127	141.0	404.0	2.7718146530000003	9.777500041	49.0	0.048752067999999996	2.0	4.0							2.250419995	-616.2231332	-1157.638374	1835.411832	0.0	1953.0	0.0	1953.0	4.425781823171579	6.851890146140741	-0.2632442557243668	4.253931566244919	5.871060893129016	2.486338289259438	-0.17185025692665956	-0.9808292530117262	2.749582544983805	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c052	58cfa830e4b0c9d6adf6c052	TCGA-B2-4101-01A-02D-2096-10_Illumina.filtered.	WGS	TCGA-B2-4101-01A-02D-2096-10_Illumina	TCGA-B2-4101-01A-02D-2096-10_Illumina.bam	138.47	1.9	0.15	58cfa830e4b0c9d6adf6c052	TCGA-B2-4101-01A-02D-2096-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B2-4101-01A	CFC999AA-802E-4A0D-8B14-BE2B19FA2A17	Primary Tumor	Illumina HiSeq	06203d35-b4db-4e6b-9c54-14edb4129481	Kidney	52.0	A9947B6C-DBC7-4BA5-AF61-7647E11E2973	F3C1A125-06E9-41C4-9558-275A3E346CC5	TCGA-B2-4101-01A-02D-2096-10	GRCh37-lite	TCGA-B2-4101	TCGA-KIRC		s9564	Baylor College of Medicine	Christiana Healthcare	None	NO	T2a	NX	Kidney Clear Cell Renal Carcinoma	Stage II	2096-10	False	KIRC	C3	KIRC.2	0.295856371				-1.3241	-0.33299999999999996	0.9608	1.3917	0.3853	0.2498	18.0	61.0	0.307153933	1.2286157340000001	77.0	0.049202357	0.0	5.0	0.8386601570000001	2.011019226	11.0	4.057029200000001	63.0	0.9792173000000001	1.77745219	187.33762430000002	-745.7840012	2712.5034170000004	0.0	648.0	0.0	648.0	8.481003309222544	1.9365136844020192	0.437294013678336	5.4881322679495845	5.043098123619696	4.442319801399447	-2.992871041272959	3.106584439217677	4.00502578772111	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c05e	58cfa830e4b0c9d6adf6c05e	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	651.89	1.9	0.14	58cfa830e4b0c9d6adf6c05e	TCGA-AG-3999-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3999-01A	60778DA8-D99E-4E51-96A2-3E900B3978D9	Primary Tumor	Illumina HiSeq	3d30dbe4-9c61-402a-afcd-c869123af4c6	Colorectal	61.0	022BA0B0-F8CC-474C-9FB9-7928B45FD756	1C65913D-665D-455E-9F40-8464E5EA0D55	TCGA-AG-3999-01A-01D-1115-02	HG18	TCGA-AG-3999	TCGA-READ		s2161	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Rectal Adenocarcinoma	Stage IIIC	1115-02	True	READ	C1		0.063095816	0.28	0.08	9.446913045	0.5798	0.165	-0.6864	-0.8558	-1.4936	0.1187					210.0	0.589356263	13.0	24.0							0.889801105	-1388.628728	-391.0536314	-510.7394856000001	0.0	853.0	1.0	791.0	6.373604163245928	6.91047415333088	-1.6779677768178778	4.742187344093052	8.708582850237594	0.7910475056334878	-1.631416819152876	1.7981086969067137	2.4690152824513656	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c062	58cfa830e4b0c9d6adf6c062	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.bam	78.5	1.92	0.14	58cfa830e4b0c9d6adf6c062	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RI-01A	BFD55808-DDDD-44C3-97D7-41600497B992	Primary Tumor	Illumina HiSeq	9283f68e-d261-4afd-b0eb-0a29fdda83ca	Breast	44.0	973EE776-E287-4568-A43D-7B16CC0094A9	71542129-1393-4608-B81C-1767A5051763	TCGA-B6-A0RI-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RI	TCGA-BRCA		s6273	Harvard Medical School	Duke	United States	NO	T4b	N1b	Infiltrating Ductal Carcinoma	Stage IIIB	A060-02	True	BRCA	C1	BRCA.LumA	0.092150144	0.25	0.07	0.312540172	0.3981	0.03	-0.0455	-1.3031	-0.2505	0.6483	7.0	2.0	0.117022335	0.526600508	82.0	0.104391729	3.0	13.0				1.098612289	3.0	1.0	1.58094652	-1076.205933	1394.288322	1472.065626	0.0	7126.0	1.0	1100.0	9.20230820027892	7.140085078648033	-0.31791387341191113	6.850932943115442	7.527850609656797	7.652308247601983	-2.3513752571634776	0.38776553100876354	7.970222121013895	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c064	58cfa830e4b0c9d6adf6c064	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted.filtered.	WGS	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted.bam	618.89	1.9	0.15	58cfa830e4b0c9d6adf6c064	TCGA-AG-4005-01A-01D-1115_101122_SN177_0123_B20APUABXX_s_3_rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-4005-01A	866DE12B-E4DF-4F19-B62E-E3FD85D4EC08	Primary Tumor	Illumina HiSeq	06bb3e36-d2de-48c4-a23d-89eae00ec7e5	Colorectal	64.0	5B98C136-7BC3-411C-B07D-F0CF657F834D	284653D0-67A2-4ABF-9F75-1F045D0DAA70	TCGA-AG-4005-01A-01D-1115-02	HG18_Broad_variant	TCGA-AG-4005	TCGA-READ		s1999	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Rectal Adenocarcinoma	Stage IV	1115-02	True	READ	C1		0.09400395199999999	0.33	0.11	15.59285328	0.6697	0.225	-0.5347	-0.2662	-0.4582	0.1992					135.0	0.41019497899999996	12.0	16.0							0.562578335	-1261.0950300000002	105.5172238	-175.1604093	0.0	427.0	0.0	427.0	6.295349862398226	4.433725273498023	-0.5482550587537981	3.575251322779841	5.23125756379996	2.0814418281018963	-2.7200985396183848	0.7975322903019366	2.6296968868556947	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c066	58cfa830e4b0c9d6adf6c066	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	710.89	1.9	0.15	58cfa830e4b0c9d6adf6c066	TCGA-AG-3894-01A-01D-1115-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-3894-01A	065B26FC-6827-44D5-83D8-1100C63FCDA6	Primary Tumor	Illumina HiSeq	8db01c5c-36a6-4060-ada7-3d57682daaf6	Colorectal	65.0	D6B7E2F3-01AD-4E77-87BB-9CBAEF03A5FB	339E9078-1166-45F6-A6BD-A2818B8918A1	TCGA-AG-3894-01A-01D-1115-02	HG18	TCGA-AG-3894	TCGA-READ		s2163	Harvard Medical School	Indivumed	Germany	NO	T3	N0	Rectal Adenocarcinoma	Stage IIA	1115-02	True	READ	C1	GI.GS	0.069722048	0.19	0.0	6.000751032999999	0.6211	0.258	-0.6401	-0.3583	-1.3179	-0.0159	45.0	101.0	0.9341105540000001	2.591403471	79.0	0.054762327	2.0	0.0							1.4018160219999998	-1847.1786309999998	25.67308902	-1304.233214	0.0	426.0	0.0	426.0	6.720534785447278	5.755453171182379	-1.400657014764716	5.155548635584011	6.348734355402138	0.5796178733242927	-1.564986149863267	0.5932811842197596	1.9802748880890086	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c070	58cfa830e4b0c9d6adf6c070	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	458.59	1.9	0.13	58cfa830e4b0c9d6adf6c070	TCGA-AY-4070-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AY-4070-01A	6BAF61B6-AE5B-42F0-ADC9-0D26FDA231F7	Primary Tumor	Illumina HiSeq	c0679a4e-afc6-4b64-80a5-35bf5e446cb1	Colorectal	50.0	C35CB7B2-7A85-4320-89AC-3A395EF8C1BE	B9EFEB1A-FA1D-4917-8FC5-149ECAF26989	TCGA-AY-4070-01A-01D-1109-02	HG18	TCGA-AY-4070	TCGA-COAD	496.0	s13388	Harvard Medical School	UNC	None	NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1109-02	True	COAD	C1	GI.CIN	0.249834657	0.69	0.43	24.39052047	0.46399999999999997	0.162	-0.3455	0.7954	-0.1937	0.1939	79.0	7.0	1.412638186	4.268624084	292.0	0.591922476	15.0	47.0							2.96111719	-307.9169203	-160.5005279	-1967.208202	1.0	496.0	1.0	186.0	4.992414747982728	4.7580013142713415	-0.6200032962128808	3.7884419436567924	5.442637805163378	1.288991298093713	-1.2039728043259355	0.6846364908920366	1.9089945943065938	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c07c	58cfa830e4b0c9d6adf6c07c	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.bam	57.81	1.95	0.16	58cfa830e4b0c9d6adf6c07c	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZH-01A	866CA8AD-ADC9-45D4-AD92-9F8F1A161DDF	Primary Tumor	Illumina HiSeq	488591c3-7ba4-421a-9fc0-36d0604c8175	Thyroid	52.0	01EE736B-F907-465B-9142-C50BE0A3461B	8B8B2852-9D53-4654-A37C-2749C0F264ED	TCGA-BJ-A0ZH-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZH	TCGA-THCA		s12096	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage IVA	A10R-02	True	THCA	C3	THCA.3	0.190365007	0.38	0.01		-1.4694	-0.1655	-0.0702	0.0688	-0.0596	-0.0693	10.0		0.056756102	0.34053661	53.0	0.011004141	0.0	0.0	0.9158981359999999	1.474081183	5.0	2.3025850930000002	10.0	1.0	1.20076956	69.31354019	-1099.364167	1285.5281300000001	0.0	460.0	0.0	460.0	6.818924065275521	8.290125283209871	-1.103658556735734	6.439434443570617	7.6395377170687215	1.6039722692292746	-0.3794896217049035	-0.6505875661411493	2.7076308259650084	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c07e	58cfa830e4b0c9d6adf6c07e	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina.bam	27.53		0.08	58cfa830e4b0c9d6adf6c07e	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B1-A47M-01A	072507CF-1249-4B28-86D4-3AB97822A74C	Primary Tumor	Illumina HiSeq	aa347261-ddce-4395-b3f2-84e8210d4d8a	Kidney	79.0	75658EDD-12F1-4BB3-BEA2-01C154CB6AE9	8FB7FCAC-6C1D-40C2-9309-B53821CBEF30	TCGA-B1-A47M-01A-11D-A25F-10	GRCh37-lite	TCGA-B1-A47M	TCGA-KIRP		s11581	Baylor College of Medicine	University of Pittsburgh	United States	NO	T3a	NX	Kidney Papillary Renal Cell Carcinoma	Stage III	A25F-10	True	KIRP	C3	KIRP.C1	0.238623173	0.04	0.13		-1.278	-0.1105	-0.079	-0.6169	-0.4547	-0.2523	45.0	263.0	0.7262073659999999	2.31827736	60.0	0.148500872	7.0	5.0				1.098612289	3.0	1.0	2.101022978	-823.6249101	-2292.080963	-193.32316840000001	0.0	659.0	1.0	408.0	7.068023852239623	0.532451427931969	0.16845979677056566	6.353370466458714	4.205426384863537	0.3138608949228159	-0.7146533857809088	3.6729749569315677	0.14540109815225022	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c0fe	58cfa830e4b0c9d6adf6c0fe	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted.bam	31.24	2.03	0.14	58cfa830e4b0c9d6adf6c0fe	TCGA-B5-A0K4-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_3_rg.sorted.bam	Alive	FEMALE			Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K4-01A	A8F38E37-978B-4435-B676-E8D4C34DA909	Primary Tumor	Illumina HiSeq	a95ec772-f010-453f-b4a3-20abf1f681e3	Uterus	51.0	A4AC1F6E-3411-47AE-9592-513B3D32223F	4612DB59-3A8E-4F32-968A-76BCE0D4F042	TCGA-B5-A0K4-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K4	TCGA-UCEC		s5389	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C4	UCEC.CN_LOW	0.067636772	0.18	0.0	4.890772944	-0.419	-0.129	-1.2074	-1.3366	0.0725	-0.1837	29.0	169.0	0.231589047	1.447431544	63.0	0.9798162990000001	9.0	1.0							1.432101464	-1365.09015	-1250.726217	-1937.809272	0.0	1757.0	0.0	1757.0	6.138424601074376	7.0079546728473465	-1.2758918616540136	5.2988487867810825	6.47988724264685	2.471464964207752	-0.8395758142932932	-0.5280674302004966	3.747356825861765	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c102	58cfa830e4b0c9d6adf6c102	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.bam	97.15	2.16	0.13	58cfa830e4b0c9d6adf6c102	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K9-01A	4485CC98-5D58-4EB4-8325-7D1A617B6461	Primary Tumor	Illumina HiSeq	71c016d1-ab89-4d8f-acb9-92767959d603	Uterus	88.0	52A96216-708F-43F2-A923-130A1C35922D	30D94271-91F3-4CF5-83C0-4708662115D0	TCGA-B5-A0K9-01A-21D-A101-02	HG19_Broad_variant	TCGA-B5-A0K9	TCGA-UCEC		s5210	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.34675396700000005	0.44	0.05	8.376547824	0.5194	0.177	-0.2334	0.0498	-0.1504	-0.0565	309.0	1474.0	6.190675072	18.28709875	40.0	0.118362497	3.0	1.0	0.627021528	1.12347176	6.0	2.5649493569999997	13.0	1.0	3.282726134	-1285.503236	-186.2598324	1903.895227	1.0	409.0	0.0	409.0	5.889639441184395	5.808038932790893	-0.9307314160289495	4.402369162724502	4.970642143386402	2.306228084272547	-1.4872702784598926	-0.8373967894044916	3.2369595003014964	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c106	58cfa830e4b0c9d6adf6c106	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.bam	96.9	1.86	0.16	58cfa830e4b0c9d6adf6c106	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TJ-01A	F74DA4C6-4291-46D2-ABD4-7D7F6EF03B00	Primary Tumor	Illumina HiSeq	d9625d1c-df48-4532-994d-9ab3a3c8f8b6	Uterus	59.0	AC35307B-AC7F-49FC-A237-5E03AB2E2276	C20AA17E-3866-4864-A4AE-44ACFD746221	TCGA-BS-A0TJ-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TJ	TCGA-UCEC		s5012	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.07152868700000001	0.21	0.0	3.766897375	0.7705	0.23199999999999998	-0.6883	0.0703	-1.2307	0.2515	318.0	2016.0	5.589081737000001	17.5282	105.0	0.00018462	0.0	0.0							1.767094245	-435.8294692	574.7496423	-1441.4838539999998	0.0	2068.0	0.0	2068.0	7.902733955098282	7.469083884921234	0.06561311184531804	5.74324970574491	6.706943832874337	0.92167527022611	-2.1594842493533726	-0.7621400520468968	0.8560621583807919	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c107	58cfa830e4b0c9d6adf6c107	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted.bam	95.02	2.03	0.15	58cfa830e4b0c9d6adf6c107	TCGA-BS-A0TA-01A-11D-A101_120403_SN1222_0094_BD0UKBACXX_s_1_rg.sorted.bam	Alive	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TA-01A	AD3D8420-F562-4CBE-AC82-C968BD4F782D	Primary Tumor	Illumina HiSeq	ee69554a-eb4c-482a-b37e-a643758f27e5	Uterus	58.0	B6A042B6-F94A-4ACC-98CB-A1A2FE72B9AD	896590DE-B00E-40A3-912D-D625F3581AD8	TCGA-BS-A0TA-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TA	TCGA-UCEC		s4437	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.MSI	0.5270991389999999	0.69	0.01	22.71104562	0.644	0.32899999999999996	0.9442	2.3057	1.2481	-0.0697	249.0	1559.0	4.446074483	12.77184453	59.0	0.00047263	0.0	2.0							2.5397056940000002	81.11156194	348.2583042	-2689.982629	1.0	740.0	1.0	394.0	7.203974336867755	7.484143898931886	0.8383749203690103	5.878304597564299	6.290221430459452	0.9240028523604937	-1.3256697393034553	-1.1939224684724343	0.08562793199148344	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c11a	58cfa830e4b0c9d6adf6c11a	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted.bam	53.44	1.91	0.17	58cfa830e4b0c9d6adf6c11a	TCGA-BS-A0TE-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_3_rg.sorted.bam	Dead	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TE-01A	09066FBF-6A1D-46C9-A4C5-C53340C3D1BA	Primary Tumor	Illumina HiSeq	a687b0ac-0eda-43c1-ab2f-cf8b3d6ffb94	Uterus	35.0	2D1226A1-1C88-422B-9A8D-316BEBEB65FD	250BF272-4CCD-41DB-ABD1-4FE2E304AB21	TCGA-BS-A0TE-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TE	TCGA-UCEC	146.0	s4607	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.MSI	0.23199868699999998	0.24	0.43	6.129520438999999	0.9992	0.39799999999999996	-0.5509	0.0059	0.2777	-0.1802	163.0	846.0	3.186107241	8.12313828	248.0	0.9479735159999999	13.0	13.0							2.9468693760000004	-890.9193263000001	945.3760341	-2259.9083809999997	1.0	146.0	1.0	58.0	7.173651759361996	7.475282545617431	-0.138105689643912	5.524993133774615	5.311959519956893	1.837785291623337	-1.6486586255873819	-2.163323025660538	1.975890981267249	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c11c	58cfa830e4b0c9d6adf6c11c	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted.bam	96.72	1.83	0.13	58cfa830e4b0c9d6adf6c11c	TCGA-BS-A0TD-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TD-01A	FFAA98A0-2B69-46DC-AEE5-C5C3F2ABBC38	Primary Tumor	Illumina HiSeq	8f5ee5b5-1b1c-4af7-a179-4b71cc7c9f12	Uterus	65.0	8BB3A057-8958-4F62-AF81-976DA2E92DF7	3EF9C5ED-860A-4FF2-AA76-C53E9EB2453E	TCGA-BS-A0TD-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TD	TCGA-UCEC		s5219	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.279078817	0.39	0.0	7.274906934	0.2583	0.08900000000000001	-0.6274	-0.2434	0.0135	-0.0307	12.0	1.0	0.358638358	0.866709365	45.0	0.000127184	0.0	0.0							3.121731625	-1451.14176	-459.61542189999994	-1944.74945	0.0	2379.0	0.0	2379.0	7.142629753172045	6.891693645434787	-0.9474633959399157	6.086577078922732	6.5552214088135745	2.5573004401840693	-1.056052674249314	-0.33647223662121295	3.504763836123985	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c120	58cfa830e4b0c9d6adf6c120	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.bam	37.3	1.98	0.16	58cfa830e4b0c9d6adf6c120	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZG-01A	A3810F36-D2B4-4A45-AD08-A4DBFB9D27AA	Primary Tumor	Illumina HiSeq	44c5a52a-3434-4e05-a510-33799f327c93	Thyroid	80.0	3AC025C9-FEC6-4997-8630-085750DC84E0	D030DC18-6E50-4679-8BF9-26A1DAEC8F79	TCGA-BJ-A0ZG-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZG	TCGA-THCA		s12101	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	True	THCA	C3	THCA.1	0.123152778	0.37	0.0		-2.4512	-0.3045	-0.7608	-0.3708	-0.4909	-0.3666	5.0		0.055840935	0.167522806	45.0	0.000188612	0.0	0.0	0.722687179	0.50092858	2.0	2.197224577	9.0	1.0	1.502791456	-450.0748456	-1083.4566320000001	1197.947717	0.0	775.0	0.0	775.0	5.892164063679703	9.362098395765164	0.3916969398546838	6.240470757947919	4.494014645652815	1.8307011173941028	0.34830669426821625	-4.8680837501123495	1.4390041775394191	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c124	58cfa830e4b0c9d6adf6c124	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted.bam	60.12	1.87	0.14	58cfa830e4b0c9d6adf6c124	TCGA-BS-A0TC-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TC-01A	7B7D2D2B-ABE6-4F32-ADD0-3715096995D1	Primary Tumor	Illumina HiSeq	402004c3-b5d0-41ad-990c-203cbf02ec5d	Uterus	69.0	C4C99327-B778-4E29-A111-75569AD38696	99E19D8C-EC6E-45D7-89E5-091D101BF466	TCGA-BS-A0TC-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TC	TCGA-UCEC		s5015	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.POLE	0.154124383	0.21	0.0	2.4361557819999997	-0.4655	-0.08	-0.7104	-0.08800000000000001	-0.5756	-0.1333	642.0	5.0	7.0831562539999995	36.52075365	71.0	0.000531873	0.0	3.0							2.400207497	-1261.5413429999999	-1270.236631	1033.041262	0.0	2602.0	0.0	2602.0	7.50292205118188	7.6476269997149515	0.09487737304578325	5.7111625819538245	6.60617312488679	2.8397280250774095	-1.791759469228055	-1.0414538748281612	2.7448506520316265	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c128	58cfa830e4b0c9d6adf6c128	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.bam	49.61	2.14	0.16	58cfa830e4b0c9d6adf6c128	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RE-01A	08DA7C4C-3067-4BCF-9D7A-78566DF72E69	Primary Tumor	Illumina HiSeq	f7dd44eb-562f-4d27-8c45-5ec7fbf49448	Breast	61.0	270BE245-2239-4E96-A917-79CCA40868BA	D5CE279A-3A7F-43E7-894C-265E9504C3FD	TCGA-B6-A0RE-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RE	TCGA-BRCA		s6769	Harvard Medical School	Duke	United States	NO	TX	N0 (i-)	Infiltrating Ductal Carcinoma	Stage X	A060-02	True	BRCA	C1	BRCA.Basal	0.149228887	0.36	0.4	2.8217284510000002	0.8333	0.273	-0.2232	-0.5676	-0.0488	0.3611	82.0	14.0	1.1390208179999999	3.836701703	288.0	0.7091048329999999	17.0	39.0	0.894199251	3.3422213710000004	42.0	1.285293024	6.0	0.717335695	3.298748757	-753.4718547	817.6360206	-2681.477654	0.0	7777.0	0.0	7777.0	7.628355486323383	6.428417902949751	-0.5029245177362625	5.591473559062344	7.089816385195116	1.618604404575386	-2.0368819272610397	0.6613984822453651	2.1215289223116485	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c12e	58cfa830e4b0c9d6adf6c12e	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.bam	107.99	2.0	0.17	58cfa830e4b0c9d6adf6c12e	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UM-01A	A7C565FC-C711-4B63-9549-4CD74D1F57C2	Primary Tumor	Illumina HiSeq	942f9e1e-4e57-4325-a7d0-0a464cda140a	Uterus	64.0	6F70F18E-5C53-4F1F-A63D-62BD27039B8D	6CD1B997-3123-4934-A06C-14A5CF1BEBFC	TCGA-BS-A0UM-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UM	TCGA-UCEC		s5009	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.	0.32566897100000003			7.749655946	0.465	0.07400000000000001	0.3358	1.6382	0.8292	-0.4396	151.0	537.0	4.933660847	14.49685276											2.627933036	-887.7987085000001	38.69053015	2864.984665	0.0	2644.0	1.0	1454.0	6.00223962027594	8.042845205771565	0.018107490627390588	5.502587297108075	7.650803117995541	2.8594518082823015	-0.4996523231678651	-0.3920420877760238	2.841344317654911	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c12f	58cfa830e4b0c9d6adf6c12f	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.bam	74.26	2.08	0.16	58cfa830e4b0c9d6adf6c12f	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MU-01A	A7329910-B1C7-4A18-B28E-8FAD79121339	Primary Tumor	Illumina HiSeq	c676fa46-db3a-402d-804d-9717141fdae6	Uterus	78.0	F0AF3F30-3D64-4BD8-9A8F-7FF7AB9BB7B0	0BB10C9F-C337-4E2E-A661-9CE12C8BEB35	TCGA-BG-A0MU-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MU	TCGA-UCEC		s5393	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.CN_LOW	0.10618328199999999	0.14	0.01	6.147435517000001	-0.0954	0.003	-0.0688	0.6334	-0.5379	-0.2625	28.0	8.0	0.5855970070000001	1.410756427	89.0	0.049513386	2.0	6.0							1.96470931	-1585.604873	85.67797702	1022.460292	0.0	617.0	0.0	617.0	6.401978616129593	7.308710231612416	-0.43858404069223006	5.4073560409855315	5.922415870492525		-0.9946225751440618	-1.3862943611198908		lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c134	58cfa830e4b0c9d6adf6c134	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.bam	40.26	2.11	0.15	58cfa830e4b0c9d6adf6c134	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RG-01A	9B13927C-7357-44FD-8385-92AE6A656B7D	Primary Tumor	Illumina HiSeq	b38ff19d-a769-4388-81e2-03263bba7985	Breast	26.0	B98AA84F-5144-4062-BADC-32E89368D684	E71ED8ED-7371-4423-83C8-6075A6FC7C39	TCGA-B6-A0RG-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RG	TCGA-BRCA		s5640	Harvard Medical School	Duke	United States	NO	T3	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True	BRCA	C2	BRCA.LumA	0.047395989000000006	0.1	0.16	0.18420608600000002	0.2191	0.027000000000000003	-0.9403	-1.1075	0.4398	0.3648	41.0	52.0	0.331711305	1.779178819	192.0	0.484761299	6.0	30.0		0.0	1.0	0.0	1.0		4.198980786	-121.82593190000001	656.2521141	-1333.6149050000001	0.0	2082.0	0.0	2082.0	8.577409886904785	7.15368343242228	-0.27093749517797916	6.731583196406454	7.320737517085446	1.9065948240470958	-1.8458266904983305	0.16705408466316607	2.177532319225075	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c136	58cfa830e4b0c9d6adf6c136	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.bam	125.71	2.0	0.17	58cfa830e4b0c9d6adf6c136	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UJ-01A	FF82548A-F1BB-4DAA-A8F7-B3831B5843AD	Primary Tumor	Illumina HiSeq	094adbd4-f2af-42bb-9509-0dcfa2c6672f	Uterus	68.0	2EA1339F-A5EB-4552-AC13-858FA70E606E	15FDA615-0A79-4211-B5DE-F61741E8937A	TCGA-BS-A0UJ-01A-12D-A101-02	HG19_Broad_variant	TCGA-BS-A0UJ	TCGA-UCEC		s5221	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.MSI	0.085062536	0.13	0.0	5.2914570780000005	-1.0114	-0.258	-0.2316	0.5293	0.2804	-0.3906	433.0	109.0	15.94382023	45.41483728	111.0	0.000146605	0.0	0.0							2.132239131	-280.80558030000003	-2144.3429170000004	1706.555961	0.0	2506.0	0.0	2506.0	6.490815496981881	8.341716724874226	0.30903032368521577	6.5533358539632145	7.1095730435815945	2.1781938108607664	0.06252035698133396	-1.2321436812926325	1.8691634871755505	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c138	58cfa830e4b0c9d6adf6c138	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.bam	110.21	1.89	0.17	58cfa830e4b0c9d6adf6c138	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UF-01A	F77D7256-2CCF-42A7-9B30-332AC24CA812	Primary Tumor	Illumina HiSeq	33e84ef1-730b-4f0b-9967-bca62c9f631c	Uterus	65.0	C805F55A-322F-4A11-AE0C-4BBC365D1BD6	D1F78FB2-7BB7-4BF7-8EC7-E2E08F579A38	TCGA-BS-A0UF-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UF	TCGA-UCEC		s5220	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.POLE	0.304054455	0.43	0.0	8.18109162	0.7737	0.141	0.3937	1.4788	0.366	0.0298	2950.0	205.0	49.16358748	221.0362917	43.0	0.0018056329999999998	0.0	0.0							1.9916199140000002	-968.8552356	-145.1185618	-1528.7345189999999	0.0	2611.0	0.0	2611.0	7.0915231577690605	7.586127173959927	-0.5185352490186715	6.634764755273345	7.010763029056365	2.264886009778275	-0.4567584024957152	-0.5753641449035616	2.7834212587969462	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c13a	58cfa830e4b0c9d6adf6c13a	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.bam	116.56	1.88	0.15	58cfa830e4b0c9d6adf6c13a	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0U8-01A	FB7475DF-30CC-4316-B9AC-37CBEEB6BA2B	Primary Tumor	Illumina HiSeq	44c78212-4860-4cf3-bd54-0e8e150cd0b1	Uterus	55.0	E3E23393-8597-4091-A343-CD544111C63B	89AB037F-B001-486F-A7EB-37AF8FBD0677	TCGA-BS-A0U8-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0U8	TCGA-UCEC		s4261	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.MSI	0.069198447	0.14	0.0	5.831079655	0.5119	0.27899999999999997	-0.8487	-0.0104	-0.9113	0.0587	187.0	856.0	3.9599017689999996	10.31169051	79.0	0.0034286	0.0	0.0							2.9557330389999996	-870.1259506000001	118.77559529999999	-1081.408362	0.0	2963.0	0.0	2963.0	6.509294991497383	6.786977378576518	-0.9458419903903815	6.0466714695492705	6.579338013798273	1.1698554423897973	-0.46262352194811296	-0.2076393647782444	2.1156974327801787	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c13e	58cfa830e4b0c9d6adf6c13e	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina.bam	19.16		0.08	58cfa830e4b0c9d6adf6c13e	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-A44B-01A	B809C2F2-185C-496A-A1D4-589294443A1D	Primary Tumor	Illumina HiSeq	148c4a68-bab6-4ff6-bcd7-fc69c33bea94	Kidney	70.0	07C08E8F-4DCA-42E4-9954-C62C32FED225	88E35D25-D98D-4576-8EBE-1CD74010ECD8	TCGA-B9-A44B-01A-11D-A25F-10	GRCh37-lite	TCGA-B9-A44B	TCGA-KIRP		s11860	Baylor College of Medicine	UNC	United States	NO	T3b	NX	Kidney Papillary Renal Cell Carcinoma	Stage III	A25F-10	True	KIRP	C3	KIRP.C2b	0.060410659000000005	0.2	0.2		-0.9014	-0.342	-1.004	-1.6708	-0.9668	-0.1279	44.0	260.0	0.92941447	3.170943486	139.0	0.662950582	12.0	21.0				0.0	1.0		2.282502386	-927.9435083999999	-1644.809002	1962.40715	0.0	361.0	0.0	361.0	7.461394056451693	0.30572524221225095	-0.3031021029011075	6.2292503751590615	3.8661085610673105	2.022891080990953	-1.2321436812926327	3.5603833188550595	2.3259931838920602	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c140	58cfa830e4b0c9d6adf6c140	TCGA-BA-6872-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-BA-6872-01A-11D-A32X-10_wgs_Illumina	TCGA-BA-6872-01A-11D-A32X-10_wgs_Illumina.bam	89.7	1.9	0.07	58cfa830e4b0c9d6adf6c140	TCGA-BA-6872-01A-11D-A32X-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-6872-01A	3E5F451A-5882-4914-AE1A-95C898C2BCCA	Primary Tumor	Illumina HiSeq	28a6e3a3-207f-4df1-bdb3-c63373ce9ba2	Head and Neck	47.0	04107A58-667D-4712-B972-61837EFF6029	C76F7FCC-2748-4B6D-805E-D21652DD5E3A	TCGA-BA-6872-01A-11D-A32X-10	GRCh37-lite	TCGA-BA-6872	TCGA-HNSC	384.0	s16028	Baylor College of Medicine	UNC	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		A32X-10	True	HNSC	C2	HNSC.Basal	0.191836898	0.42	0.25		0.6939	0.285	-0.3928	-0.1778	1.4231	0.7076			0.9729562390000001	4.30459427	290.0	0.6123593079999999	13.0	29.0	0.938805034	1.510948415	5.0	1.098612289	3.0	1.0	2.538754102	58.36163002	565.092791	-70.19127055	1.0	384.0	1.0	384.0	6.590667281491385	3.298013817493798	-1.0295330775497749	5.743369421104182	4.02618607344516	1.4729395316382217	-0.8472978603872034	0.7281722559513621	2.5024726091879965	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c147	58cfa830e4b0c9d6adf6c147	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted.bam	411.0	1.9	0.14	58cfa830e4b0c9d6adf6c147	TCGA-B7-5818-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-B7-5818-01A	6E03B415-84A1-4B91-8717-1A41EDD4A255	Primary Tumor	Illumina HiSeq	e2875187-aeca-43f4-85d8-13ecd0452ec3	Stomach	62.0	FD97CDF5-0F7F-48A2-B5DA-5C5F56A89166	0EBF1A63-C6E4-49FE-B21B-AE46FF14261D	TCGA-B7-5818-01A-11D-1598-02	HG19_Broad_variant	TCGA-B7-5818	TCGA-STAD		s15372	Harvard Medical School	Cureline	Russia	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1598-02	True	STAD	C2	GI.EBV	0.209524916	0.29	0.01		0.456	0.2935	0.5016	0.6304	-0.3767	0.0536			2.8936743710000004	9.339978661	106.0	0.24794421600000002	6.0	9.0	0.84995006	3.325024187	50.0	4.553101348	107.0	0.974377943	1.038937985	-707.1105459	71.76064057	1624.563314	0.0	356.0	0.0	356.0	7.994294986415978	6.817699271806282	0.45982683681688163	5.691709893421933	6.99205265895106	1.4767437681025906	-2.3025850929940455	0.17435338714477755	1.016916931285709	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c149	58cfa830e4b0c9d6adf6c149	TCGA-BA-4076-01A-01D-2266-10_Illumina.filtered.	WGS	TCGA-BA-4076-01A-01D-2266-10_Illumina	TCGA-BA-4076-01A-01D-2266-10_Illumina.bam	333.33	1.9	0.05	58cfa830e4b0c9d6adf6c149	TCGA-BA-4076-01A-01D-2266-10_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4076-01A	7DE19081-D5FD-468C-AD0D-F6E3E8B2AD70	Primary Tumor	Illumina HiSeq	62857418-5247-4ae1-8064-d900ef856428	Head and Neck	39.0	FD99FD83-4040-4738-8A5A-E42D36ECFE0E	E2B5C926-491D-430D-8D9C-5C73D7752D1B	TCGA-BA-4076-01A-01D-2266-10	GRCh37-lite	TCGA-BA-4076	TCGA-HNSC	415.0	s16171	Baylor College of Medicine	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		2266-10	True	HNSC	C1	HNSC.Basal	0.077182429	0.15	0.04		0.5787	0.3035	-0.9717	-0.9716	-1.0844	0.2782	71.0	53.0	2.357735115	8.152650339	254.0	0.6594124920000001	9.0	32.0		0.0	1.0	1.039720771	3.0	0.94639463	4.900389623	-579.1640716	443.16475959999997	528.3904353999999	1.0	415.0	1.0	286.0	-1.414868816487168	4.210411292466221	-1.8094635551478357	5.169100975224929	7.5268989879320305	0.5059544437711327	6.5839697917120965	3.31648769546581	2.3154179989189685	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c14d	58cfa830e4b0c9d6adf6c14d	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina.bam	116.7	1.9	0.08	58cfa830e4b0c9d6adf6c14d	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5556-01A	70741B73-9683-42BD-87FC-6A021A70103B	Primary Tumor	Illumina HiSeq	e855f092-899d-469a-981c-5094b07c31ac	Head and Neck	58.0	C00EEDDB-6AE2-48BA-8677-C174E579A724	8294A969-59A1-4D3B-895B-F07E96BF9F7A	TCGA-BA-5556-01A-01D-A32X-10	GRCh37-lite	TCGA-BA-5556	TCGA-HNSC		s16319	Baylor College of Medicine	UNC	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	A32X-10	True	HNSC	C2	HNSC.Basal	0.5222371029999999	0.7	0.25		0.4597	0.092	0.6394	1.5490000000000002	2.4389	0.4684	83.0	2.0	0.904196228	3.390735854	43.0	0.100843956	4.0	0.0	0.8120616620000001	3.224121851	53.0	4.182994321000001	71.0	0.98130623	1.3266321159999999	84.86100472	444.31670599999995	-223.8461371	0.0	725.0	0.0	725.0	6.907755278982138	4.0767426366046395	0.17982912182019595	5.2590966533947565	3.565136067855577	1.931164968897604	-1.6486586255873819	-0.5116065687490625	1.751335847077408	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c156	58cfa830e4b0c9d6adf6c156	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina.bam	155.07	1.9	0.05	58cfa830e4b0c9d6adf6c156	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4117-01A	71B35CD8-ECEE-4599-BB24-B1EF78118423	Primary Tumor	Illumina HiSeq	4d9a1f84-a989-4caa-84d2-36d42c950675	Kidney	48.0	F3871637-192D-4324-9C59-CECFFF436356	6BA5F81A-B7A0-4C18-A112-2E11094EEC85	TCGA-B9-4117-01A-02D-1402-10	GRCh37-lite	TCGA-B9-4117	TCGA-KIRP		s11776	Baylor College of Medicine	UNC	None	NO	T2	NX	Kidney Papillary Renal Cell Carcinoma		1402-10	False	KIRP	C3	KIRP.C1	0.161521491	0.52	0.11		-1.8522	-0.35	0.7154	-0.0457	0.0813	-0.1617	23.0	8.0	0.364204191	1.031911875	111.0	0.9365382459999999	34.0	8.0				3.1079722760000004	23.0	0.9912224559999999	1.7992260180000001	-224.686884	-1539.976279	1697.4752469999999	0.0	14.0	0.0	14.0	6.19915599386327	1.8461081031919013	0.10626391637745924	4.772039638223125	1.9492923394271315	3.3298852203841127	-1.4271163556401456	0.10318423623523021	3.2236213040066533	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c15e	58cfa830e4b0c9d6adf6c15e	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina.bam	379.7	1.9	0.07	58cfa830e4b0c9d6adf6c15e	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-6869-01A	FAFD6F5B-1D76-4537-BD1C-E0BD7B4E2166	Primary Tumor	Illumina HiSeq	e35c380b-a1ee-47e3-b382-139ed8640d98	Head and Neck	62.0	F4ED2C84-39F8-4AB3-8762-A9920ACC2432	3E604A1C-B95F-44FF-9723-E2FAC845DA3B	TCGA-BA-6869-01A-11D-A32X-10	GRCh37-lite	TCGA-BA-6869	TCGA-HNSC		s15615	Baylor College of Medicine	UNC	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	A32X-10	True	HNSC	C1	HNSC.Atypical	0.19658439100000002	0.36	0.05		0.2455	0.16899999999999998	-0.6898	0.2055	0.0787	0.2117	190.0	148.0	3.8824355	12.2355543	141.0	0.218232387	4.0	23.0	0.954407067	3.807114566	54.0	2.3025850930000002	10.0	1.0	2.6100083	-218.9219411	-360.02720889999995	-731.0775426	0.0	644.0	0.0	644.0	3.632219420548445	6.084744695764699	0.3706489114971795	4.618714411095849	4.928831553259248	0.42154870930486144	0.9864949905474036	-1.155913142505451	0.050899797807681946	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c164	58cfa830e4b0c9d6adf6c164	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.bam	227.7	1.9	0.15	58cfa830e4b0c9d6adf6c164	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5151-01A	A55FB87D-F606-48A5-82F5-09EACBACF41B	Primary Tumor	Illumina HiSeq	d1067ce4-863a-49f4-9061-d2e677695382	Head and Neck	72.0	63384A6A-9686-44EE-8C8F-22923968C9DE	5B29B8E2-23E6-4E6E-815C-B8D0EF534B14	TCGA-BA-5151-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-5151	TCGA-HNSC		s15488	Harvard Medical School	UNC	None	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Basal	0.43253796	0.38	0.41		0.41700000000000004	0.047	0.19899999999999998	0.2544	1.7321	0.5981	23.0	4.0	0.779458963	1.781620486	83.0	0.150123222	4.0	8.0	0.772382731	3.270350745	69.0	3.842319878	47.0	0.997966903	1.7401504769999998	374.59051989999995	619.688821	-670.8065947000001	0.0	722.0	1.0	517.0	1.433402758495717	5.402259632597754	-0.36990153327040765	5.884340960538451	8.162789638517408	0.9538131711972448	4.450938202042734	2.7605300059196543	1.3237147044676525	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c167	58cfa830e4b0c9d6adf6c167	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.bam	75.83	2.17	0.13	58cfa830e4b0c9d6adf6c167	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z9-01A	86F9ECA0-D1EA-4375-A6BC-055E44B3198A	Primary Tumor	Illumina HiSeq	2fcaeaf0-3a03-4b60-975a-31ac8afe58aa	Thyroid	57.0	AA8578FE-EDB2-4137-B363-FEB2C27D475A	B761F912-BDF6-4F1F-8CD0-0AE9DFC57A59	TCGA-BJ-A0Z9-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z9	TCGA-THCA		s12099	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A10R-02	True	THCA	C4	THCA.4	0.217871907	0.39	0.0		-1.2172	-0.2425	-0.0544	-0.4204	1.2547	0.0277	7.0		0.089773368	0.418942384	79.0	5.73e-05	0.0	0.0	0.9209394479999999	0.638346582	2.0	2.079441542	8.0	1.0	1.230053531	462.43845639999995	-853.0020982000001	1838.2938649999999	0.0	1257.0	0.0	1257.0	6.548714902249186	7.68548867598343	-0.6518536448340781	5.763760172436117	7.3978066035316505	1.7108110723346617	-0.7849547298130681	-0.2876820724517808	2.36266471716874	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c16a	58cfa830e4b0c9d6adf6c16a	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.bam	22.97	1.94	0.13	58cfa830e4b0c9d6adf6c16a	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HK-01A	24334AC1-28A3-4B61-B590-3F51E375B247	Primary Tumor	Illumina HiSeq	c4f3a9e0-4b45-4e06-9320-171c27d9e28d	Breast	81.0	8835B20E-9343-4266-A356-E0343C657130	B96AE5EC-0139-4B8D-8136-B5BFA7AF8987	TCGA-BH-A0HK-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0HK	TCGA-BRCA		s5642	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True	BRCA	C1	BRCA.Normal	0.092307582	0.22	0.02	0.9565014409999999	-0.4276	-0.08	-0.1629	0.0348	-0.2125	0.3257	31.0	9.0	1.0689954609999999	2.316156833	121.0	0.092431989	5.0	10.0	0.980986813	1.578837368	5.0	2.033662344	9.0	0.9255596190000001	2.603010823	-618.5340169	616.3151684999999	2112.084886	0.0	178.0	0.0	178.0	7.746300662231439	6.3132762702188945	0.21063737580898034	5.54907608489522	6.264486106049462	2.07115073934517	-2.197224577336219	-0.04879016416943216	1.8605133635361895	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c16c	58cfa830e4b0c9d6adf6c16c	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted.bam	52.7	1.9	0.16	58cfa830e4b0c9d6adf6c16c	TCGA-BA-5557-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_4_rg.sorted.bam	Alive	FEMALE		HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5557-01A	7E0575CE-670B-4035-8A90-4D35279707B2	Primary Tumor	Illumina HiSeq	bb531fb4-064f-47dd-8231-bd6131866968	Head and Neck	41.0	67D75889-E868-41F2-8255-5D5D1AA0A854	0DDC26B3-2D83-4539-A934-4B0FEF8D1F69	TCGA-BA-5557-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5557	TCGA-HNSC		s15617	Harvard Medical School	UNC	None	NO	T1	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1509-02	True	HNSC	C1	HNSC.Basal	0.6095925670000001	0.72	0.34		0.0426	0.001	1.1183	0.3594	0.8341	1.1797	19.0	0.0	0.49394068399999996	1.016936703	85.0	0.234781762	4.0	15.0				2.557507739	15.0	0.944409279	1.5197382469999998	418.1035657	-120.5935979	-39.51172328	0.0	623.0	0.0	623.0	7.202485980788416	3.3942637998118936	-1.6110401267452452	6.509338800228471	5.40452328746198	-0.24676896590923136	-0.6931471805599454	2.010259487650086	1.3642711608360139	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c170	58cfa830e4b0c9d6adf6c170	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted.bam	31.82	1.93	0.16	58cfa830e4b0c9d6adf6c170	TCGA-BS-A0TG-01A-32D-A101_120407_SN590_0152_AC0C7LACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TG-01A	13F31BCB-BEFD-4ED2-ADC0-DC9E9CE52B75	Primary Tumor	Illumina HiSeq	bbb0de46-a395-47cf-938b-3a6a6c59b9ec	Uterus	60.0	36E44603-A1EE-4A5B-9506-49A9358BF8D0	FABEC5F4-2EF2-41CB-A728-E21D6C49F3F7	TCGA-BS-A0TG-01A-32D-A101-02	HG19_Broad_variant	TCGA-BS-A0TG	TCGA-UCEC		s4795	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_LOW	0.15695473699999998	0.26	0.02	3.678266568	-0.23	0.069	-0.1408	0.385	1.0116	0.6185	21.0	63.0	0.40294985299999997	1.022872705	29.0	0.049828066	2.0	3.0							2.6991662730000003	-502.559104	-351.96308239999996	-3097.313944	0.0	2371.0	0.0	2371.0	7.335373191731434	7.747452902024772	-0.8472475927118217	5.809316888236385	6.705999027196611	1.6850627601156836	-1.5260563034950494	-1.0414538748281612	2.5323103528275053	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c172	58cfa830e4b0c9d6adf6c172	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted.bam	86.95	1.93	0.17	58cfa830e4b0c9d6adf6c172	TCGA-BS-A0U7-01A-21D-A101_120407_SN590_0152_AC0C7LACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0U7-01A	282DDC43-922D-4F1F-80C7-6BA2DE23B7BC	Primary Tumor	Illumina HiSeq	1d76b3a6-ff5e-4092-b273-cc2380e0810c	Uterus	63.0	803C6D51-0EBA-475A-9C3C-7B3401787907	652088F1-AB84-40C7-8B24-FD92A32DFA44	TCGA-BS-A0U7-01A-21D-A101-02	HG19_Broad_variant	TCGA-BS-A0U7	TCGA-UCEC	935.0	s4436	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.19479126100000002	0.4	0.0	0.9654238909999999	0.2997	0.03	-0.1024	0.7726	-0.5823	0.0847	90.0	226.0	1.8571367319999998	4.3510060589999995	66.0	0.090791527	3.0	0.0							2.2683422	-1075.330733	-9.066913768	2869.679393	1.0	935.0	0.0	935.0	6.8544717012003655	7.223295679562314	-0.1168493169911432	5.9606538251782695	6.461155627515417	1.9227968122659265	-0.8938178760220965	-0.7621400520468968	2.0396461292570693	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c178	58cfa830e4b0c9d6adf6c178	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina.bam	374.67	1.9	0.05	58cfa830e4b0c9d6adf6c178	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4115-01A	A121406A-30B2-4717-AE96-EDCB17D911E2	Primary Tumor	Illumina HiSeq	4971043f-212e-4a2c-a9db-7e10c9203ce1	Kidney	53.0	31769C98-8882-44E9-B61B-417903B3E4F5	0ED63D84-D3FE-4289-9255-35F4A03B703B	TCGA-B9-4115-01A-01D-1554-10	GRCh37-lite	TCGA-B9-4115	TCGA-KIRP		s11858	Baylor College of Medicine	UNC	None	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1554-10	False	KIRP	C4	KIRP.C1	0.17224545100000002	0.26	0.0		-0.9269	0.06	0.4987	-0.5494	-0.3537	-0.38799999999999996	14.0	15.0	0.645425991	1.3788646169999998	91.0	0.082005147	4.0	0.0				1.557113098	5.0	0.967488765	2.4011893769999997	-946.2701302000002	-1331.202172	-1204.50506	0.0	803.0	0.0	803.0	7.575698605178792	1.1010283323657148	0.2904533823418495	6.276415621048532	3.078890081227631	3.9969649348952876	-1.2992829841302607	1.9778617488619163	3.706511552553438	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c17e	58cfa830e4b0c9d6adf6c17e	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted.bam	598.33	1.9	0.16	58cfa830e4b0c9d6adf6c17e	TCGA-BA-4074-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4074-01A	A63CA97D-EF31-4118-9547-A6730967290F	Primary Tumor	Illumina HiSeq	da78e5e3-ea94-4ac2-8b21-69809cabb0c7	Head and Neck	69.0	7BC6B159-19B4-4711-961D-830BC9E56493	4786A24C-D127-43FB-9D9C-FF59622B7B24	TCGA-BA-4074-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4074	TCGA-HNSC	462.0	s16168	Harvard Medical School	UNC	None	NO	T2	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Mesenchymal	0.217916472	0.39	0.06		1.4033	0.912	-0.1023	-0.2615	1.0226	0.3959	79.0	71.0	1.093732144	3.4214185010000002	168.0	0.648295559	12.0	27.0				1.5607104090000001	5.0	0.9697239	3.5184408510000003	-109.80266850000001	1332.256111	-990.9211207999999	1.0	462.0	1.0	396.0	6.832384971957361	5.029136080033196	-0.5226585836771958	5.767674234964932	6.589257373955618	0.7014565923848728	-1.0647107369924282	1.560121293922422	1.2241151760620685	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c196	58cfa830e4b0c9d6adf6c196	TCGA-AK-3455-01A-01D-2233-10_wgs_Illumina.filtered.	WGS	TCGA-AK-3455-01A-01D-2233-10_wgs_Illumina	TCGA-AK-3455-01A-01D-2233-10_wgs_Illumina.bam	612.57	1.9	0.05	58cfa830e4b0c9d6adf6c196	TCGA-AK-3455-01A-01D-2233-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-AK-3455-01A	2ED3296A-5B10-40D8-8AF4-90DC031657CD	Primary Tumor	Illumina HiSeq	77412ddb-2013-4e9c-aa60-2ce76f5269a8	Kidney	71.0	2D970196-BEEE-4783-90A1-E313A789DD92	A56CD282-F6C5-4373-B3D8-676562894598	TCGA-AK-3455-01A-01D-2233-10	GRCh37-lite	TCGA-AK-3455	TCGA-KIRC	683.0	s9730	Baylor College of Medicine	Fox Chase	United States	NO	T3b	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2233-10	False	KIRC	C2	KIRC.4	0.282271221	0.44	0.0		-1.4021	-0.1195	0.5638	1.8656	0.4907	-0.4608	32.0	32.0	0.307238025	1.508259396	95.0	0.100649239	2.0	3.0	0.786630167	2.130233981	15.0	4.086051756	132.0	0.836825212	2.153205793	856.153091	-1036.220207	2669.7582239999997	1.0	683.0	0.0	683.0	7.568489161569393	0.20095678926199767	1.298533210129935	5.4602120702496695	2.420460078445905	2.9819298855261938	-2.1082770913197235	2.2195032891839075	1.683396675396259	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c198	58cfa830e4b0c9d6adf6c198	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina.bam	149.07	1.8	0.05	58cfa830e4b0c9d6adf6c198	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4116-01A	4EDD92E1-5DA5-49A3-80E4-FA456AA425B8	Primary Tumor	Illumina HiSeq	23059106-498b-44b7-a1a9-72b42dcd751c	Kidney	75.0	DAC245C0-39A0-40D3-8FE1-E33F97B95D27	E6801359-D1D7-4871-B2FB-180674A2E469	TCGA-B9-4116-01A-02D-1402-10	GRCh37-lite	TCGA-B9-4116	TCGA-KIRP		s11772	Baylor College of Medicine	UNC	None	NO	T2a	NX	Kidney Papillary Renal Cell Carcinoma		1402-10	False	KIRP	C3	KIRP.C1	0.18051490899999997	0.18	0.03		-0.9429	-0.111	-0.0745	-0.4141	-0.0478	-0.0193	26.0	6.0	0.7436136740000001	1.9448357630000002	137.0	0.167568289	4.0	7.0				2.25385759	10.0	0.9788379140000001	2.4704324580000003	49.34449847	-1523.8356449999999	-1543.987715	0.0	627.0	0.0	627.0	7.599401333415814	2.5139493956272023	0.09404515749773801	4.737200452486347	2.298370617076766	0.9389859160275602	-2.862200880929468	-0.2155787785504364	0.8449407585298222	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1a0	58cfa830e4b0c9d6adf6c1a0	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.bam	411.0	1.9	0.14	58cfa830e4b0c9d6adf6c1a0	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-B7-5818-01A	6E03B415-84A1-4B91-8717-1A41EDD4A255	Primary Tumor	Illumina HiSeq	9924779b-8261-4ea6-9925-28dd5a0aed8a	Stomach	62.0	FD97CDF5-0F7F-48A2-B5DA-5C5F56A89166	0EBF1A63-C6E4-49FE-B21B-AE46FF14261D	TCGA-B7-5818-01A-11D-1598-02	HG19_Broad_variant	TCGA-B7-5818	TCGA-STAD		s14963	Harvard Medical School	Cureline	Russia	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1598-02	True	STAD	C2	GI.EBV	0.209524916	0.29	0.01		0.456	0.2935	0.5016	0.6304	-0.3767	0.0536			2.8936743710000004	9.339978661	106.0	0.24794421600000002	6.0	9.0	0.84995006	3.325024187	50.0	4.553101348	107.0	0.974377943	1.038937985	-707.1105459	71.76064057	1624.563314	0.0	356.0	0.0	356.0	8.79346036105272	6.574946693358671	0.45982683681688163	6.8963403761668385	7.855880538820735	1.4767437681025906	-1.897119984885881	1.2809338454620645	1.016916931285709	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1a6	58cfa830e4b0c9d6adf6c1a6	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.bam	58.9	2.0	0.14	58cfa830e4b0c9d6adf6c1a6	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HB-01A	0C1023C0-D2CE-4940-8047-7642F1DC3965	Primary Tumor	Illumina HiSeq	c9a434dc-8ce3-485f-88aa-a2373f6cdfac	Breast	55.0	19193B8F-1E1B-448C-B934-93F25E60D45B	49556237-D73F-4DE9-B5D9-7169DB7A53C5	TCGA-BH-A0HB-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0HB	TCGA-BRCA		s6275	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A060-02	True	BRCA	C2	BRCA.LumA	0.21892633600000003	0.35	0.09	5.581433027	0.4531	0.27399999999999997	0.2835	0.9109	0.7308	0.1735	15.0	49.0	0.269580525	0.92855514	523.0	0.299922647	6.0	27.0	0.9672912379999999	1.5567951919999998	5.0	3.641219045	44.0	0.962218968	2.88687138	-411.2400019	751.3770423	-608.1403228999999	0.0	806.0	0.0	806.0	8.89802401856604	6.476377780566235	-0.8068036889425579	6.455676983196836	7.16952496112618	1.8380366426363484	-2.4423470353692043	0.693147180559945	2.6448403315789064	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1aa	58cfa830e4b0c9d6adf6c1aa	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.bam	213.7	1.9	0.16	58cfa830e4b0c9d6adf6c1aa	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5555-01A	8970F713-4A7A-4125-892C-6A34139371D8	Primary Tumor	Illumina HiSeq	cd7725ec-bc8e-4c93-aba5-19dbdeb78b0d	Head and Neck	54.0	2920CA1C-6035-4350-ADA4-C60D485DBFFF	4AB42DF9-A215-4965-A125-CC0C4122FF06	TCGA-BA-5555-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5555	TCGA-HNSC		s15609	Harvard Medical School	UNC	None	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	True	HNSC	C2	HNSC.Atypical	0.260293503	0.54	0.21		0.807	0.14400000000000002	-0.2171	0.3124	1.0483	0.4242	55.0	0.0	0.815427391	3.5147732389999997	183.0	0.6962147679999999	21.0	32.0	0.917140707	2.9881329610000003	26.0	2.625048159	15.0	0.969349888	2.156071433	-156.5966621	740.8779882	676.6692367	0.0	520.0	1.0	248.0	7.126991205465329	7.979899136803327	-0.028551236691811033	6.316060989249	7.158918584733497	1.5325433971516065	-0.8109302162163288	-0.8209805520698299	1.5610946338434175	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1ae	58cfa830e4b0c9d6adf6c1ae	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina.bam	45.94	1.9	0.15	58cfa830e4b0c9d6adf6c1ae	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4617-01A	A6E960AF-3CA5-42FB-B546-451C2583282D	Primary Tumor	Illumina HiSeq	dbbf365c-a7c9-4093-8ffb-acf0b6eabf20	Kidney	41.0	605B6DD3-552B-403C-98D9-C8B441B37A90	BEF23192-57CD-4301-B7A7-5E82CA62482D	TCGA-B9-4617-01A-01D-1253-10	GRCh37-lite	TCGA-B9-4617	TCGA-KIRP		s11586	Baylor College of Medicine	UNC	None	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma		1253-10	False	KIRP	C3	KIRP.C1	0.062399486	0.17	0.01		-1.8209	-0.19399999999999998	-0.1618	-0.986	-0.6626	-0.5113	25.0	66.0	0.24929011199999998	1.135654954	285.0	0.947764665	14.0	0.0				1.4270610430000001	5.0	0.88668288	1.913686215	-1233.624022	-1964.5944780000002	-188.5024181	0.0	35.0	0.0	35.0	6.843749949006225	0.7735166613518736	-0.4230490828971689	5.80576228215455	2.0876730226943208	4.879260304920406	-1.037987666851675	1.3141563613424472	5.302309387817575	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1b2	58cfa830e4b0c9d6adf6c1b2	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.bam	37.97	2.0	0.16	58cfa830e4b0c9d6adf6c1b2	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MO-01A	734EF97F-807C-480E-8DF9-FEAF041032D2	Primary Tumor	Illumina HiSeq	e165d17d-a860-4111-9ae9-3fb19605cd21	Uterus	63.0	7582CBB9-42D3-496C-991D-D76BEA4C434C	9AD06738-F4A2-47A8-972E-BF8C817326A6	TCGA-BG-A0MO-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0MO	TCGA-UCEC		s5215	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C2	UCEC.CN_LOW	0.06061735	0.78	0.05	9.959492093	-0.59	-0.011000000000000001	-0.2003	0.1056	0.1268	-0.3421	23.0	2.0	0.37797614399999996	1.133928433	41.0	0.043301803	2.0	4.0							2.55841676	-1144.6391310000001	-1238.05468	2878.004304	0.0	1309.0	0.0	1309.0	5.581525158604897	6.169889633622812	-0.19893380280698336	4.3775523542789605	5.049298438235928	2.5310324731833758	-1.2039728043259363	-1.120591195386885	2.729966275990359	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1b6	58cfa830e4b0c9d6adf6c1b6	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted.bam	333.33	1.9	0.15	58cfa830e4b0c9d6adf6c1b6	TCGA-BA-4076-01A-01D-1431_120310_SN590_0145_BD0RGYACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4076-01A	7DE19081-D5FD-468C-AD0D-F6E3E8B2AD70	Primary Tumor	Illumina HiSeq	f67d413c-c33d-4d97-9853-0b00f93f2304	Head and Neck	39.0	FD99FD83-4040-4738-8A5A-E42D36ECFE0E	54F77A3E-290A-4073-8012-4873579E95E9	TCGA-BA-4076-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4076	TCGA-HNSC	415.0	s15749	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C1	HNSC.Basal	0.077182429	0.15	0.04		0.5787	0.3035	-0.9717	-0.9716	-1.0844	0.2782	71.0	53.0	2.357735115	8.152650339	254.0	0.6594124920000001	9.0	32.0		0.0	1.0	1.039720771	3.0	0.94639463	4.900389623	-579.1640716	443.16475959999997	528.3904353999999	1.0	415.0	1.0	286.0	-0.7675321983744094	4.383853152897979	-1.8094635551478357	5.169140117232135	7.5410013172706405	0.5059544437711327	5.936672315606544	3.1571481643726615	2.3154179989189685	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1b8	58cfa830e4b0c9d6adf6c1b8	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted.bam	64.32		0.18	58cfa830e4b0c9d6adf6c1b8	TCGA-BF-A1PZ-01A-11D-A18Z_120612_SN590_0162_BC0VNGACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PZ-01A	455F982C-A067-46AC-BF89-3E535D0FFCA0	Primary Tumor	Illumina HiSeq	61217185-aa8a-467c-ba89-48231f6a81cc	Skin	71.0	2A5EE782-122E-432B-98E0-0849B6F9A3D9	25D65D8B-ED75-47D6-B7F6-95CF26CCBE06	TCGA-BF-A1PZ-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PZ	TCGA-SKCM		s7319	Harvard Medical School	Cureline	Russia	NO	T4a	N0		Stage IIB	A18Z-02	True	SKCM	C2	SKCM.RAS_Hotspot_Mutants	0.1190901	0.1	0.16		0.23800000000000002	0.114	-0.612	-0.7079	0.8755	-0.1944	90.0	1.0	3.0853450660000004	6.42515158			8.0	10.0	0.976344993	2.030252337	8.0	2.3419942519999997	11.0	0.9766874640000001	4.884418477	-602.9931837	71.85575881	-928.5924656	0.0	853.0	0.0	853.0	6.282733927469792	5.956786832226589	0.1120358151302352	5.977352277918611	6.524770869832529	1.2341436819592992	-0.30538164955118186	0.5679840376059393	1.1221078668290638	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1ba	58cfa830e4b0c9d6adf6c1ba	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.bam	65.26	1.97	0.13	58cfa830e4b0c9d6adf6c1ba	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UT-01A	E2B1D0DE-5221-44A1-8FAD-9708A3CADA14	Primary Tumor	Illumina HiSeq	ca5a88b7-6801-435a-aeef-b9ca9d963c17	Uterus	62.0	824D0DBC-293F-4893-A68C-24DEDD437EA5	12674687-D555-40DB-ACC9-7638F85D0661	TCGA-BS-A0UT-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UT	TCGA-UCEC		s4608	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.035815087			0.081570901	-0.0888	-0.094	-1.1244	-1.6898	-0.7071	0.2666	2.0	0.0	0.256639565	0.969527245	63.0	0.7857368779999999	7.0	1.0							2.201572126	-1600.193687	-886.9294057	1637.9586470000002	0.0	2212.0	0.0	2212.0	6.688794145622208	7.5264482736171345	-0.6408194288007696	6.15471165969195	6.61015754174298	1.513475962199913	-0.534082485930258	-0.9162907318741551	2.1542953910006823	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1bc	58cfa830e4b0c9d6adf6c1bc	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted.filtered.	WGS	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted.bam	251.75	1.72	0.15	58cfa830e4b0c9d6adf6c1bc	TCGA-AG-A01L-01A-01D-A077_110406_SN177_0154_B818URABXX_s_1_rg.sorted.bam	Alive	MALE			Rectum Adenocarcinoma	Aligned reads	TCGA-AG-A01L-01A	848A5838-8A06-45A9-A3D6-E4ED47B824AB	Primary Tumor	Illumina HiSeq	f1b7cb66-3e14-4411-b17a-0ad856d8c686	Colorectal	58.0	B034C90B-D0BD-466A-88BA-B61EFD36C6E4	337F94D6-ECFB-4653-A63C-49F0D1893BF0	TCGA-AG-A01L-01A-01D-A077-02	HG18_Broad_variant	TCGA-AG-A01L	TCGA-READ		s2002	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Rectal Adenocarcinoma	Stage IIIB	A077-02	True	READ	C1	GI.CIN	0.054700874000000003	0.22	0.25	11.35399254	0.5942	0.133	-1.12	-0.3961	-1.1479	-0.2256	32.0	4.0	0.46673369600000003	1.835819204	120.0	0.900046233	17.0	5.0								-1560.29285	105.1593271	-254.377135	0.0	0.0	0.0	0.0	6.592907538457587	5.330482644747834	-0.40454733239817164	4.6613861268543735	5.288371159397707	5.895404085912952	-1.9315214116032138	-0.04211148535012654	6.2999514183111245	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1c0	58cfa830e4b0c9d6adf6c1c0	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted.bam	56.7	1.9	0.15	58cfa830e4b0c9d6adf6c1c0	TCGA-BB-4225-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4225-01A	C1F50A22-38DF-41CC-A1F4-F7985504A7AC	Primary Tumor	Illumina HiSeq	4903ac5e-6fa0-41de-b272-c4139a3c0632	Head and Neck	73.0	AC42070B-F4D6-47BE-96AA-A713D66A0072	F7E6BD4D-3E7C-427E-8618-FAFB3731E597	TCGA-BB-4225-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4225	TCGA-HNSC		s16024	Harvard Medical School	Johns Hopkins	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C2	HNSC.Atypical	0.19049693899999998	0.35	0.25		0.9704	0.233	0.447	1.8278	1.3726	0.0134	33.0		0.7415959	1.4831918	127.0	0.860108675	22.0	11.0	0.853089199	4.410884048	176.0	4.756702113999999	125.0	0.9851683990000001	2.761468795	-242.00409759999997	753.5966581	-3679.009725	0.0	146.0	0.0	146.0	7.249136083767851	8.874465456922916	-0.5347411751625486	6.150523795099742	7.862864545244436	1.6718555420025338	-1.0986122886681096	-1.0116009116784803	2.206596717165082	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1c8	58cfa830e4b0c9d6adf6c1c8	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina.bam	102.31	1.74	0.09	58cfa830e4b0c9d6adf6c1c8	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BC-A217-01A	6DCFC418-AB28-4365-95EA-C1AE254F2341	Primary Tumor	Illumina HiSeq	a8b86f30-113b-4e02-98d3-b1dae29380d3	Liver	75.0	C827A8B9-359C-4A6F-B950-839B3FB0C097	2BFF30D5-BE79-4686-8164-7A7D9619D3C0	TCGA-BC-A217-01A-11D-A152-10	GRCh37-lite	TCGA-BC-A217	TCGA-LIHC		s17057	Baylor College of Medicine	UNC	United States	NO	T2	NX	Hepatocellular Carcinoma	Stage II	A152-10	True	LIHC	C2	LIHC.iCluster:3	0.080023226	0.08	0.27		0.3042	0.07200000000000001	-0.2665	0.2111	0.3903	-1.0167	45.0	10.0	0.8081864390000001	2.320277194	574.0	0.79188261	21.0	34.0	0.46681164399999997	0.970707524	8.0	1.791759469	6.0	1.0	4.254714142	-1392.1493560000001	-80.58747347	3891.861006	1.0	1397.0	0.0	1397.0	6.814699698514689	1.740376432401244	0.3199889201386025	5.464772981565673	1.974125900261959	3.6054978451748854	-1.349926716949016	0.23374946786071504	3.285508925036283	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1cc	58cfa830e4b0c9d6adf6c1cc	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted.bam	55.01		0.18	58cfa830e4b0c9d6adf6c1cc	TCGA-BF-A1PU-01A-11D-A18Z_120517_SN208_0300_BC0VYMACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Skin Cutaneous Melanoma	Aligned reads	TCGA-BF-A1PU-01A	3DD5A206-D7F3-42F1-B9CC-4B31C76D495D	Primary Tumor	Illumina HiSeq	26c2ab51-9411-4718-8733-1c3c5ba19602	Skin	46.0	D9C8128A-5990-43C8-AC08-CBDF035213D6	AAC0230D-759F-4B2E-9904-3F7822E6B13C	TCGA-BF-A1PU-01A-11D-A18Z-02	HG19_Broad_variant	TCGA-BF-A1PU	TCGA-SKCM		s7667	Harvard Medical School	Cureline	Russia	NO	T4b	N0		Stage IIC	A18Z-02	True	SKCM	C1	SKCM.BRAF_Hotspot_Mutants	0.07290150299999999	0.08	0.03		0.1199	-0.05	-1.4077	-2.2016	-1.6979	0.2661	36.0		1.012714415	2.2095587230000002			8.0	19.0		0.0	1.0		0.0		1.9015404269999998	-1368.553211	1014.950693	-2119.084451	0.0	387.0	1.0	484.0	7.053091717056422	5.984333921357816	-0.16047772298405705	5.82094803576379	5.670676362502775	-0.1321212476436382	-1.2321436812926327	-0.3136575588550419	0.028356475340418852	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1d6	58cfa830e4b0c9d6adf6c1d6	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina.bam	85.26	1.85	0.09	58cfa830e4b0c9d6adf6c1d6	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BC-A216-01A	4BBDBE77-F3CB-4B64-9826-72DEBB734784	Primary Tumor	Illumina HiSeq	b808f3c9-f5be-4c4d-af62-4389365badbb	Liver	62.0	F8B5247F-5276-4189-9041-2D914482D539	C1D9ED06-7498-4C6C-A0DE-DBF28E868109	TCGA-BC-A216-01A-11D-A152-10	GRCh37-lite	TCGA-BC-A216	TCGA-LIHC		s16672	Baylor College of Medicine	UNC	United States	NO	T3	NX	Hepatocellular Carcinoma	Stage IIIA	A152-10	True	LIHC	C1	LIHC.iCluster:3	0.168912273	0.16	0.07		0.7013	0.0315	-0.2795	0.4947	-0.4007	-0.4818	28.0	1.0	0.434042131	1.600530356	567.0	0.20920491800000002	5.0	20.0	0.90929609	1.7694084890000001	7.0	2.8676876389999997	21.0	0.941917065	2.230385874	-1257.712443	611.6685476	3403.995571	0.0	1351.0	0.0	1351.0	6.641008090185794	1.590753455521261	0.7465819907419503	5.542395801517685	3.336399826719224	2.229856259888461	-1.0986122886681096	1.7456463711979628	1.4832742691465106	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1db	58cfa830e4b0c9d6adf6c1db	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.bam	16.7	1.9	0.13	58cfa830e4b0c9d6adf6c1db	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4224-01A	58574E35-8A30-4207-B127-59FFF7C87A43	Primary Tumor	Illumina HiSeq	44a7ef3f-57df-49e2-80b9-1f0dca51067f	Head and Neck	52.0	077ACD68-8C30-41A6-BB7E-5B014866B807	E2FF93EB-AE22-4C6B-B4D5-181B9393BC64	TCGA-BB-4224-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4224	TCGA-HNSC		s15876	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C2	HNSC.Basal	0.083494882	0.26	0.19		1.3074	0.3855	-0.5595	-1.4027	0.738	-0.1906	33.0	15.0	0.509826928	1.8693654030000002	208.0	0.461543518	15.0	37.0				0.410116318	2.0	0.591672779	1.485900205	-679.6364129	1183.5314349999999	-3659.574743	0.0	278.0	1.0	175.0	7.140905736635371	8.030169753975859	-0.5745717214523746	6.345975861765484	8.030169753975859	-0.27150532486273904	-0.7949298748698879	0.0	0.3030663965896355	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1de	58cfa830e4b0c9d6adf6c1de	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.bam	62.34	1.97	0.15	58cfa830e4b0c9d6adf6c1de	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A0YX-01A	22473AD4-DF39-4716-B558-3C1409D5FA0E	Primary Tumor	Illumina HiSeq	71886c7b-a73b-4c00-9555-5fd61b5e1347	Bladder	70.0	DA614214-F84C-43AB-983C-D9D76CF2D6AE	DC052DFC-26A8-4393-8849-FA954913C622	TCGA-BT-A0YX-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BT-A0YX	TCGA-BLCA		s2867	Harvard Medical School	University of Pittsburgh	None	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	True	BLCA	C1	BLCA.3	0.456947714	0.51	0.04	24.85415126	0.6325	0.2625	0.1189	0.54	-0.3435	0.187	255.0	47.0	5.245224957	16.19178139	91.0	0.10102124800000001	1.0	16.0	0.8128249940000001	2.548608067	23.0	2.500138026	14.0	0.947360256	3.956993026	-487.7126665	247.977994	-2479.3929550000003	1.0	400.0	1.0	326.0	6.634332956072036	7.32634598946073	0.18661286717850523	5.498333135332306	5.963041146565539	1.3126662929945754	-1.13599982073973	-1.3633048428951917	1.1260534258160702	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1e1	58cfa830e4b0c9d6adf6c1e1	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.bam	93.28	1.98	0.17	58cfa830e4b0c9d6adf6c1e1	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MT-01A	082E32C5-7F82-466A-B52D-A3293A8F8E57	Primary Tumor	Illumina HiSeq	3499ad67-e5ed-4030-9fba-fac9fa52f9c5	Uterus	64.0	91F629F5-6938-4F5C-BA2E-1F519CE6B255	23FB2C48-BE95-4169-BB10-00EA361C5687	TCGA-BG-A0MT-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MT	TCGA-UCEC		s5217	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C4	UCEC.CN_LOW	0.14203947	0.19	0.02	5.039507432	0.2185	0.154	0.1154	-0.3731	0.674	-0.3874	14.0	4.0	0.379741038	0.788692924	139.0	0.155629562	3.0	16.0							2.29435229	-854.1064969	-716.326146	-3268.930664	0.0	644.0	1.0	565.0	6.992674963735178	7.529211145336392	0.49185704346035947	6.854524625254361	7.093893074078546	4.477661437107254	-0.13815033848081715	-0.4353180712578455	3.9858043936468945	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1e6	58cfa830e4b0c9d6adf6c1e6	TCGA-AL-3466-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-AL-3466-01A-02D-1402-10_wgs_Illumina	TCGA-AL-3466-01A-02D-1402-10_wgs_Illumina.bam	151.07	1.9	0.05	58cfa830e4b0c9d6adf6c1e6	TCGA-AL-3466-01A-02D-1402-10_wgs_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-3466-01A	9FC40B03-0B56-4B1F-93ED-DBC455AE3FD9	Primary Tumor	Illumina HiSeq	e3c3f7d5-b1b3-4a59-be19-a675fd939ad5	Kidney	41.0	D74C7152-798F-4913-95D3-67AC834204F0	642E1379-1061-40BC-9A4C-F7C191E84D9D	TCGA-AL-3466-01A-02D-1402-10	GRCh37-lite	TCGA-AL-3466	TCGA-KIRP	293.0	s11766	Baylor College of Medicine	Fox Chase	None	NO	T3b	N1	Kidney Papillary Renal Cell Carcinoma	Stage IV	1402-10	False	KIRP	C3	KIRP.C2b	0.16010785800000002	0.36	0.09		0.1059	0.0285	-0.3576	-0.4269	-0.6993	-0.3185	14.0	3.0	0.280575521	0.7856114590000001	470.0	0.974378915	23.0	29.0				0.9839614459999999	3.0	0.8956403059999999	3.732598437	146.8806564	420.1718153	-1421.316635	1.0	293.0	1.0	138.0	6.843749949006225	3.9737615576772356	0.016400367593497056	4.764308407326389	3.4292975747624155		-2.079441541679836	-0.5444639829148201		lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1f2	58cfa830e4b0c9d6adf6c1f2	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted.bam	70.31	1.91	0.17	58cfa830e4b0c9d6adf6c1f2	TCGA-BT-A20N-01A-11D-A14U_120921_SN208_0431_BD1D5FACXX_s_1_rg.sorted.bam	Dead	MALE			Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20N-01A	EBEDAB7C-DD7C-448E-8324-78C86F13BE8B	Primary Tumor	Illumina HiSeq	c7de2a6f-d24f-4be6-98af-307070063116	Bladder	72.0	89EC2DFD-7A0C-4631-958D-D5492BC89F8D	CE801D11-240F-4510-8010-E3D7DA8247FC	TCGA-BT-A20N-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20N	TCGA-BLCA	795.0	s2697	Harvard Medical School	University of Pittsburgh	None	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	True	BLCA	C1	BLCA.1	0.18273757899999998	0.28	0.64	4.155600154	0.9077	0.2925	-1.3335	-1.7928	-1.0122	0.0371	133.0	42.0	2.5769137509999998	6.639342488	274.0	0.7609570240000001	12.0	63.0	0.999495093	0.6927972059999999	2.0	0.6365141679999999	2.0	0.918295834	1.85374376	-1616.745447	1290.213786	-1642.787583	1.0	795.0	1.0	795.0	7.028774901301882	9.438388241076108	0.11491029596169988	5.891696331805976	8.504079003699275	3.6246286613627556	-1.1370785694959058	-0.9343092373768331	3.5097183654010555	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1f6	58cfa830e4b0c9d6adf6c1f6	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.bam	66.56	2.03	0.15	58cfa830e4b0c9d6adf6c1f6	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M4-01A	73E5310D-BA8C-4CBC-AA4F-E06206F898F4	Primary Tumor	Illumina HiSeq	6f34976e-c9a0-4b3f-afb6-d476e4d9f22d	Uterus	60.0	E6E7E411-45CF-47A1-BCF0-7AE800A61A8D	238A1E43-B716-479B-82C8-0E62A30F9BE9	TCGA-BG-A0M4-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M4	TCGA-UCEC		s4429	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C3	UCEC.MSI	0.158953021	0.28	0.0	4.438949876000001	-0.4234	-0.13699999999999998	-0.135	-1.1634	-0.7969	0.1408	213.0	721.0	4.57777271	15.5930383	53.0	0.193923555	8.0	4.0							2.509075648	-1106.318189	-649.7675167	1579.9849609999999	0.0	2167.0	0.0	2167.0	7.342081908697956	8.006700845440367	0.5047223050453975	6.473044061674346	7.119397650439464	2.1793624030168726	-0.8690378470236095	-0.8873031950009029	1.6746400979714753	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1fa	58cfa830e4b0c9d6adf6c1fa	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.bam	476.7	1.9	0.16	58cfa830e4b0c9d6adf6c1fa	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5559-01A	17B17D91-C3DF-4B89-9C10-4DB069AFF656	Primary Tumor	Illumina HiSeq	a6749339-8b87-4219-84dd-8045857cbe79	Head and Neck	71.0	FBEA64F9-B46B-4AF1-BFB2-1791D93977B6	61532C84-EDD9-492D-AF89-99086F87381E	TCGA-BA-5559-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5559	TCGA-HNSC		s16320	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1509-02	True	HNSC	C2	HNSC.Atypical	0.26018771	0.38	0.53		1.0432	0.113	1.101	1.9565	0.8305	0.3911	18.0	0.0	0.629736279	1.63158945	107.0	0.621634606	13.0	16.0	0.746758376	4.241716472	293.0	4.543870013	120.0	0.9491128670000001	1.743283208	-351.369621	1004.2528599999999	-347.4020362	1.0	2083.0	1.0	1614.0	6.132458695612006	8.800800305825987	0.1072899835090717	6.132458695612006	7.53228898036248	1.4125517012204007	0.0	-1.268511325463507	1.305261717711329	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c1fc	58cfa830e4b0c9d6adf6c1fc	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.bam	63.57	1.97	0.15	58cfa830e4b0c9d6adf6c1fc	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M2-01A	9731E0B3-C62D-43CB-8AE7-8F973D69AB19	Primary Tumor	Illumina HiSeq	9dcd7360-a8dc-49cb-bf13-8fb36c436e30	Uterus	62.0	2AF18345-2A71-4574-AC8E-83DDEED3AD57	E59EB8B5-DA68-44B3-BB18-8C42F583B2BA	TCGA-BG-A0M2-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M2	TCGA-UCEC		s4604	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.CN_LOW	0.132626262			17.30347159	0.23199999999999998	0.177	-0.4691	0.2702	-0.0038	-0.1347	11.0	7.0	0.315592628	0.774636452	88.0	0.9193151359999999	10.0	13.0							2.82288144	-762.2666582	-29.23871254	566.0926182	0.0	637.0	0.0	637.0	6.682287600403836	7.093532396903248	-2.446201877964183	6.51798454911256	6.714042775198344	1.9245659614946287	-0.16430305129127643	-0.3794896217049035	4.370767839458812	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c206	58cfa830e4b0c9d6adf6c206	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted.bam	77.69	1.98	0.17	58cfa830e4b0c9d6adf6c206	TCGA-BT-A20W-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20W-01A	4DC5CFFE-ED8C-47AB-B5FC-F9615B5414F7	Primary Tumor	Illumina HiSeq	a817f2b5-a06a-422e-869a-694baf6bb127	Bladder	71.0	CA14F475-1BE4-450C-80C3-7094D23D0B3D	A32E59E0-242F-465D-8277-E0FE26124091	TCGA-BT-A20W-01A-21D-A14U-02	HG19_Broad_variant	TCGA-BT-A20W	TCGA-BLCA	254.0	s3085	Harvard Medical School	University of Pittsburgh	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A14U-02	True	BLCA	C1	BLCA.2	0.27540437100000004	0.28	0.74	4.888273648999999	0.7563	0.1835	-0.3294	0.7284	-0.2163	0.1506	36.0	7.0	0.570086545	2.160327959	330.0	0.491498975	3.0	18.0		0.0	1.0	2.725550396	16.0	0.98303451	3.427676378	-1080.505764	635.2688836	-1955.8732989999999	1.0	254.0	0.0	254.0	6.897517869888917	7.551106020016617	0.6270490022307276	5.55862574766361	6.073004109643603	1.6061481510046713	-1.3388921222253067	-1.4781019103730135	0.9790991487739438	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c208	58cfa830e4b0c9d6adf6c208	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.bam	252.7	1.9	0.15	58cfa830e4b0c9d6adf6c208	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5558-01A	6A1AA50C-097C-4E04-8DDD-12D50F8A5AC2	Primary Tumor	Illumina HiSeq	4116c10d-23f4-49f2-bd5a-9b9466f08bfb	Head and Neck	65.0	EB749281-B3DC-43E4-812E-F5F5004A21ED	41737268-345A-4F87-B2DB-E184247E1396	TCGA-BA-5558-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5558	TCGA-HNSC		s15610	Harvard Medical School	UNC	None	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1509-02	True	HNSC	C2	HNSC.Basal	0.419550483	0.55	0.06		0.5506	0.209	0.4158	0.3275	1.5721	0.474	62.0	114.0	1.78434563	3.2571388480000003	107.0	0.255821786	7.0	23.0	0.794482055	2.7282412089999997	31.0	2.841460038	19.0	0.965025955	4.298240253	-287.9255068	44.82522319	-968.57247	0.0	1995.0	0.0	1995.0	6.53233429222235	4.35833299629159	-0.7449337743079882	5.999529761737584	4.622069944571054	1.0329490539976065	-0.532804530484766	0.2637369482794636	1.7778828283055947	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c20b	58cfa830e4b0c9d6adf6c20b	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted.bam	747.33	1.9	0.16	58cfa830e4b0c9d6adf6c20b	TCGA-BA-4078-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_1_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4078-01A	C7353D6A-82A2-4A0D-8CD4-8C8957943EDB	Primary Tumor	Illumina HiSeq	aaa9123e-a827-4226-9b51-0b04709fadb2	Head and Neck	83.0	2027EDE3-13F5-40F6-BEF6-16704981D676	66A9CFF2-397E-415E-BF54-9A75CCC80BDE	TCGA-BA-4078-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4078	TCGA-HNSC	276.0	s15493	Harvard Medical School	UNC	None	NO			Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C1	HNSC.Classical	0.058146823	0.14	0.02		0.9576	0.18899999999999997	0.1094	-0.1404	-0.0517	0.7533	206.0	13.0	3.6177075710000004	10.59875265	123.0	0.946944778	13.0	24.0	0.939010785	1.511279557	5.0	3.548582422	37.0	0.982736941	4.201370432	-1943.585812	886.3957972000001	-1467.064857	1.0	276.0	1.0	276.0	7.243370005189221	6.636493212891534	0.02426292283791276	5.356300356156842	6.636493212891534	0.8085118353520472	-1.8870696490323793	0.0	0.7842489125141344	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c21a	58cfa830e4b0c9d6adf6c21a	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted.bam	422.7	1.9	0.15	58cfa830e4b0c9d6adf6c21a	TCGA-BA-5153-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5153-01A	B3631718-9E0A-454C-BEE1-8F36EBC509D8	Primary Tumor	Illumina HiSeq	3bd56918-8f2b-4486-86ea-e479c2cab413	Head and Neck	51.0	2DC7070A-9C70-4BB1-9634-8C934BB9C8D1	F14D0AA8-E7BB-4E0E-B887-DA7B6FA0BC86	TCGA-BA-5153-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-5153	TCGA-HNSC	1762.0	s16316	Harvard Medical School	UNC	None	NO	T2	NX	Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C1	HNSC.Atypical	0.19296574600000002	0.21	0.0		1.0455	0.008	0.3007	1.5749	0.3267	0.1753	26.0	9.0	0.224900708	1.0120531879999999	70.0	0.177316565	4.0	21.0	0.8830786979999999	4.256687971	124.0	3.859637123	57.0	0.954634722	2.032251551	-479.9166973999999	986.7012609	-2167.6783969999997	1.0	1762.0	1.0	1522.0	6.229882158146566	7.052679855436104	-0.5063350184088836	5.3580431888432445	5.793137199955356	1.9580246795230796	-0.8718389693033215	-1.2595426554807472	2.4643596979319633	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c224	58cfa830e4b0c9d6adf6c224	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.bam	49.75		0.15	58cfa830e4b0c9d6adf6c224	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LS-01A	185E1520-92EE-4AF5-AF15-FBEEFB352C99	Primary Tumor	Illumina HiSeq	3c012d75-0d17-4b4d-834f-cd4767f6b023	Cervix	37.0	79248694-77E1-4FBE-8C94-64A308FC982D	DE7180EF-3E7E-43D5-8ACE-C7ED57992345	TCGA-C5-A2LS-01A-22D-A232-26	HG19_Broad_variant	TCGA-C5-A2LS	TCGA-CESC		s1356	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Endocervical Adenocarcinoma of the Usual Type		A232-26	True	CESC	C1		0.186497605	0.29	0.0	21.07986872	1.0935	0.177	-1.2337	-0.6318	-0.371	-0.5744	26.0	7.0	0.52311665	0.9780006929999999	46.0	0.095367947	4.0	7.0				1.098612289	3.0	1.0	3.0596232210000003	-561.5375481000001	804.8836209	-1568.471044	0.0	1345.0	0.0	1345.0	7.410347097821024	6.750516502555646	0.6184169308503621	5.159055299214529	5.83422577068149	1.987137230919335	-2.251291798606495	-0.9162907318741551	1.3687203000689727	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c226	58cfa830e4b0c9d6adf6c226	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted.bam	96.07	1.92	0.15	58cfa830e4b0c9d6adf6c226	TCGA-BS-A0UV-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_5_rg.sorted.bam	Alive	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UV-01A	B19425AB-A82F-4C2A-BF58-D1BD30511D74	Primary Tumor	Illumina HiSeq	91fbcf9b-f514-49ff-925b-08d6244293f7	Uterus	55.0	30945527-528A-448E-8DB4-2E0C31C9016D	A0F51177-4C00-4F97-8CD4-2E05B63B00DE	TCGA-BS-A0UV-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UV	TCGA-UCEC		s5222	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C1	UCEC.POLE	0.23965756100000002	0.3	0.03	5.503024184	1.1051	0.376	-0.5525	-0.0092	-0.9237	-0.0587	4486.0	68.0	62.56139746	234.4795886	142.0	0.12549843800000002	4.0	2.0							3.9565936560000003	-1650.764849	859.9955373	-1785.246516	0.0	2228.0	0.0	2228.0	6.892797817964535	4.733097670716247	-0.5322881277070463	5.961239613959592	6.621849405931612	0.6810258200276005	-0.9315582040049435	1.888751735215365	1.2133139477346466	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c22c	58cfa830e4b0c9d6adf6c22c	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted.bam	12.85	1.87	0.15	58cfa830e4b0c9d6adf6c22c	TCGA-BT-A0S7-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_4_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A0S7-01A	68BC786E-07C7-4964-BC88-5E2A8633626A	Primary Tumor	Illumina HiSeq	55a63ec5-a803-44ee-905f-c7bfff9162d6	Bladder	75.0	A9B73851-4609-4DF7-8EB8-45A56F4B2DD6	F415813D-F975-492B-9E4E-55CE47C967B9	TCGA-BT-A0S7-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BT-A0S7	TCGA-BLCA	200.0	s3269	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	True	BLCA	C1	BLCA.3	0.34405746299999995	0.71	0.27	0.7058478909999999	0.8849	0.3105	-0.6301	-0.0411	-1.5973	-0.0241	23.0	56.0	0.33965670299999995	1.01897011	130.0	0.287154934	19.0	22.0		0.0	1.0	0.0	1.0		5.829662532	-1345.333632	983.9912744999999	-2842.560902	1.0	200.0	1.0	200.0	6.770180006600592	6.657699798153962	0.3380578165244592	5.353113986813948	5.905712117571082	0.9902543934713093	-1.417066019786644	-0.7519876805828791	0.6521965769468501	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c236	58cfa830e4b0c9d6adf6c236	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.bam	64.48	1.98	0.16	58cfa830e4b0c9d6adf6c236	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z3-01A	331CAE6E-2868-4C58-9302-709A9FF7D025	Primary Tumor	Illumina HiSeq	ddae4f5a-aed4-4466-9434-23f6ed312d19	Thyroid	33.0	6BF032C1-B7D5-4B1C-BF41-C9BFEAFA5E7A	3D0982B1-944E-4C03-AAA4-F8FD4602D4C9	TCGA-BJ-A0Z3-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A0Z3	TCGA-THCA		s12628	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True	THCA	C3	THCA.2	0.34470090700000006	0.46	0.0		-0.9094	-0.1525	0.5793	2.2328	-0.1904	-0.0528	2.0		0.02901066	0.1450533	59.0	2.7000000000000002e-05	0.0	0.0	0.922860782	4.221821351	97.0	4.52809852	96.0	0.9920580840000001	2.167110398	364.70817139999997	-897.1891097000001	2692.235347	0.0	497.0	0.0	497.0	6.678866086371848	7.856456255007047	0.505553203819418	5.682532646824156	7.322373769076789	1.83921132228698	-0.996333439547691	-0.534082485930258	1.3336581184675618	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c23a	58cfa830e4b0c9d6adf6c23a	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted.bam	26.04	1.91	0.17	58cfa830e4b0c9d6adf6c23a	TCGA-BT-A20R-01A-12D-A16N_120920_SN1222_0151_BD1D5CACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20R-01A	F8780A4B-7F55-41D1-BF92-8513955D150E	Primary Tumor	Illumina HiSeq	e997f623-927f-4dae-8fe9-590eef9a9f59	Bladder	79.0	20231B7F-CB6A-4CD0-9C46-10D4E959D483	78460059-E3A1-40F1-89B5-2F69C6E2E0F1	TCGA-BT-A20R-01A-12D-A16N-02	HG19_Broad_variant	TCGA-BT-A20R	TCGA-BLCA	154.0	s2696	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A16N-02	True	BLCA	C2	BLCA.2	0.215896957	0.54	0.27	2.366813163	0.4369	0.201	0.1604	-0.6882	0.6785	0.5707	130.0	42.0	2.274320035	6.852496728999999	122.0	0.430756429	13.0	27.0				0.47413931299999995	2.0	0.6840384359999999	5.759216547	-930.7162933000001	1005.8694	-1965.275898	1.0	154.0	0.0	154.0	7.002889490225724	7.065805488607648	-2.178169900791021	5.82175617786961	6.970495308803322	1.2690732179320752	-1.1811333123561134	-0.09531017980432477	3.447243118723096	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c23c	58cfa830e4b0c9d6adf6c23c	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.bam	51.24		0.18	58cfa830e4b0c9d6adf6c23c	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LB-01A	D17A5AB1-3789-4652-AFF5-D8F4F2291F9C	Primary Tumor	Illumina HiSeq	de67212f-594e-409c-bd19-3d40f013b89a	Bladder	73.0	7C6178A6-6D4C-4DEF-B4AC-A064AB4A6C8A	FAD087E0-3752-4144-960B-659B59312C92	TCGA-BT-A2LB-01A-11D-A18D-02	HG19_Broad_variant	TCGA-BT-A2LB	TCGA-BLCA		s3087	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A18D-02	True	BLCA	C2	BLCA.2	0.286018042	0.5	0.13	4.931538417	0.3173	0.19899999999999998	-0.0126	0.4329	1.1926	0.4914	225.0	59.0	6.4367728820000005	14.75966991	170.0	0.7070564690000001	22.0	23.0	0.957965554	3.0444660989999996	24.0	2.9785084210000004	20.0	0.994250537	4.889354961	-968.8577431	314.4240093	-1355.669694	1.0	492.0	0.0	492.0	6.486330151295243	7.235001412230057	0.9704291592715386	5.765783996547183	5.848707051110166	2.0485602278783706	-0.7205461547480598	-1.3862943611198906	1.078131068606832	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c23e	58cfa830e4b0c9d6adf6c23e	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina.bam	66.53		0.07	58cfa830e4b0c9d6adf6c23e	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BW-A5NQ-01A	C7F1B389-AEC7-4993-8AFB-B7A56064F8FC	Primary Tumor	Illumina HiSeq	4bbd34a1-0024-44aa-9e51-9ac4c51c7f1d	Liver	63.0	C8FFE03A-62C3-4B47-9DEA-CB3377F59ABB	E30C64D5-E796-4CFC-8DC8-6E62BF97822F	TCGA-BW-A5NQ-01A-11D-A27I-10	GRCh37-lite	TCGA-BW-A5NQ	TCGA-LIHC		s16848	Baylor College of Medicine	St Joseph's Medical Center (MD)	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A27I-10	True	LIHC	C2	LIHC.iCluster:3	0.373025868	0.63	0.01		0.701	0.3385	0.3662	1.3426	0.2133	-0.8604	42.0	53.0	0.824635604	2.391443251	57.0	0.880727287	29.0	3.0	0.7687681209999999	2.8548758210000003	41.0	2.913089005	27.0	0.883869294		-920.1274331000001	840.1991373999999	2666.560234	0.0	0.0	0.0	0.0	6.0127366823835215	3.157000421150114	1.3975740529678449	4.531132141459306	2.8883944957591465	1.5624876113147035	-1.4816045409242158	-0.2686059253909674	0.1649135583468586	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c246	58cfa830e4b0c9d6adf6c246	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted.bam	747.33	1.9	0.16	58cfa830e4b0c9d6adf6c246	TCGA-BA-4078-01A-01D-1431_120612_SN590_0161_AC0VUTACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-4078-01A	C7353D6A-82A2-4A0D-8CD4-8C8957943EDB	Primary Tumor	Illumina HiSeq	cf3b040a-b4be-41ce-a172-1a295ebd79b2	Head and Neck	83.0	2027EDE3-13F5-40F6-BEF6-16704981D676	66A9CFF2-397E-415E-BF54-9A75CCC80BDE	TCGA-BA-4078-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-4078	TCGA-HNSC	276.0	s15877	Harvard Medical School	UNC	None	NO			Head and Neck Squamous Cell Carcinoma		1431-02	True	HNSC	C1	HNSC.Classical	0.058146823	0.14	0.02		0.9576	0.18899999999999997	0.1094	-0.1404	-0.0517	0.7533	206.0	13.0	3.6177075710000004	10.59875265	123.0	0.946944778	13.0	24.0	0.939010785	1.511279557	5.0	3.548582422	37.0	0.982736941	4.201370432	-1943.585812	886.3957972000001	-1467.064857	1.0	276.0	1.0	276.0	7.518314849683589	6.958767674546308	0.02426292283791276	6.345594588861758	7.803464753233453	0.8085118353520472	-1.1727202608218317	0.8446970786871457	0.7842489125141344	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c258	58cfa830e4b0c9d6adf6c258	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.bam	95.63	2.11	0.16	58cfa830e4b0c9d6adf6c258	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z5-01A	0FE3B19A-F5E4-497E-92DA-32FF6C77B066	Primary Tumor	Illumina HiSeq	84ec4e2b-c502-4348-b6ce-ae4a912e603c	Thyroid	58.0	D17746B4-EDEA-45DB-9AD1-5EE4973F007C	0AB5F114-C3CC-4DB4-87DF-1B339DDC54C2	TCGA-BJ-A0Z5-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z5	TCGA-THCA		s12352	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	True	THCA	C3	THCA.3	0.057257191				-1.5336	-0.287	-0.409	-0.5658	-0.5021	-0.3649					60.0	0.011003603999999998						1.609437912	5.0	1.0	1.087547775	-376.80425049999997	-967.6922521	203.392084	0.0	448.0	0.0	448.0	5.982446735868669	6.753437918597781	-0.9738842885231219	4.8613615913485	5.924158563713255	2.1348069477677862	-1.1210851445201686	-0.8292793548845254	3.108691236290908	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c260	58cfa830e4b0c9d6adf6c260	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.bam	48.29		0.14	58cfa830e4b0c9d6adf6c260	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HL-01A	09329A53-D58D-4480-95D8-32043E40DE6E	Primary Tumor	Illumina HiSeq	84c6e022-f737-4fae-a2c7-812ef4f00adf	Cervix	76.0	2A3CC87B-B120-49EC-93E6-8BDDBAE5C97C	04FC6219-3EAC-4BB8-82CA-CD0AA6B0ACE3	TCGA-C5-A3HL-01A-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HL	TCGA-CESC		s1516	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C1		0.208800137	0.34	0.01	4.210388125	1.1024	0.2785	-0.6925	-0.3161	-0.1299	0.1155			0.0	0.0	41.0	0.044891821	0.0	7.0	0.907011542	3.1434624639999997	32.0	1.5607104090000001	5.0	0.9697239	1.955469528	-587.0025987	331.313221	-1991.080905	0.0	621.0	0.0	621.0	5.957455231005234	7.130898830296347	0.21010592517875915	5.146525014788906	6.304220257111879	2.4707940813856037	-0.8109302162163288	-0.8266785731844679	2.2606881562068444	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c266	58cfa830e4b0c9d6adf6c266	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted.filtered.	WGS	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted.bam	43.3		0.15	58cfa830e4b0c9d6adf6c266	TCGA-C5-A1BQ-01C-11D-A20X_140106_SN590_0243_AC371BACXX_s_2_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A1BQ-01C	E77C3F70-08D1-40D3-B038-F09A519423CC	Primary Tumor	Illumina HiSeq	58d97d84-99da-4b08-ae63-7e49f4b861b7	Cervix	65.0	6EF38E19-07AC-4032-8FB4-59129A126D3F	359691B6-9EB5-40F2-8F9E-16AA5A1D32F4	TCGA-C5-A1BQ-01C-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A1BQ	TCGA-CESC	604.0	s1170	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO			Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.266807141	0.29	0.04	18.641328299999998	1.0443	0.371	0.2206	0.7818	0.9508	-0.1752			0.0	0.0	84.0	0.203097319	5.0	15.0	0.9113545809999999	2.730174332	20.0	3.76697443	48.0	0.973076422	1.81783096	-466.406818	687.0667317000001	-522.4802152	1.0	604.0	0.0	604.0	8.262494471446471	5.53880955619686	0.8766602962418644	6.60426639484294	7.395107546562485	1.8932623978678962	-1.6582280766035324	1.856297990365626	1.0166021016260318	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c272	58cfa830e4b0c9d6adf6c272	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.bam	34.66	1.95	0.15	58cfa830e4b0c9d6adf6c272	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZA-01A	4C513413-263E-4C7B-B997-7B688C47B698	Primary Tumor	Illumina HiSeq	787aed3e-08d4-4fa8-93e1-c04216a9875f	Thyroid	67.0	A61A9EC7-B893-44A5-AB6F-A390C168BE88	F3A353BB-07C3-49D1-BED2-2F8F5A328E1C	TCGA-BJ-A0ZA-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZA	TCGA-THCA		s12744	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A10R-02	True	THCA	C3	THCA.1	0.113151734	0.14	0.0		-1.8529	-0.32299999999999995	-0.3753	-0.0727	-0.8744	-0.5342	6.0		0.05663453	0.22653812	49.0	8.94e-05	0.0	0.0	0.903801926	4.288478795	115.0	1.609437912	5.0	1.0	1.3794134530000002	-773.7804901000001	-821.6784187000001	1766.8488730000001	0.0	574.0	0.0	574.0	6.328508049097486	8.111061194320369	-0.5578980085002435	5.615558241241361	7.263763333933166	0.2405197960369425	-0.7129498078561252	-0.8472978603872034	0.798417804537186	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c278	58cfa830e4b0c9d6adf6c278	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.bam	82.72	2.05	0.16	58cfa830e4b0c9d6adf6c278	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K1-01A	40A3ED98-3892-449C-B07E-7B7612BD997E	Primary Tumor	Illumina HiSeq	fb29a0da-eb80-43a5-be71-85cf2d58268c	Uterus	69.0	B514F636-DEE3-45F3-BB31-197CA6A171F1	D4814366-AEF2-453B-8DC7-A731B5E53FE8	TCGA-B5-A0K1-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K1	TCGA-UCEC		s5211	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.CN_LOW	0.093312268	0.18	0.0	3.445768343	0.4276	0.162	-1.0289	-1.1532	-0.9183	-0.1832	18.0	2.0	0.431058129	1.149488344	57.0	1.47e-05	0.0	0.0							2.5984348390000003	-1536.678423	-567.7149147999999	-1368.432288	0.0	1110.0	0.0	1110.0	4.921037503119445	8.245362595615578	-1.4078928550075638	5.455119989049702	7.296282040918432	0.36272476970861156	0.5340824859302575	-0.9490805546971459	1.7706176247161753	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c28c	58cfa830e4b0c9d6adf6c28c	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina.bam	40.09		0.07	58cfa830e4b0c9d6adf6c28c	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AD-A5EJ-01A	613AA3E8-A70B-45A9-9C08-0C2346C8BF00	Primary Tumor	Illumina HiSeq	ce0bf9ea-efa0-4c54-8970-a703051d667e	Colorectal	74.0	F675116A-BFEC-47AE-AC24-9B61DD3CC6C1	711C8A16-3CF8-42D8-B29E-FD1E9EF1C82B	TCGA-AD-A5EJ-01A-11D-A28G-10	GRCh37-lite	TCGA-AD-A5EJ	TCGA-COAD		s13538	Baylor College of Medicine	International Genomics Consortium	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A28G-10	True	COAD	C1	GI.HM-indel	0.24285841	0.32	0.0	10.02232405	0.9002	0.4025	-0.6945	-0.6096	-0.7535	0.1247	663.0	4125.0	12.22771395	37.38963198	66.0	0.011378296000000001	0.0	1.0	0.96889586	2.485168814	13.0	0.0	1.0			-1012.9114210000001	770.8239391	-300.3128526	0.0	0.0	0.0	0.0	7.7929680552854315	3.816573281004203	-1.2345446428301707	5.441592798121954	3.7451872219176536	1.9523410393856038	-2.3513752571634776	-0.07138605908654938	3.1868856822157743	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c290	58cfa830e4b0c9d6adf6c290	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.bam	42.9	1.9	0.14	58cfa830e4b0c9d6adf6c290	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4294-01A	ACAB1362-C8A0-448B-8533-0CD84D97959C	Primary Tumor	Illumina HiSeq	23c036ca-ac6a-45dc-9100-558b2249f3bc	Stomach	65.0	CB5D3EDE-205D-43F6-A3E3-DB287FB1783B	97DB8928-FACC-4095-984F-07C52A759DB4	TCGA-BR-4294-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4294	TCGA-STAD		s15374	Harvard Medical School	Asterand	Russia	NO	T2a	NX	Stomach  Intestinal Adenocarcinoma  Tubular Type		1128-02	True	STAD	C3	GI.CIN	0.025715177999999998	0.06	0.15		-1.6556	-0.191	-0.4333	-0.7799	-1.3092	-0.5503			0.24866263800000002	0.870319233	117.0	0.9082675440000001	16.0	5.0	0.831647303	0.576453983	2.0	1.695742534	6.0	0.946411928		-2304.804164	-1009.140458	4263.08412	0.0	0.0	0.0	0.0	8.572627898304338	8.745489160485183	-0.40329026918180755	7.31986492980897	9.081961397106395	1.0879019269844883	-1.252762968495368	0.33647223662121295	1.491192196166296	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c292	58cfa830e4b0c9d6adf6c292	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	504.59	1.9	0.15	58cfa830e4b0c9d6adf6c292	TCGA-AY-4071-01A-01D-1109-02_IlluminaHiSeq-DNASeq_whole.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AY-4071-01A	315EF7F6-CA21-4D87-8F19-40BD455885EC	Primary Tumor	Illumina HiSeq	0335df8b-3dec-4304-95e5-47210ed06ba3	Colorectal	63.0	7D09112D-53F5-4B72-993A-337C55A0C902	8DE6361C-E9B5-45FF-A328-67B0DED836B9	TCGA-AY-4071-01A-01D-1109-02	HG18	TCGA-AY-4071	TCGA-COAD	29.0	s12887	Harvard Medical School	UNC	None	NO	T1	N0		Stage I	1109-02	True	COAD	C1	GI.CIN	0.163318772	0.4	0.34	0.494969166	0.069	0.046	0.0694	1.1627	0.23199999999999998	0.054000000000000006	71.0	62.0	0.9605915009999999	3.172862836	130.0	0.420760133	14.0	19.0							0.849620011	-904.5439912999999	-496.5165693	946.3406602	1.0	29.0	0.0	29.0	4.655601039614982	4.031748597543868	-0.49169951508304677	3.7462307505854016	4.539973439609801	1.5246877681842337	-0.9093702890295812	0.5082248420659328	2.0163872832672807	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c294	58cfa830e4b0c9d6adf6c294	TCGA-BP-4781-01A-01D-2098-10_Illumina.filtered.	WGS	TCGA-BP-4781-01A-01D-2098-10_Illumina	TCGA-BP-4781-01A-01D-2098-10_Illumina.bam	69.07	1.9	0.16	58cfa830e4b0c9d6adf6c294	TCGA-BP-4781-01A-01D-2098-10_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4781-01A	80C4FC5B-DC7D-4308-8C81-6E83625963B5	Primary Tumor	Illumina HiSeq	d6c662c6-17e1-4d7c-ab4b-9a002c00648b	Kidney	78.0	15423D9C-91C3-4FE5-9880-A28840ACB75A	FBF937F1-5F30-470C-8A77-46CD1C41E073	TCGA-BP-4781-01A-01D-2098-10	GRCh37-lite	TCGA-BP-4781	TCGA-KIRC		s8836	Baylor College of Medicine	MSKCC	None	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2098-10	True	KIRC	C3	KIRC.3	0.13015091				-0.9953	-0.2275	0.8461	-0.2389	0.3376	0.27					111.0	0.457283909						3.376443384	31.0	0.983242855	1.78626717	1090.835458	-1265.507251	2696.981065	0.0	2080.0	0.0	2080.0	8.56389250132178	1.2348827031951366	1.0488011953645706	5.403230413685704	4.15189335054767	2.217716191382063	-3.160662087636076	2.9170106473525337	1.1689149960174923	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c298	58cfa830e4b0c9d6adf6c298	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.bam	48.65	2.08	0.16	58cfa830e4b0c9d6adf6c298	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0GY-01A	7D9D3522-EC3B-4EFE-8C8E-C0E675276EF5	Primary Tumor	Illumina HiSeq	bcac7e1b-ddeb-43d6-ba44-db40336bf564	Breast	67.0	A7E71EAC-1768-4FC2-8EBA-1576D22E0F43	F5C72179-9BDA-4BC6-B006-93EB616804BC	TCGA-BH-A0GY-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0GY	TCGA-BRCA		s6771	Harvard Medical School	University of Pittsburgh	None	NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True	BRCA	C2	BRCA.LumA	0.19402960600000002	0.52	0.02	1.39549361	0.2656	0.07400000000000001	0.1374	0.2782	0.8335	0.4471	11.0	2.0	0.184626735	0.9539047970000001	195.0	0.810152835	26.0	22.0	0.599458419	0.964791106	5.0	2.630253356	15.0	0.971272008	3.093846287	37.4274489	963.5508025	-2200.503779	0.0	923.0	0.0	923.0	8.067149039910106	6.564513514054104	-1.0914801777884628	6.074718875219899	6.8158279423350105	2.10898394389186	-1.9924301646902063	0.2513144282809061	3.2004641216803225	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c29a	58cfa830e4b0c9d6adf6c29a	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.filtered.	WGS	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.bam	91.47	2.12	0.14	58cfa830e4b0c9d6adf6c29a	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JR-01A	A766D113-BC3F-4448-A4E5-F391FB0C0E22	Primary Tumor	Illumina HiSeq	1e3ae5a0-6439-4dba-a151-f107d43c65cf	Uterus	73.0	07381A09-5CBD-4744-86EC-41A81E470204	E4F782AB-1668-4730-95D9-CB28E3CF61FD	TCGA-B5-A0JR-01A-13D-A043-02	HG19_Broad_variant	TCGA-B5-A0JR	TCGA-UCEC		s4786	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True	UCEC	C1	UCEC.MSI	0.145675061	0.26	0.0	24.13367512	0.725	0.239	-0.2897	0.6839	-0.8973	-0.3142	109.0	252.0	5.470589902	15.99777912	60.0	0.118704335	3.0	1.0	0.942157538	1.9591615230000001	8.0	3.0146300139999997	22.0	0.975279395	2.3534116000000003	-1468.9604880000002	-72.32840259	2391.5585730000003	0.0	1731.0	0.0	1731.0	6.126956516545139	7.032697809367686	0.4512213326686184	4.771121362909957	4.2705803869952	1.5735709996049745	-1.3558351536351823	-2.762117422372486	1.1223496669363562	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c29c	58cfa830e4b0c9d6adf6c29c	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted.bam	66.31	1.98	0.16	58cfa830e4b0c9d6adf6c29c	TCGA-BS-A0T9-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_3_rg.sorted.bam	Dead	FEMALE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0T9-01A	4EB95566-0E73-4260-853E-F7DF650667A0	Primary Tumor	Illumina HiSeq	2c61f255-688e-4a53-83fd-bea3b66d5a15	Uterus	39.0	3C9FF865-013F-427A-8D4D-C8E60EA346A1	CB5B905D-7287-41B3-9B49-B2F7FF7D2173	TCGA-BS-A0T9-01A-11D-A12F-02	HG19_Broad_variant	TCGA-BS-A0T9	TCGA-UCEC	1428.0	s4260	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A12F-02	True	UCEC	C1	UCEC.CN_LOW	0.19985227600000002	0.52	0.02	5.146875606	-0.6304	-0.033	-0.4129	0.0008	-0.0573	0.6564	25.0		0.465195331	1.4503148540000002	51.0	0.09686555	4.0	0.0							3.873432345	-1044.2009679999999	-969.1321989	-1423.2404060000001	1.0	1428.0	1.0	634.0	5.834524031593167	7.664933039199219	0.1506194058296748	5.854326658889347	6.971785858639274	6.509327848225623	0.019802627296179764	-0.6931471805599454	6.358708442395948	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c29e	58cfa830e4b0c9d6adf6c29e	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.bam	194.2	1.9	0.15	58cfa830e4b0c9d6adf6c29e	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4366-01A	525A6978-2D7B-4F3A-AC68-13FE8CBBBDCC	Primary Tumor	Illumina HiSeq	c4b9424f-d0da-48ae-8723-69cbccfdefc6	Stomach	87.0	8C2D2CCE-E071-42E8-89B2-77C56B4F3472	5AF4101A-F7F6-4014-BC9C-02446DA9CBDC	TCGA-BR-4366-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4366	TCGA-STAD		s15235	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True	STAD	C4	GI.CIN	0.09180486800000001	0.2	0.26		0.6706	0.10800000000000001	0.2457	-0.3931	0.7791	0.0035			1.041534158	3.34979905	704.0	0.47111474	7.0	43.0	0.597023573	2.122626604	35.0	1.906154747	7.0	0.979569765		565.4768322000001	580.9634718	382.7098045	0.0	0.0	0.0	0.0	7.549959980804508	6.535655864717773	-1.7689862078262482	5.704133290306178	5.773515812670876	0.7381998445008884	-1.8458266904983305	-0.7621400520468968	2.5071860523271363	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2a2	58cfa830e4b0c9d6adf6c2a2	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina.bam	91.4	1.9	0.16	58cfa830e4b0c9d6adf6c2a2	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4807-01A	33CF0893-0411-4758-AA90-602BFEDF0850	Primary Tumor	Illumina HiSeq	929b4e29-102f-48e2-a919-ff967127437e	Kidney	42.0	26307437-2F30-4647-81AC-F6BAE5BE6113	A54AAC0E-4108-49CF-BF50-687031C7CDA6	TCGA-BP-4807-01A-01D-2098-10	GRCh37-lite	TCGA-BP-4807	TCGA-KIRC		s9447	Baylor College of Medicine	MSKCC	None	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2098-10	True	KIRC	C3	KIRC.1	0.117910664				-1.1557	-0.2725	0.8326	-0.0778	0.2673	0.2932					91.0	0.050384751	2.0	5.0				2.890371758	18.0	1.0	1.602125196	560.1990047	-640.0605377	3296.084737	0.0	211.0	0.0	211.0	6.408894823274419	3.746995263910213	0.27241280010694713	5.140383497810912	5.493157141699395	3.8703103009532156	-1.268511325463507	1.7461618777891825	3.5978975008462686	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2a3	58cfa830e4b0c9d6adf6c2a3	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina.bam	32.02		0.08	58cfa830e4b0c9d6adf6c2a3	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B1-A47N-01A	F1EC5A7B-0973-4C38-9908-862196DF9541	Primary Tumor	Illumina HiSeq	57987e56-d118-4f55-98c4-340866fcf3e8	Kidney	62.0	C5EDE5F5-35D2-4059-9F0C-6736ABC6F899	BD2CC59D-F5CE-46ED-BEB0-4C80B24CBE71	TCGA-B1-A47N-01A-11D-A25F-10	GRCh37-lite	TCGA-B1-A47N	TCGA-KIRP		s11855	Baylor College of Medicine	University of Pittsburgh	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True	KIRP	C3	KIRP.C1	0.09216739199999999	0.17	0.1		-2.056	-0.3415	-0.1113	0.1998	-0.3185	-0.4507	12.0	149.0	0.189867504	0.732346086	59.0	0.18266139	8.0	0.0				1.5607104090000001	5.0	0.9697239	2.394762226	-1140.007433	-1875.1469359999999	-342.4053659	0.0	1110.0	0.0	1110.0	7.728132792117677	0.2716552027398844	-0.20200730540194234	6.475369823622309	3.9729571768523773	3.2286564100565482	-1.252762968495368	3.701301974112493	3.4306637154584907	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2aa	58cfa830e4b0c9d6adf6c2aa	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.bam	204.9	1.9	0.15	58cfa830e4b0c9d6adf6c2aa	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4201-01A	8520654B-2192-46CF-9D72-1DDB885A7C55	Primary Tumor	Illumina HiSeq	359db0d8-a78f-4d9d-9a3e-9f1a04472df0	Stomach	66.0	B42CC87B-4BB0-433D-8AFB-CB314B8CBA30	FE12C75F-5A26-40A8-BEF0-742FAD4CD0E5	TCGA-BR-4201-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4201	TCGA-STAD		s14529	Harvard Medical School	Asterand	Russia	NO	T2a	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True	STAD	C2	GI.HM-indel	0.398502426	0.64	0.02		0.6782	0.252	0.8198	0.7311	0.5379	0.4906			12.57900682	38.15732141	96.0	0.07328246	4.0	4.0	0.9220403509999999	3.980898254	75.0	3.2578093989999997	31.0	0.948695847	1.01586962	1016.8346970000001	769.8424	-2515.656477	1.0	940.0	0.0	940.0	7.66262451817008	6.076232596069541	-0.08544412594005824	6.780235337971606	6.931435635963858	0.876621995435439	-0.8823891801984738	0.8552030398943167	0.9620661213754972	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2c4	58cfa830e4b0c9d6adf6c2c4	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina.bam	58.87		0.08	58cfa830e4b0c9d6adf6c2c4	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AD-A5EK-01A	E8EC26BD-C88D-42B9-AC8A-AB121B8140F8	Primary Tumor	Illumina HiSeq	e84aec8b-4304-43e0-96c7-d605fc64dd11	Colorectal	51.0	C48314EE-C778-4B82-8E5A-4923DF4C8413	D0A0D845-32E2-4590-B909-29BD27B92900	TCGA-AD-A5EK-01A-11D-A28G-10	GRCh37-lite	TCGA-AD-A5EK	TCGA-COAD		s13537	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2	N0	Colon Adenocarcinoma	Stage I	A28G-10	True	COAD	C1	GI.CIN	0.039024043	0.16	0.03	14.60143944	0.7377	0.1815	-1.0194	-1.3206	0.1196	-0.0457	48.0	1.0	0.924155792	1.848311584	218.0	0.947589232	21.0	11.0				1.386294361	4.0	1.0	0.9141735990000001	-1183.228917	226.0330866	-2254.79805	0.0	500.0	0.0	500.0	6.3532099478598205	3.054373060855328	-0.7347393236559314	6.183310911064423	5.254534497864857	2.61380267487233	-0.16989903679539742	2.2001614370095295	3.3485419985282614	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2c6	58cfa830e4b0c9d6adf6c2c6	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.bam	42.45	1.95	0.16	58cfa830e4b0c9d6adf6c2c6	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A1HS-01A	A73C0842-39C5-4C2C-AA6A-F31341A4F36E	Primary Tumor	Illumina HiSeq	ed90abf4-1d04-41ce-9de3-9dcf24c1e375	Bladder	75.0	0A01E5BA-5549-4027-9E84-1BBB163A8F07	B8F18CDA-053F-4E40-8978-7524A4C0B49A	TCGA-CF-A1HS-01A-11D-A13U-02	HG19_Broad_variant	TCGA-CF-A1HS	TCGA-BLCA		s2875	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True	BLCA	C2	BLCA.3	0.298075798	0.46	0.5	2.489487476	1.0639	0.38	-0.037000000000000005	-0.5607	0.9484	0.2588	159.0	20.0	2.168840682	6.447101752999999	298.0	0.741083246	14.0	45.0		0.0	1.0	0.693147181	2.0	1.0	1.583941789	-519.6362673	1051.646384	-1024.578941	0.0	382.0	1.0	133.0	7.01204021641303	6.791845487707435	0.16186746800735108	5.941598804711617	6.686484972049609	0.8901819187070881	-1.0704414117014132	-0.10536051565782634	0.728314450699737	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2ca	58cfa830e4b0c9d6adf6c2ca	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.bam	73.32	1.95	0.16	58cfa830e4b0c9d6adf6c2ca	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0RY-01A	F299AD43-BB16-46CE-9617-48CC6C6F29E7	Primary Tumor	Illumina HiSeq	5464e1b6-9efc-49a0-bd5b-4fcd152a7718	Uterus	68.0	260692E1-9B2C-4F8B-952D-1B95C042E659	8DB9ED84-C708-4075-B93D-CC58E84E6D99	TCGA-BG-A0RY-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0RY	TCGA-UCEC		s4258	Harvard Medical School	University of Pittsburgh	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C4	UCEC.CN_LOW	0.156545297			4.503569111	-0.2976	-0.002	-0.166	-1.1196	-0.5660000000000001	0.0425	18.0	9.0	0.47739112899999997	1.3426625509999999	78.0	0.94719405	9.0	4.0							3.174542457	-1445.560606	-681.1824278	1641.8062730000001	0.0	469.0	0.0	469.0	5.569202913847668	6.877811402609065	-1.6607793487164564	4.421800461010126	5.3517550991140155	0.4874870772169655	-1.1474024528375417	-1.5260563034950492	2.148266425933422	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2ce	58cfa830e4b0c9d6adf6c2ce	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted.bam	73.22	2.09	0.15	58cfa830e4b0c9d6adf6c2ce	TCGA-B5-A0JN-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JN-01A	B60F22AC-A659-4F33-B01D-820E86A9A5C9	Primary Tumor	Illumina HiSeq	19c2a28e-bdeb-46af-b33e-e9849fc553ed	Uterus	84.0	684C6894-FD49-4934-8962-9628ECE734FB	EB2131FF-4AE0-4814-81F3-A480A0DEBB2E	TCGA-B5-A0JN-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JN	TCGA-UCEC		s4245	Harvard Medical School	Duke	United States	NO			Serous endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_HIGH	0.08281237799999999	0.26	0.48	7.39572064	0.7825	0.3195	-1.1829	-1.4482	0.2663	-0.1462	91.0	52.0	1.1724863890000001	3.68904254	578.0	0.735750646	9.0	58.0		0.0	1.0	1.33217904	4.0	0.960964047	4.906354498	-1489.7448539999998	-316.0421873	-2144.600779	0.0	2445.0	0.0	2445.0	6.421309523472461	6.798541194008321	0.436756144487884	5.248589262650629	6.144614726601656	1.8959829750988062	-1.1727202608218312	-0.6539264674066638	1.4592268306109222	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2d0	58cfa830e4b0c9d6adf6c2d0	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.bam	52.72	1.93	0.17	58cfa830e4b0c9d6adf6c2d0	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-CE-A27D-01A	75A93F0E-CD41-43C6-A303-FF37E31395E9	Primary Tumor	Illumina HiSeq	c2d55126-05aa-44ef-97c3-ae2ac400c1b9	Thyroid	28.0	1807CEEE-28E1-4E8D-A1C4-6F6AD60EE310	CE991BB3-A63D-40C1-BFAF-3C4498D2C6EE	TCGA-CE-A27D-01A-11D-A16N-02	HG19_Broad_variant	TCGA-CE-A27D	TCGA-THCA		s12362	Harvard Medical School	ILSbio	Vietnam	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True	THCA	C3	THCA.2	0.264828555	0.46	0.01		-0.7718	-0.157	0.8038	2.1947	0.6432	0.0236	2.0		0.029877725	0.119510898	57.0	1.55e-05	0.0	0.0	0.8939771809999999	3.835572838	73.0	4.397995081	88.0	0.9822792570000001	2.019350659	791.4958429999999	-774.8244218	1573.066973	0.0	374.0	0.0	374.0	7.325187707882924	7.5265829265494055	0.06762925875139847	6.28720004103125	6.679285066162201	0.6644185904745754	-1.037987666851675	-0.8472978603872034	0.5967893317231769	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2d1	58cfa830e4b0c9d6adf6c2d1	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina.filtered.	WGS	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina.bam	660.34	1.9	0.16	58cfa830e4b0c9d6adf6c2d1	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B2-4099-01A	1ADB05D4-E1CA-4EDE-81C7-FF24A243ABAE	Primary Tumor	Illumina HiSeq	5a0ccacd-ed1b-47b2-818a-592a0cf426ad	Kidney	83.0	E242ADB8-DB67-475E-A0E4-52A622666B12	252A1C43-F954-44D7-8E31-6BCD0157A05C	TCGA-B2-4099-01A-02D-2095-10	GRCh37-lite	TCGA-B2-4099	TCGA-KIRC		s9732	Baylor College of Medicine	Christiana Healthcare	None	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2095-10	False	KIRC	C4	KIRC.4	0.155410087	0.36	0.18		-0.9849	0.023	1.0439	0.5281	0.6087	-0.2182	33.0	32.0	0.5053564970000001	1.5160694890000002	61.0	0.071146652	1.0	5.0				3.044820482	22.0	0.985046478	1.7894693019999999	69.65365538	-1368.3409	1567.896688	0.0	972.0	0.0	972.0	6.642114223121515	1.7210856288905543	0.6895174125093664	4.749507513346776	4.526344083822379	4.31748811353631	-1.8926067097747392	2.805258454931825	3.6279707010269435	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2d6	58cfa830e4b0c9d6adf6c2d6	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.bam	333.7	1.9	0.15	58cfa830e4b0c9d6adf6c2d6	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6707-01A	DF3DF249-86C2-43D4-ABE1-796CD7DF653F	Primary Tumor	Illumina HiSeq	e2babdbd-1849-48ed-8726-1e3788be6064	Stomach	75.0	36F691AA-B737-4369-AD62-84F987F697A6	AA430360-2BE7-4C92-A10C-52588D8A6061	TCGA-BR-6707-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6707	TCGA-STAD		s14890	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	True	STAD	C2	GI.EBV	0.314321927	0.47	0.05	12.99713931	0.8012	0.3605	0.5224	1.8079	0.455	-0.1421			0.48856874200000006	1.6668815890000002	69.0	0.119751038	8.0	3.0	0.6957997490000001	3.313519428	117.0	4.375688112	109.0	0.9327144820000001	1.006561378	-459.3748624	1008.204753	-2892.1372260000003	0.0	491.0	1.0	426.0	8.300031711779575	7.48080424592826	0.541486276160776	5.9974466187855295	6.439350371100098	1.637355078883135	-2.3025850929940455	-1.0414538748281612	1.095868802722359	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2d8	58cfa830e4b0c9d6adf6c2d8	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted.bam	56.18		0.16	58cfa830e4b0c9d6adf6c2d8	TCGA-BT-A3PH-01A-11D-A221_120902_SN1222_0147_AC195DACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A3PH-01A	932BCDD4-5145-49E8-9A95-8A546396F572	Primary Tumor	Illumina HiSeq	9096dde9-2391-4c22-b816-2057b8adb483	Bladder	76.0	33A83E54-3BE5-4A68-8AB0-D31D0BCD3B67	4C010558-360B-44AF-A980-A1CCDF3AB9C7	TCGA-BT-A3PH-01A-11D-A221-26	HG19_Broad_variant	TCGA-BT-A3PH	TCGA-BLCA	142.0	s2699	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	True	BLCA	C1	BLCA.1	0.070766964	0.17	0.11	9.476114699	0.8282	0.2305	-1.4121	-1.4625	-1.7947	-0.1876	77.0	1.0	3.767455255	11.94487752	138.0	0.754187811	13.0	19.0		0.0	1.0		0.0		2.464404271	-1679.360189	1249.80197	-2682.494776	1.0	142.0	1.0	142.0	6.621938133139869	5.0429506210621815	-2.44797063295605	6.463714127924974	6.697508968776752	-0.32262910252901555	-0.15822400521489444	1.6545583477145702	2.1253415304270344	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2da	58cfa830e4b0c9d6adf6c2da	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.bam	179.2	1.9	0.15	58cfa830e4b0c9d6adf6c2da	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4370-01A	A2A71CB0-9DBD-45CC-8867-DA84500515E7	Primary Tumor	Illumina HiSeq	a1feb789-c851-4608-a5c1-382bb432c4c7	Stomach	74.0	CFB7901B-E4E1-42FE-802D-DCD34F8C4912	B27FAC46-97C3-4262-B8CB-6E15AA75483A	TCGA-BR-4370-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4370	TCGA-STAD		s14883	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True	STAD	C1	GI.HM-indel	0.301009814	0.58	0.07		0.2392	-0.042	0.8189	1.0212	0.8959	0.6018			9.04912713	25.95743501	89.0	0.104253006	4.0	0.0	0.8598084859999999	4.589260536	208.0	3.5538613580000002	40.0	0.963398615		-90.80946252	408.9638104	-1945.6151510000002	0.0	0.0	0.0	0.0	7.048820719260739	6.1872369016260595	-0.2905143624292933	5.390592642657207	5.558628242203685	1.0095096369256868	-1.6582280766035324	-0.6286086594223743	1.3000239993549803	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2db	58cfa830e4b0c9d6adf6c2db	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted.filtered.	WGS	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted.bam	13.51	1.77	0.15	58cfa830e4b0c9d6adf6c2db	TCGA-C4-A0F0-01A-12D-A10R_120926_SN590_0181_AC19HCACXX_s_5_rg.sorted.bam	Alive	MALE			Bladder Urothelial Carcinoma	Aligned reads	TCGA-C4-A0F0-01A	40398C03-A9CC-476B-9EE9-AECF161BE43F	Primary Tumor	Illumina HiSeq	38f56daa-7d69-4fe0-8895-10e22397ee2a	Bladder	60.0	54234A11-8674-4B01-B2EF-A4C6D772AA43	5584A4A7-2EA1-46D8-8960-8905689D5720	TCGA-C4-A0F0-01A-12D-A10R-02	HG19_Broad_variant	TCGA-C4-A0F0	TCGA-BLCA		s2862	Harvard Medical School	Indivumed	Germany	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A10R-02	True	BLCA	C2	BLCA.3	0.254038091	0.61	0.35	3.57439734	1.0972	0.6865	-0.3964	-0.3531	0.8806	0.0325	49.0	90.0	0.940982196	2.309683571	145.0	0.525021365	22.0	27.0				1.732867951	6.0	0.9671320179999999	2.167773619	-1353.133053	1148.315152	-3044.810834	0.0	59.0	0.0	59.0	6.972879566025357	4.028517920293198	0.06870833598922876	6.685197493573575	7.918929767466766	1.2737881223211458	-0.2876820724517808	3.8904118471735685	1.2050797863319171	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2e0	58cfa830e4b0c9d6adf6c2e0	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted.bam	75.72	2.03	0.15	58cfa830e4b0c9d6adf6c2e0	TCGA-BT-A20P-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_3_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20P-01A	F48937ED-E294-41F0-8872-7010391167A9	Primary Tumor	Illumina HiSeq	814688fe-5071-40b6-bb89-643389543580	Bladder	81.0	6B43EEEC-4FEB-4062-827A-E63ED8CE3820	022AEFEC-CBAC-46C1-9F17-AC087BD7164E	TCGA-BT-A20P-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20P	TCGA-BLCA	544.0	s3272	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	True	BLCA	C1	BLCA.1	0.03720472	0.07	0.0	6.055585302999999	0.3534	0.0335	-1.3219	-1.5618	-0.124	-0.1013	22.0	11.0	0.73101978	2.589028386	249.0	0.236864784	7.0	11.0					0.0		2.115935769	-1894.8219210000002	515.8377843999999	-528.2095919	1.0	544.0	0.0	544.0	7.113793362393407	7.8550277484650195	0.2001825674234503	5.909820558067471	6.794155787779758	1.294204182382961	-1.203972804325936	-1.0608719606852626	1.0940216149595108	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2e4	58cfa830e4b0c9d6adf6c2e4	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.bam	487.7	1.9	0.14	58cfa830e4b0c9d6adf6c2e4	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6802-01A	7C831A1D-3253-4AF4-A0FF-7FE9FF9AF1CE	Primary Tumor	Illumina HiSeq	73cec875-41a5-40bd-9d13-9e1ed4dd64d0	Stomach	65.0	E3BF04C2-961F-4511-AF63-5A0E8AE6377B	0B4F4B0B-EF5C-4717-875A-7B8C5342DBC4	TCGA-BR-6802-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6802	TCGA-STAD		s14885	Harvard Medical School	Asterand	Russia	NO	T3	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1880-02	True	STAD	C2	GI.HM-indel	0.518376717	0.67	0.03	10.87630018	0.6916	0.2055	0.4411	1.5288	1.5454	0.3521			4.237968953999999	11.29176963	75.0	0.11765751099999999	4.0	0.0	0.799493178	4.469955951	268.0	4.286752553	133.0	0.87657393	1.283661188	-12.21485429	444.2357221	-676.4832679	0.0	940.0	1.0	807.0	8.08717921038666	8.188133414510478	1.0184299844284217	5.889954633050441	7.271842682636322	1.2422590150337252	-2.197224577336219	-0.9162907318741551	0.22382903060530346	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2ec	58cfa830e4b0c9d6adf6c2ec	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.bam	118.7	1.9	0.15	58cfa830e4b0c9d6adf6c2ec	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6566-01A	43F0421C-6578-4D77-9314-EF0305C7EFBD	Primary Tumor	Illumina HiSeq	ae711b74-3be9-4959-addd-03427c07f35b	Stomach	64.0	EEB8703E-5F0A-429D-9A5C-7C5227EB7A01	7BAAEED3-AA68-4825-84F1-0516B543C762	TCGA-BR-6566-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6566	TCGA-STAD		s14884	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True	STAD	C2	GI.HM-indel	0.365471172	0.53	0.14	9.637525033	0.5982	0.392	0.4579	1.2399	0.4469	0.4414			7.930490425	22.61764417	59.0	0.17096611899999997	4.0	1.0	0.718527813	4.011897391000001	266.0	4.079541565	83.0	0.92321537	2.572225478	-280.8308963	318.1332846	1740.5796879999998	0.0	997.0	0.0	997.0	7.8046592970561015	7.2650800117623655	-0.13418194019164886	5.5020742040620565	6.677293346860247	3.6652985115250294	-2.3025850929940455	-0.5877866649021186	3.7994804517166783	higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c2f5	58cfa830e4b0c9d6adf6c2f5	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.bam	91.7	1.9	0.14	58cfa830e4b0c9d6adf6c2f5	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6803-01A	2F90209B-7464-4D7E-83D1-67850C263DED	Primary Tumor	Illumina HiSeq	af361f62-8dd0-4336-9fa9-41cdc800b18e	Stomach	54.0	E56FE72A-760A-4A60-9013-EA611080BA3F	D2F16739-9EAA-465D-95BA-D13C3AEB9A40	TCGA-BR-6803-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6803	TCGA-STAD		s15308	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IIA	1880-02	True	STAD	C3	GI.GS	0.392919894	0.7	0.23	18.7364255	-0.1669	-0.078	0.5354	1.8066	0.1459	0.4335			0.170342308	0.312294232	81.0	0.196924806	3.0	5.0	0.882452344	5.20879262	366.0	5.335718202	265.0	0.956268201	2.0003593619999998	-686.6269583	-245.8217583	629.8116093	0.0	949.0	0.0	949.0	6.340359303727752	5.7467355301854095	0.3427244278802629	4.143134726391533	4.830444798311255	3.8331529432703606	-2.197224577336219	-0.9162907318741551	3.490428515390098	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c319	58cfa830e4b0c9d6adf6c319	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.bam	27.7	1.9	0.15	58cfa830e4b0c9d6adf6c319	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6705-01A	B14F2FCB-E869-475E-BC7C-ADAF6E7E636F	Primary Tumor	Illumina HiSeq	cf5ffdf8-e424-4a51-862f-816cba0c92e0	Stomach	68.0	DB8D0AC1-23B7-49AB-8BB3-44782156F038	F55A158B-F7DB-4786-9553-65DEBCAE80BA	TCGA-BR-6705-01A-12D-1880-02	HG19_Broad_variant	TCGA-BR-6705	TCGA-STAD		s15239	Harvard Medical School	Asterand	Ukraine	NO	T3	N3a	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIB	1880-02	True	STAD	C1	GI.CIN	0.40756388299999996	0.83	0.38	10.30912604	0.1472	0.0155	0.3162	1.0090000000000001	0.045	0.8693			0.749152831	2.276272062	140.0	0.160026413	4.0	10.0	0.79970664	3.666628938	98.0	3.5737655630000003	59.0	0.87645193	2.600981364	-344.21308650000003	92.57776419	-1211.81859	1.0	779.0	1.0	779.0	7.8595418465411315	7.7619578185428715	-0.485729937040628	6.013715156042801	6.609278308604486		-1.8458266904983305	-1.1526795099383853		higher	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c31b	58cfa830e4b0c9d6adf6c31b	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.bam	82.74	1.89	0.17	58cfa830e4b0c9d6adf6c31b	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TI-01A	DF857BC6-FD6A-4713-BEF9-6EE1301E5FB1	Primary Tumor	Illumina HiSeq	ea49ec05-391f-4ccc-8dbf-11ec80154839	Uterus	64.0	2F52C850-8E70-4EAB-88F3-D35DC55E385B	E1707EDD-FAC5-4213-BA50-2538F9F90EE5	TCGA-BS-A0TI-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TI	TCGA-UCEC		s5010	Harvard Medical School	University of Hawaii	None	NO			Endometrioid endometrial adenocarcinoma		A101-02	True	UCEC	C2	UCEC.CN_HIGH	0.195157742	0.47	0.29	6.070962051	0.5393	0.24100000000000002	-0.0244	0.7521	1.2955	-0.0298	35.0	68.0	0.502615028	2.513075137	317.0	0.510198085	6.0	54.0							2.919436305	-955.3098369999999	17.75719914	-507.7634915	0.0	1882.0	0.0	1882.0	6.700238983553626	7.643782335171782	0.012636333718904824	6.058385097381231	7.015173675749407	1.7310711738278581	-0.6418538861723944	-0.6286086594223743	1.7184348401089533	lower	flr_F1_F2
13722.58cfa830e4b0c9d6adf6c31e	58cfa830e4b0c9d6adf6c31e	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.bam	67.64	2.28	0.18	58cfa830e4b0c9d6adf6c31e	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A27C-01A	7FEE9D6F-C0EA-43C2-89C2-66D965A077A8	Primary Tumor	Illumina HiSeq	ecc65751-9b59-49c3-a142-7a4c61174649	Bladder	52.0	EAD6792B-4E52-4C28-891C-6D8696873A13	1E553EB3-8C42-48A1-87A7-BFA8541CE568	TCGA-CF-A27C-01A-11D-A16N-02	HG19_Broad_variant	TCGA-CF-A27C	TCGA-BLCA		s2873	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A16N-02	True	BLCA	C4	BLCA.1	0.032224743	0.02	0.08	0.9883168609999999	-0.2654	-0.0175	-1.7876	-1.7772	-0.6781	-0.6954	70.0	21.0	1.51435714	3.815015102	160.0	0.19036567399999998	3.0	13.0				1.039720771	3.0	0.94639463	2.4224402990000002	-1631.279844	-441.5982327	1007.6502720000001	0.0	425.0	0.0	425.0	6.0777378045321555	8.664729185221969	0.3608056047970265	5.266807588315826	7.910957382845589	1.9605359767453339	-0.8109302162163288	-0.7537718023763804	1.5997303719483074	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c338	58cfa831e4b0c9d6adf6c338	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted.bam	127.2	1.9	0.14	58cfa831e4b0c9d6adf6c338	TCGA-CG-4476-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_7_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4476-01A	442D7415-D095-4962-8296-A14390BAD40A	Primary Tumor	Illumina HiSeq	87a698be-8fb0-4ced-842b-fdc852b98aa8	Stomach	69.0	37F5444F-A58D-4899-A11B-9C09ECD357FC	0C5818D8-5C20-4E4B-99CF-6F378CA6EBE7	TCGA-CG-4476-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4476	TCGA-STAD		s14983	Harvard Medical School	Indivumed	Germany	NO	T4b	N3a	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIC	1154-02	True	STAD	C2	GI.CIN	0.280260254	0.72	0.25	7.341158127000001	0.2374	0.031	0.8505	1.3030000000000002	0.0439	0.2885			0.715104836	3.175065473	195.0	0.577159466	15.0	24.0	0.901499353	4.005047233	85.0	3.749769882	49.0	0.963500263		114.6021004	685.5125836	613.0811003	0.0	0.0	0.0	0.0	8.990483081653124	7.9253304043168935	-0.6171338118861833	6.953601154392084	7.882770789898098	2.0541237336955467	-2.0368819272610397	-0.04255961441879608	2.67125754558173	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c33c	58cfa831e4b0c9d6adf6c33c	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted.bam	128.2	1.9	0.14	58cfa831e4b0c9d6adf6c33c	TCGA-CG-4475-01A-01D-1154_121026_SN1120_0198_BC188JACXX_s_7_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4475-01A	CAD2ADC1-0F41-4651-9C80-AE9961E2DC8D	Primary Tumor	Illumina HiSeq	8d322c4d-bfdb-40cc-a222-87ff33a87718	Stomach	76.0	3E5D09C6-8F98-4701-BD24-FCA581343DE8	86D8A371-57BB-4DC7-9872-0EB4542208DC	TCGA-CG-4475-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4475	TCGA-STAD		s14706	Harvard Medical School	Indivumed	Germany	NO	T3	N1		Stage IIB	1154-02	True	STAD	C4	GI.CIN	0.174603171	0.57	0.13	19.30040088	0.5432	0.157	0.2667	-0.6874	-0.6055	0.4199			0.562206505	1.264964637	351.0	0.565153096	13.0	60.0	0.911486881	2.582436795	17.0	2.338371705	11.0	0.9751767440000001	1.275797392	611.0768866000001	195.6476907	785.2994304	0.0	699.0	0.0	699.0	8.804175018753625	7.908203318863015	-0.43933711834089173	7.012415549525571	7.243227015269767	0.2591789143722085	-1.7917594692280552	-0.664976303593249	0.6985160327131003	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c342	58cfa831e4b0c9d6adf6c342	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted.bam	128.2	1.9	0.14	58cfa831e4b0c9d6adf6c342	TCGA-CG-4475-01A-01D-1154_130815_VM001_0006_VMR0006CXX_s_5_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4475-01A	CAD2ADC1-0F41-4651-9C80-AE9961E2DC8D	Primary Tumor	Illumina HiSeq	77dce8cf-5642-43d4-8111-4f72d2ef30ef	Stomach	76.0	3E5D09C6-8F98-4701-BD24-FCA581343DE8	86D8A371-57BB-4DC7-9872-0EB4542208DC	TCGA-CG-4475-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4475	TCGA-STAD		s14639	Harvard Medical School	Indivumed	Germany	NO	T3	N1		Stage IIB	1154-02	True	STAD	C4	GI.CIN	0.174603171	0.57	0.13	19.30040088	0.5432	0.157	0.2667	-0.6874	-0.6055	0.4199			0.562206505	1.264964637	351.0	0.565153096	13.0	60.0	0.911486881	2.582436795	17.0	2.338371705	11.0	0.9751767440000001	1.275797392	611.0768866000001	195.6476907	785.2994304	0.0	699.0	0.0	699.0	8.804175018753625	7.908203318863015	-0.43933711834089173	7.012415549525571	7.243227015269767	0.2591789143722085	-1.7917594692280552	-0.664976303593249	0.6985160327131003	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c34a	58cfa831e4b0c9d6adf6c34a	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted.bam	563.0	1.9	0.15	58cfa831e4b0c9d6adf6c34a	TCGA-CG-5718-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_6_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5718-01A	D5C58161-05ED-4472-81ED-176216F49929	Primary Tumor	Illumina HiSeq	98032563-24e7-466c-9f90-1ba67975f2f9	Stomach	78.0	5865A287-63C4-44F7-92D5-C4F3C323AF89	1A108108-EEAC-4EE8-AFD7-871AFA69054B	TCGA-CG-5718-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5718	TCGA-STAD		s14903	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True	STAD	C2	GI.CIN	0.267027506	0.42	0.1		0.5251	0.0645	0.4309	0.9792	0.5435	0.0623			0.694528186	2.112523232	278.0	0.524285718	11.0	38.0	0.811923403	5.2942448980000005	679.0	4.70416155	130.0	0.966436211	3.892365355	-239.98426780000003	-530.3815371999999	3503.6101049999997	1.0	1095.0	0.0	1095.0	7.6817909632754215	6.362781767783584	-0.40685728430406154	5.484566385939202	6.057400118232403	1.2580709848692901	-2.197224577336219	-0.30538164955118186	1.6649282691733518	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c350	58cfa831e4b0c9d6adf6c350	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted.bam	152.0	1.9	0.15	58cfa831e4b0c9d6adf6c350	TCGA-CG-5717-01A-11D-1598_121029_SN208_0438_AC18NJACXX_s_5_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5717-01A	BDC3899E-15AE-421F-829B-0E07FBD27C60	Primary Tumor	Illumina HiSeq	34ec4e75-2398-4904-adf0-34500892e1a5	Stomach	58.0	CEA37BBD-1BCC-4205-BE3D-DAFAC2E30256	64826993-D765-4895-BE39-BE5ECC72807B	TCGA-CG-5717-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5717	TCGA-STAD	212.0	s14488	Harvard Medical School	Indivumed	Germany	NO	T2b	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True	STAD	C2	GI.GS	0.34702931	0.77	0.37		-0.1245	-0.062	0.3252	1.3188	1.3838	0.1066			0.769065825	2.563552751	103.0	0.043015412999999995	4.0	8.0	0.847844094	4.051951628	119.0	4.820342447	142.0	0.9726615540000001	2.503709475	-353.14706689999997	-760.2152597	1206.262271	1.0	212.0	1.0	120.0	7.499976540952122	6.878722492216346	-0.5249396468224238	5.302751963615903	6.447939576123892	1.3523731497534557	-2.197224577336219	-0.4307829160924541	1.8773127965758794	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c356	58cfa831e4b0c9d6adf6c356	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted.bam	281.2	1.9	0.14	58cfa831e4b0c9d6adf6c356	TCGA-CG-4477-01A-01D-1154_130815_VM001_0007_VMR0007CXX_s_2_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4477-01A	18D0AAE7-9694-4252-B8FE-16E62DADAB07	Primary Tumor	Illumina HiSeq	6fb461b5-4d42-4cba-bc62-bb8f68c3deed	Stomach	58.0	6D7C7B4E-6913-487D-9DC3-DDA901434192	3AE56504-30EE-4C03-9F69-C5B415DE6738	TCGA-CG-4477-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4477	TCGA-STAD		s14637	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	True	STAD	C2	GI.CIN	0.30151113	0.51	0.14	31.11498554	0.8605	0.28800000000000003	0.9962	1.3133	1.2385	0.1422			0.9621760090000001	3.0239817419999997	141.0	0.693291047	4.0	34.0	0.828144186	4.774409491	319.0	3.3654988789999996	32.0	0.9710777079999999	0.944525932	752.3872243	413.015928	-2252.340252	0.0	942.0	1.0	365.0	7.793999089503995	5.590412762866599	0.042078838380462336	5.596774512167776	5.382773398088354	1.5620015367534115	-2.197224577336219	-0.2076393647782444	1.519922698372949	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c366	58cfa831e4b0c9d6adf6c366	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted.bam	135.0	1.9	0.14	58cfa831e4b0c9d6adf6c366	TCGA-CG-5720-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_2_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5720-01A	7C9EA4FA-4CBC-4941-945A-E531E1D48304	Primary Tumor	Illumina HiSeq	6cf7bbf9-63f5-40e8-b595-c9012a1825ba	Stomach	71.0	1B2E1B50-8D4E-4E62-9B1B-B484936BD6EB	98CE6D0E-465C-40FA-9408-33AA7A25FBB2	TCGA-CG-5720-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5720	TCGA-STAD	30.0	s14984	Harvard Medical School	Indivumed	Germany	NO	T2	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1598-02	True	STAD	C1	GI.CIN	0.265836527	0.37	0.1		0.4981	0.21100000000000002	0.5672	1.1759	-0.0714	0.2953			0.832098599	1.750276364	68.0	0.080261268	0.0	13.0	0.705954393	4.224386106	397.0	5.228332571	260.0	0.9402323159999999	1.26877527	333.24582960000004	354.64869980000003	1518.026574	1.0	30.0	0.0	30.0	8.241703159729818	8.675490364685992	-0.2374560140246531	6.583475083126286	8.481334350245035	0.9118957058210576	-1.6582280766035324	-0.19415601444095776	1.1493517198457108	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c36c	58cfa831e4b0c9d6adf6c36c	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.bam	193.3	1.9	0.14	58cfa831e4b0c9d6adf6c36c	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5803-01A	33901C6F-9180-4A19-866C-F4AC6BEC76DA	Primary Tumor	Illumina HiSeq	1002025d-03b9-46ab-988a-576f59957cac	Stomach	78.0	EB71264D-C896-4910-BF46-D6F129B83941	EABD49CE-0F0C-443D-9BF4-0ADD2C2532B2	TCGA-CD-5803-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5803	TCGA-STAD		s15118	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True	STAD	C2	GI.CIN	0.453905874	0.73	0.39	15.41677368	0.1141	-0.025	1.163	2.4366	1.8413	0.7149			0.255432982	0.8798247140000001	53.0	0.169324008	9.0	2.0	0.571994553	2.292172756	55.0	6.329508715	687.0	0.9689505209999999	2.019566044	303.98998839999996	437.3332568	-550.9052582	1.0	341.0	1.0	300.0	8.799887847356972	8.172258583048105	0.4706691866746301	6.497302754362927	7.255967851173949	3.246191635515164	-2.3025850929940455	-0.9162907318741551	2.775522448840534	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c375	58cfa831e4b0c9d6adf6c375	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted.bam	281.2	1.9	0.14	58cfa831e4b0c9d6adf6c375	TCGA-CG-4477-01A-01D-1154_121212_SN1120_0205_AC1F18ACXX_s_2_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4477-01A	18D0AAE7-9694-4252-B8FE-16E62DADAB07	Primary Tumor	Illumina HiSeq	854ac518-e119-4ce6-97c4-b123e75a99ee	Stomach	58.0	6D7C7B4E-6913-487D-9DC3-DDA901434192	3AE56504-30EE-4C03-9F69-C5B415DE6738	TCGA-CG-4477-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4477	TCGA-STAD		s14907	Harvard Medical School	Indivumed	Germany	NO	T2a	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1154-02	True	STAD	C2	GI.CIN	0.30151113	0.51	0.14	31.11498554	0.8605	0.28800000000000003	0.9962	1.3133	1.2385	0.1422			0.9621760090000001	3.0239817419999997	141.0	0.693291047	4.0	34.0	0.828144186	4.774409491	319.0	3.3654988789999996	32.0	0.9710777079999999	0.944525932	752.3872243	413.015928	-2252.340252	0.0	942.0	1.0	365.0	7.793999089503995	5.590125530349903	0.042078838380462336	5.596774512167776	5.382486165571658	1.5620015367534115	-2.197224577336219	-0.2076393647782444	1.519922698372949	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c37a	58cfa831e4b0c9d6adf6c37a	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.bam	46.0	1.9	0.17	58cfa831e4b0c9d6adf6c37a	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5813-01A	152B9D8A-19FD-4665-B9E4-4FEDFB1608CD	Primary Tumor	Illumina HiSeq	ccc0d204-3529-43aa-b108-62d12f6465bd	Stomach	60.0	09E42E33-D2EC-406C-9A42-36D9D2EBD6C6	2118F0C5-3178-40EA-850D-C3F6F8752DD9	TCGA-CD-5813-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5813	TCGA-STAD		s14408	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1598-02	True	STAD	C3		0.322316763			6.047253347000001	0.0134	-0.0695	1.0436	2.1695	0.1578	0.5749			1.3116049440000002	4.105893737					0.798243825	4.581754248	311.0	4.940591888	197.0	0.935150742	1.220384747	35.32646395	-84.71289643	-2106.2404539999998	1.0	377.0	1.0	315.0	8.430981494597171	8.776434636236168	0.9663069527278101	6.639222025369117	8.594113079442213	2.0589915417626443	-1.7917594692280552	-0.18232155679395445	1.0926845890348342	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c37e	58cfa831e4b0c9d6adf6c37e	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted.bam	46.0	1.9	0.16	58cfa831e4b0c9d6adf6c37e	TCGA-CG-5719-01A-11D-1598_121029_SN208_0439_BD1KHKACXX_s_1_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5719-01A	263F67E0-0A28-42E6-B3F3-1DDD0D397220	Primary Tumor	Illumina HiSeq	e6237df3-92e8-4e8b-92a4-b09d3515f16f	Stomach	54.0	606573EE-ED11-4DB5-ABAF-E842EC575EEE	9008E364-B8F3-4923-B0CC-6ED34AA7BAC3	TCGA-CG-5719-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5719	TCGA-STAD		s15247	Harvard Medical School	Indivumed	Germany	NO	T4	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	True	STAD	C1	GI.CIN	0.294667472	0.57	0.19		0.0545	0.08900000000000001	0.4566	0.596	0.2409	0.7006			0.651560399	1.5580792159999999	144.0	0.38063041799999997	9.0	24.0	0.291458557	1.1933317559999999	60.0	4.00825267	64.0	0.963781042	2.316582537	78.44067564	128.7960113	391.8895318	0.0	31.0	0.0	31.0	8.726427117538877	8.631659622102577	-1.0759859803611875	6.606163581338786	7.938512441542631	3.25650923610091	-2.120263536200091	-0.6931471805599454	4.332495216462098	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c384	58cfa831e4b0c9d6adf6c384	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.bam	374.0	2.0	0.17	58cfa831e4b0c9d6adf6c384	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5801-01A	DF822EA3-E0E6-4AD3-A228-E20E3A737DAC	Primary Tumor	Illumina HiSeq	5196b0dd-1d41-47f4-84a8-999f211443f4	Stomach	69.0	9D0DF8D7-8D59-4983-9BBF-C6C106BDEFEC	F32CB4AA-D842-427A-8B7E-371764308512	TCGA-CD-5801-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5801	TCGA-STAD		s15317	Harvard Medical School	ILSbio	Vietnam	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	True	STAD	C2	GI.EBV	0.39567483	0.69	0.09		0.3505	0.1805	0.805	1.8621	0.8053	0.0434			3.0439897769999997	9.700939384	75.0	0.526165904	24.0	7.0	0.8811665959999999	4.882776336	255.0	4.401351149	175.0	0.852184615	1.270254223	-284.9064459	-61.31462862	-2470.859664	1.0	401.0	1.0	401.0	9.058062936530606	8.09925056179696	0.5990622273274254	6.615715901161401	7.965719169172438	1.3055518339712102	-2.4423470353692043	-0.13353139262452274	0.7064896066437849	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c388	58cfa831e4b0c9d6adf6c388	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted.bam	224.0	1.9	0.14	58cfa831e4b0c9d6adf6c388	TCGA-CG-5723-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_3_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5723-01A	0F00AD32-E4BE-49D4-A02A-D233BFC913C5	Primary Tumor	Illumina HiSeq	9e55e0ac-b9dd-42dd-afe7-d6f93c1dcc88	Stomach	83.0	4CCD9CCB-BF50-44EB-AA55-133D8824C433	9A2DC75A-E7BE-4226-9D8C-940946F75958	TCGA-CG-5723-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5723	TCGA-STAD		s14417	Harvard Medical School	Indivumed	Germany	NO	T2	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True	STAD	C2	GI.HM-indel	0.391660484	0.53	0.0		0.7412	0.4165	0.7443	1.1943	1.1394	0.1693			14.48462175	44.46174152	145.0	0.015855661	0.0	4.0	0.721444272	4.24247684	358.0	3.631674155	87.0	0.8131994790000001	2.661783724	595.5217062	278.06865919999996	-2796.756231	0.0	3196.0	0.0	3196.0	8.279189777195004	6.564735729483182	-0.6382881058361968	5.976604684200959	1.6360972640958753	0.09854488912276627	-2.3025850929940455	-4.928638465387307	0.736832994958963	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c392	58cfa831e4b0c9d6adf6c392	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted.bam	177.7	2.0	0.17	58cfa831e4b0c9d6adf6c392	TCGA-CD-5799-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5799-01A	C991697F-77F9-412A-9BD1-0E47F7387CB2	Primary Tumor	Illumina HiSeq	a59236bd-649f-4f2d-a702-4fb190d7f92c	Stomach	45.0	A3180E0E-EB99-49DD-8252-5FEA05A9885F	74F06FDA-C4D0-4542-AC92-68677B595800	TCGA-CD-5799-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5799	TCGA-STAD		s14633	Harvard Medical School	ILSbio	Vietnam	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True	STAD	C1	GI.CIN	0.202172532	0.37	0.5	12.02986635	0.7307	0.4855	-0.4904	-0.4492	0.1006	0.3028			0.373071065	0.803537678	205.0	0.573794512	19.0	25.0	0.847097606	2.987171557	34.0	1.80474849	7.0	0.927457257	1.567188995	10.90137971	581.9242166	1114.3195130000001	0.0	396.0	0.0	396.0	7.753623546559745	8.863120586808206	0.2591974951684467	5.761193381869539	8.052190370591877	1.6185414781745935	-1.9924301646902063	-0.8109302162163288	1.3593439830061467	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c39a	58cfa831e4b0c9d6adf6c39a	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted.bam	211.0	1.9	0.16	58cfa831e4b0c9d6adf6c39a	TCGA-CG-5721-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_1_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5721-01A	588ABAEA-AB16-42F4-9457-5901EE791B5F	Primary Tumor	Illumina HiSeq	450e30b5-bcb4-4169-a48f-bbf3db7feda2	Stomach	58.0	B79123B9-5094-426D-8267-FD4A1C9F2778	8DE4E4AE-4C98-4D4E-BC77-2C205D817E01	TCGA-CG-5721-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5721	TCGA-STAD		s14555	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	True	STAD	C2	GI.HM-indel	0.45173348	0.51	0.0		0.7074	0.2275	1.1306	1.9369	1.358	0.0661			35.53772402	102.94681059999999	72.0	0.001549965	0.0	0.0	0.839268791	4.471520192	206.0	5.127564712	369.0	0.867491308	2.1810783959999998	658.8358914	634.5276371	-450.31793550000003	0.0	183.0	0.0	183.0	8.29014201527101	6.385249386854587	0.3938482291460036	6.680704102836909	6.881686273168478	1.0281979528337808	-1.6094379124341003	0.4964368863138908	0.6343497236877771	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c39e	58cfa831e4b0c9d6adf6c39e	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.bam	54.44		0.16	58cfa831e4b0c9d6adf6c39e	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2M1-01A	8911C80C-C903-48E4-AF5B-FFEDEF9ABC47	Primary Tumor	Illumina HiSeq	374c6310-126e-48e8-8b83-145f75714a4b	Cervix	37.0	065BB06F-5BB7-4F79-B374-97A3011F22AE	E2DAD681-2B26-43A0-804B-0F2DD17B1EFE	TCGA-C5-A2M1-01A-11D-A18I-02	HG19_Broad_variant	TCGA-C5-A2M1	TCGA-CESC		s1518	Harvard Medical School	Medical College of Wisconsin	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma		A18I-02	True	CESC	C2		0.23361153399999998	0.29	0.01	8.995685493	1.0752	0.4275	0.3207	0.8992	0.6322	-0.5182	36.0	13.0	0.747644732	1.744504375	148.0	0.140327834	4.0	18.0	0.8605685959999999	2.063553368	11.0	2.847365157	64.0	0.684646599	1.919008557	-349.04305800000003	915.5139426000001	-1115.315069	0.0	1169.0	0.0	1169.0	8.483274398212611	8.23767768163085	0.09268984221843424	6.8738364857785115	7.426747465414521	0.9940734657434509	-1.6094379124341003	-0.8109302162163288	0.9013836235250167	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3a0	58cfa831e4b0c9d6adf6c3a0	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted.bam	68.38	1.71	0.17	58cfa831e4b0c9d6adf6c3a0	TCGA-BT-A20U-01A-11D-A14U_120927_SN208_0433_BD1D5JACXX_s_7_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20U-01A	83B41D35-69B1-4218-BE1A-8821D8A6899C	Primary Tumor	Illumina HiSeq	9947c8cb-fa3d-4cc2-942e-b013f7a47faa	Bladder	70.0	D29E555F-8467-45C8-9124-0E6A757B1ADF	8D4442E9-3312-4607-A59F-49538B19FA71	TCGA-BT-A20U-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20U	TCGA-BLCA	455.0	s3270	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	True	BLCA	C1	BLCA.3	0.360535795	0.5	0.11	5.903938247	0.7393	0.233	-0.5251	-0.7592	-0.5692	0.2691	37.0	0.0	0.6330737820000001	2.200685052	73.0	0.048607334	0.0	9.0		0.0	1.0	1.039720771	3.0	0.94639463	3.5634266439999998	-887.7752449999999	1184.980475	-1495.61126	1.0	455.0	0.0	455.0	6.8065527734729745	5.999147721742642	-0.7911558970828094	6.305777485560485	5.706160597061168	1.1007376879804232	-0.5007752879124894	-0.29298712468147414	1.8918935850632326	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3a6	58cfa831e4b0c9d6adf6c3a6	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina.bam	75.65	1.95	0.08	58cfa831e4b0c9d6adf6c3a6	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-A1HT-01A	670C1CBC-4494-45F1-BB8B-18DB82D4F7E0	Primary Tumor	Illumina HiSeq	f7c13bc4-5edc-4964-8267-e7956bf2fdd0	Liver	50.0	96F911ED-2064-4745-AD07-6C47B0A0C7CD	6B25A78F-20DC-4CCC-B4C0-F9885D16725D	TCGA-CC-A1HT-01A-11D-A12Z-10	GRCh37-lite	TCGA-CC-A1HT	TCGA-LIHC		s16850	Baylor College of Medicine	ILSbio	Vietnam	NO	T3	N0	Hepatocellular Carcinoma	Stage IIIA	A12Z-10	True	LIHC	C2	LIHC.iCluster:1	0.668101555	0.79	0.2		0.6898	0.289	1.0362	1.1936	1.2695	-0.1039	52.0	49.0	0.5623452210000001	2.172697444	120.0	0.210070667	11.0	26.0	0.558488589	1.2859675	10.0	4.201724105	72.0	0.982476534	5.444076292	312.43575939999994	289.39738189999997	462.2118454	1.0	101.0	0.0	101.0	6.625657584824256	2.529653057763701	0.7069893458856588	5.290656518091916	4.1370450831770125	2.2520913508998297	-1.3350010667323398	1.6073920254133114	1.5451020050141708	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3a8	58cfa831e4b0c9d6adf6c3a8	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.bam	44.0	1.9	0.13	58cfa831e4b0c9d6adf6c3a8	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5798-01A	E42F45C6-FD00-44CF-A210-C8803DA326A1	Primary Tumor	Illumina HiSeq	5b2c6e2f-0b61-49e1-bef5-6d7408918d47	Stomach	82.0	72855D36-60BE-498F-96E9-0F10DC05B3A0	F9D13E07-70F4-48F3-B49E-06984C9E39EE	TCGA-CD-5798-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5798	TCGA-STAD		s15455	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1598-02	True	STAD	C1	GI.GS	0.21468515	0.81	0.12	7.397488205	-0.4826	0.0385	0.44799999999999995	0.4746	0.5479	0.758			0.686125196	2.201318338	81.0	0.014317638	1.0	4.0	0.913639758	2.411147701	14.0	3.412538102	34.0	0.9677224090000001	2.024380551	569.085339	-465.1901313999999	-2561.064676	0.0	408.0	0.0	408.0	8.532081803909989	9.303817704310134	0.6929872701094566	6.740322334681934	8.541677652263237	2.3110971495281607	-1.7917594692280547	-0.7621400520468968	1.618109879418704	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3ac	58cfa831e4b0c9d6adf6c3ac	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted.bam	195.0	1.9	0.15	58cfa831e4b0c9d6adf6c3ac	TCGA-CG-5722-01A-21D-1598_121011_SN208_0434_AC18MYACXX_s_2_rg.sorted.bam	Alive	FEMALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5722-01A	F35E8FEF-F61D-4614-B73F-F7E1D0F21F52	Primary Tumor	Illumina HiSeq	05762233-5294-478d-b462-14b931579f63	Stomach	67.0	30D63C9D-E36A-4654-86B5-5D7A622089C2	F262DDED-846F-4DEB-8FC3-EF0DF814ECA4	TCGA-CG-5722-01A-21D-1598-02	HG19_Broad_variant	TCGA-CG-5722	TCGA-STAD		s14642	Harvard Medical School	Indivumed	Germany	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1598-02	True	STAD	C2	GI.EBV	0.366538762	0.75	0.09		0.445	0.257	0.8255	2.6049	0.1242	0.0007			0.7237039559999999	2.055319236	68.0	0.19183515899999998	17.0	1.0	0.8399254840000001	5.136893655	453.0	4.323003662	266.0	0.7742467129999999	1.479281039	-828.7715582000001	116.04166229999998	-1558.793817	0.0	30.0	0.0	30.0	7.402451520818245	5.424950017481403	0.5049559375316967	5.2052269434820255	4.662809965434507	1.6173988736032214	-2.197224577336219	-0.7621400520468968	1.1124429360715247	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3b0	58cfa831e4b0c9d6adf6c3b0	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.bam	20.53	2.0	0.15	58cfa831e4b0c9d6adf6c3b0	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0H7-01A	2021ED1F-DC75-4701-B8B8-1386466E4802	Primary Tumor	Illumina HiSeq	d5ab471a-88d1-4966-865a-f7fa29214fe4	Breast	65.0	69BFA6CE-ED46-4321-A107-347C49D68951	E0E60B71-1EFA-4896-B89F-D05974CDCF48	TCGA-BH-A0H7-01A-13D-A060-02	HG19_Broad_variant	TCGA-BH-A0H7	TCGA-BRCA		s5801	Harvard Medical School	University of Pittsburgh	None	NO	T1c	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A060-02	True	BRCA	C2	BRCA.Normal	0.08777341	0.37	0.19	0.856940202	0.0691	0.064	-0.3336	-0.0182	0.6323	0.6474	22.0	0.0	0.47185223	1.445047455	595.0	0.826884862	17.0	39.0	0.9993375040000001	0.692687973	2.0	3.170148321	25.0	0.98486195	1.1604242390000001	19.37608477	770.8091352999999	989.3475957999999	0.0	702.0	0.0	702.0	6.902742737158593	6.21023491360997	-0.4063834201483214	5.0569160466602625	5.472635970479191	5.458583760992518	-1.8458266904983305	-0.737598943130779	5.864967181140839	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3b2	58cfa831e4b0c9d6adf6c3b2	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted.bam	127.2	1.9	0.14	58cfa831e4b0c9d6adf6c3b2	TCGA-CG-4476-01A-01D-1154_121029_SN208_0438_AC18NJACXX_s_1_rg.sorted.bam	Alive	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-4476-01A	442D7415-D095-4962-8296-A14390BAD40A	Primary Tumor	Illumina HiSeq	fa01457a-1a83-47ed-b744-7494b9756706	Stomach	69.0	37F5444F-A58D-4899-A11B-9C09ECD357FC	0C5818D8-5C20-4E4B-99CF-6F378CA6EBE7	TCGA-CG-4476-01A-01D-1154-02	HG19_Broad_variant	TCGA-CG-4476	TCGA-STAD		s14554	Harvard Medical School	Indivumed	Germany	NO	T4b	N3a	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIC	1154-02	True	STAD	C2	GI.CIN	0.280260254	0.72	0.25	7.341158127000001	0.2374	0.031	0.8505	1.3030000000000002	0.0439	0.2885			0.715104836	3.175065473	195.0	0.577159466	15.0	24.0	0.901499353	4.005047233	85.0	3.749769882	49.0	0.963500263		114.6021004	685.5125836	613.0811003	0.0	0.0	0.0	0.0	8.990483081653124	7.9253304043168935	-0.6171338118861833	6.953601154392084	7.882770789898098	2.0541237336955467	-2.0368819272610397	-0.04255961441879608	2.67125754558173	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3b6	58cfa831e4b0c9d6adf6c3b6	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina.filtered.	WGS	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina.bam	73.73	1.92	0.07	58cfa831e4b0c9d6adf6c3b6	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-5262-01A	1B428ADA-EB3F-40C2-B4BF-1BBF6B61729D	Primary Tumor	Illumina HiSeq	c98a5543-b4b7-42ad-807e-73cdbbf77345	Liver	67.0	DC595EED-D459-40FD-8417-6A1C56759EC8	47E5FF56-9534-4FCF-A593-33027E877F93	TCGA-CC-5262-01A-01D-A21X-10	GRCh37-lite	TCGA-CC-5262	TCGA-LIHC		s16851	Baylor College of Medicine	ILSbio	None	NO	T4	N0	Hepatocellular Carcinoma	Stage IIIC	A21X-10	False	LIHC	C2	LIHC.iCluster:2	0.44429405200000005	0.61	0.0		-0.2111	0.0845	0.1395	0.4733	0.6602	-0.1476	59.0	9.0	0.846660517	3.062918929	79.0	0.145817735	3.0	14.0				2.51265853	13.0	0.97961331	2.747798436	-886.3167735	-230.9388195	1218.4804900000001	1.0	103.0	0.0	103.0	5.580964055435275	2.6090546447845604	-0.24711587503156152	5.738149638957688	4.1162184637640244	1.608446094847217	0.15718558352241274	1.507163818979464	1.8555619698787784	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3b8	58cfa831e4b0c9d6adf6c3b8	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted.bam	362.0	1.9	0.15	58cfa831e4b0c9d6adf6c3b8	TCGA-CG-5724-01A-11D-1598_121011_SN208_0434_AC18MYACXX_s_7_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5724-01A	0B4E8D73-459D-4930-9D1A-ABB8D53E1844	Primary Tumor	Illumina HiSeq	b1cebb86-fe73-4b53-899d-9e6a4caa800b	Stomach	59.0	4D624B21-5AEE-42B8-B192-8AFECB51434D	8611C0AC-38E4-4BFD-A1C4-56CABFCF6374	TCGA-CG-5724-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5724	TCGA-STAD	366.0	s15248	Harvard Medical School	Indivumed	Germany	NO	T3	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IV	1598-02	True	STAD	C2	GI.CIN	0.22508269399999997	0.35	0.31		1.0065	0.6	0.113	0.2401	0.4614	0.4247			0.918516955	2.583328935	263.0	0.563571818	13.0	50.0	0.8955782259999999	3.368448929	43.0	3.714567725	50.0	0.949526043	3.262347147	-1283.3829449999998	480.58703219999995	-2088.0920530000003	1.0	366.0	1.0	122.0	8.279595683131879	7.750200726090709	0.3180029974826164	6.797991142207662	7.000964078879719	1.767011299538861	-1.4816045409242158	-0.749236647210989	1.4490083020562445	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3be	58cfa831e4b0c9d6adf6c3be	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina.bam	125.45	1.93	0.08	58cfa831e4b0c9d6adf6c3be	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-5261-01A	1AD7F17E-B3B8-40E9-AAB8-5A17E0AEC408	Primary Tumor	Illumina HiSeq	43047cdb-fea6-4e20-9248-30ae5624c5a7	Liver	44.0	538998F3-5230-4963-8B67-D34DE695E97D	A2F143D6-BA07-4FF0-960D-B29C3C716665	TCGA-CC-5261-01A-01D-A12Z-10	GRCh37-lite	TCGA-CC-5261	TCGA-LIHC		s16582	Baylor College of Medicine	ILSbio	None	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A12Z-10	True	LIHC	C3	LIHC.iCluster:1	0.283040301	0.51	0.18		-0.0582	-0.242	0.2377	1.3255	-0.3599	-0.0193			0.0	0.0	122.0	0.456123944	14.0	28.0				3.165672167	25.0	0.9834713540000001	0.55379582	-1042.245853	240.13481349999998	4214.054039	1.0	97.0	0.0	97.0	6.659293919683638	3.5265833161955618	-0.18457127652797023	4.787491742782047	3.2343660885783896	2.0618891280056837	-1.8718021769015916	-0.29221722761717217	2.246460404533654	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3c2	58cfa831e4b0c9d6adf6c3c2	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted.bam	56.34	2.11	0.15	58cfa831e4b0c9d6adf6c3c2	TCGA-BT-A20Q-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_5_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20Q-01A	419DEAAC-EA45-4BDD-9FA0-B5CD8429B44F	Primary Tumor	Illumina HiSeq	9d2dc2d3-8995-42b8-9bee-010c8bce06e0	Bladder	73.0	F3906CD4-31C7-48A8-935B-5B7FAFEC1AE7	72AF980B-98A8-4572-8AF9-EFD4294700F9	TCGA-BT-A20Q-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20Q	TCGA-BLCA	593.0	s3083	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A14U-02	True	BLCA	C1	BLCA.2	0.21912309800000002	0.32	0.0	5.160367415	-0.4592	-0.032	0.1466	0.7527	0.5972	0.5919	35.0	87.0	0.798330115	2.702040388	185.0	0.154824566	5.0	11.0	0.8047555340000001	3.506085536	78.0	3.2509410410000004	28.0	0.9756127	1.577130567	-1416.637424	448.12771039999996	-2342.717158	1.0	593.0	1.0	593.0	6.845015139785945	9.432900896220278	0.08835174258556466	5.856403746332164	8.243316829346442	1.5143801279598605	-0.9886113934537812	-1.1895840668738364	1.4260283853742957	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3c4	58cfa831e4b0c9d6adf6c3c4	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted.bam	63.78	1.88	0.16	58cfa831e4b0c9d6adf6c3c4	TCGA-BT-A20O-01A-21D-A14U_120921_SN208_0431_BD1D5FACXX_s_3_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20O-01A	C0E7FBE7-B9CB-4E65-941B-CD7D581C54EC	Primary Tumor	Illumina HiSeq	c345a912-f3c8-4622-9793-88cf795fc964	Bladder	75.0	5ECD84AD-44FD-4599-BF3D-AB725E0404EC	13596E86-7CD8-4A07-941F-E936D0004F6B	TCGA-BT-A20O-01A-21D-A14U-02	HG19_Broad_variant	TCGA-BT-A20O	TCGA-BLCA	370.0	s3090	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A14U-02	True	BLCA	C2	BLCA.4	0.661803895	0.84	0.25	24.097056100000003	0.8088	0.2475	1.7066	2.5309	1.2793	0.1693	95.0	48.0	1.211451647	4.603516257	69.0	0.02359439	0.0	4.0	0.868756234	4.358793134	151.0	3.793747872	66.0	0.9055037	4.742483084	1055.44674	680.1730132	-1606.84168	1.0	370.0	1.0	315.0	7.667704043021286	9.500353815578157	0.4992200776456831	6.587783887365328	8.260662928650142	1.8222879667993857	-1.0799201556559574	-1.239690886928015	1.3230678891537027	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3cb	58cfa831e4b0c9d6adf6c3cb	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.bam	60.19		0.16	58cfa831e4b0c9d6adf6c3cb	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HD-01B	12427B02-6E3F-461C-B271-6AB230F628E7	Primary Tumor	Illumina HiSeq	475d850b-49e8-4f15-9f59-8d65bf9cf22d	Cervix	51.0	56AA88C8-AF6D-42BE-8672-074476F6575A	03576AE9-4222-48C3-A428-D85AEC400BD6	TCGA-C5-A3HD-01B-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HD	TCGA-CESC		s1171	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO			Cervical Squamous Cell Carcinoma		A20X-26	True	CESC	C2		0.06828218900000001	0.09	0.13		1.2589	0.33	-1.4469	-1.3889	0.47100000000000003	-0.2935			0.0	0.0	238.0	0.707417429	1.0	64.0				1.098612289	3.0	1.0	1.997623226	-743.0523991	1093.3989390000002	-2189.912148	0.0	1582.0	0.0	1582.0	8.553042844309935	8.142977549884368	-0.5391415438832784	6.155147571511565	7.198515941043516	1.6791148422792463	-2.3978952727983707	-0.9444616088408513	2.218256386162525	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3d4	58cfa831e4b0c9d6adf6c3d4	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted.bam	62.13		0.16	58cfa831e4b0c9d6adf6c3d4	TCGA-C5-A3HF-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_1_rg.sorted.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HF-01A	085DF27C-9BC2-425A-9A49-547D692EA028	Primary Tumor	Illumina HiSeq	4b4bea19-4db4-4996-8037-4129a4494419	Cervix	24.0	79C43439-BC01-4033-85FA-3191A79277C6	0C08A31F-1414-42E3-986A-00BAF9C926F8	TCGA-C5-A3HF-01A-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HF	TCGA-CESC	543.0	s1358	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO			Mucinous Adenocarcinoma of Endocervical Type		A20X-26	True	CESC	C2		0.302954648	0.58	0.11		0.5454	0.256	-0.2496	1.0316	0.4902	0.005	19.0	0.0	0.272755905	0.608455479	61.0	0.195178695	2.0	8.0	0.8798916090000001	3.572749735	58.0	3.1949847680000003	28.0	0.958820132	2.1005895359999998	-717.4222272999999	246.55177769999997	521.1805948	1.0	543.0	1.0	450.0	8.278377470707733	7.575892296537915	-0.11989903144446035	6.709761552793887	7.105888667292179	3.2498980023471806	-1.5686159179138455	-0.47000362924573524	3.3697970337916408	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3d6	58cfa831e4b0c9d6adf6c3d6	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted.bam	206.0	1.9	0.15	58cfa831e4b0c9d6adf6c3d6	TCGA-CG-5734-01A-11D-1598_121023_SN208_0436_AC1CMBACXX_s_7_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5734-01A	2A227292-C73D-45FC-AB68-CDFAF7AEF9E7	Primary Tumor	Illumina HiSeq	4cac9679-5c5e-4b51-b7a0-0d82ab2c2237	Stomach	68.0	A0237637-3859-47D9-A60E-0AF8C6884B4A	12BCC59A-0A89-4087-B976-A22F66D8190C	TCGA-CG-5734-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5734	TCGA-STAD	243.0	s14990	Harvard Medical School	Indivumed	Germany	NO	T3	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	True	STAD	C2	GI.CIN	0.409986464	0.81	0.51		-0.0504	0.0365	0.9166	2.0598	0.7695	0.2745			0.546533093	1.927248276	72.0	0.11387276699999999	16.0	11.0	0.752017413	4.471059824	382.0	2.705276697	119.0	0.566061267	1.191334305	926.9822498	-653.8509246	1236.098164	1.0	243.0	0.0	243.0	8.466478676871736	8.148011795385319	-1.0245803997494836	6.761730584633311	7.6173835443231495	0.7915141683826299	-1.7047480922384255	-0.5306282510621703	1.8160945681321135	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3dc	58cfa831e4b0c9d6adf6c3dc	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted.bam	217.0	1.9	0.16	58cfa831e4b0c9d6adf6c3dc	TCGA-CG-5726-01A-11D-1598_121011_SN208_0435_BD1E43ACXX_s_2_rg.sorted.bam	Dead	MALE			Stomach Adenocarcinoma	Aligned reads	TCGA-CG-5726-01A	863AD936-E2A0-471C-8D95-3A548BB94AFA	Primary Tumor	Illumina HiSeq	87491384-bbcf-4127-8cf0-59e692b8e37b	Stomach	73.0	C881739A-982C-436F-9BE2-4638DB792C53	D472F361-BC94-44A5-9158-5BD999C96C27	TCGA-CG-5726-01A-11D-1598-02	HG19_Broad_variant	TCGA-CG-5726	TCGA-STAD	881.0	s15130	Harvard Medical School	Indivumed	Germany	NO	T1	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IA	1598-02	True	STAD	C1	GI.HM-indel	0.07220496700000001	0.1	0.0		0.9811	0.36700000000000005	-0.9091	-0.7891	-0.2366	-0.3072			11.59449101	31.83475062	91.0	0.331502366	6.0	0.0	0.90289022	3.183916429	34.0	3.050638616	29.0	0.9059609759999999	1.3059124340000001	-1137.8271619999998	481.19601789999996	1955.8351480000001	1.0	881.0	0.0	881.0	7.85748078694253	7.1270055470091975	-0.6250670417564085	5.6602562096063105	6.239702352008295	1.247411153423421	-2.197224577336219	-0.8873031950009029	1.8724781951798293	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3dd	58cfa831e4b0c9d6adf6c3dd	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.bam	249.7	1.9	0.15	58cfa831e4b0c9d6adf6c3dd	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5744-01A	4E76DE8E-CB0D-4B83-8AB4-53BC67A7A9D3	Primary Tumor	Illumina HiSeq	b48809ce-93ac-45d2-b127-bf6ee8bd6870	Prostate	64.0	DCCEAF54-0BCE-4650-9980-9843ABCE0C41	B3198EFA-5613-4B16-BA05-4F0AACCCC00F	TCGA-CH-5744-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5744	TCGA-PRAD		s3771	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.15276103300000002	0.41	0.0	1.588894464	-1.3137	-0.1455	-0.7112	-0.486	-0.9857	-0.3405	9.0	31.0	0.277900301	0.528010572	136.0	0.050484465	1.0	12.0	0.9262895309999999	1.284109953	4.0	2.813355405	17.0	0.9929910190000001	2.118788579	391.02456889999996	-792.738995	3679.1758950000003	0.0	60.0	0.0	60.0	8.698792265059861	8.715076368994215	-0.5591812371947864	6.85296557456153	8.184448117932046	4.150348964117548	-1.8458266904983305	-0.5306282510621703	4.709530201312334	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3e2	58cfa831e4b0c9d6adf6c3e2	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.bam	245.7	1.9	0.15	58cfa831e4b0c9d6adf6c3e2	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5743-01A	2DEE4BD8-B00E-4F8A-BFEA-5D8D1A068202	Primary Tumor	Illumina HiSeq	1c58f516-3239-499a-bbcd-f5a8d619d796	Prostate	66.0	6BD8573D-535F-4F6D-8EAF-60918B5DA578	EE5F51E6-F989-4380-A86F-29CBF50BA03A	TCGA-CH-5743-01A-21D-1572-02	HG19_Broad_variant	TCGA-CH-5743	TCGA-PRAD		s3588	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.139631628			0.402481972	-1.5765	-0.21600000000000003	0.0632	0.4329	-0.2874	-0.1027			0.0	0.0	45.0	4.1200000000000005e-05						3.4040404339999997	31.0	0.9912793	1.9919464269999998	725.7720073	-699.7186323	2359.219608	0.0	425.0	1.0	425.0	7.495541943884256	7.571988449377439	-0.11332059963118213	5.703782474656202	6.8182166470010594	1.9380174482564048	-1.7917594692280547	-0.7537718023763804	2.0513380478875867	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3e3	58cfa831e4b0c9d6adf6c3e3	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina.bam	91.26	1.95	0.08	58cfa831e4b0c9d6adf6c3e3	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-5260-01A	CA8AFB2C-BE3D-41E8-8DBC-19FE7AB6154B	Primary Tumor	Illumina HiSeq	94aaf939-2195-4c49-b867-778f3670e7ff	Liver	61.0	7F347680-CD4D-4289-8F8F-3B0541381A42	3BACC189-01B8-46CC-A442-F393C0F428C6	TCGA-CC-5260-01A-01D-A12Z-10	GRCh37-lite	TCGA-CC-5260	TCGA-LIHC		s16581	Baylor College of Medicine	ILSbio	None	NO	T4	N0	Hepatocellular Carcinoma	Stage IIIC	A12Z-10	True	LIHC	C3	LIHC.iCluster:1	0.23558531600000002	0.39	0.1		-0.0936	-0.1475	0.0961	-0.3008	-0.0268	0.2028	31.0	9.0	0.306861453	1.304161174	164.0	0.317378982	5.0	17.0				2.45831133	12.0	0.989297256	2.10814455	-947.4802195	147.41710790000002	-415.5950245	1.0	87.0	0.0	87.0	6.1508396510720456	1.8119738450889313	0.3981302173900042	4.980768398421791	1.7753145281728067	2.805875232858506	-1.1700712526502546	-0.03665931691612467	2.4077450154685023	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3e6	58cfa831e4b0c9d6adf6c3e6	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.bam	146.7	1.9	0.15	58cfa831e4b0c9d6adf6c3e6	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5745-01A	AC67D0DF-7DC0-4A1A-8B47-BEEC9B94DE86	Primary Tumor	Illumina HiSeq	c1d27dca-0355-41e5-a53b-0af94a125c6a	Prostate	68.0	BDA91E83-643B-4FAE-BFE9-B4660F3BDF02	780758FF-58EE-4B4B-AC71-DE15C89C4625	TCGA-CH-5745-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5745	TCGA-PRAD		s3770	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3		0.10142666800000001			1.6447573359999998	-2.0801	-0.299	-0.3197	0.2856	-0.2293	-0.0248	15.0	3.0	0.111037336	0.610705348						0.0	1.0	2.949012331	21.0	0.968628871	1.3737098580000002	121.15763909999998	-775.334911	3723.552304	0.0	91.0	0.0	91.0	8.108623268354593	8.186974692682611	0.1568611564808905	5.911398691018374	7.270683960808455	2.0717469195187936	-2.197224577336219	-0.9162907318741551	1.9148857630379035	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3ec	58cfa831e4b0c9d6adf6c3ec	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.bam	196.7	1.9	0.14	58cfa831e4b0c9d6adf6c3ec	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5748-01A	0AF98331-9305-41E9-AF55-30390016D65E	Primary Tumor	Illumina HiSeq	02aa8440-93b8-43d7-a58b-6c4421e05321	Prostate	64.0	A499BF51-B137-4DA9-87A3-D1B1A0F04695	24A0496A-CA69-4AE3-BF8A-92289C738E9F	TCGA-CH-5748-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5748	TCGA-PRAD		s3413	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.2-ETV1	0.048943579	0.76	0.06	0.748612864	-0.9824	-0.1535	-1.1101	-0.6391	-0.7165	-0.6567	20.0		0.391501925	0.810968273	81.0	0.031112121	0.0	7.0		0.0	1.0	2.2718685130000003	10.0	0.986659959	2.130368743	-612.0510049	-428.15209680000004	2965.545576	0.0	31.0	0.0	31.0	8.16961956172385	8.721951624579019	-0.4458003157744804	5.818244304560373	7.9598115725321215	3.6148084635249087	-2.3513752571634776	-0.7621400520468968	4.060608779299389	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3f0	58cfa831e4b0c9d6adf6c3f0	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.filtered.	WGS	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.bam	82.12		0.18	58cfa831e4b0c9d6adf6c3f0	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LX-01A	B82F4C6D-530F-4B0E-8F33-995633CB254A	Primary Tumor	Illumina HiSeq	ef574f7b-2b69-4be8-83f3-cc02df579a0a	Cervix	54.0	41BEBEA3-11C2-4748-8E60-082CFB8E0251	F4772B1E-699C-4C3D-9E0B-1BD4634A7F36	TCGA-C5-A2LX-01A-11D-A18I-02	HG19_Broad_variant	TCGA-C5-A2LX	TCGA-CESC		s1175	Harvard Medical School	Medical College of Wisconsin	United States	NO	T2	N1	Cervical Squamous Cell Carcinoma		A18I-02	True	CESC	C2		0.299283268	0.39	0.07	3.4304676	0.9555	0.377	0.5925	2.2697	1.2308	-0.1178	84.0	2.0	1.254918854	3.7875732689999997	148.0	0.7895593240000001	11.0	30.0	0.930830142	3.30942514	35.0	4.034722266	60.0	0.98543789	3.308192413	-169.13628359999998	555.579796	-2834.348181	0.0	2526.0	0.0	2526.0	8.11237787214957	7.59135704669855	0.1192395369502246	5.809792779155526	7.06072879563638	1.0454175340577492	-2.3025850929940455	-0.5306282510621703	0.9261779971075247	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3f8	58cfa831e4b0c9d6adf6c3f8	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted.bam	30.7	1.9	0.14	58cfa831e4b0c9d6adf6c3f8	TCGA-CH-5771-01A-21D-1572_130104_SN208_0446_BD1KR5ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5771-01A	3ACD8328-76F7-4F43-9660-394B95748C3D	Primary Tumor	Illumina HiSeq	93b110cf-3f4b-4f72-8025-320b77838b0a	Prostate	63.0	19C87DE2-7936-4277-8AA8-3942D36E7579	83F4BDB9-ED8B-4472-87BB-74C901B1A350	TCGA-CH-5771-01A-21D-1572-02	HG19_Broad_variant	TCGA-CH-5771	TCGA-PRAD		s3931	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.3-ETV4	0.16307887599999998				-1.4851	-0.2755	0.1044	0.2457	-0.3672	0.1944	7.0	1.0	0.139540037	0.613976163	86.0	0.035652174						3.271689322	27.0	0.99267332	2.347212763	50.37008824	-637.8268699	2520.329834	0.0	396.0	0.0	396.0	7.4460014983241205	7.832162978958239	0.20007887682708014	5.248776920987901	7.203554319535865	3.9869651415929406	-2.197224577336219	-0.6286086594223743	3.7868862647658603	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3fc	58cfa831e4b0c9d6adf6c3fc	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.bam	257.7	1.9	0.16	58cfa831e4b0c9d6adf6c3fc	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5788-01A	C039014F-821C-43D6-9D3C-914F9C8D98FA	Primary Tumor	Illumina HiSeq	8bd51d54-e1be-4a0a-bad5-3b8013692b90	Prostate	69.0	144E0265-C04E-4538-A721-94DEF2570486	ADB6611D-7A44-4FFE-A48B-FF8E24696B38	TCGA-CH-5788-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5788	TCGA-PRAD		s3595	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C4	PRAD.5-SPOP	0.055470449000000005	0.16	0.03		-0.132	-0.0765	-1.15	-2.0049	-1.5590000000000002	-0.5298	19.0	1.0	0.391231616	0.754518117	417.0	0.267051013	5.0	28.0				0.693147181	2.0	1.0	1.9382210690000001	-600.2635485000001	776.2387974	714.4105002	0.0	821.0	0.0	821.0	8.895766604056087	8.545144347276322	-0.3956677324419461	6.662174382548992	8.234989418972482	3.3296862514784804	-2.2335922215070942	-0.3101549283038394	3.725353983920426	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c3fe	58cfa831e4b0c9d6adf6c3fe	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.bam	61.7	1.9	0.17	58cfa831e4b0c9d6adf6c3fe	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5792-01A	8A5F2D7F-835C-4726-B238-F82D6A7F25BD	Primary Tumor	Illumina HiSeq	1c4a46f6-fc5f-44b1-b30a-5baaa806e78b	Prostate	57.0	DA5F8107-7B69-45B5-8BEB-21D17B066CB4	5975F57F-2918-46C2-B59F-38FAA67A49BA	TCGA-CH-5792-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5792	TCGA-PRAD		s3933	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.8-other	0.174723	0.62	0.0		-1.1889	-0.22	0.193	0.7568	-0.5953	0.1478	16.0	6.0	0.225333902	0.87316887	207.0	0.08729621300000001	0.0	19.0	0.9168603609999999	1.642793234	6.0	3.727905199	44.0	0.985126423	3.102187971	-310.9007167	-592.4889886	3156.803307	0.0	91.0	0.0	91.0	9.128479345495863	9.64824040122751	-0.10217453128228027	7.091597418234823	8.955093220667564	2.2865882579528183	-2.0368819272610397	-0.6931471805599454	2.3887627892350984	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c401	58cfa831e4b0c9d6adf6c401	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.bam	145.7	2.0	0.17	58cfa831e4b0c9d6adf6c401	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5791-01A	829BED0C-C40D-44FD-AEE8-6C7589DB60F9	Primary Tumor	Illumina HiSeq	e2778c71-6feb-40df-8b1e-8d8f0e889beb	Prostate	72.0	C14B5C15-994B-4739-870B-A50984D274A1	500F071A-6697-4880-BBD0-9054CCAE108A	TCGA-CH-5791-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5791	TCGA-PRAD		s3417	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.10619253199999999	0.34	0.15		-1.2021	-0.2585	-0.7354	-0.6425	-0.8978	-0.3591	10.0	1.0	0.337991504	0.84497876	155.0	0.24700748100000003	1.0	12.0				1.791759469	6.0	1.0	2.0746855440000003	-864.6951375	-694.7305992	2926.528282	0.0	1004.0	1.0	396.0	7.922623574217287	8.467757819144817	0.13123165991299135	5.620038481223242	7.426303944316655	3.1788215847042762	-2.3025850929940455	-1.0414538748281612	3.0475899247912848	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c404	58cfa831e4b0c9d6adf6c404	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.bam	285.7	1.9	0.15	58cfa831e4b0c9d6adf6c404	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5790-01A	2B5EF82D-E137-43F6-BFEF-B202F20EE187	Primary Tumor	Illumina HiSeq	22e486a4-e20b-4211-b3fd-35f37d14e718	Prostate	64.0	5C8782C0-0B0D-4AFF-B996-423D214FF5FF	9BA30DBB-2730-48A1-94E5-10CCA134728F	TCGA-CH-5790-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5790	TCGA-PRAD		s3936	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.033826769	0.19	0.05		-1.9479	-0.264	-0.8332	-0.9014	-1.4325	-0.4314	11.0		0.11241436199999999	0.505864629	97.0	0.033568356	1.0	8.0				1.386294361	4.0	1.0	1.853984531	-791.394034	-333.49798210000006	3818.813539	0.0	974.0	0.0	974.0	7.08114820503179	7.317986787512426	-0.16054546103577882	5.23532151453346	6.40169605563827	4.108685679492758	-1.8458266904983305	-0.9162907318741551	4.269231140528538	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c406	58cfa831e4b0c9d6adf6c406	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.filtered.	WGS	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.bam	43.33		0.15	58cfa831e4b0c9d6adf6c406	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HE-01A	BC63DD2A-B8F6-4B30-A8D7-CE193BCD17F1	Primary Tumor	Illumina HiSeq	1d64c1f3-438b-4576-b2bc-74c1a26a2aca	Cervix	44.0	506D8B22-EE8D-4FB3-BB57-5CA79D6F5637	D0321E82-FF46-450C-AAF2-9FDCA2FF2590	TCGA-C5-A3HE-01A-21D-A232-26	HG19_Broad_variant	TCGA-C5-A3HE	TCGA-CESC		s1514	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A232-26	True	CESC	C2		0.389414644	0.61	0.25	1.176315789	0.9735	0.4055	0.3297	1.4680000000000002	0.5328	-0.3135					97.0	0.42811877299999995	10.0	13.0	0.898096263	3.218344969	36.0	2.9909852000000003	38.0	0.8222444959999999	1.8083055419999998	-1157.212406	780.4349786	347.97803439999996	0.0	548.0	1.0	252.0	7.267990544115626	7.389332302389004	0.24023215877547888	5.422163853617295	6.76072364296663	1.9349642884494143	-1.8458266904983305	-0.6286086594223743	1.6947321296739353	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c412	58cfa831e4b0c9d6adf6c412	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.bam	52.7	2.0	0.15	58cfa831e4b0c9d6adf6c412	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5794-01A	A80D3EE7-60DD-49BB-B049-9335AFC035F5	Primary Tumor	Illumina HiSeq	2cf518ee-af91-4cf0-a277-263170f71791	Prostate	65.0	D1A1CCFE-1215-4B34-94A9-C9765264F617	9D7EACBC-B476-4813-9215-AC0073382A25	TCGA-CH-5794-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5794	TCGA-PRAD		s3775	Harvard Medical School	Indivumed	Germany	NO	T2b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.045833265	0.43	0.0		-0.7472	-0.0795	-0.905	-1.0639	-1.2930000000000001	-0.2759	6.0	1.0	0.344010926	0.573351543	139.0	0.044033416	0.0	4.0				1.9459101490000001	7.0	1.0	2.8038356369999997	-854.4936916000001	-547.6555221	3380.179363	0.0	882.0	0.0	882.0	8.051978078902298	8.1356765166267	0.2023348522347832	5.854753501566079	7.507067857204326	2.5577768087808144	-2.197224577336219	-0.6286086594223743	2.3554419565460316	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c414	58cfa831e4b0c9d6adf6c414	TCGA-CJ-4639-01A-01D-2095-10_Illumina.filtered.	WGS	TCGA-CJ-4639-01A-01D-2095-10_Illumina	TCGA-CJ-4639-01A-01D-2095-10_Illumina.bam	90.64	1.9	0.15	58cfa831e4b0c9d6adf6c414	TCGA-CJ-4639-01A-01D-2095-10_Illumina.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4639-01A	3E976301-4042-4AC0-8F01-EF2F1A8161A6	Primary Tumor	Illumina HiSeq	d3739e9e-1149-4ec1-bb8d-f3b495ed1b4d	Kidney	49.0	11B1DCA7-6FCE-41C0-9580-A28CCF83E55C	063CFACF-9933-4A2D-8921-0AEB76E12779	TCGA-CJ-4639-01A-01D-2095-10	GRCh37-lite	TCGA-CJ-4639	TCGA-KIRC		s9168	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T2	N0	Kidney Clear Cell Renal Carcinoma	Stage II	2095-10	False	KIRC	C3	KIRC.1	0.202343988	0.41	0.0		-1.2446	-0.39799999999999996	0.6041	1.0174	0.494	-0.055999999999999994	30.0	85.0	0.28058607	1.6273992069999998	63.0	0.094538334	2.0	5.0				3.85655168	54.0	0.966800477	1.12049332	757.7907458	-1002.820827	2897.532013	0.0	3229.0	0.0	3229.0	8.831809265108099	-0.47834608624291697	0.5400594636645061	5.43339352640782	2.4287391526269877	2.6582453713903638	-3.3984157387002782	2.9070852388699047	2.1181859077258576	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c418	58cfa831e4b0c9d6adf6c418	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina.filtered.	WGS	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina.bam	215.7	1.9	0.15	58cfa831e4b0c9d6adf6c418	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4878-01A	7CA06DBE-F073-4AEE-86FF-A545FAD5EA93	Primary Tumor	Illumina HiSeq	cb7f204c-4503-4691-b1c7-fe363b44f4de	Kidney	71.0	24814EED-FDDB-475A-822E-EFFF92202954	DE4C3F91-D164-47DF-9971-FEBA840D247C	TCGA-CJ-4878-01A-01D-2098-10	GRCh37-lite	TCGA-CJ-4878	TCGA-KIRC		s9567	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2098-10	True	KIRC	C3	KIRC.2	0.08285034299999999				-1.1293	-0.1955	0.019	-0.6419	0.1866	-0.0787					79.0	0.108271854	3.0	14.0				1.559581156	5.0	0.9690222559999999	1.262587466	-244.0617296	-708.3513118	1691.190132	0.0	2186.0	0.0	2186.0	7.661432959282114	1.18571503575237	0.14017740733956408	6.092817041368269	4.11245443781941	2.7648904548140285	-1.5686159179138455	2.9267394020670396	2.6247130474744647	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c41a	58cfa831e4b0c9d6adf6c41a	TCGA-CJ-4899-01A-01D-2100-10_Illumina.filtered.	WGS	TCGA-CJ-4899-01A-01D-2100-10_Illumina	TCGA-CJ-4899-01A-01D-2100-10_Illumina.bam	109.4	1.9	0.16	58cfa831e4b0c9d6adf6c41a	TCGA-CJ-4899-01A-01D-2100-10_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4899-01A	900B5F21-E8FB-4A3F-B8E3-EF098716E508	Primary Tumor	Illumina HiSeq	ad992cd4-c4d5-4f87-b721-a2cbdf70f57d	Kidney	42.0	E2D40747-F751-4CCB-A45C-A60B06046DB1	9C181313-5B4C-41C5-9AD5-A5A86FE609AA	TCGA-CJ-4899-01A-01D-2100-10	GRCh37-lite	TCGA-CJ-4899	TCGA-KIRC		s9568	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2100-10	False	KIRC	C3	KIRC.1	0.17577852800000002	0.6	0.0		-1.046	-0.2925	0.8107	0.5729	0.3484	0.3516	19.0	42.0	0.257562227	0.829922733	99.0	0.144677886	3.0	2.0	0.96067689	1.055411437	3.0	3.0903647010000004	28.0	0.92742348	1.29500969	353.362116	-342.24683450000003	1992.7619300000001	0.0	1528.0	0.0	1528.0	7.0289512872347615	1.9275399143681362	0.5375266936911411	5.662075011971972	4.771499630499837		-1.366876275262789	2.8439597161317005		lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c420	58cfa831e4b0c9d6adf6c420	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted.bam	59.68	2.07	0.17	58cfa831e4b0c9d6adf6c420	TCGA-BT-A20T-01A-11D-A14U_120926_SN1222_0152_AC187DACXX_s_7_rg.sorted.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A20T-01A	096B4F32-10C1-4737-A0DD-CAE04C54EE33	Primary Tumor	Illumina HiSeq	e605a62d-c633-415e-bba0-2174fd3ad94e	Bladder	63.0	52F538EF-B05D-4C76-9976-CE6D49158016	3929BC99-B4FC-4EB9-BDEA-1986EA49AF2A	TCGA-BT-A20T-01A-11D-A14U-02	HG19_Broad_variant	TCGA-BT-A20T	TCGA-BLCA	453.0	s2871	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A14U-02	True	BLCA	C1	BLCA.2	0.144387136	0.25	0.26	4.116488949	0.1913	0.07	-0.2393	0.0539	0.33899999999999997	0.3351	112.0	75.0	2.442283931	6.723818724	222.0	0.71242855	5.0	25.0		0.0	1.0	2.2008276490000003	12.0	0.8856782	3.578491575	-755.8021294	150.1353221	-3769.9904539999998	1.0	453.0	1.0	314.0	5.266974115982325	7.185834573813491	0.2041036700703096	4.130974295242595	6.117993943812135	0.947392914424268	-1.13599982073973	-1.0678406300013554	0.7432892443539584	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c422	58cfa831e4b0c9d6adf6c422	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina.bam	62.92		0.08	58cfa831e4b0c9d6adf6c422	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BW-A5NP-01A	56A82A56-0241-4D3D-9DE2-696B0C36DF91	Primary Tumor	Illumina HiSeq	ce91806d-fb1a-452a-ad2e-51c7bdfbeb15	Liver	26.0	C13884B6-EAEF-4E1C-8FA7-5FE76548D32F	1C00925B-7328-4DB0-B930-04AAB2D80719	TCGA-BW-A5NP-01A-11D-A27I-10	GRCh37-lite	TCGA-BW-A5NP	TCGA-LIHC		s16972	Baylor College of Medicine	St Joseph's Medical Center (MD)	United States	NO	T2	N0	Hepatocellular Carcinoma	Stage IV	A27I-10	True	LIHC	C3	LIHC.iCluster:1	0.024179361				-0.2198	-0.08199999999999999	-1.2363	-1.1464	-1.3942	-0.8924	37.0	7.0	0.5837873579999999	1.806960869	154.0	0.738237832						0.0	1.0			-1567.623726	-713.5864589	3595.7864670000004	0.0	0.0	1.0	102.0	4.0098378828474806	2.296958068500227	-0.6077275996346716	5.5853742436059	2.4788789039904824	3.303044623891822	1.5755363607584187	0.1819208354902555	3.910772223526494	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c424	58cfa831e4b0c9d6adf6c424	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.bam	52.7	1.9	0.17	58cfa831e4b0c9d6adf6c424	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4725-01A	3BE2ACE5-1C2A-49E9-8DA9-CEED6119530B	Primary Tumor	Illumina HiSeq	7ddc2537-f164-4a40-befe-6e0a3deed186	Head and Neck	60.0	DD42AB2F-E936-4ACE-93D8-60375E03F2FE	C8B71532-685F-47AC-B019-B898A8D1670D	TCGA-CN-4725-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4725	TCGA-HNSC		s15755	Harvard Medical School	University of Pittsburgh	None	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	True	HNSC	C1	HNSC.Basal	0.16235240199999998	0.41	0.18		0.8290000000000001	0.22699999999999998	-0.8343	-1.4368	0.0268	0.5405	24.0	7.0	0.5584038339999999	1.31224901	175.0	0.8773077420000001	25.0	17.0				2.163955657	9.0	0.984858662	1.511701835	-1029.887249	1065.9952349999999	-1593.5612039999999	0.0	1157.0	0.0	1157.0	7.791316186233374	3.7000983720936826	-0.3391328645165663	6.215779825474954	5.9198081303431245	2.152619425408115	-1.5755363607584192	2.219709758249442	2.491752289924681	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c426	58cfa831e4b0c9d6adf6c426	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.bam	81.7	1.9	0.14	58cfa831e4b0c9d6adf6c426	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4727-01A	12D05E8F-8D13-47C1-B713-2250F6ABCEF9	Primary Tumor	Illumina HiSeq	f26c4909-b285-4ca0-ac40-fe65ad4a6a1a	Head and Neck	56.0	F102AEF0-94B8-4D26-8055-35B76DA9DD5F	E42C764C-98DB-4E55-A625-B1443E6C4B3A	TCGA-CN-4727-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4727	TCGA-HNSC		s15495	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True	HNSC	C1	HNSC.Classical	0.351785659	0.53	0.06		0.6938	0.317	-0.982	-1.6592	-0.268	0.4339	159.0	63.0	3.0809316489999996	10.50317608	165.0	0.5232932220000001	14.0	29.0					0.0		2.361847533	412.7812816	-108.8066041	-911.8087935000001	0.0	1560.0	0.0	1560.0	6.573755658599984	5.896668940770373	-0.6178521123205915	6.6293255097547945	6.884055594328258	-0.27235046897998405	0.055569851154810834	0.987386653557885	0.3455016433406074	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c42c	58cfa831e4b0c9d6adf6c42c	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.bam	16.84		0.18	58cfa831e4b0c9d6adf6c42c	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LD-01A	9DD97821-7AFD-4982-8B1D-F14F845B79F7	Primary Tumor	Illumina HiSeq	205bfe9f-2bc9-4236-930c-a862874ad8e0	Bladder	78.0	AEB379D5-B157-4BCE-82C5-0CD0077DB01F	BF6A16B2-9DC9-4E9A-A810-2EBA7E9B56A1	TCGA-BT-A2LD-01A-12D-A210-26	HG19_Broad_variant	TCGA-BT-A2LD	TCGA-BLCA		s3089	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A210-26	True	BLCA	C2	BLCA.4	0.292105701	0.41	0.75	1.999907497	0.7155	0.1475	-0.7559	-0.1286	1.1728	0.2105	49.0	63.0	0.9173697540000001	2.6041463990000002	261.0	0.6252822920000001	5.0	33.0	0.334704658	0.23199959	2.0		0.0		4.006658251	-806.322723	1097.789291	-2456.274492	1.0	623.0	1.0	555.0	5.591495670644759	6.54497148841296	0.3255713717877122	4.00970928954117	5.639262865869342	1.540057819257896	-1.5817863811035897	-0.9057086225436182	1.2144864474701837	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c430	58cfa831e4b0c9d6adf6c430	TCGA-CJ-4918-01A-01D-2101-10_Illumina.filtered.	WGS	TCGA-CJ-4918-01A-01D-2101-10_Illumina	TCGA-CJ-4918-01A-01D-2101-10_Illumina.bam	41.4	1.9	0.16	58cfa831e4b0c9d6adf6c430	TCGA-CJ-4918-01A-01D-2101-10_Illumina.bam	Dead	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4918-01A	267FF78B-BCEB-466E-8582-C560FE227FF0	Primary Tumor	Illumina HiSeq	6b97d11a-5289-440f-a2df-5c10c9cb91fc	Kidney	64.0	8262BF2A-F944-4101-8E43-51658B580747	81D0D6BB-7319-4B67-BCF7-36DF24E76B43	TCGA-CJ-4918-01A-01D-2101-10	GRCh37-lite	TCGA-CJ-4918	TCGA-KIRC	93.0	s9305	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	N0	Kidney Clear Cell Renal Carcinoma	Stage IV	2101-10	False	KIRC	C3	KIRC.3	0.356268701	0.64	0.0		-0.9248	-0.249	0.9591	1.1361	0.0914	0.6065	29.0	31.0	0.503856758	1.735506609	68.0	0.053517630999999996	0.0	4.0	0.837636343	2.4663691	19.0	3.587834535	38.0	0.986322901	2.112607261	102.45205759999999	-337.81510610000004	-1809.041254	1.0	93.0	1.0	33.0	8.689348664917473	1.2224644078311258	0.7785547079676007	5.427652842866345	4.283873876903548		-3.2616958220511285	3.061409469072422		higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c438	58cfa831e4b0c9d6adf6c438	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.bam	85.7	1.9	0.16	58cfa831e4b0c9d6adf6c438	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5772-01A	ECF9F8BE-7830-4626-8617-694C68EF4074	Primary Tumor	Illumina HiSeq	97cf547a-bc4b-4b08-9f8e-c1986b18aa30	Prostate	63.0	068AC08D-1A9E-4C71-B436-4ED861A9DCF8	5C9AAB80-29D2-4D85-A9FE-99FA22222CA4	TCGA-CH-5772-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5772	TCGA-PRAD		s4128	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.7-IDH1	0.061299062	0.2	0.13		-1.2313	-0.073	-0.8168	-0.9456	-0.5278	-0.5087	29.0	8.0	0.523824821	0.96494046	75.0	0.090232248	0.0	4.0				0.0	1.0		2.219805964	-670.1813279	-749.7539230000001	688.5234012	0.0	486.0	0.0	486.0	8.467267382646511	9.279049869983329	-0.027504132188106212	6.762519290408086	8.930743175715111	2.0097283647522475	-1.7047480922384255	-0.3483066942682158	2.0372324969403537	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c43a	58cfa831e4b0c9d6adf6c43a	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina.filtered.	WGS	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina.bam	85.7	1.9	0.15	58cfa831e4b0c9d6adf6c43a	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4870-01A	78048432-2DE1-498C-9CF1-9C5BD43DAA39	Primary Tumor	Illumina HiSeq	22d3d6f1-5686-493f-b205-6ecc2602d2b8	Kidney	58.0	F7D03CD3-2D55-400A-BB29-F86CCAE475EC	267A9862-17BD-4056-BA4A-1F373736FFBB	TCGA-CJ-4870-01A-01D-2098-10	GRCh37-lite	TCGA-CJ-4870	TCGA-KIRC		s9566	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2098-10	True	KIRC	C3		0.086769389				-1.6735	-0.17	0.2714	-0.2071	0.0836	0.0865					109.0	0.099344895						2.043191871	8.0	0.982567593	0.731779347	-18.40242855	-1626.537237	1990.332873	0.0	1498.0	0.0	1498.0	7.230770021428235	-0.45600961004194396	0.060011944273957285	6.085637717125232	3.1364149415259126	3.941679870920566	-1.1451323043030028	3.5924245515678566	3.8816679266466085	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c440	58cfa831e4b0c9d6adf6c440	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.bam	148.7	1.9	0.15	58cfa831e4b0c9d6adf6c440	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5789-01A	BE5411DC-3CAA-4B25-9B94-CE463E8E52B4	Primary Tumor	Illumina HiSeq	fc8da645-2fde-4ef8-9ee7-8b8101580793	Prostate	61.0	3C42EB4B-DB63-4F81-8D28-A439E932C716	1D569000-EA8E-4D54-A581-AEE36E66688E	TCGA-CH-5789-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5789	TCGA-PRAD		s3779	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.15498187800000002	0.0	0.0		-1.8892	-0.2645	-0.3817	-0.5184	-1.2029	-0.2155	1.0		0.055569922	0.0	53.0	5.89e-06	0.0	0.0				2.163955657	9.0	0.984858662	1.6564678380000002	290.41445120000003	-299.2372084	2630.824642	0.0	304.0	0.0	304.0	7.578656850594763	8.557054724841368	0.3311452041956754	5.327365051988268	7.640763992967212	3.59705046906027	-2.251291798606495	-0.9162907318741551	3.2659052648645948	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c442	58cfa831e4b0c9d6adf6c442	TCGA-CJ-4885-01A-01D-2098-10_Illumina.filtered.	WGS	TCGA-CJ-4885-01A-01D-2098-10_Illumina	TCGA-CJ-4885-01A-01D-2098-10_Illumina.bam	75.7	1.9	0.15	58cfa831e4b0c9d6adf6c442	TCGA-CJ-4885-01A-01D-2098-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4885-01A	5338D435-68FB-4F0D-A3E6-C843F703F75F	Primary Tumor	Illumina HiSeq	e9c31511-6628-44c2-a7cf-b25609056ad9	Kidney	64.0	A30B3254-3963-48D1-9710-7C3CAC0B1993	72C0603B-AD49-4E53-8164-2B69614BB743	TCGA-CJ-4885-01A-01D-2098-10	GRCh37-lite	TCGA-CJ-4885	TCGA-KIRC		s9171	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage IV	2098-10	True	KIRC	C3	KIRC.4	0.08265120299999999				-1.7912	-0.2005	0.196	-0.0134	-0.106	-0.02					68.0	0.307313627	11.0	5.0				2.232694477	12.0	0.898502355	1.7675131519999998	-15.11905698	-1317.110344	1592.152478	0.0	3451.0	1.0	2041.0	8.839257105591374	-0.6008300296105205	0.31849708215354755	5.438059723929218	2.595254706956865	4.971027839501476	-3.4011973816621555	3.1960847365673857	4.652530757347929	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c446	58cfa831e4b0c9d6adf6c446	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.bam	300.7	1.9	0.16	58cfa831e4b0c9d6adf6c446	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5750-01A	DC40CF49-B208-4F59-B5F0-CFBDD02970B2	Primary Tumor	Illumina HiSeq	d0338227-feec-4f2e-bcfa-89c723bb89b5	Prostate	72.0	0386D0E9-7BD8-467F-BA97-A379C1D67A83	E1FEA0C9-E1D6-49C2-9DFF-9DC87F7776E9	TCGA-CH-5750-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5750	TCGA-PRAD		s3591	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.2-ETV1	0.042993464	0.25	0.0	16.55266082	-0.5526	-0.122	-0.2742	0.8982	-0.1178	-0.4385	16.0	52.0	0.27698147100000003	0.8863407090000001	59.0	0.011795693000000001	0.0	2.0	0.852745725	2.250444855	14.0	3.35498757	29.0	0.996344764	2.414363699	-437.24486490000004	-664.2839357999999	2503.886187	0.0	396.0	0.0	396.0	8.241966560231802	8.41385840036994	0.20147133601733014	5.990674761625307	7.785249740947565	1.6967767467207673	-2.251291798606495	-0.6286086594223743	1.4953054107034371	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c44a	58cfa831e4b0c9d6adf6c44a	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.bam	214.7	1.9	0.15	58cfa831e4b0c9d6adf6c44a	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5741-01A	B3BF57D4-E31A-4740-B438-FA826FB79550	Primary Tumor	Illumina HiSeq	ae88c859-e075-4e3a-ba86-e6018e71fa98	Prostate	56.0	B22CBB75-E6E5-443D-AB4E-1CFD0079C69A	6AC2CA6C-FC79-4E5D-B08F-029A4AC2577B	TCGA-CH-5741-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5741	TCGA-PRAD		s3589	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C3	PRAD.1-ERG	0.025867155	0.18	0.0	4.53780023	-1.5619999999999998	-0.065	-1.4103	-1.1748	-1.3965	-0.8754	9.0	0.0	0.11168859099999999	0.474676511	103.0	0.057592752000000004	0.0	12.0							2.598125973	-1098.007791	-1395.8343300000001	2516.3066519999998	0.0	395.0	0.0	395.0	7.861341795599989	8.290449417069535	-0.3571120599514235	5.610049996993494	7.59730223650959		-2.251291798606495	-0.6931471805599454		higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c450	58cfa831e4b0c9d6adf6c450	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina.bam	61.1		0.08	58cfa831e4b0c9d6adf6c450	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BW-A5NO-01A	EE63C44B-91F4-4004-8DEA-192EAB527036	Primary Tumor	Illumina HiSeq	b36db6ae-5ff9-4608-9db1-8dd5dc62fd82	Liver	50.0	3CBD785D-CAD5-4299-8FE8-695CA8DB726D	81A8B064-E735-455F-B2DB-AF7AE11DAAC4	TCGA-BW-A5NO-01A-11D-A27I-10	GRCh37-lite	TCGA-BW-A5NO	TCGA-LIHC		s16580	Baylor College of Medicine	St Joseph's Medical Center (MD)	United States	NO	T3a	NX	Hepatocellular Carcinoma	Stage IIIA	A27I-10	True	LIHC	C4	LIHC.iCluster:3	0.126662267	0.29	0.55		-0.5409	-0.1495	-0.2647	0.1404	0.3126	-0.7988	52.0	16.0	1.05496663	3.428641546	469.0	0.671669915	17.0	25.0	0.908934062	1.768704016	7.0	0.693147181	2.0	1.0	3.982604753	-1043.963988	-232.5235787	3524.79635	0.0	20.0	0.0	20.0	7.271472037709915	5.2345398093651925	-0.14450445632632836	5.19203049603008	7.479017271551958	2.7754760090873383	-2.079441541679836	2.244477462186765	2.9199804654136665	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c456	58cfa831e4b0c9d6adf6c456	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina.filtered.	WGS	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina.bam	201.0	1.9	0.05	58cfa831e4b0c9d6adf6c456	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CA-6717-01A	268C01B3-D2CE-44C0-A2FE-EA846A1253CC	Primary Tumor	Illumina HiSeq	da552d40-23e1-469c-9fe7-ff2904a35ebe	Colorectal	57.0	D412011F-061C-43D6-8FA7-F917DA658AFF	2DF02F2B-9F1C-4249-B3B4-B03079CD97D9	TCGA-CA-6717-01A-11D-1835-10	GRCh37-lite	TCGA-CA-6717	TCGA-COAD		s13038	Baylor College of Medicine	ILSbio	Vietnam	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1835-10	False	COAD	C1	GI.HM-SNV	0.419474585			1.208664021	0.6997	0.313	0.5702	1.4572	-0.5039	0.4487	4533.0	159.0	58.89418386	246.32682909999997	37.0	9.54e-07			0.928894041	4.169467578	89.0	3.975841178	54.0	0.996705209	1.528041309	-647.1946347	847.6181852	-279.10888389999997	0.0	388.0	0.0	388.0	7.115920547115634	2.7109027416105675	-0.4950451995849705	5.5934940116711624	6.259963800142989	1.8002126049391134	-1.5224265354444708	3.5490610585324216	2.295257804524084	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c45e	58cfa831e4b0c9d6adf6c45e	TCGA-CJ-5681-01A-11D-1534-10_wgs_Illumina.filtered.	WGS	TCGA-CJ-5681-01A-11D-1534-10_wgs_Illumina	TCGA-CJ-5681-01A-11D-1534-10_wgs_Illumina.bam	253.4	1.9	0.05	58cfa831e4b0c9d6adf6c45e	TCGA-CJ-5681-01A-11D-1534-10_wgs_Illumina.bam	Dead	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-5681-01A	2939C03A-6F3F-4F7B-B246-34361BAADEB9	Primary Tumor	Illumina HiSeq	7efcb420-d7ac-41f1-847f-17a9ec6d10d5	Kidney	44.0	252836BE-AFF6-4967-8887-D93B178A4FF9	9AE0744A-9BC1-4CD7-B7CF-C6569ED9E4AA	TCGA-CJ-5681-01A-11D-1534-10	GRCh37-lite	TCGA-CJ-5681	TCGA-KIRC	552.0	s9170	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage IV	1534-10	False	KIRC	C4	KIRC.1	0.119581514	0.16	0.0		-0.3298	-0.242	0.0757	-0.8254	-1.2397	-0.3068	11.0	78.0	0.166031963	0.5534398779999999	1155.0	0.078057579	0.0	7.0				2.48490665	12.0	1.0	1.826729934	-688.4120095	-732.5050011	3778.520072	1.0	552.0	1.0	17.0	6.908062923962259	1.457476544492252	0.8336730973366782	5.917664219934382	4.804291229811678	0.37558094925849583	-0.9903987040278768	3.3468146853194263	-0.4580921480781823	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c467	58cfa831e4b0c9d6adf6c467	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.bam	226.7	1.9	0.15	58cfa831e4b0c9d6adf6c467	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5751-01A	721E76D0-4B1D-4E78-ADB8-1344B8030062	Primary Tumor	Illumina HiSeq	c152f07f-eb7f-464d-ba51-ce1b55777952	Prostate	68.0	6D8CE214-3A06-4F7C-858B-709A40EBBE25	FC06702A-2C27-42FD-A925-D0DB20C358E7	TCGA-CH-5751-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5751	TCGA-PRAD		s3425	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True	PRAD	C2	PRAD.8-other	0.40694659200000005	0.46	0.6	0.395976875	0.1766	-0.086	0.5309	2.0208	0.6948	-0.2433	14.0	2.0	0.165538207	0.689742527	270.0	0.5297939389999999	3.0	26.0	0.827026237	3.283535581	53.0	4.400051461	85.0	0.990411177	2.410729385	-504.34006469999997	-30.91046005	-2658.6387050000003	0.0	1065.0	1.0	365.0	8.57772369115627	8.242718751022842	0.45532179684209695	6.7318970006579395	7.837253642914678	3.45843417769371	-1.8458266904983305	-0.4054651081081646	3.003112380851613	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c46a	58cfa831e4b0c9d6adf6c46a	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	806.02	1.9	0.13	58cfa831e4b0c9d6adf6c46a	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	ASIAN		Colon Adenocarcinoma	Aligned reads	TCGA-CA-5256-01A	17633A60-E12B-4A7C-BD8A-C16341DDC606	Primary Tumor	Illumina HiSeq	21c81645-36f0-4e4a-8f23-b589998bcb76	Colorectal	54.0	D4D5DEB6-6CFB-4E25-9824-8F7DC8D5B451	A8F8AAD6-F8C5-4133-A651-454C047A19D0	TCGA-CA-5256-01A-01D-1405-02	HG18	TCGA-CA-5256	TCGA-COAD		s13544	Harvard Medical School	ILSbio	None	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	True	COAD	C1	GI.CIN	0.12083937199999999	0.34	0.16	11.0202603	0.7662	0.4525	-0.5942	0.1866	-0.9041	-0.3918	32.0	74.0			97.0	0.8444377740000001	19.0	6.0							1.087828799	-1984.152909	175.85601359999998	-1532.095135	0.0	379.0	0.0	379.0	6.210600077024653	5.053635032568925	-0.5247758020633689	5.494980040612649	5.91863247005553	0.44761954786219826	-0.7156200364120036	0.864997437486605	0.9723953499255672	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c470	58cfa831e4b0c9d6adf6c470	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina.filtered.	WGS	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina.bam	376.7	1.9	0.05	58cfa831e4b0c9d6adf6c470	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CA-6718-01A	DF5AB6CC-6F68-4B6B-95E2-954C6B57BA9C	Primary Tumor	Illumina HiSeq	3f12f1a7-45cc-4500-b7e1-8ac12465fbfe	Colorectal	46.0	F235AFBB-DC2A-41DD-B373-77C0AACEFB37	0980E7FD-051D-45E9-9CA6-2BAF073DA4E8	TCGA-CA-6718-01A-11D-1835-10	GRCh37-lite	TCGA-CA-6718	TCGA-COAD		s13037	Baylor College of Medicine	ILSbio	Vietnam	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1835-10	False	COAD	C2	GI.HM-SNV	0.328323077	0.52	0.04	13.01722267	1.1573	0.39299999999999996	0.5123	0.9631	1.3165	0.187	1803.0	74.0	17.42767715	89.14486172	91.0	0.114100442	2.0	11.0	0.81480432	3.203668511	51.0	3.176082815	25.0	0.9867056040000001	1.489660811	181.99409550000001	914.7297297	-1306.384417	1.0	306.0	1.0	207.0	5.962550536943339	5.399708217254787	0.1869797930653574	4.89783979995091	6.681715024193179	1.6546982459000077	-1.0647107369924282	1.2820068069383916	1.4677184528346503	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c47a	58cfa831e4b0c9d6adf6c47a	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.bam	57.66		0.17	58cfa831e4b0c9d6adf6c47a	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A3PK-01A	73041FCF-F3B6-4851-B34D-1D62A1FCF6FE	Primary Tumor	Illumina HiSeq	637e8bd5-61ee-4d45-8cc5-e3b89950d020	Bladder	80.0	F09E1EEB-BCD5-4DBA-92F0-7D4B34B81CE7	EE975BE9-76BF-4B5A-BF4C-155750C168CD	TCGA-BT-A3PK-01A-21D-A221-26	HG19_Broad_variant	TCGA-BT-A3PK	TCGA-BLCA		s2858	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A221-26	True	BLCA	C2	BLCA.3	0.62102208	0.72	0.5	13.79950575	0.7279	0.3465	0.1167	-0.1509	1.1436	0.7091	166.0	50.0	2.94139647	9.059501127	94.0	0.170668748	5.0	21.0	0.7951365640000001	2.5906316869999997	26.0	2.150060224	10.0	0.933759291	4.5431766819999995	-28.21567467	170.7700676	-0.19093361399999997	1.0	303.0	1.0	303.0	6.638256097613956	8.004395928276423	-0.54806446670695	6.045192375610993	7.51191944317863	0.8042793603464189	-0.5930637220029626	-0.49247648509779385	1.3523438270533688	lower	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c480	58cfa831e4b0c9d6adf6c480	TCGA-CJ-5682-01A-11D-2103-10_Illumina.filtered.	WGS	TCGA-CJ-5682-01A-11D-2103-10_Illumina	TCGA-CJ-5682-01A-11D-2103-10_Illumina.bam	155.4	1.9	0.15	58cfa831e4b0c9d6adf6c480	TCGA-CJ-5682-01A-11D-2103-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-5682-01A	4C325EE1-9B8E-45D4-A0A7-E47EC1EAC402	Primary Tumor	Illumina HiSeq	5586870f-0a22-4bd6-b331-defce06a0f46	Kidney	60.0	3D38F604-E571-422D-B645-BF73A0348243	DACD4CC2-FC2B-4FBD-ADF6-C8A46AE69C91	TCGA-CJ-5682-01A-11D-2103-10	GRCh37-lite	TCGA-CJ-5682	TCGA-KIRC		s9450	Baylor College of Medicine	MD Anderson Cancer Center	None	NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage IV	2103-10	False	KIRC	C3	KIRC.2	0.10784948400000001				-1.0155	-0.2725	0.33399999999999996	0.6292	0.2475	0.4236	29.0	172.0	0.447154686	1.8445130809999999	61.0	0.55203888	20.0	0.0		0.0	1.0	2.323396823	13.0	0.905825613	1.695250278	726.6743931	-148.9007823	1265.828693	0.0	3736.0	1.0	55.0	7.757550019567928	1.9003413915644476	0.15097102690987851	5.164162726785857	4.317635432334455	4.33411108791511	-2.59338729278207	2.417294040770007	4.183140061005232	higher	flr_F1_F2
13722.58cfa831e4b0c9d6adf6c485	58cfa831e4b0c9d6adf6c485	TCGA-CM-4752-01A-01D-140